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Introduction 
1 
I. Introduction  
I.1. General Motivation 
I.1.1. Heterocycle molecules with biological activity 
Heteroatomic ring systems are one of the essential parts of most biologically active 
drug molecules. The main properties of the heteroaromatic rings are correlated with the fact 
that they can furnish analogies to the biologically active molecules present in the human body. 
The hormones, nucleic acids, neurotransmitters, all have in their structures at least one 
heteroaromatic ring.  
Oxadiazoles (furodiazoles) are five-membered ring derivatives which include one 
oxygen and two nitrogen atoms in their cyclic system. Depending on the position occupied by 
the oxygen and nitrogen atoms in the ring, oxadiazoles are categorized in four different 
groups[1]: 1,2,3-oxadiazole, 1,2,4-oxadiazole, 1,2,5-oxadiazole and 1,3,4-oxadiazoles (Figure 
1). 
 
Figure 1. Oxadiazole systems. 
 
The 1,2,3-Oxadiazole ring system is stabilized mainly in the diazo-oxide form. One of the 
important features of these compounds is their ability to stabilize themselves in a higher 
oxidation state. Sydnones and sydnonimines derivatives are the best representantives of this 
class.[2] Taking into consideration the biological activity of these compounds, two of the 
sydnonimines derivatives, Molsidomine and Sydnocarb, must be acknowledged (Figure 2). 
Molsidomine has a long-lasting effect as vasodilatation agent and decreases the effort of the 
heart in cases of ischemic heart disease. It behaves similar to nitroglycerine in the treatment of 
angina pectoris.[3] Sydnocarb acts on the central nervous system and has been used as a 
psycho-stimulant.[4] Other sydnones and sydnonimines are reported to have anti-
inflammatory, antitumor, antibacterial, analgesic and antipyretic activity.[5] 
Figure 2. Bioactive 1,2,3-oxadiazoles. 
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1,2,5-Oxadiazoles (Furazans) and their corresponding oxides (furoxans and benzofuroxans) 
are well known for their biological properties. This class of compounds is reported to have 
antimicrobial, immunosuppressive, vasodilator or anticancer activity.[6] In recent studies on 
the development of new anti-ulcer drugs, calcium channel modulators or vasodilator 
compounds, the furoxan and the benzofuroxan systems were designed along with other 
traditional drug moieties in a single molecule.[7] The most conclusive examples are the 
furoxan and the benzofuroxan derivatives bearing as substituent dihydropyridine in an attempt 
to develop calcium channel modulators (Figure 3). Isradipine, a calcium channel blocker of 
the dihydropyridine class has selective effects on coronary arteries and the sinus node,[8] in 
order to reduce the risk of stroke and heart attack. The nitro derivative has an opposite effect, 
hence, it is a calcium channel activator.[9] 
 
Figure 3. Bioactive 1,2,5-oxadiazoles. 
 
Many furoxan derivatives were tested for antibacterial, antiprotozoal (T. vaginalis and 
Entamoeba histolytica), antifungal and mutagenic activities.[10] 
 
1,3,4-Oxadiazoles are considered good biomimetic and reactive pharmacophores.[11] Because 
of their biological activities,[12-14] these heterocycles are used also in the development of 
pesticides,[15] compounds with anti-peripheral vasomotility,[16] central nervous system 
stimulants, anti-inflammatory and hypotensive drugs,[17] insecticidals,[18] bactericidals,[19] 
analgesics, anticonvulsives, antiemetics, diuretics,[20] hypoglycemics,[21] muscle relaxants,[22] 
herbicidals[23] and fungicidals.[24] 
 
1,2,4-Oxadiazoles [furo(ab1)diazoles], were reported for the first time by Tiemann and 
Krüger[25] in 1884. For a long time, this heterocycle was just mentioned in a small number of 
publications. However, since 1960, the 1,2,4-oxadiazoles have received more attention from 
the chemistry community due to their unusual tendency to go through molecular 
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rearrangements. The application of this heterocycle in medicinal and material chemistry has 
led to an increasing number of publications dealing with 1,2,4-oxadiazoles. 
 
I.1.2. Medicinal aspects of organic and organometallic compounds 
I.1.2.1. 1,2,4-Oxadiazole abundance in nature 
To the best of our knowledge, there are only a few examples of natural products possessing a 
1,2,4-oxadiazole core or structure based on it. The 3-substituted indole alkaloids, 
Phidianidines A and B (Fig. 4), were isolated by Carbone et al. from the aeolid opisthobranch 
Phidiana militaris.[26] They are selective inhibitors of dopamine transporter DAT and partial 
agonists of the μ opioid receptor.[27] Moreover, these selective molecules are attractive as CNS 
targets because neither Phidianidine A nor B are cytotoxic. A further example is quisqualic 
acid (Fig. 4). This metabolite was obtained from the seeds of Quisqualis indica and Q. 
fructus[28] and is a strong agonist for AMPA (α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid) receptors and group I metabotropic glutamate receptors.[29] 
Figure 4. Natural products possessing 1,2,4-oxadiazole core. 
 
I.1.2.2. Medicinal chemistry of 1,2,4-oxadiazoles 
The five-membered heterocyclic 1,2,4-oxdiazole motif is of general and increasing synthetic 
and pharmacological interest and forms an important constituent of biologically active 
compounds including natural products.[30] Sawyer et al. have described such compounds as 
bioisosters for amides and esters.[31] The hydrolytic and metabolic stability of 1,2,4-
oxadiazoles is increased as a result of the five-membered ring. Since the neutral 1,2,4-
oxadiazole system can act as a bioisoster for amide and carboxylic acid groups, researchers 
implemented this structural motif in bioactive molecules. Several bioactive peptides 
(hormones analogues, enzyme inhibitors or neurotransmitters) undergo fast hydrolysis by 
peptidase enzymes present in the human body which limits their therapeutic properties. To 
surmount this obstacles efforts have been undertaken to replace the amide moiety by the 
1,2,4-oxadiazole system. 
A series of 1,2,4-oxadiazole-5-one and 1,2,4-oxadiazole-5-thione, isosters of 
nicotinamide and pyrazinamide, were reported to have antitubercular activity (Figure 5).[32] 
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Pivaloyloxymethyl derivatives of these isosters were synthesized with the purpose of 
increasing the lipophilicity and thereby improving the cellular permeability. These 
compounds are supposed to be modified by esterases to the active species after penetration of 
the mycobacterial cell wall. The potency of these compounds was found to be up to 16 times 
higher than pyrazinamide. 
 
Figure 5. 1,2,4-Oxadiazole isosters for nicotinamide and pyrazinamide. 
 
Another bioactive 1,2,4-oxadiazole derivative was isolated by Hennen et al. (Fig. 6).[33] They 
have compared the specific absorption rate (SAR) of Ribavarin, Tiazofurin and their 
analogues as antiviral and antineoplastic agents. The results showed that the 1,2,4-oxadiazole-
containing compound induces 46% inhibition of leukemia L1210 and 43% inhibition of 
Leukemia P388 at 1x10-4 M in cell culture. 
Figure 6. An 1,2,4-oxadiazole isoster for Ribavarin and Thiazofurin. 
 
Saunders et al.[34] established the importance of the 1,2,4-oxadiazole system as a bioisoster 
for ester derivatives of muscarinic derivatives. The oxadiazole-substituted muscarinic ligands 
(Fig. 7) were found to be efficient against Alzheimer’s disease. 
 
Figure 7. 1,2,4-Oxadiazole bioisosters for esters derivatives of muscarinic derivatives. 
 
Oxadiazole [(-)-2β-(1,2,4-oxadiazol-5-methyl)-3β-phenyltropane] (Fig. 8) is a phenyl tropane 
derivative acting as a stimulant drug with almost five times higher activity than cocaine. In 
addition it inhibits the monoamine reuptake.[35] 
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Figure 8. 1,2,4-Oxadiazole-phenyltropane derivative with stimulant effect. 
 
The oxadiazole ring system is also present in the molecular structure of some commercial 
drugs with different therapeutic properties, such as antiinflammatory, vasodilator, anesthetic 
or antitussive (Figure 9).[36] 
 
Figure 9. Examples of drugs containing the 1,2,4-oxadiazole unit. 
 
Other biological properties of 1,2,4-oxadiazole containing molecules, with a wide 
spectrum of action, from anti-parasites to anti-inflammatory activity, are summarized in Table 
1. 
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Table 1. Literature reported bioactive 1,2,4-oxadiazole. 
1,2,4-Oxadiazole derivative Biological properties 1,2,4-Oxadiazole derivative Biological properties 
 
 
-strong aldose reductase  
inhibitor 
-analog for the marketed  
drug Zopolrestat [37] 
 
 
-bioisosters of esters re- 
ported to possess anti- 
rhinoviral activity [45] 
 
 
-potent 5-HT1D agonist  
analog for Sumatriptan,  
drug used in the treatment 
of migraine [38] 
 
 
-apoptosis inducer. 
-antitumoral activity  
against breast and colo- 
rectal cancer cell lines [46] 
 
-activ against kinetoplastid 
parasites (Leishmania  
donovani, Trypanosoma  
brucei) [39]  
 
-antiviral and antineo- 
plastic agent [33] 
 
 
-Interleukin-8 (IL-8)  
antagonists that could  
lead to powerful antiinfla-
mmatory agents [40] 
 
 
-strong SH2 inhibitors 
 of the tyrosine kinase 
ZAP-70 [31] 
 
 
-antispasmodic and  
antitussive activity [41] 
-analgesic and anti- 
inflammatory activity [42] 
 
 
-strong inhibitor agent 
 of human Ache [47] 
 
 
-active against in the rat  
carrageen footpad edema  
and mycobacterium 
footpad edema [43] 
 
-excellent Sphingosine- 
1-phosphate-1(S1P1)  
receptor agonist with  
very good selectivity  
against S1P2 and S1P3  
receptor subtypes (S1P1  
IC50 = 0.6 µM) [48] 
 
-inhibitors for Trypsin  
Glucuronidase and 
Soybean Lipoxygenase 
-good antioxidant 
character 
-antiinflammatory activity  
in the rat carragenan paw  
edema assay [44]  
 
-good palm CoA inhibi- 
tor (IC50=0.38 µM) [49] 
 
 
-isosteres of nicotinamide 
and pyrazinamide, repor- 
ted to have antitubercular 
 activity [32]  
 
-hypocholestermic agent 
[50] 
 
Furthermore, 1,2,4-oxadiazoles are widely employed in synthetic chemistry e.g. in the 
search for antitumor agents. Cancer consists of more than one hundred different diseases, all 
characterized by uncontrolled growth and spread of abnormal cells. In this context, the 
identification of drugs inducing apoptosis represents an attractive approach for the discovery 
of new anti-cancer agents. By means of a high-throughput screening (HTS) assay, 1,2,4-
oxadiazole A (Fig. 10) was found to act as an apoptosis agent.[46] A series of 1,2,4-oxadiazole-
5-carboxamides B have been synthesized and tested as inhibitors of the glycogen synthase 
kinase 3 (GSK-3), a key regulator of both differentiation and cellular proliferation.[51] 
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Figure 10. Examples of antitumoral drugs containing 1,2,4-oxadiazole core. 
 
An alternative anti-tumor strategy involves the inhibition of the tumor growth, such as 
angiogenesis. Integrin αvβ3 is a receptor that has been found on the surface of many tumor 
cells and it recognizes the arginine–glycine–aspartic acid (RGD) sequence. Antagonists of 
this receptor are able to inhibit angiogenesis. 1,2,4-Oxadiazole-butanoic acids such as C were 
tested as nonpeptidic analogues of αvβ3 antagonists.[52] 
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I.1.2.3. Cancer pathology 
A tumor is a cell modification generated by an alteration in the metabolism or by a 
genetic mutation. The abnormal growth of cells (when the cell cycle and cellular role is not 
working properly) and their proliferation in a chaotic fashion are defined as cancer. 
The etymology of cancer has the origins from Greek word carcinos. The Greek 
physician Hippocrates used this term to report characteristics of the pathology. 
Although cancer is noted from ancient times and many research programs were developed in 
the last decades in the attempt to find a cure, it is still responsible - according to World Health 
Organization - for more than 12 million deaths per year, making it the second most frequent 
cause of death after heart diseases.[53,54] 
Human living conditions and the aging of the human body are considered the two most 
important factors responsible for cancer development. The malignant tumours related to a 
hereditary origin is just around 5%.[55] This illness is strongly correlated with the living 
environment of individuals. The most frequent causes for the development of different forms 
of tumours involves live style (drugs, cigars, alcohol), working conditions (heavy metal, 
asbestos, benzene) or a non-balanced alimentation.[56] Overall the human body can be affected 
by hundreds of cancer types of which lung cancer is among the most frequently observed. At 
the opposite end, kidney or pancreatic cancers belong to the less common ones. 
Based on the tissue affected or the initial tumor from which they develop, the cancer tumours 
are classified in carcinomas, sarcomas, lymphoma, blastoma and germ cell tumor. Although 
cell origins are different, they exhibit resembling symptoms and proliferation stages. The first 
stage of cancer development is usually associated with no visible symptoms, but as the tumor 
advances to higher stages the patient can manifest ulceration, pain and bleeding. Usually the 
tumor growth is blocking the circulatory system and organs making them unable to function 
properly.[57] 
 
I.1.2.4. Organic chemistry in anticancer research 
Starting in 1950 many research groups, especially in the chemotherapy field, have 
undertaken great efforts in order to study the physiology and behaviour of tumor cells and to 
develop effective anticancer drug-systems. The first approach in the area of anticancer 
chemotherapy was the successful clinical use of Mustardgen against human lymphoma.[58] 
This warfare chemical (chlormethine) represents the nitrogen analogue of mustard gas. At the 
same time, an American pediatric pathologist, Sidney Farber, noticed that folic acid (vitamin 
B9) played an important role in the proliferation of acute lymphoblastic leukemia. By using 
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aminopterin and amethopterin (folic acid antagonists) against acute lymphoblastic leukemia 
cells he observed a tumor regression.[59] Some years later methotrexate successfully treated 
choriocarcinoma. Because of his accomplishments Farber became known as “father of the 
anticancer chemotherapy”. In the next years several metabolites and their analogues were 
investigated with repect to their anticancer activity. 6-Mercaptopurine and 5-Fluorouracil 
proved to have very good anti-cancer properties.[60,61] 
 
Figure 11. First chemotherapeutic drugs used. 
 
The next step included the screening of a large number of chemical and natural drugs as 
potential anticancer agents. Starting with 1954 many natural compounds have been used as 
drugs in anti-cancer therapy. The most eloquent examples include Vincristine (extract from 
Vinca Rosea), Paclitaxel (extract from Taxus) and Topotecan (extract from Camptotheca 
Acuminata).[62] 
 
Figure 12. Natural compounds drugs used in anticancer therapy. 
 
Besides searching for active natural product drugs, also the total syntheses of drugs like 
Fludarabine phosphate (nitrosourea derivate) or Daunorubicine, Doxorubicine (anthracycline 
compound) were performed (Fig. 13).[63,64] In 1966, Tamoxifen, the first estrogenic receptor 
antagonist, was synthesized by Dora Richardson.[65,66] After successful clinical trials of 
Tamoxifen and its analogues and after having established the link between breast cancer and 
contraception, the FDA (Food and Drugs Administration) approved their use as anticancer 
agents. 
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Figure 13. Synthetic compounds drugs used in anticancer therapy. 
 
I.1.2.5. Metal complexes in anticancer research 
Compared to chemotherapy with organic compound, the chemotherapy with metal containing 
drugs has started in the second part of the 19th century. The pioneer compound, potassium 
arsenite (Fig. 14), was used until 1950 for treatment of a large number of conditions under the 
name of Fowler´s solution and it also proved to have anti-leukemic effect.[67] 
 
Figure 14. Chemotherapeutic arsenic based drugs. 
 
At the beginning of the 20th century, Salvarsan (Fig. 14), an organoarsenamide derivative, was 
involved in the treatment of syphilis, a disease caused by the infection with the spirochaete 
bacterium Treponema pallidum.[68] The drug was produced by the German company Hoechst 
and it became a blockbuster in the world’s drug market. However, its days of fame ended 
around 1940, when penicillin was discovered. Some years later, gold-containing drugs like 
Aurofin or Aurothiosulphate were reported to exhibit good anti-rheumatic properties (Fig. 
15).[69] 
 
Figure 15. Anti-rheumatic gold containing drugs. 
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The milestone compound Cisplatin was discovered by Barnett Rosenberg in 1965. He 
observed the generation of a soluble platinum complex during the electrolysis of platinum 
electrodes which inhibited binary fission in Escherichia coli bacteria.[70] Starting from 1978, 
Cisplatin is extensively used as anticancer agent against several types of tumours (lung, 
testicular, ovarian).[71,72] However, the extreme side effects of the Cisplatin therapy 
(nephrotoxicity, neurotoxicity, nausea, hair loss etc.)[73] has led to the development of other 
platinum-containing compounds that are more tolerable by the human body, like Carboplatin 
and Oxaliplatin (Fig. 16).[74] 
 
Figure 16. Platinum complexes used as antitumor agents. 
 
Another successful metal in the area of medicinal chemistry is ruthenium. These compounds 
feature a wide range of bioactivity including strong cytotoxicity, but at the same time they 
show only mild undesired side effects along with convincing anti-metastatic properties, which 
make ruthenium complexes the second most studied class of metal complexes after platinum 
compounds.[75] The best representatives of Ru-containing drugs include KP1019 and NAMI-A 
which are currently in clinical trials (Fig. 17).[76] 
 
Figure 17. Ruthenium complexes with good antitumor activity. 
 
In some cases, researchers designed the analogous metal complex of already marketed 
compounds in order to surmount resentence to the benchmark drug (Fig. 18). This approach 
was successfully used in the case of Tamoxifen and Chloroquine. The metallocenyl derivative 
of Tamoxifen, namely Ferrocifen, manages to interact with both estrogenic receptors positive 
and negative.[77] Ferroquine, the metallocenyl complex of Chloroquine, proved to be active 
against malaria strains which had become resistant to the standard drug Chloroquine.[78] 
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Figure 18. Metallocenyl complexes of Tamoxifen and Chloroquine. 
 
Although the total number of drugs with a metal core actively employed in cancer treatment is 
not impressive, a large number of metal compounds are actively designed and screened. Many 
studies are based on carbene chemistry, Theobromine silver derivatives, complexes of 
Phenantroline with rhodium or iridium etc..[79-82] 
 
I.1.2.6. N-heterocyclic carbenes in anticancer research 
The pharmacological applications of NHC metal compounds have only slowly evolved 
in the last years compared to the rapid growth of the homogeneous transition metal catalysts 
containg NHC ligands. Although NHC metal complexes readily generated in a simple 
synthetic approach, their pharmaceutical properties is still underdeveloped. 
The design of new NHC metal complexes with various substituents leading to superior 
antitumor properties represents the highly topical field of chemical research. In the last 
decades gold-containing derivatives have been employed for the development of novel 
bioactive drugs including those with anticancer activity. The fact that Au(III) and Pt(II), both 
d8 ions, adopt a square planar ligand arrangement along with the immuno-modulatory 
properties of the gold(I)-containing anti-rheumatic compounds and the insertion of gold (I and 
III) in the molecule of antitumoral agents, represent the main arguments for the design and 
screening of new gold-containing drugs for anticancer activity.[83] 
Although Auranofin and its analogues opened the path of gold containing complexes with 
applications in chemotherapy, some areas of activity remains still open for studies.[84] In order 
to fill this gap, many different ligands (NHCs, porphyrines, phosphines, dithiocarbamates 
etc.) have been introduced in the coordination gold sphere over the last years in order to 
develop new bioactive molecules.[85-88] 
Lipophilicity of mono-NHC-gold(I) complexes, known as mitochondria targeting complexes, 
play an important role in achieving the desired biological activity.[89] Using this hypothesis, 
many research groups dedicated their work to improve the biological properties of Au–NHC 
complexes by tuning the ligand lipophilicity. 
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Weaver et al. reported the anti-cancer activity for a series of NHC-Au(I) complexes against 
prostate, bladder and breast tumor cell lines.[90] The best results were obtained for two 
compounds (Figure 19), with an IC50 value of 0.18 μM against a bladder tumor cell line and 
0.9-1.9 μM for other two tumor cell lines. 
 
Figure 19. NHC-Au(I) complexes reported by Weaver et al.. 
 
Nevertheless, when their cytotoxicity was compared to a human breast carcinoma cell 
line and a normal breast epithelial cell line, they, unfortunately, showed no selectivity. 
Ott et al. explored a series of benzimidazole-NHC gold(I) complexes as TrxR and GR 
(glutathione reductase) inhibitors (Figure 20) and their results are consistent with a selective 
inhibition of TrxR over GR. Furthermore all gold compounds showed significant 
antiproliferative effect with IC50 values in the low micromolar range.
[91]
 
 
Figure 20. NHC-Au(I) complexes reported by Ott et al.. 
 
Using the silver transmetallation route, Patil et al. manage to synthesize and evaluate the 
biological activity of cyanobenzyl and benzyl NHC-Au(I) complexes (Figure 21), which 
showed only moderate activity against human cancerous renal cell line Caki-1.[92] 
 
Figure 21. NHC-Au(I) complexes reported by Patil et al. 
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An interesting series of diarylimidazolin-2-ylidene gold(I) NHC complexes were prepared 
and evaluated for their biological activity by Liu et al.. Some of this complexes revealed 
increased growth inhibitory effects against MCF-7, MDA-MB 231 and HT-29 (Fig. 22).[93,94] 
 
Figure 22. NHC-Au(I) complexes reported by Liu et al., Ray et al. and Barrios et al.. 
 
Furthermore Ray et al. studied the antiproliferative properties of some NHC-Au(I) complexes 
against HeLa cells, but only low growth inhibitory effect were found.[95] Similar in vitro 
results were conducted by Barrios et al. on other compound against PEST (peptide sequence 
that is rich in proline (P), glutamic acid (E), serine (S), and threonine (T)).[96] 
 
I.1.2.7. Lipinski's Rule of Five 
After the physical-chemical investigation of a huge number of drugs and possible drugs 
already in clinical testing, Christopher Lipinski at al.[97-99] managed to establish a guiding 
principle for the prognosis of compound absorption through the cell membrane. The main 
remark from the medicinal chemist was that the majority of the drugs used are rather small, 
lipophilic molecules. The rule was elaborated in 1997 and stated that the membrane 
permeability and body absorption is favourable when the molecules have the following 
properties:  
- The molecular weight is smaller than 500g/mol. 
- The sum of hydroxyl and amine groups (hydrogen bond donors) is less than 5. 
- The sum of nitrogen and oxygen atoms (hydrogen bond acceptors) is less than 10. 
- The lipophilicity value of the molecule is less than 5. 
However, natural products and the substrates used for transporters do not follow this rule. 
Although the rule is very valuable and intensively used, it has also some limitations. An 
analysis of cca. 60 of the pharmaceutic blockbuster drugs from 2007 under the criteria of 
Lipinski´s rule of five, revealed that 7 of them (Docetaxel, Montelukast, Atorvastatin, 
Telmisartan, Leuprolide, Tacrolimus and Olmesartan) did not match the rule parameters and 5 
of them missed just one of the requested criteria.[100] 
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Nevertheless, in order to synthesise, screen and evaluate in short time period a large 
number of compounds with a high probability of becoming a hit-molecule in medicinal 
chemistry, the Lipinski´s Rule of five provides an excellent starting point. 
 
I.2. 1,2,4-Oxadiazoles 
I.2.1. Chemical reactivity of 1,2,4-oxadiazoles 
 
 
Figure 23. Multifunctional features of 1,2,4-oxadiazole ring. 
 
1,2,4-Oxadiazole has an aromaticity index of IA = 48. This feature makes them one of 
the weakest aromatic systems within the class of five-membered heterocycles,[101,102] which 
results in an increased tendency to rearrange into more stable systems. The molecular 
rearrangements of the 1,2,4-oxadiazole ring can be traced to the labile O-N bond by 
employing several thermal or photochemical procedures, and this property can be used as an 
alternative route in the synthesis of several other heterocycles.[103] 
The electrophilic character of C(3) and C(5)[104-107] allows the generation of 
compounds which are usually very difficult to prepare. One example includes the irreversible 
ring-degeneration rearrangement taking place on 1,2,4-oxadiazole when it is attacked by an 
external bidentate nucleophile.[108] This property is further enhanced in the presence of 
electron-withdrawing substituents. The pyridine-like nitrogen N(4) present in the 1,2,4-
oxadiazole ring may act as a nucleophile[109] and makes the molecule slightly basic.[110] On the 
other hand the N(2) nitrogen has an ambiphilic character.[111] Another important attribute of 
the 1,2,4-oxadiazole ring is the capability of the oxygen atom of the ring moitey acting as an 
internal leaving-group.[112] 
All these properties suggest that the 1,2,4-oxadiazole ring is a versatile heterocycle. 
The reactivity is strongly correlated with the nature of the substituents and the reaction 
conditions involved. 
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I.2.2. Synthetic aspect of 1,2,4-oxadiazoles 
 
Scheme 1. General synthetic pathways regarding 1,2,4-oxadiazoles. 
 
“Give me a nitrile and I will build you a 1,2,4-oxadiazole!”[113] This affirmation made by Pace 
et al. condenses the two most frequently employed synthetic pathways in the preparation of 
substituted 1,2,4-oxadiazoles[30,114-118] (Scheme 1): The 1,3-dipolar cycloaddition of nitriles a 
with nitrile oxides b; the cyclodehydration of amidoxime derivatives e. The amidoximes can 
be readily generated from nitriles a and hydroxylamine, NH2OH, followed by coupling with 
activated carboxylic acids or their derivatives including amidoxime itself. The main benefit of 
these synthetic routes is their complementarity. The nitrile precursor substituent (R1 in the 
scheme 1) can be implemented at either C(5), as in c, or C(3), as in f, of the final 1,2,4-
oxadiazole. However, the limitation of these methods lies with the accessibility of the 
precursors. 
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Tabel 2. Synthetic pathways for 1,2,4-oxadiazoles. 
 
Cyclisation of 
amidoximes 
with amides  
1,2,4-Oxadiazoles can be synthesized from the corresponding amide by reacting an 
amidoxime with an amide at elevated temperatures (160-180°C). 
 
 
Oxidation of 
imino group 
 
The guanidine derivative can be successfully oxidized with sodium hypochlorite in order to 
obtain the 1,2,4-oxadiazole.[119] 
 
 
Pyrolyses of 
amidoximes and 
their esters 
 
Amidoximes at 170°C, in the presence of fatty acids with low molecular weight,[120] nitrous 
acid or chlorine[121] produce 1,2,4-oxadiazole. 
 
 
Starting from 
benzamidoximes 
 
By reacting benzamidoximes derivatives with succinic, acetic, propionic or butyric 
anhydride it is generated the corresponding 1,2,4-oxadiazoles.[122] 
 
 
Ring closure of 
monoximes of 
diacylamides  
The imidyl chloride of dibenzamide can be reacted with hydroxylamine in order to form 
1,2,4-oxadiazole.[123] 
 
 
Oxidation of 
1,2,4-
oxadiazolines 
 
Aromatic amidoximes can be reacted with aldehydes to give as condensation products the 
corresponding dihydro-1,2,4-oxadiazoles.[124,125] 
 
 
Dehydration 
with 
rearrangement 
of glyoximes 
 
The reaction of α-benzildioxime with polyphosphoric acid (PPA) at 120°C generates 
exclusively 1,2,4-oxadiazole.[126] 
 
 
Ring 
transformations 
 
When refluxed in acetic anhydride, adenine 3-N-oxide is fast converted into 4-formamido 
and 4-acetamido-5-(5-methyl-1,2,4-oxadizol-3-yl)imidazole. 
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I.3. Motivation 
1,2,4-Oxadiazole heterocycles represent an interesting biological functionality since they are 
bioisosteres of esters and amides.[31,127,128] Furthermore these compounds seem to have a 
much better hydrolytic and metabolic stability. 
 
Scheme 2. Retrosynthetic scheme for 3,5-substituted 1,2,4-oxadiazole system. 
 
In an attempt to produce new pyrroline-based insecticides, Bayer CropScience 
reported the preparation of 5-(4-bromophenyl)-3-(tert-butyl)-1,2,4-oxadiazole[129] by an 
cyclisation reaction between tert-butyl amidoxime and the methyl ester of p-bromo benzoic 
acid (Scheme 3). 
 
Scheeme 3. Reported synthesis of 3-(tert-butyl)-5-(phenyl)-Br substituted derivative. 
 
The 1,2,4-oxadiazole ring is 3-substituted with an tert-butyl group which confers 
stability to the ring whereas the bromophenyl substituent in 5-position allows for further 
reactivity. This is the only reported example of an 3-(tert-butyl)-5-(phenyl)-substituted 1,2,4-
oxadiazole and it was employed as a coupling reagent in order to produce the bioactive 
insecticide agent 3-(tert-butyl)-5-(4'-(2-(2,6-difluorophenyl)-3,4-dihydro-2H-pyrrol-5-yl)-3'-
fluoro-[1,1'-biphen-yl]-4-yl)-1,2,4-oxadiazole (Figure 24).  
 
Figure 24. Reported 3-(tert-butyl)-5-(phenyl)-substituted insecticide derivative. 
 
Taking these aspects into consideration, the strategy was to employ this molecular 
fragment to build a library of possible bioactive compounds.  
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II. Objectives 
Aim of this dissertation was the synthesis, characterisation and antitumor evaluation of 
distinct 1,2,4-oxadiazole-containing compounds and their corresponding NHC-Au(I) 
complexes (Figure 25).  
 
Figure 25. Graphic illustration of the target compounds. 
 
The implementation of the 1,2,4-oxadiazole unit was chosen for its known ability of 
acting as a bioisoster for amides, carbamates, esters and hydroxamic esters. The N-
heterocyclic carbene complexes (Arduengo-type) bearing on one side the 1,2,4-oxadiazole 
heterocycle has been assigned as a second key ligand in the development of novel compounds 
with antitumor properties. The metal of choice was gold(I), known for providing coordinative 
stability and good antitumor activity. Appropriate tuning of the NHC core by inserting other 
bioactive ligands should furnish distinguished biological activity. In addition to gold (I), other 
metal centers were created (silver, rhodium, ruthenium and palladium) and tested for their 
antitumor activity. A professional antitumor evaluation will determine the potential of the 
target compounds as anticancer agents.  
The antitumor activity of these compounds will be tested in a monolayer cell survival 
and proliferation assay using human tumor cell lines of different origin/histotype which allow 
for the analysis of their potency and tumor selectivity. Central theme of this PhD dissertation 
is to gather sufficient synthetic and biological information to establish a very versatile 
synthetic methodology for the preparation of 1,2,4-oxadiazole related compounds and to tune 
their application as as antitumoral agents. 
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III. Results and discussion. 1,2,4-Oxadiazole containing ligands 
III.1. Introduction 
Clapp reviewed the synthesis of 1,2,4-oxadiazoles[118] and pointed out that two general 
methods dominate their preparation (~95%): 
a) The condensation of amidoximes with carboxylic acid derivatives. 
b) The dipolar cycloaddition of nitrile oxides to nitriles. 
The general approach for the synthesis of 1,2,4-oxadiazoles is illustrated in Scheme 4.  
 
Scheme 4. Common synthetic strategies towards 1,2,4-oxadiazoles; a. amidoxime route; b. 1,3 dipolar 
cycloaddition route 
 
Using route a, the amidoxime route, the carboxylic acid has to be employed in an 
activated form. The activated carboxylic acid can be prepared beforehand or in situ by several 
methods,[130] e.g. as an acyl chloride or by the use of N,N′-carbonyldiimidazole (CDI). In the 
first step the amidoxime is O-acylated with the activated derivative in a condensation 
reaction. The O-acylated amidoxime can either be isolated or immediately undergo the 
cyclisation to the heterocyclic oxadiazole ring. This cyclodehydration reaction takes place 
upon heating to temperatures above 115°C.[131,132] Microwave techniques have also been 
employed in the synthesis of these heterocycles, but the advantage of CDI is that it activates 
the carboxylic acid in situ and can be used for step 1 and step 2 in DMF. 
 
III.2. One step synthesis of new members belonging to 1,2,4-oxadiazole 
family 
Scheme 5 presents the one-pot synthesis of 1,2,4-oxadiazols starting from tert-butyl-
amidoxime and 4-substituted-benzoic acids. Activation of the 4-substituted-benzoic acid with 
CDI and further acylation of the tert-butyl-amidoxime in DMF as solvent furnished the O-
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acylamidoxime, which was not isolated; on heating to 120°C for several hours, it underwent a 
cyclodehydration reaction, delivering the cyclized products in good to moderate yields after 
purification.  
 
Scheme 5. One-pot synthesis of 1,2,4-oxadiazols using the amidoxime route; i. 1,1 eq. CDI in DMF, 30 minutes; 
ii. 1,1 eq. CDI in DMF, 120°C, 4h. 
 
III.2.1. One step synthesis of halogen containing 1,2,4-oxadiazoles. 
III.2.1.1. Synthesis of 3-(tert-butyl)-5-(4-iodophenyl)-1,2,4-oxadiazole (1) 
One of the first molecule obtained, 3-(tert-butyl)-5-(4-iodophenyl)-1,2,4-oxadiazole 
(1), belongs to this class of compounds. Its synthesis is depicted in scheme 6. 
 
Scheme 6. Synthesis of 3-(tert-butyl)-5-(4-iodophenyl)-1,2,4-oxadiazole (1). 
 
Using 4-iodobenzoic acid as starting material the new 1,2,4-oxadiazole derivative was 
generated in good yields (85%) and fully characterized. The 1H NMR spectrum shows the 
expected number of resonances, a multiplet belonging to the four aromatic protons at 7.96-
7.79 ppm and the nine protons of the t-butyl group at 1.42 ppm as a singlet. The mass 
spectrometry gives the molecular peak signal M+ 328.0 along with other fragments. Crystals 
suitable for X-ray diffraction analysis were obtained by slow diffusion of hexane in a 
concentrated solution of 1 in DCM. 
 
Figure 26. Molecular structure of 3-(tert-butyl)-5-(4-iodophenyl)-1,2,4-oxadiazole (1). Atoms are drawn as 50% 
thermal ellipsoids. Selected bond lengths [Å] and angles [°]: C1-N1 1.380(2), C1-N2 1.305(2), N2-O 
1.4228(16), C6-O 1.3434(18), C6-N1 1.299(2), C10-I 2.0965(16), N1-C1-N2 115.04(14), C11-C10-I 
120.60(11). 
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The molecular structure of 1 was established by X-ray diffraction analysis and shown 
in Figure 26. The compound 1 crystallizes in the monoclinic space group P21/c. The planar 
molecule features a C10-I bond length of 2.0965(16) Å and the angle C11-C10-I is 
120.60(11)°. 
 
III.2.1.2. Synthesis of 3-(tert-butyl)-5-(4-fluorophenyl)-1,2,4-oxadiazole (2) 
4-Fluorobenzoic acid was used as starting material in order to prepare 3-(tert-butyl)-5-
(4-fluorophenyl)-1,2,4-oxadiazole (2) in moderate yields (45%) as shown in Scheme 7. The 
low yield for this one-pot cyclisation is explained by the formation of the imidazole 
substituted 1,2,4-oxadiazole (30) as a secondary product. 
 
Scheme 7. Synthesis of 3-(tert-butyl)-5-(4-fluorophenyl)-1,2,4-oxadiazole (2). 
 
The m/z indicates the molecular peak at M+ = 220.1, along with characteristic fragments at 
M+-15 and M+-97. The 1H-NMR spectrum of 2 recorded in CDCl3 gives the coresponding 
signals attributed to the four protons in the aromatic area along with the t-Bu signal at 1.43 
ppm. 
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III.2.2. One step synthesis of amino containing 1,2,4-oxadiazoles. 
III.2.2.1. Synthesis of 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)aniline (3) 
Scheme 8 presents the one-pot synthesis of 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)aniline 
(3) starting from tert-butyl-amidoxime and 4-aminobenzoic acid. Activation of the 4-
aminobenzoic acid with CDI and further acylation of the tert-butyl-amidoxime in DMF as 
solvent furnished the O-acylamidoxime, which was not isolated. Heating to 120°C for four 
hours induced the cyclodehydration reaction to yield aniline 3 in 59% yield after purification. 
 
Scheme 8. One-pot synthesis of 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)aniline (3) using the amidoxime route. 
 
The structure of compound 3 was confirmed by X-ray structure determination (Figs. 
27 and 27a). It crystallizes with two molecules in the asymmetric unit, which differ in the 
relative orientation of the rings (interplanar angles 22 and 9°). Three of the four NH 
hydrogens are involved in hydrogen bonds, leading to ribbons of H-bonded rings parallel to 
the a axis. 
 
Figure 27. Molecular structure of 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)aniline (3). Atoms are drawn as 50% 
thermal ellipsoids. One hydrogen at N1’ is eclipsed. 
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Figure 27a. Packing diagram of compound 3. Hydrogen bonds are indicated as dashed lines. 
 
Following the second synthetic route, the 1,3-dipolar cycloaddition, with the purpose 
of increasing the yield of compound 3, we used p-toluenesulfonic acid (PTSA)-ZnCl2 as a 
catalyst for the synthesis of aniline 3 from amidoximes and organic nitriles.[133] Tert-butyl-
amidoxime and 4-aminobenzonitrile were mixed in DMF with catalytic amounts of PTSA-
ZnCl2. First, tert-butyl-amidoxime is activated by PTSA-ZnCl2. This results in the formation 
of a Lewis acid-ammonia complex as a leaving group forming the the nitrile oxide. The 1,2,4-
oxadiazole moiety is established by the 1,3-dipolar cycloaddition of nitrile oxide to the 4-
aminobenzonitrile. However, the Lewis acid might also be involved in the formation of the 
heterocycle via a Lewis acid catalyzed [3+2] cycloaddition reaction. Unfortunately, the yield 
for this reaction was only very low (<20%). 
 
III.2.2.2. Synthesis of 3-tert-butyl-5-(4-nitrophenyl)-1,2,4-oxadiazole (4) 
In order to obtain compound 3 via the 1,3-dipolar cycloaddition route we changed the 
protocol. We synthesized in situ the nitro derivative 3 (3-tert-butyl-5-(4-nitrophenyl)-1,2,4-
oxadiazole) using the same catalyst pair as described above. The hydrogenation of the nitro 
compound 4 to the corresponding amine 3 was conducted in the same reaction vessel without 
isolation of the intermediate. The overall yield in this case was 64%. Intermediate 4 was also 
isolated in one case for its full characterisation. After a series of test reactions using various 
acids as catalyst (p-toluensulfonic acid-PTSA, 2-mesitylenesulfonic acid-MSA and 
methanesulfonic acid-MeSA) in combination with ZnCl2 and ZnBr2, MSA-ZnBr2 in 
acetonitrile proved to be the best combination to achieve a facile preparation of compound 4 
from tert-butyl-amidoxime and 4-nitrobenzonitrile under mild conditions. The results of the 
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screening process are summarized in Table 1. The optimized yield was 93% which makes this 
route far more practical than the amidoxime route presented in Scheme 9 for which the yield 
was just 59%. 
Table 3. Optimal conditions for the 1,3 dipolar cycloaddition route.a) 
Entry Catalyst 1 Catalyst 2 Solvent Time (h) Yield % 
1 PTSA ZnCl2 DMF 5 64 
2 MSA ZnCl2 DMF 3 76 
3 MeSA ZnCl2 DMF 12 56 
4 PTSA ZnBr2 DMF 5 70 
5 MSA ZnBr2 DMF 3 79 
6 MeSA ZnBr2 DMF 12 58 
7 PTSA ZnCl2 MeCN 2 82 
8 MSA ZnCl2 MeCN 2 92 
9 MeSA ZnCl2 MeCN 12 63 
10 PTSA ZnBr2 MeCN 2 86 
11 MSA ZnBr2 MeCN 2 93 
12 MeSA ZnBr2 MeCN 12 65 
a) General conditions: tert-butylamidoxime (1 eq), 4-nitrobenzonitrile (1 eq), catalyst 1 (0.3 eq), catalyst 2 (0.3 eq), 80ºC. 
 
 
Scheme 9. One-pot synthesis of 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)aniline (3) using the 1,3 dipolar 
cycloaddition of amidoxime to the nitrile oxide route. 
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The molecular structure of compound 4 was confirmed by X-ray structure 
determination (Figs. 28 and 28a). The interplanar angle in compound 4 is only 3(16)°and the 
molecules are linked to ribbons parallel to the b axis by two C–HO interactions. 
 
Figure 28. Molecular structure of 3-tert-butyl-5-(4-nitrophenyl)-1,2,4-oxadiazole (4). Atoms are drawn as 50% 
thermal ellipsoids. 
 
 
Figure 28a. Packing diagram of compound 4 showing C–HO interactions. 
 
III.2.3. One step synthesis of 1,2,4-oxadiazoles bearing heteroatoms. 
III.2.3.1. Synthesis of 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)benzonitrile (5) 
As a precursor for several 1,2,4-oxadiazol derivatives, 4-(3-(tert-butyl)-1,2,4-
oxadiazol-5-yl)benzonitrile (5) was generated from commercially available 4-cyanobenzoic 
acid and tert-butyl-amidoxime (Scheme 10). Activation of the 4-cyanobenzoic acid with CDI 
(1,1'-carbonyldiimidazole) and further acylation of the tert-butyl-amidoxime in DMF as 
solvent furnished the O-acylamidoxime, which was not isolated. On heating to 120°C for 
several hours, it underwent cyclisation with the elimination of one molecule of water, 
delivering the nitrile 5 in 76% yield after purification.  
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Scheme 10. One pot synthesis of 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)benzonitrile (5) using the amidoxime 
route; i. 1,1 eq. CDI in DMF, 30 minutes; ii. 1,1 eq. CDI in DMF, 120°C, 4h. 
 
Compound 5 was fully characterized. The 1H NMR data in CDCl3 reveal the aromatic 
protons at 8.25 and 7.80 ppm along with nine protons of the t-butyl group at 1.43 ppm as a 
sharp singlet. The MS data include the molecular peak m/z = 227.1 (M+) and two main 
characteristic defragmentation fragments (M+ - 15, M+ - 97). The solid-state structure of 5 was 
established by X-ray diffraction analysis (Figure 29). 
 
Figure 29. Molecular structure of 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)- benzonitrile (5). Atoms are drawn as 
50% thermal ellipsoids. Selected bond lengths [Å] and angles [°]: C1-N1 1.3074(17), C1-N2 1.3871(15), N1-O1 
1.4163(14), C5-O 1.3437(15), C5-N2 1.3013(17), C12-N3 1.1438(18), C9-C12-N3 179.16(14). 
 
Slow evaporation in open atmosphere of a concentrated solution of 5 in DCM gave colorless 
crystals suitable for single X-ray diffraction measurement. The molecule crystallizes with 
imposed mirror symmetry in the monoclinic space group P21/m, whereby only the methyl 
group at C4 and two hydrogens of the methyl group at C3 lie outside the mirror plane. 
 
III.2.3.2. Synthesis of 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenol (6) 
The reaction of 4-hydroxybenzoic acid with (Z)-N'-hydroxypivalimidamide under the 
general condition presented for the cyclisation formed 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-
yl)phenol (6) as a colorless solid in moderate yield (64%). 
 
Scheme 11. Synthesis of 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenol (6). 
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The 1H NMR specrum recorded in DMSO-d6 features one broad resonance 
corresponding at 10.45 ppm which belongs to the OH group, the resonances in the aromatic 
region integrated to 4 protons and the t-butyl signal appears at 1.33 ppm. The m/z shows the 
M+= 218.2 and two main fragments (M+-15 and M+-97) characteristic for these molecules 
(Figure 30). 
 
Figure 30. Fragmentation pattern of 3-(tert-butyl)-1,2,4-oxadiazol compounds. 
 
III.2.3.3. Synthesis of 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)benzaldehyde (7) 
The synthesis of 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)benzaldehyde (7) is shown in 
scheme 12. The acid of choice in this case was 4-formylbenzoic acid. Compound 7 was 
characterized by NMR spectroscopy and MS analysis (230.1 M+). The aldehyde proton, 
present at 10.11 ppm in the 1H NMR, along with of the C-carbonyl at 191,28 ppm in the 13C 
NMR spectroscopy clearly proves the structure of the new compound. Crystals suitable for X-
ray diffraction analysis were obtained by slow evaporation from a concentrated solution of 7 
in DCM. 
 
Scheme 12. Synthesis of 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)benzaldehyde (7). 
 
The solid-state molecular structure of 7 was established by X-ray diffraction analysis 
and shown in Figure 31. The compound crystallizes in the monoclinic space group P21/m with 
two molecules in the unit cell. The planar molecule present a C12-O2 double bond 
(1.2039(14) Å), with the angle C9-C12-O2 of 124.87(11)°. In the five-membered ring, the 
bond lengths C1-N1 is 1.3099(14) Å, considerably shorter than the C1-N2 bond 1.3847(12) Å 
and therefore consistent with a C1-N1 double bond. 
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Figure 31. Molecular structure of 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)benzaldehyde (7). Atoms are drawn as 
50% thermal ellipsoids. Selected bond lengths [Å] and angles [°]: C1-N1 1.3099(14), C1-N2 1.3847(12), N1-O1 
1.4217(11), C5-O1 1.3455(12), C5-N2 1.3006(13), C12-O2 1.2039(14), C9-C12-O2 124.87(11). 
 
III.2.3.4. Synthesis of 1-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)ethan-1-one (8) 
Starting from commercially available 4-acetylbenzoic acid we produced in very good 
yield pure 1-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)ethan-1-one as a colorless solid 
(Scheme 13). The MS analytics shows the M+ signal at m/z = 244.1 followed by two main 
fragments that correspond to the loose of a methyl group (M+ - 15) and the t-butyl group with 
the opening of the oxadiazole ring (M+ - 97). 
 
Scheme 13. Synthesis of 1-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)ethan-1-one (8). 
 
The 1H NMR spectrum shows the expected number of signals: The multiplets at 8.25 and 8.10 
ppm belong to the four aromatic protons, the resonances at 2.67 and 1.35 ppm correspond to 
the the methyl and t-butyl groups, respectively. The solid-state molecular structure of 8 was 
established by X-ray diffraction analysis and shown in Figure 32. 
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Figure 32. Molecular structure of 1-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)ethan-1-one (8). Atoms are 
drawn as 50% thermal ellipsoids. Selected bond lengths [Å] and angles [°]: C1-N1 1.3061(15), C1-N2 
1.3819(14), N1-O1 1.4193(12), C6-O1 1.3418(14), C6-N2 1.2993(14), C13-O2 1.2172(14), C10-C13-O2 
120.92(10). 
 
The compound 8 crystallizes in the triclinic space group P-1 with two molecules in the 
unit cell. This planar molecule features a C13-O2 double bond (1.2172(14) Å), with the angle 
C10-C13-O2 of 120.92(10)°. In the five-membered ring, the C1-N1 bond is 1.3061(15) Å, 
shorter than the C1-N2 bond 1.3819(15) Å. 
 
III.2.3.5. Synthesis of 3-(tert-butyl)-5-(4-(1-methoxyethyl)phenyl)-1,2,4-oxadiazole (9) 
3-(tert-Butyl)-5-(4-(1-methoxyethyl)phenyl)-1,2,4-oxadiazole (9) was obtained in very 
good yield starting from 4-(1-methoxyethyl)benzoic acid using the same reaction sequence as 
described in the general (Scheme 14). 
 
Scheme 14. Synthesis of 3-(tert-butyl)-5-(4-(1-methoxyethyl)phenyl)-1,2,4-oxadiazole (9). 
 
The spectral data are also in agreement with the proposed molecular structure. The 
m/z shows the molecular peak at M+ = 260.2 and some specific fragments e.g. M-CH3 and M-
(t-Bu). The 1H NMR spectrum of 9 recorded in CDCl3 features the specific aromatic signals 
along with a multiplet at 4.29 ppm attributed to the CH, two singlets (3.17 ppm, 1.38 ppm) for 
the methyl groups and the specific t-Bu singlet at 1.35 ppm. 
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III.2.4. One step synthesis of 1,2,4-oxadiazoles bearing unsaturated rests 
III.2.4.1. Synthesis of 3-(tert-butyl)-5-(4-ethynylphenyl)-1,2,4-oxadiazole (10) 
 
Scheme 15. Synthesis of 3-(tert-butyl)-5-(4-ethynylphenyl)-1,2,4-oxadiazole (10). 
 
Because of the fact that 4-ethynylbenzoic acid was used on a multi-gram scale and it is 
expensive, it was therefore necessary to synthetize it.[134] A modified synthetic route was 
developed that is much cheaper and more convenient than previously described methods and 
furnishes essentially quantitative yields. I took advantage of the sensitivity of the ester linkage 
toward potassium or sodium hydroxide to cleave the 2-hydroxypropyl group and saponify the 
ester simultaneously in l-butanol or 2-propanol to prepare 4-ethynylbenzoic acid in high yield. 
Methyl p-bromobenzoate (MBB) was mixed with a small excess of 2-methyl-3-butyn-2-ol in 
a deoxygenated, dried triethylamine/pyridine mixture (volume ratio 5/2) in the presence of 
catalytic amounts of dichloro-bis(triphenylphosphine)palladium, triphenylphosphine, and 
cuprous iodide, and the solution was refluxed; the sodium or potassium salt of ethynylbenzoic 
acid precipitated quantitatively from the reaction mixture. Crystalline ethynylbenzoic acid 
changes color upon standing from colorless to off-white and then to light tan, which suggested 
that it is not very stable at room temperature and light (it polymerizes slowly). In contrast its 
sodium and potassium salts are stable. 
Scheme 16. Synthetic route for 4-ethynylbenzoic acid; i. MeOH, H2SO4; ii. HOC(CH3)2CCH, PdCl2(PPh3)2, 
Et3N; iii. NaOH, BuOH, HCl. 
 
The 1H NMR spectrum of 10 recorded in CDCl3 reveals two typical 1,4-substituted 
aromatic signals and two singlets, one at 3.26 ppm correlated to the alkyne proton and the 
other one at 1.43 ppm corresponding to t-Bu group. Also the 13C NMR spectrum shows 
clearly the typical alkyne signals at 82.69 ppm (Cq) and 80.25 ppm (CH). 
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III.2.4.2. Synthesis of 3-tert-butyl-5-(4-vinylphenyl)-1,2,4-oxadiazole (11) 
    The general procedure is reliable for most of the benzoic acid derivatives, but in some cases 
the nature of the substituents on the phenolic ring renders synthetic transformations more 
challenging. In some cases the substituent results in side reactions that disturb the cyclisation 
step or dramatically diminish the isolated yields. In other cases the benzoic acid derivative is 
either not commercially available or it is too expensive. Therefore starting from an already in 
4-position substituted produced 1,2,4-oxadiazoles, new molecules were designed, isolated and 
characterized. 
The first example is the 3-tert-butyl-5-(4-vinylphenyl)-1,2,4-oxadiazole (11) that 
cannot be obtained from the corresponding 4-vinylbenzoic acid using the general synthetic 
route outlined above. In this case the cyclisation takes place, but a polymeric mixture of the 
1,2,4-oxadiazole compound is formed (Scheme 17). 
 
Scheme 17. Synthetic routes for the synthesis of and 3-tert-butyl-5-(4-vinylphenyl)-1,2,4-oxadiazole (11). 
 
For this reason I had to develop other methods to prepare compound 11. Two 
alternative, synthetic routes using as intermediates 3-tert-butyl-5-(4-ethynylphenyl)-1,2,4-
oxadiazole (10) and 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)benzaldehyde (7) are shown in 
scheme 17. For one of these routes the selective hydrogenation of (10) using Lindlar catalyst 
was considered, but the disadvantage of this method was that in the final step a mixture of 11 
and 3-tert-butyl-5-(4-ethylphenyl)-1,2,4-oxadiazole (12) was obtained. For the second 
synthetic path, the 4-formylbenzoic acid used as precursor is commercially available, but the 
yields for the transformation are low. Both methods were tested in parallel. 
After isolation of 3-tert-butyl-5-(4-ethynylphenyl)-1,2,4-oxadiazole (10) the next step 
was the hydrogenation in the presence of the Lindlar catalyst. Performing the reaction at low 
Results and discussion. 1,2,4-Oxadiazole containing ligands 
33 
temperature (-10°C) and with a short reaction time (30 min) in THF as solvent the desired 
vinyl oxadiazole could be obtained as the major product. 
The second route to afford 3-tert-butyl-5-(4-vinylphenyl)-1,2,4-oxadiazole (11) started 
from the 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)-benzaldehyde (7), which was converted a 
Witting reaction.[135] 
 
Scheme 18. Synthesis of 3-tert-butyl-5-(4-vinylphenyl)-1,2,4-oxadiazole (11) starting from 7. 
 
The reaction of methyltriphenyl-phosphonium bromide with DBU (1,8-diazabicyclo[ 
5.4.0]undec-7-ene) as a base in refluxing tetrahydrofuran or toluene afforded 
methylenetriphenylphosphorane, which further reacted with benzaldehydes to give the styrene 
derivative in good yield. Several amine bases (triethylamine, pyridine, DBN and DBU) were 
screened for the synthesis of 3-tert-butyl-5-(4-vinylphenyl)-1,2,4-oxadiazole (11) starting 
from with methyltriphenylphosphonium bromide and 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)-
benzaldehyde (7). However, only DBU provided the product 11 in high yield and purity. 
 
III.2.4.3. Synthesis of 3-tert-butyl-5-(4-ethylphenyl)-1,2,4-oxadiazole (12) 
The hydrogenation process of 3-tert-butyl-5-(4-ethynylphenyl)-1,2,4-oxadiazole in the 
presence of the Lindlar catalyst is unfortunately not very selective. The vinyl group is also 
hydrogenated to an ethyl group. Higher temperatures and prolonged reaction time only result 
in increasing quantities of the ethyl derivate. After 2h at room temperature complete 
hydrogenation to the 3-tert-butyl-5-(4-ethylphenyl)-1,2,4-oxadiazole (12) was achieved and 
every attempt to avoid the formation of 12 failed. Furthermore separation of 12 from the vinyl 
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derivative 11 cannot be achieved because of very similar polarities of these compounds. After 
0.5 h at -10°C the starting alkyne was still present in the reaction mixture (Scheme 19). 
 
Scheme 19. Hydrogenation of 3-tert-butyl-5-(4-ethynylphenyl)-1,2,4-oxadiazole. i: H2, Lindlar catalyst, THF, -
10º C, 30 min, 90% (11) / 10% (11); ii: H2, Lindlar catalyst, THF, r.t., 100 % (12). 
 
III.2.4.4. Synthesis and structural characterization of alkynyl bromides derivates 
III.2.4.4.1. Synthesis of 3-tert-butyl-5-(4-ethylphenyl)-1,2,4-oxadiazole (13) 
As shown in Scheme 20, 5-(4-(bromoethynyl)phenyl)-3-(tert-butyl)-1,2,4-oxadiazole 
(13) was synthesized from the 3-(tert-butyl)-5-(4-ethynylphenyl)-1,2,4-oxadiazole (10) at low 
temperature (0°C) and N-bromosuccinimide (NBS) as bromine source. 
 
Scheme 20. Synthesis of 5-(4-(bromoethynyl)phenyl)-3-(tert-butyl)-1,2,4-oxadiazole (13) starting from 10. 
 
Even if the mono-bromide derivative is preferentially formed, the formation of the 
more brominated derivatives (14 and 15) was unavoidable. The best yield obtained for the 
mono brominated compound was 63%. In the 1H NMR spectrum of 13 recorded in CDCl3, the 
signal at 3.26 ppm which belongs to the alkyne proton is absent and the masse m/z = 304/306 
clearly shows the characteristic isotopic distribution due to the presence of bromine. The 
mono-brominated by-product (E)-3-(tert-butyl)-5-(4-(1,2-dibromovinyl)phenyl)-1,2,4-
oxadiazole (14) is detected in the 1H NMR spectrum at 7.23 ppm corresponding to the vinylic 
CH-proton. Mass spectrometry clearly shows the presence of two brome atoms in the 
molecule (m/z = 384/386). The 3-(tert-butyl)-5-(4-(1,2,2-tribromovinyl)phenyl)-1,2,4-
oxadiazole (15) give rise to a simple 1H NMR spectrum, four aromatic and nine t-butyl 
protons and the mass of m/z = 464/466. Crystals suitable for X-ray diffraction analysis for 
compound 13 were obtained by slow diffusion of hexane into a concentrated solution of 13 in 
DCM. 
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Figure 33. Molecular structure of 5-(4-(bromoethynyl)phenyl)-3-(tert-butyl)-1,2,4-oxadiazole (13). Atoms are 
drawn as 50% thermal ellipsoids. Selected bond lengths [Å] and angles [°]: C1-N1 1.3031(16), C1-N2 
1.3939(16), N1-O 1.4150(12), C6-O 1.3438(14), C6-N2 1.3030(15), C14-Br 1.8099(13), C13-C14-Br 177.1(6). 
 
The solid-state molecular structure of 13 was established by X-ray diffraction analysis 
and shown in Figure 33. The compound crystallizes in the orthorhombic space group Pna21. 
The planar molecule features a C14-Br bond length of 1.8099(13) Å and a C13-C14-Br angle 
of 177.1(6)°. 
 
III.2.5. Synthesis of second generation 1,2,4-oxadiazoles 
III.2.5.1. Synthesis of 1,2,4-oxadiazole derivatives bearing amidine and tioamide 
functional groups 
III.2.5.1.1. Background 
In pharmaceutical chemistry, amidoximes, amidine and thioamides are important 
precursors for the synthesis of several heterocycles, such as oxadiazole, imidazole and 
thiazole, all of which are known to be bioactive scaffolds.  
 
Figure 34. Structural representation of amidoxime, amidine, thioamide and the correspondent heterocycles. 
 
In addition, thioamides derivatives show antitumor activity,[136] for example 6-
mercaptopurine, marketed as Purinethol, is used in the treatment of lymphocytic leukemia. 
 
Figure 35. Structural representation of 6-mercaptopurine. 
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III.2.5.1.2. Synthesis of (Z)-4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)-N' hydroxy-benzimid-
amide (16) 
Many synthetic routes have been reported in the literature for the synthesis of 
amidoximes,[137-140] but one of the more common methods represents the addition of 
hydroxylamine to a nitrile (Scheme 21). 
 
Scheme 21. Synthesis of (Z)-4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)-N'-hydroxybenzimidamide (16). 
 
The amidoxime (Z)-4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)-N'-hydroxybenzimidamide 
(16) was prepared by treatment of 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)benzonitrile with 
hydroxylamine in the presence of K2CO3 in refluxing iso-propanol. Although other bases 
(K3PO4, NaOMe, NaOH) and solvents (ethanol, methanol) were used, the best yields were 
obtained with isopropyl alcohol as the appropriate solvent, which ensured homogeneity of the 
reaction mixture during the reaction (64% yield). The compound shows in the 1H NMR 
spectrum four protons in the aromatic region, two broad signals at 4.9 ppm and 1.62 ppm 
integrating for two and one protons of the amino and hydroxyl groups, respectively, and the 
1.44 ppm signal attributed to the nine protons of the t-butyl group. The MS shows m/z = 
260.1 (M+).III.2.5.1.3. Synthesis of (Z)-4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)-N' hydroxy-benzimid-
amide (17) 
Amidine derivatives are usually prepared from nitriles using one of the several 
reported pathways, such as the Pinner method,[141] transformation via a thioimidate [142] or by 
alkylchloroaluminium amides reaction. 
 
 
Scheme 22. Synthesis of (Z)-4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)-N' hydroxy-benzimidamide (17). 
 
More elegantly, Anbazhagan et al. generated amidine compounds by reduction of 
amidoximes.[143] They have explored several hydrogen transfer reagent such as ammonium 
formate which circumvents hydrogen gas for the conversion of amidoximes to amidines. 
Definitely, ammonium formate in the presence of Pd/C system reduces amidoximes, 
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providing the corresponding amidines in good yield (69%). 4-(3-(tert-Butyl)-1,2,4-oxadiazol-
5-yl)benzimidamide (17) was obtained starting from (Z)-4-(3-(tert-butyl)-1,2,4-oxadiazol-5-
yl)-N'-hydroxybenzimidamide (16) using the above described method. The 1H NMR spectrum 
indicates four protons in the aromatic zone, one broad signal accounting for three protons of 
the amidine group at 4.95-5.45 ppm and the 1.44 ppm signal attributed to the nine protons of 
the t-butyl group. The MS-ESI spectrum gives a mass of 245.13 (M+H+). 
 
III.2.5.1.4. Synthesis of 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)benzothioamide (18) 
 
Scheme 23. Synthesis of 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)benzothioamide (18). 
 
The straightforward reaction of 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)benzonitrile (5) with 
sodium hydrogen sulfide and magnesium chloride in dimethylformamide (DMF) generated 
the new 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)benzothioamide (18) in excellent yield 
(92%).[144] 
 
 
Figure 36. Molecular structure of 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)benzothioamide (18). Atoms are drawn 
as 50% thermal ellipsoids. Selected bond lengths [Å] and angles [°]: C10-C13 1.496(2), N3-C13 1.322(19), C13-
S 1.675(15), C10-C13-N3 115.53(13)°, N3-C13-S 122.92(12)°, C10-C13-S 121.54(11)°. 
 
The solid-state molecular structure of 18 was established by X-ray diffraction analysis 
and shown in Figure 36. The compound 18 crystallizes in the triclinic space group P-1 with 
one molecule in the asymmetric unit. All bond distances and angles are within the expected 
range. 
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III.2.5.2. Synthesis of 1,2,4-oxadiazole derivatives bearing hydroxylamine moieties 
III.2.5.2.1. Background 
Various phenoxyamine derivatives proved to be biologically active and consequently 
employed as herbicides and antiproliferative agents.[145-148] 
Figure 37: Examples of phenoxyamines which exhibit biological activity. 
 
N-arylhydroxylamines are also considered important precursors and intermediates for 
several other research branches such as polymerization inhibitors,[149,150] reagents [151-155] and 
bioactive pharmaceuticals.[156,157] 
III.2.5.2.2. Synthesis of O-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)hydroxylamine 
(20) 
Phenoxyamines have been obtained by reacting the fluorobenzenes and ethyl 
acetohydroxamate (Zinner’s method)[158,159] or from t-butyl-N-hydroxycarbamate (Carpino’s 
method)[160] with a base followed by hydrolysis with an acid. A number of substituted 
phenoxyamine derivatives have been synthesized by these methods. However, this reaction is 
limited to phenoxyamine derivatives bearing strong electron-withdrawing substituents in 
ortho- and/or para-position such as 2- or 4-nitrophenoxy-, 2,4- or 2,6-dinitrophenoxy- and 
2,4,6-trinitrophenoxy-amines.[161] 
 
Scheme 24. Synthesis of O-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)hydroxylamine (20). 
 
Since the method developed by Zinner is reproducible and ethylacetohydroxamate is 
commercially available, we investigated the synthesis of O-(4-(3-(tert-butyl)-1,2,4-oxadiazol-
5-yl)phenyl)hydroxylamine (20) starting from 3-(tert-butyl)-5-(4-fluorophenyl)-1,2,4-
oxadiazole (2). The first reaction step is the substitution of 3-(tert-butyl)-5-(4-fluorophenyl)-
1,2,4-oxadiazole by the potassium salt of ethylacetohydroxamate in DMF. The intermediate 
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ethyl (E)-N-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenoxy)acetimidate (19) was isolated in a 
good yield (68%). 
 
Figure 38. Molecular structure of ethyl (E)-N-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenoxy)acetimidate (19). 
Atoms are drawn as 50% thermal ellipsoids. Selected bond lengths [Å] and angles [°]: C10-O2 1.371(12), O2-
N3 1.440(11), N3-C13 1.279(13), C13-C14 1.489(15), C10-O2-N3 111.69(7)°, O2-N3-C13 108.06(8)°, N3-C13-
C14 113.18(9)°. 
 
The solid-state molecular structure of 19 was established by X-ray diffraction analysis 
and is shown in Figure 38. The compound 19 crystallizes by slow evaporation of diethyl ether 
in the triclinic space group P-1 with one molecule in the asymmetric unit. The short value of 
the N3-C13 bond (1.279 Å) definitely is consistent with a double bond. 
In the second step, the acetimidate derivative 19 was reacted with aqueous HClO4 
(70%) in dioxane at room temperature to afford O-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-
yl)phenyl)hydroxylamine (20) in moderate yield (51%). The 1H NMR spectrum shows the 
disappearence of the acetamidate group (CH3 as a singlet at 2.14 ppm and the CH2-CH3 from 
4.25 ppm and 1.37 ppm) and the formation of a brought signal attributed to the NH2 group at 
6.11-5.82 ppm. The mass spectra also changed from 303.1 (M+), mass of the intermediate, to 
233.1 (M+) the mass of the hydroxylamine derivative. 
 
Figure 39. Molecular structure of ethyl O-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)hydroxylamine (20). 
Atoms are drawn as 50% thermal ellipsoids. Selected bond lengths [Å] and angles [°]: O2-C10 1.371(15), O2-
N3 1.457(14), C10-O2-N3 113.09(10). 
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The solid-state structure of 20 was established by X-ray diffraction analysis and is 
depicted in Figure 39. The compound 20 crystallizes from a concentrated DCM solution at 
room temperature in the orthorhombic space group P212121 with one molecule in the 
asymmetric unit. The molecule is almost planar with the length bonds and angles in the 
expected range. 
 
III.2.5.2.3. Synthesis N-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)hydroxylamine (21) 
A possible synthetic pathway of N-arylhydroxylamines starts from nitroarenes. This 
process can lead to nitrosoarenes, azoarenes, azoxyarenes, hydroxylamines or amines. In 
order to selectively reduce this unit several reducing agents were screened.[162] One of the 
most successful reagents represents the mixture between sodium borohydride and metal salts, 
such as NaBH4/CoCl2,
[163] NaBH4/Cu(OAc)2,
[164] NaBH4/Sb,
[165] NaBH4/NiCI2,
[166] 
NaBH4/BiCl3.
[167] 
 
Scheme 25. Synthesis of N-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)hydroxylamine (21). 
 
In order to generate N-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)hydroxylamine 
(21) we treated the already prepared 3-(tert-butyl)-5-(4-nitrophenyl)-1,2,4-oxadiazole (4) with 
the BiCl3/KBH4 mixture at room temperature in ethanol/water (Scheme 25). The 
hydroxylamine derivative was isolated in good yields (76%) and the spectral data confirmed 
the proposed molecular structure. The mass recorded is 233.1 (M+) and the 1H NMR spectrum 
shows the OH proton at 6.49 ppm. The NH proton was detected along with other two 
aromatic protons at 7.14-6.96 ppm. 
 
III.2.5.3. Synthesis of 1,2,4-oxadiazole derivatives bearing secondary amine units 
III.2.5.3.1. Background 
The synthesis of new compounds containing secondary amines functionalities, 
important intermediates in pharmaceutical and fine chemicals development [168] is an attractive 
area in modern organic and medicinal chemistry synthesis. The reductive amination, in which 
a carbonyl unit is transformed into a tertiary amine, represents one of the most frequently used 
synthetic routes for the production of amines in the pharmaceutical industry. 
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Scheme 26. The reductive amination of an aldehyde with a secondary amine. 
 
Having this motivation in mind, it was planed the synthesis of two secondary amines 
derivatives from 1,2,4-oxadiazole, a long chained (1-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-
yl)phenyl)-N-methylmethanamine) and a short chain derivative (4-(3-(tert-butyl)-1,2,4-
oxadiazol-5-yl)-N-methylaniline) as illustrated in Figure 40. 
 
Figure 40. 1,2,4-Oxadiazole targets functionalized with secondary amine. 
 
 
III.2.5.3.2. Synthesis of 1-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)-N-
methylmethanamine (23) 
The starting sequence for this compound involves also the preparation of 4-(((tert-
butoxycarbonyl)(methyl)amino)methyl)benzoic acid, an exotic and quite expensive chemical 
compound. Starting from 4-(chloromethyl)benzoic acid and tert-butyl methylcarbamate, the 
wanted precursor was obtained without any problems.[169] 
 
Scheme 27. Synthetic path of 1-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)-N-methylmethanamine (23). 
 
With the benzoic acid precursor in hand, 1-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-
yl)phenyl)-N-methylmethanamine (23) was synthesed in two steps. The first step was the 
cyclisation between the acid and the amidoxime in order to build the oxadiazole ring. The 
reaction worked well and at the end the tert-butyl (4-(3-(tert-butyl)-1,2,4-oxadiazol-5-
yl)benzyl)(methyl)carbamate (22) was isolated in an 86% yield. The second step was the 
classical elimination of the Boc group in the presence of HCl. The MS-EI shows m/z = 245.2 
(M+). The 1H NMR reveals the presence of the aromatic protons, the -CH2 at 3.84 ppm, the -
CH3 at 2.47 ppm and just one t-butyl group at 1.43 ppm (verifying that the Boc group was 
indeed cleaved). 
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III.2.5.3.3. Attempt for synthesis of 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)-N-
methylaniline 
The reaction sequence is presented in Scheme 28. 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-
yl)aniline (3) was reacted with Boc-anhydride in basic conditions (NaOH) in order to 
deprotonate the molecule and to activate the anhydride. tert-Butyl-(4-(3-(tert-butyl)-1,2,4-
oxadiazol-5-yl)phenyl)carbamate (24) was obtained in very good yield and purity. 
 
Scheme 28. Synthetic path to 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)-N-methylaniline. 
 
The second step was the introduction of the methyl function followed by the 
elimination of the Boc group under acid conditions, but somehow the introduction of the 
methyl group failed. The deprotonation with NaH and addition of MeI resulted in a dark 
solution from which the desired compound could be isolated. The reaction was repeated twice 
with the same outcomet. However, the intermediate tert-butyl-(4-(3-(tert-butyl)-1,2,4-
oxadiazol-5-yl)phenyl)carbamate (24) was characterized and tested for antitumor activity for 
comparison with 1-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)-N-methylmethanamine 
(23). 
The MS-ESI shows 318.2 (M + H+), 340.2 (M + Na+) and 657.4 (2xM + Na+). The 1H 
NMR spectrum shows the disappearance of one proton from the –NH2 group (the signal is 
shifted and the integration now accounts for one proton) and another singlet appears at 1.41 
ppm for the Boc group. 
 
Figure 41. Molecular structure of tert-butyl-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)carbamate (24). 
Atoms are drawn as 50% thermal ellipsoids. 
 
The solid-state structure of 24 was established by X-ray diffraction analysis and 
shown in Figure 41. The compound 24 crystallizes from a saturated chloroform solution in the 
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monoclinic space group P21/c with one molecule in the asymmetric unit. The molecule 
presents the tert-butyl group out of the plan of the molecule. The length bonds and angles are 
unexceptional. 
 
III.2.6. In vitro anti-tumor activity of second generation 1,2,4-oxadiazole 
Compounds 13, 17, 18, 20, 21, 23 and 24 were tested for in vitro anti-tumor activity 
against a panel of 12 cell lines was assessed using a monolayer cell survival and proliferation 
assay. As presented in Figure 42, the seven tested 1,2,4-oxadiazole compounds revealed not 
an impressive antitumoral activity against the panel of 12 cell lines. Clearly, the strongest 
activity from these seven candidates belongs to the alkynyl-bromide 1,2,4-oxadiazole 
derivative 13. With a geometric mean IC50 value of 33.95 µM (Figure 42) this compound 
proved to be a moderate antitumor agent. The amidine 17 and thioamide 18 with mean IC50 
value of 63.13 µM (17) and 57.16 µM (18), respectively, display a weak anti-tumor activity 
against the 12 cell lines tested. The remaining substances have only marginal or no anti-tumor 
activity.  
 
Figure 42. In vitro anti-tumor activity of compounds 13, 17, 18, 20, 21, 23 and 24 towards 12 human tumor cell 
lines. 
 
Figure 43 (Heatmap presentation of individual IC50 values) illustrates the tumor 
selectivity of the seven compounds investigated. It can be easily observed that 13, although it 
has a moderate mean IC50, it shows good selectivity against RXF 486 (renal tumor cell) and 
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MAXF 401 (mammary tumor cell) lines. Another compound that reveals moderate selectivity 
against the PRXF 22Rv1 (prostate tumor cell) line is the amidine 17. Unfortunately, the 
remaining molecules exhibit no tumor selectivity. 
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Figure 43. Heatmap presentation of individual IC50 values for compounds 13, 17, 18, 20, 21, 23 and 24 in a 
panel of 12 human tumor cell lines. 
 
III.3. 1,2,4-Oxadiazole compounds bearing cyclic and heterocyclic 
substituents 
III.3.1. Synthesis of 1,2,4-oxadiazole derivatives bearing N-phenyl-
maleimide or N-phenyl-succinimide functionalities 
III.3.1.1. Background  
The maleimide motif is a five-menbered heterocycle with various applications in 
pharmacological chemistry. Kratz et al. synthesized maleimide derivatives of Doxorubicin 
and Camptothecin. After intravenous administration these designed anticancer drugs bind 
rapidly to circulating albumin.[170-172] Endogenous albumin could be seen as a drug carrier and 
according to the pathophysiology of tumor tissue it accumulates in solid tumors.[173,174] 
Therefore, designed prodrugs have a higher antitumor efficacy in vivo than the free drugs. 
Furthermore, maleimides possess strong antifungal activities against important human 
opportunistic pathogenic fungi. These antifungal drugs appear to be excellent candidates for 
further development.[175,176] Barrett et al. pointed out that the possibility of performing 
chemical modifications is a requirement to develop novel drugs and a strong activity is just 
the starting point.[177] 
Another moiety worth investigating is succinimide, because N-phenylsuccinimides are 
regarded as one of the most efficacious agricultural fungicides.[178,179] They have also been 
shown to be selective nephrotoxic compounds.[180] 
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Taking into consideration the biological activity of natural products containing the 
1,2,4-oxadiazol moiety, such as phidianidines A and B (selective inhibitors of DAT), it was 
worthy synthesizing, isolating and characterizing novel natural product analogues of 1,2,4-
oxadiazole derivatives that carry N-phenyl-maleimide or N-phenyl-succinimide functionalities 
in order to improve the biological activity. The new derivatives have been tested for their in 
vitro anti-tumor activity towards a panel of 11 cell lines. 
 
III.3.1.2. Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)pyrrolidine-2,5-dione 
(26) 
A variety of methods have been reported for the preparation of this class of compound. 
Their preparation essemtially follows a two-step protocol. First it is necessary to synthesize 
the amide derivative 25. This step was performed under inert conditions by mixing an 
equimolar amount of aniline 3 and succinic anhydride in a minimum volume of 
dichloromethane (Scheme 29). Compound 25 was obtained after a short reaction time and in 
high yield (91%). The methy ester derivative, 4-(4-(3-tert-butyl-1,2,4-oxadiazol-5-
yl)phenylamino)-4 oxobutanoate (27), was prepared by addition of a diethyl ether solution of 
diazomethane to a suspension of amide 25. For the synthesis of imide 26 the starting material, 
amide 25, was mixed with an equimolar amount of sodium acetate in acetic anhydride and the 
mixture was heated for 4 h at 80-85ºC; resulting in the corresponding N-aryl-succinimide 13 
in very good yield (87%). 
 
Scheme 29. Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)pyrrolidine-2,5-dione (26). 
 
The structures of compounds 26 and 27 were also confirmed by X-ray structure 
analysis (Figs. 44-45). In compound 26 the oxazole and phenyl rings are approximately 
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coplanar (6(12)°), but the pyrrolidine ring is rotated by 52(14)° with respect to the phenyl 
ring. 
 
Figure 44. Molecular structure of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)pyrrolidine-2,5-dione (26). 
Atoms are drawn as 50% thermal ellipsoids. 
 
The main packing interaction is an offset stacking parallel to the c axis (not shown). 
Compound 27 has an interplanar angle of 14(3)°; the molecules are associated into ribbons 
parallel to [110] by one long N–HN and two shorter C–HO interactions. 
 
 
Figure 45. Molecular structure of 4-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenylamino)-4 oxobutanoate (27). 
Atoms are drawn as 50% thermal ellipsoids. 
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Figure 45a. Packing diagram of compound (27). Dashed lines indicate hydrogen bonds. 
 
III.3.1.3. Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-1H-pyrrole-2,5-
dione (29) 
The synthesis of amide 28 was performed by mixing an equimolar amount of aniline 8 
and maleic anhydride in dichloromethane (Scheme 30). The amide 28 was obtained with a 
good yield (84%). For the synthesis of imide 29 the amide 28 was mixed with an equimolar 
amount of sodium acetate in acetic anhydride and the mixture was heated for 4 h at 80-85ºC. 
 
Scheme 30. Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-1H-pyrrole-2,5-dione (29). 
The structure of compound 28 was also confirmed by X-ray structure analysis (Figs. 46, 46a). 
In compound 28 the interplanar angle is 11°; the intramolecular hydrogen bond is almost 
symmetrical (O4 – H04 1.03(3), H04O2 1.47(3) Å). The molecules are linked to form layers 
perpendicular to the hexagonal c axis by one C–HO and one three-centre (N–H, C–H) O 
interaction. The Z-configuration of the double bond is unequivocally. 
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Figure 46. Molecular structure of (Z)-4-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenylamino)-4-oxobut-2-enoic 
acid (28). Atoms are drawn as 50% thermal ellipsoids. 
 
 
Figure 46a. Packing diagram of compound 28. Dashed lines indicate hydrogen bonds. 
 
Results and discussion. 1,2,4-Oxadiazole containing ligands 
49 
III.3.1.4. In vitro anti-tumor activity towards human tumor cell lines of N-phenyl-
maleimide or N-phenyl-succinimide derivatives and intermediates. 
In vitro anti-tumor activity of synthesized compounds 3, 25-29 towards a panel of 11 
cell lines was assessed using a monolayer cell survival and proliferation assay. Derivative 29 
was with a mean IC50 value of 9.4 µM the most potent compound. In contrast compounds 3, 
27, 26, 28 and 25 exhibit only marginal anti-tumor activity towards the 11 cell lines 
investigated (Figure 47). 
 
 
Figure 47. In vitro anti-tumor activity of compounds 3, 25-29 towards 11 human tumor cell lines. 
 
Activity screening of different compounds in a cell line panel with various tumor 
histo-types enable us to analyse their protency and tumor selectivity. Promissing candidates 
can then be taken to further be developed. The tumor selectivity of the compounds is 
illustrated in Figure 48, representing a heat-map presentation of the individual IC50 values. 
Overall, good antitumor potency (mean IC50 < 30µM) combined with good selectivity (range 
of activity > 8 or at least 2 above-average sensitive cell lines) was found for 29. 
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Figure 48. Individual IC50 values [µM] of compounds 3, 25-29 in a panel of 11 human tumor cell lines. 
 
III.3.2. Synthesis of 1,2,4-oxadiazole derivatives bearing imidazole moiety 
III.3.2.1. Background 
The five-membered heterocyclic imidazole moiety can be found in a wide range of 
natural products.[181-183] Its bioactivity has made it a popular substructure in various synthetic 
products such as fungicides and herbicides,[184,185] plant growth regulators[186] and curative 
drug compounds.[187,188] In green chemistry and organometallic chemistry  imidazoles have 
found applications as ionic liquids[189-192] and imidazole-related N-heterocyclic carbenes.[193-
197] Although aromatic substituted imidazoles are important precursors for ionic liquids and 
N-heterocyclic carbenes, only a limited number of synthetic protocols are known.[198,199] 
Many of the employed protocols are either too expensive for large scale production or furnish 
only very low yields. 
III.3.2.2. Synthesis of 5-(4-(1H-imidazol-1-yl)phenyl)-3-(tert-butyl)-1,2,4-oxadiazole (30) 
During the synthetisof 3-(tert-butyl)-5-(4-fluorophenyl)-1,2,4-oxadiazole (2) it was 
noted that a by-product precipitated during work-up and the side product was identified as 5-
(4-(1H-imidazol-1-yl)phenyl)-3-(tert-butyl)-1,2,4-oxadiazole (30). 
 
Scheme 31. Synthesis of 5-(4-(1H-imidazol-1-yl)phenyl)-3-(tert-butyl)-1,2,4-oxadiazole via the F-derivative 2. 
Results and discussion. 1,2,4-Oxadiazole containing ligands 
51 
Its formation is rationalized in Scheme 31. Activation of the 4-fluorobenzoic with 
carbonyldiimidazole (CDI) generates imidazole which reacts with 2to give 5-(4-(1H-
imidazol-1-yl)phenyl)-3-(tert-butyl)-1,2,4-oxadiazole (30). Unfortunately, this synthesis is not 
very reproducible with yields varying from 8 to 50%. 
Grindev et al. prepared a series of imidazoles by a simple procedure in which aqueous 
solution of glyoxal, formaldehyde and ammonium salts of amines were heated to 95°C.[198] 
Following this method, it was possible to form the desired imidazoles with an aromatic 
substituent in 1-position relatively low yield (14%).  
Gardiner modified the procedure by adding ammonium chloride and by using dioxane 
in the solvent mixture.[199] However, in my case similar yields as obtained by Gridnev’s 
method were observed. Furthermore, increasing the reaction time and raising the temperature 
did also not improve the reaction outcome. Finally the conditions described by Liu et al. were 
explored.[200] This group developed a two-step protocol for the synthesis of sterically hindered 
imidazoles with acceptable yields. 
 
Scheme 32. Preparation of 1-arylimidazoles according to Liu et al.. 
 
The reaction is usually performed in methanol; however, other alcohols (ethanol and 
n-butanol) could also be used. Using this modified recipe, the 5-(4-(1H-imidazol-1-
yl)phenyl)-3-(tert-butyl)-1,2,4-oxadiazole (30) was obtained in 48% yield after the 
purification by flash chromatography (Scheme 33). 
 
 
Scheme 33. Synthesis of 5-(4-(1H-imidazol-1-yl)phenyl)-3-(tert-butyl)-1,2,4-oxadiazole (30). 
 
The 1H NMR spectrum (CDCl3) displays the typical resonances corresponding to the 
imidazole moitey at 7.97 (1 H) ppm, 7.40 (1 H) ppm and 7.27 (1 H) ppm. The mass spectra 
show m/z = 268.1 (M+), the loss of a methyl group (M-15). In the 13C NMR spectrum the 
specific signals of the imidazole unit are found at 135.96 ppm, 131.81 ppm and 118.29 ppm. 
Results and discussion. 1,2,4-Oxadiazole containing ligands 
52 
III.3.2.3. Synthesis of 5-(4-((1H-imidazol-1-yl)methyl)phenyl)-3-(tert-butyl)-1,2,4-
oxadiazole (31) 
The benzylic imidazole 5-(4-((1H-imidazol-1-yl)methyl)phenyl)-3-(tert-butyl)-1,2,4-
oxadiazole was synthesized starting from the 1,2,4-oxadiazole-nitrile compound 5. In a first 
step the benzylic amine ((4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)methanamine) was 
generated by reducing the nitrile functionality[201] and then, using the same procedure as for 
the phenyl type, the new benzyl imidazole derivative (31) was isolated (Scheme 34). 
 
Scheme 34. Synthesis of 5-(4-((1H-imidazol-1-yl)methyl)phenyl)-3-(tert-butyl)-1,2,4-oxadiazole (31). 
 
The final yield after purification was low (30%). One of the reasons for the lower 
yield could be that the amine precursor was not pure enough. Despite several attempts only a 
purity of 75% was achieved. The spectral data shows in the 1H NMR spectrum the aromatic 
protons (two at 8.10 ppm and two at 7.26 ppm), the imidazole signals at 7.58, 7.14 and 6.92 
ppm (each for one proton), two singlet attributed to the methylene bridge at 5.21 (two 
protons) and at 1.43 ppm for the nine protons of the t-butyl group. The mass spectra has the 
molecular peak M+ = 282.2. Crystals suitable for X-ray diffraction analysis were obtained by 
slow evaporation of a methanolic solution of 31. 
 
Figure 49. Molecular structure of 5-(4-((1H-imidazol-1-yl)methyl)phenyl)-3-(tert-butyl)-1,2,4-oxadiazole (31). 
Atoms are drawn as 50% thermal ellipsoids. Selected bond lengths [Å] and angles [°]: O1-C6 1.356(3), O1-N2 
1.422(2), N1-C6 1.297(3), N1-C1 1.392(3), N2-C1 1.304(3), N3-C14 1.341(3), N3-C16 1.369(3), N3-C13 
1.466(3), N4-C14 1.321(3), N4-C15 1.377(3), C10-C13-N3 111.50(19). 
 
The solid-state structure of 31 was established by X-ray diffraction analysis and 
shown in Figure 49 and selected bond distances and angles are listed in the figure caption. 
The compound crystallizes in the triclinic space group P-1 with two molecules in the 
asymmetric unit, which differ in the relative orientation of the rings. 
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III.3.3. Synthesis of 1,2,4-oxadiazole derivatives bearing 2-oxazoline moiety 
 
Figure 50. 1,2,4-Oxadiazoles bearing 2-oxazoline moiety as target molecules. 
 
III.3.3.1. Background 
Another substituent that was inserted into the 1,2,4-oxadiazole-containing molecules is 
the 2-oxazoline system, which is a five-membered heterocycle with significant applications in 
the synthesis of organic compounds[202] and in the field of drug discovery and 
development.[203,204] These bioactive molecules are usually generated by heating N-acyl 
derivatives of β-hydroxylamines, or by reacting them with thionyl chloride, sulfuric acid, or 
phosphorus pentoxide.[205] They can also be prepared by condensation of carboxylic acids 
with β-hydroxylamines at high temperatures under strongly acidic conditions.[204] Other 
synthetic protocols include the use of imino-ether hydrochlorides, nitriles and isocyanides.[205] 
Vorbrüggen et al.[204] reported a one-pot synthesis starting from readily available carboxylic 
acids using Ph3P/CCl4 as an activating agent. Finally, carboxylate esters can be directly 
transformed into 2-oxazolines using lanthanum chloride as catalyst.[206] 
This class of heterocyclic compounds has received much attention, since many 
compounds carrying a 2-oxazoline motif have biological activity (Figure 51).  
 
Figure 51. Biologically active compounds containing the 2-oxazoline moiety. 
 
2-Indolyloxazolines are potential candidates as oral anticancer agents because of their 
potent inhibition of tubulin polymerization.[207] Another example is D-fluviabactin, which, in 
Results and discussion. 1,2,4-Oxadiazole containing ligands 
54 
a model of iron overload in chronically transfused thalassemia patients, has been shown to 
efficiently sequester and remove iron from animals.[208] Deflazacor (commercially available as 
Dezacor, Flantadin and Lantadin) is a corticosteroid derivative used as an inflammatory 
agent.[209] L-161, 240 has been reported as a strong antibacterial agent, with a minimal 
inhibitory concentration comparable to those of other clinically relevant antibiotics, such as 
Ampicillin or Rifampicin.[210] In addition, 2-oxazolines have also been described as potential 
prodrug precursors of carboxylic acids.[211] 
 
III.3.3.2. Synthesis of 3-(tert-butyl)-5-(4-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)phenyl)-
1,2,4-oxadiazole (35) 
Starting from 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)benzonitrile 5 it was planned to 
generate 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)benzoic acid (32). The acid derivative is one of 
the intermediates in the synthesis of the main target product, 3-(tert-butyl)-5-(4-(4,4-
dimethyl-4,5-dihydrooxazol-2-yl)phenyl)-1,2,4-oxadiazole (35). Scheme 35 shows the 
general approach for the synthesis of 35. 
 
 
Scheme 35. General synthetic route for 3-(tert-butyl)-5-(4-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)phenyl)-1,2,4-
oxadiazole (35). 
 
The hydrolysis of nitriles is one of the main synthetic routes for building amides and 
carboxylic acids.[212] Because of the limited reactivity of nitriles, their transformation in most 
cases requires harsh reaction conditions, such as strongly acidic[213] or basic,[214] generating as 
intermediate the corresponding amide, which in most cases is hydrolyzed (Scheme 36). 
 
Scheme 36. Hydrolysis of 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)benzonitrile in basic conditions. 
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From the carboxylic acid 32, the methyl ester derivative, methyl 4-(3-(tert-butyl)-
1,2,4-oxadiazol-5-yl)benzoate (33), was generated rapidly and quantitatively by reaction with 
diazomethane (1 N in diethyl ether). The solid-state structure of 33 was established by X-ray 
diffraction analysis and is shown in Figure 52. Similarly to 5, 33 crystallized in the 
monoclinic space group P21/m with imposed mirror symmetry, although the ester group is 
slightly disordered to both sides of the mirror plane. 
 
Figure 52. Molecular structure of methyl 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)benzoate (33). Only one position 
of the disordered ester group is shown. Atoms are drawn as 50% thermal ellipsoids. Selected bond lengths [Å] : 
N1-C1 1.309(2), N2-C1 1.389(2), O1-N1 1.428(2), O1-C5 1.346(2), N2-C5 1.299(2), O(2)-C(12) 1.207(2), O3-
C12 1.346(3), O3-C13 1.452(3). 
 
In order to introduce the oxazoline motif into the 1,2,4-oxadiazol system, we first had 
to generate the amide intermediate 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)-N-(1-hydroxy-2-
methylpropan-2-yl)benzamide (34) from the acid 32 (Scheme 37). The acyl chloride 
derivative was generated in situ by reacting the acid with SOCl2 at room temperature and used 
further (without purification, as a solution in DCM) in the highly exothermic reaction with 2-
amino-2-methyl-1-propanol at low temperature. Control of the temperature is crucial because 
at temperatures above 0°C several byproducts are generated and the purification is more 
difficult. 
Scheme 37. Synthesis of the amido derivative 34 via the acyl chloride route. 
 
The amide 34 was cyclized to the corresponding oxazoline 35 by the dropwise 
addition of thionyl chloride at 0 °C. After treatment with aqueous NaOH and extraction with 
diethyl ether, the oxazoline 35 was isolated as a colorless solid in good yield (86%). The 
solid-state structure of 35 was established by X-ray diffraction analysis (Figure 53). The 
compound crystallizes without imposed symmetry in the monoclinic space group P21/c. The 
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ring systems display typical bond lengths and angles. The oxadiazole and the central ring are 
essentially parallel (interplanar angle 1(15)°), whereas the oxazole ring is rotated by 11.5(13)° 
with respect to the central ring. This rotation is sufficiently small that the molecule still 
displays approximate mirror symmetry (r.m.s. deviation 0.2 Å). 
 
 
Figure 53. Molecular structure of 3-(tert-butyl)-5-(4-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)phenyl)-1,2,4-
oxadiazole (35). Atoms are drawn as 50% thermal ellipsoids. Selected bond lengths [Å]: N1-C1 1.3039(14), N2-
C1 1.3876(12), O1-N1 1.4194(11), O1-C6 1.3453(12), N2-C6 1.2982(13), O2-C13 1.3621(12), O2-C14 
1.4498(12), N3-C13 1.2680(14), N3-C15 1.4834(12). 
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III.3.3.3. Attempt for the synthesis of 3-(tert-butyl)-5-(4-((4,4-dimethyl-4,5-
dihydrooxazol-2-yl)methyl)phenyl)-1,2,4-oxadiazole 
In our attempt to synthesize 3-(tert-butyl)-5-(4-((4,4-dimethyl-4,5-dihydrooxazol-2-
yl)methyl)phenyl)-1,2,4-oxadiazole, a longer chain oxazoline derivative, we failed to generate 
the amide intermediate (Scheme 38). In a first step the cyanide compound 2-(4-(3-(tert-butyl)-
1,2,4-oxadiazol-5-yl)phenyl)acetonitrile 36 was prepared from 4-(cyanomethyl)benzoic acid. 
The reaction followed the general synthetic protocol but the yield and purity for 36 were 
dramatically lower. All attempts to purify the compound failed and I was forced to use it 
despite 40% impurities. 
Scheme 38. Proposed synthetic route for 3-(tert-butyl)-5-(4-((4,4-dimethyl-4,5-dihydrooxazol-2-yl)methyl)-
phenyl)-1,2,4-oxadiazole. 
 
It was possible to synthesize and isolate the acid derivative 2-(4-(3-(tert-butyl)-1,2,4-
oxadiazol-5-yl)phenyl)acetic acid 37 using the same saponification method as for compound 
32. The solid-state structure of 37 was established by X-ray diffraction analysis and shown in 
Figure 54. The compound crystallizes in the orthorhombic space group Pbcn without imposed 
symmetry. Molecules are connected by the well-known carboxylic acid dimer motif across 
inversion centers. 
 
Figure 54. Molecular structure of ethyl 2-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)acetic acid (37). Atoms 
are drawn as 50% thermal ellipsoids. Selected bond lengths [Å] : N1-C1 1.3840(14), N2-C1 1.3038(13), O1-N2 
1.4256(11), O1-C6 1.3520(12), N1-C6 1.3002(13), O2-C14 1.2159(13), O3-C14 1.3195(13). 
 
The formation of the amide derivative in the next step was not successful. The reaction 
was repeated 3 times with minor modifications of the protocol (lower temperature, shorter 
time), but all attempts failed. The reaction mixture changed color from colorless to black and 
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no signs of the amide derivative were detected. Other synthetic routes are currently still under 
investigation. 
 
III.3.3.4. In vitro anti-tumor activity towards human tumor cell lines of 1,2,4-oxadiazole 
bearing oxazoline and imidazole moieties. 
In vitro anti-tumor activity of three compounds was assessed using a monolayer cell 
survival and proliferation assay in a panel of 11 cell lines, comprising colon, gastric, lung, 
ovarian, pancreatic, prostate, renal and uterus cancer, as well as melanoma. Concentration-
dependent activity was detected for compound 35 across all cell lines tested. By exhibiting a 
geometric mean IC50 value of 17. µM (Figure 55), IC50 values for the individual cell lines 
were in the range from 11.9 µM (UXF 1138, uterus cancer) and 24.2 µM (MEXF 462, 
melanoma). Overall, good potency was found for the oxazoline derivative 35 towards all cell 
lines investigated. The other two imidazole derivatives 30 and 31, with a mean IC50 value of 
43.9 µM and 54.9 µM respectively, have only moderate anti-tumor activity towards the 12 
cell lines tested. 
 
Figure 55. In vitro anti-tumor activity of compounds 30, 31 and 35 towards 11 human tumor cell lines. 
 
In Figure 56 the tumor selectivity of compounds 30, 31 and 35 is illustrated. Although 
the oxazoline compound has good activity, it shows no selectivity. Nevertheless, the two 
imidazole derivatives 30 and 31 have just moderate activity, but they show some promising 
selectivity. Compound 30 is selective towards MAFX 401 cell line (mammary tumor cell), 
whereas its analogue 31 with a longer chain proved to have good selectivity against UXF 
1138 cell line (uterus tumor cell). 
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Figure 56. Individual IC50 values [µM] of compounds 30, 31 and 35 in a panel of 11 human tumor cell lines. 
 
III.3.4. Synthesis of 1,2,4-oxadiazole derivatives bearing pyrazol-
pyrimidines moiety 
Figure 57. Target 1,2,4-oxadiazoles bearing pyrazol-pyrimidine moiety. 
 
III.3.4.1. Background 
Pyrazol-pyrimidines and related fused heterocycles are bioactive and act as central 
nervous system depressants,[215] narcoleptic agents,[216] anti-tuberculosis agents,[217] adenosine 
receptors[218] and as powerful antitumor agents.[219-221] Along with indolocarbazoles and 2-
indolinone derivatives, these heterocycles act as inhibitors for RET (REarranged during 
Transfection).[222-225] Alternatively pyrazole-pyrimidine-based compounds can also be used as 
scaffolds in the inhibition of the PFPK7 kinase of Plasmodium falciparum.[226] Additionally, 
the pyrazole-pyrimidine derivative A is a good inhibitor of many tyrosine kinases (TKs) in 
cancer treatment,[227] whereas compound B is a promising candidate as an RET protein kinase 
inhibitor.[228] Medley et al. demonstrated that C is strong covalent inhibitor of interleukin-2 
inducible T cell kinase (Itk) (Fig. 58).[229] 
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Figure 58. Examples of bioactive pyrazol-pyrimidines derivatives. 
 
The plan was to attach the pharmacologically active 1,2,4-oxadiazole-substituted phenyl to 
the pyrazole moiety of pyrazole-pyrimidines.[230] 
In previous work it was reported the synthesis of 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-
yl)aniline (3) as a precursor to several natural product analogues, which were tested in vitro 
for antitumor activity toward a panel of 11 cell lines using a monolayer cell survival and 
proliferation assay.[231,232] 
 
Scheme 39. One pot synthesis of 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)aniline (3) using the amidoxime route: i. 
1,1 eq. CDI in DMF, 30 minutes; ii. 1,1 eq. CDI in DMF, 120°C, 4h. 
 
III.3.4.2. Attempt for the synthesis of 1-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)-6-
methyl-3-(methylthio)-1,5-dihydro-4H-pyrazolo-[3,4-d]pyrimidin-4-one (40*) 
Using the amine 3 as starting points, the idea was to construct pyrazole-pyrimidine 
derivatives bearing 1,2,4-oxadiazole unit to increase their antitumor activity. One of the first 
synthetic targets was 1-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)-6-methyl-3-
(methylthio)-1,5-dihydro-4H-pyrazolo-[3,4-d]pyrimidin-4-one (40*). The first step was the 
transformation of amine 3 to the corresponding hydrazine derivative 3-(tert-butyl)-5-(4-
hydrazinylphenyl)-1,2,4-oxadiazole (38) using known procedures  (Scheme 40).[233,234] 
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Scheme 40. Synthetic route to compounds 38, 39 and 40. Reagents and conditions: i. NaNO2, H2SO4, SnCl2, 
HCl, 0 °C; ii. MeOH, reflux; iii. Ac2O, AcOH, reflux. 
 
After the successful isolation of the hydrazine derivative, the next step was the 
reaction with 2-(bis(methylthio)methylene)malononitrile under reflux in methanol in order to 
generate 5-amino-1-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)-3-(methylthio)-1H-
pyrazole-4-carboni-trile (39). The structure of 39 was confirmed by an X-ray structure 
determination (Figs. 59 and 59a). It crystallizes in the monoclinic space group C2/c. Bond 
lengths and angles are unexceptional, as is the case for all other structures reported here. The 
central ring subtends an interplanar angle of 19(3)° to the oxadiazole ring and 28(2)° (in the 
same direction) to the pyrazole ring (for which all substituents also lie in the ring plane). The 
hydrogens of the NH2 group are involved in classical hydrogen bonds H02N13 (short and 
linear) and H01N2 (longer and rather angled, probably attributable to the steric hindrance of 
the central ring), leading to ribbons of H-bonded rings parallel to [112]. 
 
Figure 59. Molecular structure of 5-amino-1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(methylthio)-1H-
pyrazole-4-carbonitrile (39). Atoms are drawn as 50% thermal ellipsoids. 
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Figure 59a. Packing diagram of compound 39. Hydrogen bonds are indicated as dashed lines. 
 
The final step was the cyclisation of the pyrazole derivative 32 in the presence of 
Ac2O and AcOH at reflux using reported procedures.
[235] However, the cyclisation to the 
desired product (40*) failed. The reaction was repeated twice, and in each case, the product 
was N-(1-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)-4-cyano-3-(methylthio)-1H-pyrazol-
5-yl)-acetamide (40). Derivatives 40 and 40* can easily be confused, since they have the same 
exact mass and give rise to similar NMR signals. However, I succeeded in growing crystals 
from the isolated product, and in our case, the final product is indeed 40. With this result in 
hand, I decided to abandon this route of building novel pyrazole-pyrimidines and to pursue 
other synthetic strategies. 
The solid-state structure of 40 was established by X-ray diffraction analysis and is 
shown in Figure 60. Compound 40 crystallizes in the monoclinic space group P21/n. The three 
rings adopt a similar arrangement as in 39, with the central ring subtending an angle of 20(2)° 
to the oxadiazole and 23(3)° to the pyrazole ring (so that the five-membered rings are almost 
mutually parallel). The molecules are linked to form chains parallel to the a axis by the 
classical hydrogen bond H01O2; the amide group is thus both donor and acceptor (Fig. 60a). 
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Figure 60. Molecular structure of N-(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl) phenyl)-4-cyano-3-(methylthio)-
1H-pyrazol-5-yl)acetamide (40). Atoms are drawn as 50% thermal ellipsoids. 
 
 
Figure 60a. Packing diagram of compound 40. Hydrogen bonds are indicated as dashed lines. 
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III.3.4.3. Synthesis of the key intermediate 5-amino-3-((4-(3-(tert-butyl)-1,2,4-oxadiazol-
5-yl)phenyl)amino)-1H-pyrazole-4-carbonitrile (43) 
The key intermediate 37 was accessed using a previously described general method for 
generating pyrazole derivatives (Scheme 41).[236,237] 
 
Scheme 41. Synthesis of the 5-amino-4-cyano-1H-pyrazole key intermediate 43. Reagents and conditions: i. 
Na2CO3, Thiophosgene, H2O/dichloro-methane, 0 °C – r.t.; ii. Malononitrile, CH3I, DMF, NaH, 0 °C – r.t. – 
55ºC; iii. Hydrazine, MeOH, reflux. 
 
Starting from the available amine derivatives 3, the corresponding isothiocyanates 41 
(3-(tert-butyl)-5-(4-isothiocyanatophenyl)-1,2,4-oxadiazole) was formed in excellent yields 
(96%) and good purity. The structure of 41 was also confirmed by X-ray structure analysis 
(space group P21/n; Figs. 61, 61a); the two rings along with the isothiocyanate group are co-
planar (mean deviation 0.02 Å). The thiocyanate group displays bond lengths N11-C17 and 
C17-S1 of 1.1720(17) Å and 1.5752(13) Å, respectively, and it is also aprroximately linear, 
with angles C17-N11-C14 162.74(14)° and N11-C17-S1 175.98(12)°. In the absence of 
classical H bond donors, the molecules are linked by the "weak" interactions H13O1, N2 
(three-centre) and H16S to form ribbons parallel to [101]. 
 
Figure 61. Molecular structure of 3-tert-butyl-5-(4-isothiocyanatophenyl)-1,2,4-oxadiazole (41). Atoms are 
drawn as 50% thermal ellipsoids. 
Results and discussion. 1,2,4-Oxadiazole containing ligands 
65 
 
Figure 61a. Packing diagram of compound 41. Hydrogen bonds are indicated as dashed lines. 
 
Further treatment of 41 with malononitrile, in the presence of NaH and CH3I, afforded 
2-(((4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl) amino)-(methylthio)methylene)-
malononitrile (42). The molecular structure of 42 was also established by X-ray 
crystallography. In compound 42 (Figs. 62, 62a), the oxadiazole and the phenyl ring are 
approximately co-planar. The molecule crystallized in space group P1  with two molecules in 
the asymmetric unit, which differ slightly in the relative orientation of the rings; a least-
squares fit gave an r.m.s. deviation of 0.10 Å (excluding t-butyl groups). The NH hydrogens 
are involved in hydrogen bonds H01N12' and H01'N12, thereby connecting the molecules 
by translation to form chains parallel to the y axis. 
 
Figure 62. Molecular structure of 2-((4-(3-tert-butyl-1,2,4-oxadiazol-5-yl) phenylamino)-
(methylthio)methylene) malononitrile (42). Only one of the two independent molecules is shown, with only one 
position of the disordered t-butyl group. Atoms are drawn as 50% thermal ellipsoids. 
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Figure 62a. Packing diagram of compound 42. Hydrogen bonds are indicated as dashed lines. 
 
Cyclisation of 42 with hydrazine monohydrate in refluxing methanol gave the 
pyrazoles 43 in excellent yields (93%). The solid-state structure of 43 was established by X-
ray diffraction analysis (Fig. 63). The compound crystallizes as a methanol solvate in the 
space group P21/n. The central ring subtends angles of 19(18)° and 16(2)° to the oxadiazole 
and pyrazole rings respectively. Within the asymmetric unit, the methanol forms a hydrogen 
bond O–HN12. There are four further hydrogen bond donors (NH groups) in the molecule 
of 43, and these are all involved in hydrogen bonding; the net result is to link the molecules to 
form highly corrugated sheets perpendicular to the b axis (Fig. 63a). 
 
Figure 63. Molecular structure of 5-amino-3-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenylamino)-1H-pyrazole-4-
carbonitrile (43) as its methanol solvate. Atoms are drawn as 50% thermal ellipsoids. The dashed line indicates a 
hydrogen bond. 
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Figure 63a. Packing diagram of compound 43. Hydrogen bonds are indicated as dashed lines. 
 
III.3.4.4. Synthesis of N3-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)-6-phenyl-1H-
pyrazolo[3,4-d]pyrimidine-3,4-diamine (47) and other pyrazolo[3,4-d]pyrimidine 
derivatives 
 
After the generation of the pyrazol intermediate, the synthesis of several novel 
pyrazolo[3,4-d]pyrimidines bearing a 1,2,4-oxadiazole unit was readily achieved (Scheme 
42).
 
Scheme 42. Synthesis of pyrazolo[3,4-d]pyrimidine derivatives. Reagents and conditions: i. HCOOH, reflux 2 h; 
ii. CS2, pyridine, reflux 24 h; iii. HCONH2, reflux 5 h; iv. Benzamidine, NaOAc, Naphthalene, 230°C 1 h. 
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3-((4-(3-(tert-Butyl)-1,2,4-oxadiazol-5-yl)phenyl)amino)-1,5-dihydro-4H-pyrazolo-
[3,4-d]pyrimidin-4-one (44) was obtained in moderate yield (63%) by refluxing compound 43 
in formic acid for several hours. When the formic acid was replaced by CS2 in dry pyridine, 3-
((4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)amino)-1,7-dihydro-4H-pyrazolo[3,4-d] pyri-
midine-4,6-(5H)-dithione (45) was isolated, but only in low yield (16%). When formamide 
was employed as an alternative cyclisation reagent, the pyrazol derivative 43 was converted 
after heating at reflux for 5 h to N3-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)-1H-
pyrazolo[3,4-d]pyrimidine-3,4-diamine (46).  
In order to construct a more bulky derivative bearing one aromatic ring directly 
connected to the pyrazol-pyrimidine core, it was used benzamidine hydrochloride as a 
cyclization reagent. However, high temperatures are required in order to achieve ring closure. 
All the attempts at generating N3-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)-6-phenyl-
1H-pyrazolo[3,4-d]pyrimidine-3,4-diamine (47) using the usual organic solvents with high 
boiling points (120-150°C) produced only trace amounts of the desired product. To increase 
the reaction temperature, I tried to perform this reaction without solvents at 200°C. 
Unfortunately, decomposition occurred within 5 min (the mixture turned black) and 
the desired products were only isolatedin very low yield. This problem was solved by using 
naphthalene as the solvent; after 30 min at 220°C, the desired compounds were isolated. 
The solid-state structure of 47 was determined by X-ray analysis (Figs. 64 and 64a). It 
crystallizes with three independent molecules and five DMSO in the asymmetric unit. The 
molecules of 47 are very approximately planar (except for the t-butyl groups), but the rings 
are mutually rotated in a manner that differs significantly in the three molecules (e.g. in 
molecule 2, the ring C31-C36 is much more strongly rotated with respect to the other rings). 
The packing is at first sight complex, but the overall scheme is clear; two complete formula 
units form an aggregate with overall inversion symmetry. In the centre of the aggregate, two 
molecules 3 are connected by hydrogen bonds N1"–H01"N7". Molecule 3 is connected to 
molecule 2 via DMSO 4, with the hydrogen bonds N8"–H04"O4 and N8'–H04'O4. 
Molecule 2 is connected to molecule 1 by the hydrogen bonds N1'–H01'N7 and N1–
H01N7'. Finally, the remaining DMSO molecules are hydrogen bonded at the periphery of 
the aggregate (DMSO 2 rather weakly, with N8–H04O2 2.57 Å). 
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Figure 64. Molecular structure of N3-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl) phenyl)-6-phenyl-1H-pyrazolo[3,4-
d]pyrimidine-3,4-diamine (47); one of three independent molecules (solvent omitted) Atoms are drawn as 50% 
thermal ellipsoids. 
 
 
Figure 64a. Packing diagram of compound 47. Hydrogen bonds are indicated as dashed lines. 
 
III.3.4.5. In vitro anti-tumor activity towards human tumor cell lines of 1,2,4-oxadiazole 
derivatives bearing pyrazol-pyrimidines moiety and intermediates. 
The in vitro anti-tumor activity of the compounds 39, 43-47 was assessed in a panel of 
12 human tumor cell lines by using monolayer cell survival and proliferation assays. As 
shown in Figure 65, good potency with a mean IC50 value of 5.66 µM was detected for 
compound 47. Furthermore, at a lower level, anticancer activity was established for 43, 46, 
44, 39 and 45 with mean IC50 values in the range from 31.3 µM to 57.1 µM.  
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Figure 65. In vitro anti-tumor activity of compounds 39, 43-47 in a panel of 12 human tumor cell lines (mean 
IC50 values). 
 
Figure 66 shows the individual IC50 values as a heatmap presentation. The most active 
compound, 47, displayed individual IC50 values in the range from 2.76 µM (OVXF 899) to 
9.27 µM (PXF 1752). However, these compounds showed no pronounced selectivity for any 
of the tested cell lines. 
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Figure 66. Heatmap presentation of individual IC50 values of eight compounds (39, 43-47) in a panel of 12 
human tumor cell lines. 
 
For a deeper exploration of tumor selectivity, compound 47 was tested in a panel of 42 
cell lines covering 15 different tumor histotypes. Across this broad panel, a mean IC50 value 
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of 5.858 µM was detected, with pronounced activity towards the renal cancer cell line RXF 
393 (IC50 = 1.143 µM). In addition, the cell lines HT-29 (colon), MEXF 1341 (melanoma) 
and OVXF 899 (ovary) showed above-average sensitivity. 
 
Figure 67. IC50 mean graph presentation for compound 47 in a panel of 42 human tumor cell lines. 
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IV. Results and discussion. N-Heterocyclic Carbenes (NHC) 
derivatives containing 1,2,4-oxadiazole motif 
IV.1. General Introduction 
The starting point of N-heterocyclic carbenes (NHC) chemistry and the related 
transition metal complexes began in 1968, when Öfele[238] reported the first transition metal 
NHC complex by deprotonating an imidazolium salt with a metal hydride (Scheme 43). 
 
Scheme 43. Pioneer transition metal NHC complex reported by Öfele. 
 
At the same time, as a result of parallel work, Wanzlick and Schönherr[239] published 
independently another metal NHC complex obtained by treating the imidazolium salt with the 
acetate salt of the metal (Scheme 44). 
 
Scheme 44. Pioneer transition metal NHC complex reported by Wanzlick. 
 
Several years later, in 1975, the first functionalized NHC metal complexes reported by 
Clarke and Taube[240] entered the field of biochemistry. They coordinated ruthenium to 
xanthine derivatives through the carbenic carbon of the imidazole. 
 
Figure 68. Xanthine NHC complexes of Ruthenium. 
 
The isolation of the first free stable carbene by Arduengo et al.[241] in 1991 represented 
a breakthrough in the chemistry of transition metal carbene complexes. In the next two and a 
half decades the chemistry of NHC compounds and their metal complexes,[242-246] along with 
catalysis application[247] flourished. Even if the NHC chemistry has flourished in the last 25 
years, their practical use has been limited by the instability of the free carbenes. Nevertheless, 
the imidazolium salt precursors can be handled with less difficulty and they represented the 
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ground for another significant step in the development of NHC chemistry. In 1998 Lin and 
Wang developed a reaction procedure in which the silver(I)-NHC complex was generated 
from the treatment of an imidazolium salt with Ag2O (Scheme 45).
[248] This silver(I)-NHC 
compound can then serve as a carbene transfer agent for transition metals.[249,250] 
 
Scheme 45. Silver(I) intermediate route reported by Lin and Wang. 
 
IV.2. Synthesis and structural characterization of imidazolium salts 
IV.2.1. General Aspects 
Imidazolium salts are imidazole derivatives in which the two nitrogen atoms of the 
heterocycle are alkylated. Furthermore they are biologically active, and particularly known for 
their antitumor properties.[251-254] However, at the same time their natural abundance is scarce. 
Figure 69 depitcs two natural compounds isolated from Lepidium meyenii, Lepidiline A and 
Lepidiline B, which manifest strong cytotoxicity against tumor cell lines.[255] 
 
Figure 69. Natural imidazolium salts derivatives. 
 
Besides the medicinal aspect, the imidazolium salts may also act as ionic liquids at 
ambient temperature [189,256] and as the main precursors for N-heterocyclic carbenes (NHCs) or 
bis-imidazolidines, which are known for their application in the synthesis of organic 
compounds.[257-259] 
 
IV.2.2. Synthetic aspects 
Numerous preparative protocols are described in the literature for the synthesis of 
imidazolium salts.[196] The three most frequently employed methods are represented in Figure 
70. One pathway involves the formation of a Schiff base intermediate as a coupling result 
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between the amine and glyoxal under acidic conditions (Path A). The diimine can be isolated 
or can be reacted further with formaldehyde generating the corresponding imidazolium 
salt.[260-262] This method has its limitations in the sense that just primary amines can be used as 
starting materials and only symmetrically substituted imidazolium salts can be produced. 
 
Figure 70. General representation for the synthesis of imidazolium salts. 
 
The other two routes for the synthesis of imidazolium salts (usually unsymmetrically) 
required the formation of an N-substituted imidazole derivative. This key intermediate can be 
generated using a one-pot reaction among glyoxal, ammonium chloride, paraformaldehyde 
and amine (Path B), or by alkylating the potassium imidazolide (Path C). After the N-
substituted imidazole is generated, another alkylation with an appropriate alkyl, acyl or benzyl 
reagent will provide the corresponding imidazolium salts.[263,264] 
 
IV.2.3. Motivation 
In previous work, it was described the synthesis of several natural product analogues 
starting from 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)aniline (3).[231] All derivatives were tested 
in vitro for antitumor activity towards a panel of 11 cell lines by using a monolayer cell 
survival and proliferation assay. 
 
Scheme 46. Reported 1,2,4-oxadiazole bearing maleimide moiety. 
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One of the compounds, 1-(4-(5-(tert-butyl)-1,2,4-oxadiazol-3-yl)phenyl)-1H-pyrrole-2,5-
dione (29) (Scheeme 46), showed good anti-tumor potency combined with good selectivity, 
with an IC50 mean value of 9.4 μM. Taking these results into consideration, it was envisioned 
to replace the maleimido group by an imidazole core. This exchange opens the road to the 
chemistry of 1,2,4-oxadiazole-containing NHC-metal complexes, which could lead to an 
improved antitumor activity in the target molecules. Starting from 5-(4-(1H-imidazol-1-
yl)phenyl)-3-(tert-butyl)-1,2,4-oxadiazole (8), the idea beyond was to generate the 
imidazolium salts that incorporate 1,2,4-oxadiazole unit, which would be interesting 
precursors for NHCs. The imidazolium salts can be created with particular hydrophobic 
substituents attached to the imidazole heterocycle. With these compounds containing the 4-(5-
(tert-butyl)-1,2,4-oxadiazol-3-yl)phenyl group in hand, I intended to synthesize 
organometallic complexes. 
 
IV.2.4. Synthesis of symmetrical imidazolium salts containing 1,2,4-
oxadiazoles. 
IV.2.4.1 Synthesis of 1,3-bis(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-imidazolium 
chloride (48) 
The symmetrical imidazolium chloride 48 was generated directly from the amine 3 
using literature-reported protocols [265,266] in a one-pot reaction as shown in Scheme 47. The 
practical work was straightforward. The primary amine 3 was refluxed in toluene along with 
aqueous glyoxal, paraformaldehyde and HCl. After removing the volatiles and several 
trituration procedures with acetone, the desired 1,2,4-oxadiazole-containing imidazolium 
chloride was obtained in satisfactory yield (55%). 
 
Scheme 47. Synthesis of (1,3-bis(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)imidazolium chloride (48) i. 
glyoxal, toluene; ii. paraformaldehyde, HCl, toluene, reflux. 
 
Attempts to isolate the Schiff base intermediate as pure compound for a proper chemical 
characterization were unsuccessfully, mainly caused decomposition during the purification 
procedure. The chemical structure of the final imidazolium salt was confirmed by 1H NMR 
spectroscopy and MS (HR-ESI) spectrometry. The characteristic signal for the N-CH-N 
proton was registered at 10.76 ppm. Due to the low solubility of the compound the 13C NMR 
Results and discussion. NHC derivatives containing 1,2,4-oxadiazole motif 
76 
spectra could not be measured. The HR-ESI also confirmed the charged mass signal of the 
molecule. 
IV.2.5. Synthesis of unsymmetrical imidazolium salts containing 1,2,4-
oxadiazoles. 
By constructing the unsymmetrical imidazolium salts, it could be systematically 
inserted besides the 1,2,4-oxadiazole unit another second substituent. As second substituents 
were chosen some commonly used units (methyl, benzyl) and a wide variety of other organic 
moieties that are known to be biologically active, i.e. anthracene, indol, 2-pyridine, 2,3,4,5-
tetra-O-acetyl-D-glucopyranose, quincorine (QCI) and quincoridine (QCD). These groups 
should influence the transport of the final agents to the target cells. 
The unsymmetrical imidazolium salts were synthesized following a two steps protocol 
starting from compound 3. In the first step, the N-substituted imidazole 30 was generated 
using classic literature-reported protocol reported by Liu et al. (Scheme 48).[200] He developed 
a two-step protocol for the synthesis of 1-arylimidazoles in good yields using different 
substituted aniline compounds. 
 
Scheme 48. Synthesis of 1-arylimidazoles reported by Liu et al.. 
 
First, a phenyl-imino-ketone intermediate was developed in-situ by reacting the amine 
with glyoxal derivatives in methanol at room temperature. Then, the imidazole ring was 
closed in the presence of H3PO4, NH4Cl and formaldehyde at reflux. Using this method, the 
1,2,4-oxadiazole amine xx was treated with glyoxal and then with formaldehyde, NH4Cl and 
H3PO4. The final imidazole substituted with 1,2,4-oxadiazole unit was obtained in acceptable 
yields (48-50%). 
 
Scheme 49. Synthesis of imidazole derivative starting from 4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)aniline (8); i. 
glyoxal, MeOH, rt; ii. NH4Cl, 37% aq. formaldehyde, H3PO4, MeOH, reflux. 
 
After having prepareda stock solution of 5-(4-(1H-imidazol-1-yl)phenyl)-3-tert-butyl-
1,2,4-oxadiazole nine imidazolium salts 49-57 with various counter ions (Cl-, Br-,I- or NO3
-) 
were generated were generated from the alkylation methodology (Scheme 50). 
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Scheme 50. General synthesis of 4-(3-(tert-butyl)-1,2,4-oxadiazol imidazolium salts; i. R-X (Cl, Br, I) toluene, 
reflux; ii. 2,3,4,5-tetra-O-acetyl-D-glucopyranosylbromide, AgNO3, CH3CN, 50°C; iii. CH2Br2, reflux. 
 
IV.2.5.1. Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-methyl-imidazo-
lium iodide (49) 
The synthesis of the 1,2,4-oxadiazole-containing imidazolium salts started with 1-(4-
(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-methyl-imidazolium iodide (49), the most 
straightforward from all imidazolium salts. The alkylation with MeI in THF was fast, clean 
and proceeded with excellent yield (98%). 
 
Scheme 51. Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-methyl-imidazolium iodide (49); i. 
MeI, THF, rt. 
 
The new compound was characterized by IR, 1H NMR, 13C NMR spectroscopy and 
MS (HR-ESI). The characteristic N-CH-N resonances were observed in the 1H and 13C NMR 
spectra at 9.98 and 137.4 ppm, respectively. The HR-ESI revealed, as expected, the charged 
masse signal of the molecule, without the iodine counterion. 
 
IV.2.5.2. Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(benzyl)-imidazo-
lium bromide (50) 
The next alkylating agent used in the synthesis of novel 1,2,4-oxadiazole-containing 
imidazolium salt was the inexpensive and commercially available benzyl bromide. 
 
Scheme 52. Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(benzyl)-imidazolium bromide (50). 
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This reaction proceeded as expected. The two reagents were mixed equimolar quantities in 
toluene under reflux and the solid obtained after precipitation with diethylether was properly 
characterized. In the 1H NMR spectrum, the NHC proton at 10.41 ppm and the two CH2-
bridge protons at 5.61 ppm, both display as singlets. The HR-ESI result is also in good 
correlation with the expected charged mass. 
 
IV.2.5.3. Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(2-pyridine)-
imidazolium bromide (51). 
Another alkylating agent used intensively in the design of imidazolium salts and their 
corresponding NHC carbenes is the 2-bromopyridine molecule.[267-269] Usually this unit is 
inserted in the NHC chemistry in order to obtain pincer type complexes with catalytic 
applications. 
 
Scheme 53. Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(2-pyridine)-imidazolium bromide 
(51). 
 
The imidazolium salt 51 was generated after reacting the 1,2,4-oxadiazole-imidazole 
with an excess of 2-bromopyridine for 48 hours at elevate temperature (160°C). The resulting 
salt containing the pyridine ring as second substituent was obtained in excellent yield and 
purity. The structure of the new compound correlates to the registered analytics. Besides the 
signals attributed to the phenyl, backbone imidazole and pyridine rings, the 1H NMR spectra 
shows clearly the C2 proton of the imidazolium ring at 10.88 ppm. 
Until this point all synthetic work related to the generation and isolation of the 
imidazolium salts (48-51) in good yields and purity turned out to be straightforward. The 
implementation of more sterically demanding and sensible groups on the imidazole ring turns 
out to be quite challenging from a synthetic point of view. Starting with the introduction of 9-
methyl anthracene things started becoming more complicated. 
 
IV.2.5.4. Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(9-methyl-
anthracene)-imidazolium chloride (52). 
The number of reported imidazolium salts that contains the anthracene skeleton is 
rather small. Most of the papers investigate the fluorescent properties of these derivatives 
along with the cation-anion interaction in imidazolium salts.[270,271] The inspiration for the 
addition of the fluorescent antracenyl ligand on the 1,2,4-oxadiazole-imidazole core came 
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from the work of Citta et al.[272] who reported the synthesis of an antracenyl imidazolium salt 
used as precursor for two NHC complexes which were later screened for their cytotoxic 
properties against human ovarian cell lines resistant to cisplatin and for nontumorigenic 
human kidney cell lines. Karatas et al. also investigated the activity of several antracenyl-
containing benzimidazole derivatives as tyrosinase inhibitors.[273] 
 
Figure 71. Reported imidazolium salts which include the antracenyl motif. 
 
In order to obtain the oxadiazole-antracenyl-imidazolium salt 52, the imidazole 
derivative 30 had to be refluxed in toluene for several days (Scheme 54). Although the yields 
for other antracenyl imidazolium salts were reported as good to very good (50-90%), in my 
case the yield of pure substance did not exceed 24%. One reason for this is that the reaction 
was never complete and the only purification method available was the product precipitation 
from toluene.  
 
Scheme 54. Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(9-methyl-anthracene)-imidazolium 
chloride (52). 
 
The new synthesized compound was characterized by IR, 1H NMR and 13C NMR 
spectroscopic methods and by mass spectrometry (HR-ESI). In the 1H NMR spectra it was 
possible to observe the particular N-CH-N resonance at 10.49 ppm as singlet along with the 
protons belonging to the anthracene skeleton and 1,2,4-oxadiazole ligand. The 13C NMR 
spectrum was also in accordance with the structure of the novel compound. The N-C-N signal 
was registered at 147.2 ppm. Furthermore, the HR-ESI result was congruent with the charged 
molecule. 
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IV.2.5.5. Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-((2-ethyl)indole)-
imidazolium bromide (53). 
3-Substituted indole is another unit worth incorporating into the 1,2,4-oxadiazole 
containing imidazolium salts. This moiety is present in several natural products known for 
their broad spectrum of bioactive properties, e.g. antitumor activity.[274,275] Figure 72 displays 
two representative natural compounds containing 3-substituted indole, Trachycladindole E 
and Hyrtinadine A.  
 
Figure 72. Structures of natural products that incorporate the 3-substituted indole unit. 
 
The first one belongs to a group of cytotoxic agents Trachycladindoles A-G extracted from 
the Australian marine sponge Trachycladus laevispirulifer. This class of substances show 
selective cytotoxicity against lung (A549), colorectal (HT29) and breast (MDA-MB-231) 
cancer cell lines.[276] Hyrtinadine A is a cytotoxic bis-indole alkaloid isolated from a marine 
sponge, Hyrtios sp..[277] Although the indole-containing compounds have remarkable 
biological activities, this moiety has so far not been considered as a fragment for the 
construction of imidazolium salts or related NHC derivatives. The only literature example is 
represented by the work of X.-L. Xu et al..[278] They synthesized a series of new 1-((indol-3-
yl)methyl)-1H-imidazolium salts and tested them in vitro against several human cell lines. 
 
Fgure 73. Reported 1-((indol-3-yl)methyl)-1H-imidazolium salts. 
 
Some of these compounds turned to be good candidates against myeloid liver 
carcinoma (SMMC-7721), lung carcinoma (A549), and breast carcinoma (MCF-7). 
In order to integrate the cytotoxic activity of 3-substituted indole into the 1,2,4-
oxadiazole-imidazole, the commercially available 3-(2-bromoethyl)indole was used as 
alkylating reagent. The ethyl arm of the indole was chosen because of its availability, cost and 
advantageous steric properties. The yield of this reaction was satisfactory (20%) considering 
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the sensitivity of the reagent involved and the fact that many flash chromatography 
purifications were required. 
 
Scheme 55. Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-((2-ethyl)indole)-imidazolium 
bromide (53). 
 
The pure compound was characterized IR, 1H NMR and 13C NMR spectroscopy. 
Characteristic for this compound are the 1H NMR singlet resonances at 11.04 ppm and 10.09 
ppm belonging to the NHIndole and the NCHN, respectively. The ethyl bridge gave signals at 
4.6 ppm and 3.43 ppm. The calculated HR-ESI mass for M+ (412.2137) agrees with the 
experimentally determined one (412.2135). 
 
IV.2.5.6. Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(2,3,4,5-tetra-O-
acetyl-D-glucopyranosyl)-imidazolium nitrate (54). 
Ubiquitous carbohydrates represent a special class of N-alkyl ligands for NHCs that 
have so far been neglected for the biological applications. They play a crucial biological role 
in the complex mechanisms of living organisms (storage and transport of energy, key function 
in the immune system, fertility, pathogenesis, blood clotting).[279-281] Hence, carbohydrates are 
ubiquitous building blocks in the design of novel bioactive compounds.[282] 
As substituents they have the advantage of their intrinsic chirality and water solubility. 
Nevertheless, carbohydrate-based NHCs and their imidazolium precursors are an emerging 
field and so far their applications are confined to catalysis,[283-288] but not as possible bioactive 
agents. Figure 74 shows the carbohydrate-based imidazolium salts so far reported in the 
literature. 
Figure 74. Reported carbohydrate-based imidazolium salts in catalytic studies. 
 
Therefore with the purpose of establishing a new structural class of highly active, 
stable, stereo-selective bioactive compounds, the synthesis of 1,2,4-oxadiazole-carbohydrate-
based imidazolium salt and their NHCs derivatives was attempted. 
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Scheme 56. Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(2,3,4,5-tetra-O-acetyl-D-
glucopyranosyl)-imidazolium nitrate (54). 
 
As showed in Scheme 56, the 1,2,4-oxadiazole substituted imidazole derivative 30 was 
treated with a suitable acetyl protected glucose bearing a bromine atom at the anomeric site as 
leaving group. The reaction was performed at 50°C in the presence of AgNO3 as bromide 
abstractor. After work-up the remaining residue was a anomeric mixture of isomers from 1-
(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(2,3,4,5-tetra-O-acetyl-D-glucopyra-nosyl)-
imidazolium nitrate. It is worth mentioning that despite the low yield (18%) it was obtained 
solely the β-anomer by combining precipitation from methanol and chromatography methods. 
The 1H NMR spectroscopy revealed the β-configuration of the new carbohydrate 
imidazolium salt. The proton attributed to the anomeric center gives in the 1H NMR spectra a 
doublet at 6.46 ppm with the coupling constant JHH = 8.6 Hz. The other 
1H NMR specific 
signals attributed to the carbohydrate moiety along with the imidazolium C2 proton signal 
confirm the structure of the new compound. 
 
IV.2.5.7. Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(QCI)-
imidazolium bromide (55) and 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(QCD)-
imidazolium bromide (56). 
Quinuclidine containing compounds have a variety of pharmacological properties. In 
Scheme 57 the most relevant derivatives possessing the quinuclidinic core from the medicinal 
point of view are summarized. Some of them are very strong muscarinic agonists and 
antagonists,[34,289] others like CP-96345 are NK1-receptor antagonist,
[290-292] 5-HT3-
antagonists[293,294] and Squalene synthase inhibitors.[295,296] More recent studies reported that 
quinuclidine-containing compounds are inhibitors agents against Tumor Necrosis Factor α 
(TNF α)[297] and can act as antimicrobial FTsZ (Filamenting temperature-sensitive mutant Z) 
inhibitors.[298] 
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Scheme 57. Examples of quinuclidine containing compounds with medicinal aplications. 
 
One available source of this bioactive core is the family of cinchona alkaloids and 
their derivatives, well-known for their application in medicine,[299] food industry [source of 
bitterness] and asymmetric catalysis.[300-302] 
The two members used as quinuclidinic nucleus in the design of new chiral 
imidazolium salts are quincorine [QCI = (2S,4S,5R)-2-hydroxymethyl-5-vinyl-2-quinuclidine] 
and quincoridine [QCD = (2R,4S,5R)-2-hydroxymethyl- 5-vinyl-2-quinuclidine]. These two 
pseudo-enantiomeric 1,2-amino alcohols were obtained by Hoffmann et al.[303] as a cleavage 
result of the natural products quinine and quinidine. 
 
Scheme 58. Cleavage of quinine into QCI. 
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The four stereogenic centers along with the possibility of functionalization at both 
ends (C9 and C10) make the QCI and QCD skeletons attractive building blocks in the 
synthesis of novel compounds.[304-310] 
The synthetic strategy was quite simple: Use a quinuclidine derivative as alkylating 
agent and implement it on the imidazole already substituted with 1,2,4-oxadiazole unit. 
However, the practical synthesis proved to be more complicated. The first step was the 
synthesis of the C9-halogenated quincorine and quincoridine derivatives. Following the work 
of Hoffmann et al.[311] it was possible to obtain the C9-bromide derivative of QCI and QCD, 
respectively (Scheme 59). 
 
Scheme 59. Two step synthesis of C9-bromide derivative of QCI: i. Et3N, MsCl, DCM, rt; ii. LiBr, dioxane, 
reflux. 
 
The unprotected quincorine and quincoridine were first transformed into the 
corresponding O-mesylated compounds. After isolation and purification, these derivatives 
were reacted with LiBr in refluxing dioxane for several hours to afford after column 
chromatography the desired C9-bromides in good yields, which is remarkable considering 
that these compounds are very sensitive. 
After the isolation of these brominated compounds, the next step was the alkylation 
reaction with 5-(4-(1H-imidazol-1-yl)phenyl)-3-tert-butyl-1,2,4-oxadiazole (30) at 120°C in 
toluene. 
 
Scheme 60. Alkylation of 1,2,4-oxadiazole imidazole with the C9-bromide QCI/QCD. 
 
The isolated yields were not consistent from run to run. Sometimes the imidazolium 
salts were obtained in 15% yield, sometimes in 65% yield. The main reason for this is that 
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QCI- / QCD-C9-Br tend to react with themselves at elevated temperatures to form bromide 
salts, thus becoming inactive as electrophiles (Figure 75). This problem was solved by adding 
more equivalents of the QCI- / QCD-C9-Br and by heating for shorter period of time. 
 
Figure 75. Self-alkylation of C9-bromide QCI/QCD identified in the MS (ESI). 
 
The formation of the two chiral imidazolium salts 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-
yl)phenyl)-3-(QCI)-imidazolium bromide (55) and 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-
yl)phenyl)-3-(QCD)-imidazolium bromide (56) was confirmed by IR, 1H and 13C NMR 
spectroscopy. Apart from the complex signals of the quinuclidinic core, in the 1H NMR 
spectrum the characteristic signals for the carbenic proton (QCI-9.26 and QCD-10.96 ppm), 
the backbone of the imidazole ring and the rest from the 1,2,4-oxadiazole part (tert-butyl and 
phenyl) can be found. Even more, the two imidazolium salts were unambiguously confirmed 
by HR-ESI mass spectrometry. 
 
IV.2.5.8. Synthesis of 1,1′-[4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl]-3,3′-
methylenediimidazolium bis-(bromide) (57). 
The synthesis of bis-imidazolium salt containing 1,2,4-oxadiazole unit was mainly 
inspired by the work of Haque et al..[312,313] They reported the synthesis and the antitumor 
activity of some bulky bis-imidazolium salts with octyl, nonyl and decyl terminal chains 
(Figure 76). 
 
Figure 76. Structures of reported bis-imidazolium salts with antitumor activity. 
 
The compounds were investigated for their cytotoxic abilities against HCT-116 (human colon 
cancer), HT-29 (human colorectal adenocarcinoma) and MCF-7 (human breast 
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adenocarcinoma) cell lines. Moreover, they showed anti-proliferative selectivity against HT-
29 cell line. 
The synthesis of 1,1′-[4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl]-3,3′-methylene-
diimidazolium bis-(bromide) (57) started from the 5-(4-(1H-imidazol-1-yl)phenyl)-3-(tert-
butyl)-1,2,4-oxadiazole and dibromethane. The reaction was straightforward and formed the 
product in good purity and yield (78%) 
 
Scheme 61. Synthesis of 1,1′-[4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl]-3,3′-methylene-diimidazolium bis-
(bromide) (57). 
 
The new bis-imidazolium salt was characterized by IR, 1H NMR spectroscopy and 
mass spectrometry (HR-ESI). At 10.56 ppm in the 1H NMR spectra is visible the typical 
NCHN singlet signal integrated for two protons. Another notable signal is the methylene 
bridge at 7.02 ppm as a sharp singlet. The presence of the two imidazolium rings is also 
confirmed by the HR-ESI mass spectrometry which shows half of the double charged 
molecular mass. 
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IV.2.5.9. Remarkable aspects in 1H and 13C NMR spectroscopy of the 1,2,4-oxadiazole related 
imidazolium salts. 
Imidazolium salt Solvent 
δH [ppm] 
(NHC*HX)  
δC[ppm] 
(NHC*HX) 
48  
DMSO-d6 10.76 b) 
49  
DMSO-d6 9.98 137.4 
50  
DMSO-d6 10.41 137.8 
51  
DMSO-d6 10.88 137.6 
52  
DMSO-d6 10.49 147.2 
53  
DMSO-d6 10.09 138.4 
54  
CDCl3 11.09 137.8 
55  
MeOH-d4 9.26 139.3 
56  
CDCl3 10.96 136.6 
57  
DMSO-d6 10.56 b) 
Table 4. Notable features in the 1H and 13C NMR spectra of the imidazolium salts. 
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In Table 4 are summarize notable features in the 1H and 13C NMR spectra of the 
imidazolium salts. The imidazolium protons resonante between 9.26 and 11.09 ppm, whereas 
the corresponding imidazolium carbons can be found at ca. 136.57-147.23 ppm. 
 
IV.2.6. In vitro anti-tumor activity of 1,2,4-oxadiazole-containing 
imidazolium salts towards human tumor cell lines. 
The imidazolium salts 48-57 were tested compare the anti-tumor activity after the 
incorporation of a metal. Furthermore, in recent publications [313,314] the anti-tumor activity of 
imidazolium salts was described, so there is a general interest in their activity. 
The in vitro anti-tumor activity of the imidazolium salts compounds 48-57 was 
assessed in a panel of 12 human tumor cell lines by using a monolayer cell survival and 
proliferation assay. As presented in Figure 77, good potency with mean IC50 values <10 µM 
was detected for one compound, namely 49. In addition compound 52 presented a moderate 
activity (mean IC50 = 25.4 µM). The other tested compounds (48, 50, 51, 53-57) showed 
marginal or none in vitro anticancer activity. 
 
Figure 77. In vitro anti-tumor activity of compounds 48-57 in a panel of 12 human tumor cell lines (mean IC50 
values). 
 
Although is an accepted fact that after the incorporation of metal to an imidazolium 
salt through metal-NHC bond enhances its activity, compound 49 has an activity higher than 
the anti-tumor activity of the corresponding Au(I) complex. Compound 49 is in some aspects 
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different from the remaining imidazolium salts. It features the smallest substituent (a methyl-
group), possesses an iodide counterion and it also has the best solubility in organic solvents. 
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52 μM 39,39 8,99 24,60 16,46 20,51 26,99 100,00 28,40 10,66 39,48 100,00 7,60 25,40
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Figure 78. Heatmap presentation of individual IC50 values for compounds 3-12 in a panel of 12 human tumor 
cell lines. 
 
The individual IC50 values of the tested compounds are presented in Figure 78. 
Compound 49, the most active from the imidazolium salts showed an individual IC50 values in 
the area 2.12 µM (GXF 251) to 44.76 µM (OVXF 899), corresponding to a 21-fold difference 
between the most sensitive and the least sensitive cell line. This shows a high level of tumor 
selectivity. Interestingly, four of the tested compounds (49, 52, 51 and 48) presented in their 
activity profile selectivity pattern against the gastric tumor cell line (GXF 251).  
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IV.3. Synthesis and structural characterization of gold(I)-NHC complexes 
with 1,2,4-oxadiazole substituents  
IV.3.1. General Aspects 
Gold complexes bearing N-heterocyclic carbene (NHC) are currently one of the most 
promising classes of substances for drug research.[315-317] The story of neutral gold complexes 
started when Auranofin, a triethylphosphine gold(I) glucose-thiolate, was marketed in 1982 as 
an anti-rheumatic substance.[318] The oral availability of this substance represented a 
breakthrough in this area. Furthermore, the pharmacological behavior of this new class of 
metal complexes was shown to be different from that of the well-established platinum species 
(“Cisplatin”),[316,319] so that gold complexes became an important area of anti-cancer research. 
Inspired by the success of N-heterocyclic carbenes (NHC) in catalysis,[320] the idea was born 
to exchange the phosphine for an NHC ligand, which also acts as a strong sigma donor.[96,321-
336] This replacement enhances the stability of the resulting complexes. An important feature 
of gold(I)-NHC complexes is their antimitochondrial activity,[96,324,325] which is important for 
the development of these substances as anti-tumor agents. The imidazole core allows facile 
variation of the N-substituents and of the backbone with the aim to modify properties such as 
lipophilicity, steric demand and donor strength of the NHC. Several complexes have been 
presented in the last few years and their biological activity is often impressive. Chloro(1-p-
methyl-benzyl-3-methyl-imidazolin-2-ylidene)gold(I) was tested against protein tyrosine 
phosphatases and was found to exhibit potency in the low micromolar range.[293,326] A further 
target is the inhibition of thioredoxin reductase. In this direction gold(I) complexes of N-
substituted benzimidazolin-2-ylidene with alkyl or benzyl groups[327] or of backbone-modified 
or N-arylated imidazolin-2-ylidenes[328] were also studied. The introduction of derivatives 
with additional amino groups[329] or with modifications in the aryl units of the backbone[94] 
has also been presented and their application as antitumoral drugs was described. Quite 
simple gold-NHC complexes, such as (imidazolin-2-ylidene) gold(I) chloride, were shown to 
have remarkable anti-cancer activity based on their antiproliferative properties against cis-
platin-resistant cell lines.[330] Still new decorations of the imidazole core are developed and 
tested for biological activity.[331] 
I decided to introduce the motif of 1,2,4-oxadiazole-substituted phenyl groups into the 
chemistry of imidazolin-2-ylidene-gold(I) complexes as a substituent at the nitrogen atom and 
to probe the effect on the biological activity. To the best of my knowledge, such structures 
have not yet been established in the chemistry of gold(I)-NHC complexes. 
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IV.3.2. Synthetic aspects 
Several methods of generating gold(I) complexes have been described in the literature 
[321,328,332-341] (Scheme 62). The free carbene can be generated and subsequently reacted with a 
gold-containing precursor, usually [Au(DMS)Cl] or [Au(THT)Cl] (DMS = dimethyl-sulfide, 
THT = tetrahydrothiophene). However, this method requires special conditions because of the 
high reactivity of the free carbene, and not all free carbenes are sufficiently stable. Another 
approach uses silver[321,335] or copper[336,337] transmetallation protocols. 
 
Scheme 62. General pathways in the synthesis of NHC-M complexes starting from imidazolium salts. 
 
At first, a silver complex is generated from the reaction of the imidazolium salt with a 
weak silver base such as Ag2O. One can either isolate these intermediates or use the reaction 
mixture for further reactions with an appropriate gold source, e.g. [Au(DMS)Cl] or 
[Au(THT)Cl]. We evaluated this method, but the yields were lower than those described in 
the literature and, considering that our ligands are not easy to synthesize, we tried to improve 
the protocol. Several protocols in the literature describe the in situ generation of the free 
carbene by using the base KO-tBu to deprotonate the imidazolium salts in anhydrous THF, 
whereupon the gold source is added. Nevertheless, this reaction did not proceed cleanly in our 
hands, and several unidentified byproducts were formed, making the isolation of the desired 
gold compounds difficult. The byproduct formation raised questions regarding the stability of 
the free 1,2,4-oxadiazol-modified NHC, which might be the reason for the observed 
problems. It is reasonable to assume that these occur between the generation of free NHC and 
the addition of the gold source. Therefore, I added the imidazolium salts together with KO-t-
Bu and [Au(DMS)Cl] to the reaction flask, and under an inert atmosphere, the solvent (dry 
THF) was added by syringe. The reaction was monitored by thin layer chromatography, and 
the results were very promising. After 15 minutes, the reaction was complete and no 
byproducts were observed, making the purification easy and the yields higher.
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IV.3.3. Synthesis and structural characterization of 1,2,4-oxadiazole-Au(I)-
NHC complexes 
IV.3.3.1. Synthesis of Chloro(1,3-bis(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-1H-
imidazolin-2(3H)-ylidene) gold(I) (58). 
Using the silver transmetallation route, the 1,3-bis(4-(3-tert-butyl-1,2,4-oxadiazol-5-
yl)phenyl)imidazolium chloride (48) was transformed into the corresponding chloro(1,3-
bis(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-1H-imidazolin-2(3H)-ylidene) gold(I) 
complex without any difficulties (Scheme 63). The yield could have been better (59%), but 
taking into consideration that all manipulations and purifications were made under normal 
atmospheric conditions and not into the inert atmosphere glovebox, can be that a part of the 
gold complex get destroyed. 
 
Scheme 63. Synthesis of chloro(1,3-bis(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-1H-imidazolin-2(3H)-
ylidene) gold(I) (58): i. Ag2O, DCM, dark, rt; ii. Au(DMS)Cl, DCM. 
 
The structure of the gold(I)-NHC complex 58 was supported by the IR, UV/Vis, 1H 
NMR, 13C NMR, MS (HR-ESI) and elemental analysis. The 1H NMR resonance correlated to 
the carbenic proton of the precursor at 10.76 ppm disappears. In the 13C NMR the C-Au signal 
is formed at 170.9 ppm. Although neutral NHC-Au(I) complexes usually give not good 
signals in the electrospray ionisation, compound 58 gave the corresponding (M + Na+) HR-
mass. The NHC-chlorogold(I) complex 58 was analyzed by X-ray diffraction analysis (Fig. 
79). The coordination at gold, via the NHC carbon atom and a chloride ligand, is as expected 
close to linearity, with C-Au-Cl 175.96(11)° and bond lengths Au-C 1.990(4) and Au-Cl 
2.2883(9) Å, which may be regarded as typical for NHC-Au-Cl complexes. A search of the 
Cambridge Structural Database [342] yielded 145 carbene-chlorogold(I) structures, with 189 
values for these bond lengths; the average values were C-Au 1.985, Au-Cl 2.287 Å. The two 
aromatic rings subtend interplanar angles of 54 and 46° in opposite directions (unprimed and 
primed atoms respectively) to the NHC ring. The compound crystallizes as a chloroform 
disolvate, and both chloroform molecules are connected to the gold complex via weak 
hydrogen bonds (H98Cl1 2.68, H99N2 2.35 Å). Despite the bulky NHC ligand, 58 forms 
inversion-symmetric dimers through aurophilic interactions with AuAu 3.2498(3) Å, a 
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feature which is often observed in the solid-state molecular structures of gold(I) 
complexes.[343-349] 
 
Figure 79. Molecular structure of chloro(1,3-bis(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-2(3H)-
ylidene)gold(I) (58), including the two chloroform molecules. Atoms are drawn as 50% thermal ellipsoids. Weak 
hydrogen bonds are shown as dotted lines. 
 
IV.3.3.2. Synthesis of Chloro(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-methyl-
1H-imidazolin-2(3H)-ylidene) gold(I) (59) 
The methyl group is one of the most encountered features as second substituent in 
NHC-complexes due to its stability and the straightforward synthetic protocols. In Figure 80 
are presented some examples of antitumoral NHC-Au(I)-Cl complexes that have the methyl 
group as second substituent on the imidazole ring. These compounds are reported to be active 
agains the ovarial tumor cell A 2780[330] or as selective thioredoxin reductase (TrxR).[327,328] 
 
Figure 80. Examples of methyl substituted NHC-Au(I)-X complexes. 
 
The unsymmetrical 1,2,4-oxadiazole-NHC-Au(I)-Cl complex having the methyl group 
as second substituent was obtained via the transmetallation route starting from the 
corresponding 1-(4-(3-tert-butyl-1,2,4-oxadiazole-5-yl)phenyl)-3-methyl-imidazolium iodide 
(Scheme 64). 
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Scheme 64. Synthesis of chloro(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-methyl-1H-imidazolin-2(3H)-
ylidene) gold(I) (59): i. Ag2O, DCM, dark, rt; ii. Au(DMS)Cl, DCM. 
 
The new complex was isolated in acceptable yields (52%) over two steps and properly 
characterized by IR, UV/Vis, 1H NMR, 13C NMR, MS (EI) and elemental analysis. All 
analytics agree with the proposed structure. The formation of the C-Au bond is proven by the 
disappearence of the N-CH-N resonance at 9.98 ppm in the 1H NMR and the shift of the C-
carbenic resonance from 137.4 to 171.3 ppm. 
The molecular structure of 59 is depicted in Figure 81 and shows the expected linear 
monocarbene gold(I) complex with bond lengths of Au-CNHC 1.977(4), Au-Cl 2.2822(9) Å 
and a bond angle at gold of 172.61(10)°. The six-membered ring and the NHC ring subtend an 
interplanar angle of 40°. 
 
Figure 81. Molecular structure of chloro(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-methyl-1H-imidazol-
2(3H)-ylidene)gold(I) (59). Atoms are drawn as 50% thermal ellipsoids. Hydrogen atoms are omitted for clarity. 
 
IV.3.3.3. Synthesis of Bromo(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(benzyl)-
1H-imidazolin-2(3H) ylidene) gold(I) (60). 
Benzyl substituent is also frequently encountered in the design of NHC-Au(I) 
complexes. Most of the reported compounds have been tested for their catalytic properties, 
but just a few examples of medicinal application are mentioned (Figure 82). Gust et al. 
prepared a series of 4,5-diarylimidazole-Au complexes and investigated them for antitumor 
activity.[94] All his complexes are thioredoxin reductase (TrxR) inhibitors. Another NHC-
Au(I) complex TrxR inhibitor was described by Rubbiani et al..[327] 
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Figure 82. Reported benzyl substituted NHC-Au(I)-X complexes with antitumor activity. 
 
The starting material for preparing bromo(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-
yl)phenyl)-3-(benzyl)-1H-imidazolin-2(3H) ylidene) gold(I) was the corresponding 
imidazolium salt 50. First attempts for the synthesis were a little bit disappointing. Using the 
silver transmetallation route, which was successful for the previously compounds, the isolated 
yield was less than 10%. After several struggles to improve the reaction protocol, I gave up 
and tried another established procedure. KO-tBu was used as a base for the deprotonation of 
the imidazolium salt in THF and then the gold source was added. Unfortunately, this 
methodology was equally unsuccessful. Not only that the yield was low, also the compound 
could not be purified because many byproducts were present in the reaction mixture. Finally, 
the way of adding the ingredients to this reaction solved the problem. The imidazolium salt 
was mixed together with KO-tBu and [Au(DMS)Cl] under nitrogen atmosphere and then dry 
THF was added. The reaction was very fast (5-15 min), clean and in very good yields (78%). 
 
Scheme 65. Synthesis of bromo(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(benzyl)-1H-imidazolin-2(3H) 
ylidene) gold(I) (60): i. KOtBu, [Au(DMS)Cl], THF, rt. 
 
The IR, UV/Vis, 1H NMR, 13C NMR, MS (HR-ESI) and elemental analysis confirm the 
expected chemical structure. The C-Au resonance in the 13C NMR spectroscopy is shifted 
from 137.8 ppm in the imidazolium salt to 173.7 ppm in the gold complex. Single crystals 
suitable for X-ray diffraction were obtained by slow diffusion of pentane into a solution of 60 
in dichloromethane. The X-ray structure of compound 60 is shown in Figure 83. There are 
two independent molecules in the asymmetric unit, which are closely similar (r.m.s.d. 0.14 Å 
excluding terminal butyl carbons). The bond lengths C17-Au 1.989(8), 2.007(8) Å and Au-Br 
2.3826(10), 2.3959(10) Å are in the normal range of NHC-Au-Br complexes; a CCDC 
search[361] gave 14 hits, 15 values for this fragment, with mean bond lengths of Au-C 1.985, 
Au-Br 2.394 Å. As usual, the angle around the metal centre C(17)-Au-Br is almost linear at 
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177.6(2), 176.9(2)°. The central NHC ring subtends an interplanar angle of 37° with the 
aromatic ring C11-16 but is almost perpendicular (79°) to the ring C21-26. Values are almost 
identical for the second molecule. 
 
Figure 83. Molecular structure of 60; one of two independent molecules. Atoms are drawn as 50% thermal 
ellipsoids. Hydrogen atoms are omitted for clarity. 
 
The molecular packing involves broad layers of molecules, with molecule 1 occupying 
the region x ≈ ½ (Fig. 83a) and molecule 2 at x ≈ 0. The molecules are linked by short 
HimidazoleAu contacts (2.86, 2.92 Å) and very long AuAu contacts (4.25, 4.21 Å). It is often 
a moot point whether HAu contacts represent genuine interactions or a merely a chance 
consequence of the sterically exposed nature of two-coordinate gold atoms.[350] 
 
Figure 83a. Packing of compound 60, first independent molecule only, viewed parallel to the a axis in the region 
x ≈ ½. HAu and AuAu contacts are indicated by dashed lines. Other H atoms and the oxadiazole ring systems 
are omitted for clarity. 
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IV.3.3.4. Synthesis of Bromo(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(2-
pyridine)-1H-imidazolin-2(3H)-ylidene)gold(I) (61) 
NHC pincer-like complexes containing the 2-pyridine unit directly connected to the 
imidazole heterocycle are rarely reported.[267-269] Furthermore, no gold NHC complex of this 
type was found in the literature. However, the synthesized derivative 61(bromo(1-(4-(3-tert-
butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(2-pyridine)-1H-imidazolin-2(3H)-ylidene)gold(I)) 
could still be compared with the 1,3-benzimidazol-2-ylidene gold(I) complexes investigated 
by Dinda et al. despite the fact that the pyridine ligand is connected through a methylene 
bridge. The in vitro evaluation of the two complexes showed moderate activity against mouse 
melanoma (B16F10), human cervical carcinoma (HeLa) and human hepatocarcinoma 
(HepG2).[351] 
 
Figure 84. NHC-Au(I) complexes reported by Dinda et al.. 
 
By reacting the pyridine-appended imidazolium salt 51 with KOtBu and [Au(DMS)Cl] 
in THF in the absence of the light, the wanted bromo(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-
yl)phenyl)-3-(2-pyridine)-1H-imidazolin-2(3H)-ylidene)gold(I) was isolated in very good 
yield (85%) and accurately characterized.  
 
Scheme 66. Synthesis of bromo(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(2-pyridine)-1H-imidazolin-
2(3H)-ylidene)gold(I) (61): i. KOtBu, [Au(DMS)Cl], THF, r.t. 
 
Typical features of the asymmetric complex besides the pyridine signals are the 
imidazole protons (doublets at 8.03 and 7.48 ppm, JHH = 2.0 Hz) and the C-Au resonance at 
172.7 ppm. The high-resolution electron ionization mass spectrum (HR-EI) shows the 
predicted molecular peak (M 621.0433) along with the expected fragments given by the loose 
of Br (M-Br 542.0) and Br-Au (M-Br-Au 345.1). Single crystals suitable for X-ray diffraction 
were obtained by slow evaporation of a concentrated solution of 61 in dichloromethane. 
The structure of compound 61, which crystallizes as a dichloromethane solvate, is 
shown in Fig. 85. The Au-Br and C-Au bond lengths are 2.3962(3) Å and 1.987(3) Å 
respectively, with the usual linear coordination at gold, C17-Au-Br 177.88(8)°. The solvent 
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molecule is connected to the molecule of 61 by an acceptably linear contact (HBr 3.00 Å, C-
HBr 166°) that may reasonably be classified as a "weak" hydrogen bond. This ensemble 
also includes an intramolecular Cl2O contact of 3.34 Å, which may be recognized in Fig. 
85a although it is not drawn explicitly. The six-membered rings C11-16 and N5, C20-24 
subtend interplanar angles of 47(4)° and 51(4)° respectively with the central NHC ring and 
are approximately perpendicular to each other. The pyridinic nitrogen atom N5 is clearly 
identifiable by its shorter ring bonds [1.328(4), 1.343(4) Å] and its narrow ring angle of 
115.9(3)°. 
 
Figure 85. Molecular structure of bromo(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(2-pyridine)-1H-
imidazol-2(3H)-ylidene)gold(I) (61) as its dichloromethane solvate. Atoms are drawn as 50% thermal ellipsoids. 
The dashed bond is a weak hydrogen bond. 
 
The most striking intermolecular contact is the aurophilic interaction AuAu of 
3.3373(3) Å, forming centrosymmetric dimers. These are further linked via weak hydrogen 
bonds H19N5 (2.44 Å, 148°) and H12O (2.45 Å, 156°) to form a layer structure parallel to 
the planes (110) (Fig. 85a). 
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Figure 85a. Packing diagram of 61 (solvent omitted) with view direction approximately parallel to the b axis. 
Dashed bonds indicate weak hydrogen bonds or AuAu interactions. 
 
IV.3.3.5. Synthesis of Chloro(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(9-methyl-
anthracene)-1H-imidazolin -2(3H) -ylidene)gold(I) (62) 
The Au(I)-NHC-Cl complex bearing anthracenyl substituent was investigated by Citta 
et al. (Fig. 86). The fluorescent complex was tested for cytotoxicity against normal and tumor 
cell lines. The results showed good activity, but noselectivity.[272] 
 
Figure 86. Anthracenyl NHC-Au(I) complex reported by Citta et al.. 
 
Starting from 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(9-methyl-
anthracene)-imidazolium chloride (52), it was possible to obtain the desired gold complex in 
63% yield using the synthetic protocol developed previously (mix all ingredients and add the 
solvent at the end). The new 1,2,4-oxadiazole-antracenyl NHC-Au(I) complex was fully 
characterized by IR, UV/Vis, 1H NMR, 13C NMR, MS (HR-ESI) and elemental analysis. 
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Some specific features of the molecule are the C-Au resonance at 170.6 ppm, the two 
backbone proton signals of the imidazole ring as two doublets (7.01 and 6.49 ppm) with a JHH 
= 2 Hz and the methylene bridge between the imidazole and anthracenyl as a singlet at 6.32 
ppm.  
 
Scheme 67. Synthesis of chloro(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(9-methyl-anthracene)-1H-
imidazolin -2(3H) -ylidene)gold(I) (62): i. KOtBu, [Au(DMS)Cl], THF, r.t. 
 
Single crystals suitable for X-ray diffraction were obtained by slow evaporation of a 
concentrated solution of 62 in dichloromethane. The X-ray structure of compound 62 is 
shown in Fig. 87. The coordination at gold is described by the bond lengths and angles CNHC-
Au 1.982(2), Au-Cl 2.2719(5) Å, CNHC-Au-Cl 177.35(6)°. The central NHC ring subtends 
interplanar angles of 47° to the ring C11-16 and 63° to the anthracenyl system. 
 
Figure 87. Molecular structure of chloro(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(9-methyl-
anthracene)-1H-imidazol-2(3H)-ylidene)gold(I) (62). Atoms are drawn as 50% thermal ellipsoids. Hydrogen 
atoms are omitted for clarity. 
 
The packing of 62 involves ribbons of molecules parallel to [101] linked by the 
"weak" but short hydrogen bonds H20ACl 2.71 and H16O 2.41 Å and a borderline 
AuAu contact of 3.977 Å (Fig. 87a). 
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Figure 87a. Packing of compound 62, showing two ribbons parallel to [101]. Hydrogen bonds and AuAu 
contacts are indicated by dashed lines. Other H atoms are omitted for clarity. 
 
IV.3.3.6. Synthesis of Bromo(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-((2-
ethyl)indole)-1H-imidazolin-2(3H)-ylidene)gold(I) (63) 
To the best of my knowledge this type of indole containing NHC-Au complexes has 
not yet been reported in the literature. Bromo(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-
3-((2-ethyl)indole)-1H-imidazolin-2(3H)-ylidene)gold(I) (63) was prepared starting from the 
imidazolium salt analog 53 using the procedure described previously. 
 
 
Scheme 68. Synthesis of bromo(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-((2-ethyl)indole)-1H-
imidazolin-2(3H)-ylidene)gold(I) (63): i. KOtBu, [Au(DMS)Cl], THF, r.t. 
 
The chemical structure of the new complex was undoubtedly confirmed by IR, 
UV/Vis, 1H NMR, 13C NMR, MS (EI) and elemental analysis. The characteristic NCN-Au 
resonance was observed in the 13C NMR spectrum at 173.7 ppm. Furthermore the indole-NH 
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signal and the ethylene bridge are found at 8.31 ppm (singlet) and 4.5 and 3.34 ppm (triplet), 
respectively; the other units of the molecule show no unusual resonances in 1H NMR 
spectrum. 
 
IV.3.3.7. Synthesis of Chloro(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(2,3,4,5-
tetra-O-acetyl-D-glucopyranosyl)-1H-imidazolin-2(3H)-ylidene)gold(I) (64) 
The 1,2,4-oxadiazole-carbohydrate gold(I)-NHC complex 64 was prepared from the 
coresponding imidazolium salt 54 in good yield (52%) and purity (Scheme 69).  
 
Scheme 69. Synthesis of chloro(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(2,3,4,5-tetra-O-acetyl-D-
glucopyranosyl)-1H-imidazolin-2(3H)-ylidene)gold(I) (64) ): i. KOtBu, [Au(DMS)Cl], THF, r.t. 
 
The structure of the compolex was confirmed by IR, NMR, HR-ESI and elemental analyses.  
 
IV.3.3.8. Synthesis of Bromo(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(QCI)-1H-
imidazolin-2(3H)-ylidene)gold(I) (65) 
The complex 65 was prepared starting from its precursor, 1-(4-(3-tert-butyl-1,2,4-
oxadiazol-5-yl)phenyl)-3-(QCI)-imidazolium bromide (55), in acceptable yield (41%) and 
good purity. The lack of chromophores along with the basicity of the molecule made the 
purification rather tedious. The new complex was thoroughly characterized by IR and NMR 
spectroscopy as well as mass spectrometry. The 1H NMR spectrum of this unique complex 
misses the specific N-CH-N resonance from 9.26 ppm. Furthermore, the two unsymmetrical 
imidazole protons revealed themselves at 7.51 and 7.28 ppm as doublets with a coupling 
constant of JHH = 1.98 Hz. At the same time the 
13C NMR spectrum supported the formation 
of the metal-carbene bond (NCN-Au) with a downfield resonance at 181.8 ppm. The 
structural assignment was further strengthened by EI-mass spectrometry (693.1 / 695.1 
M+100) and elemental analyses. 
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Scheme 70. Synthesis of bromo(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(QCI)-1H-imidazolin-2(3H)-
ylidene)gold(I) (65): i. KOtBu, [Au(DMS)Cl], THF, r.t. 
 
The molecular structure of the enantiomerically pure compound 65 is shown in Fig. 
86. The dimensions around the gold atom are C17-Au 1.994(3), Au-Br 2.4010(4) Å, and C17-
Au-Br 177.42(10)°. The QCI substituent shows a C28-C29 bond length of 1.319(5) Å, 
consistent with a CC double bond. 
 
Figure 88. Molecular structure of bromo(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(QCI)-1H-imidazol-
2(3H)-ylidene)gold(I) (65). Atoms are drawn as 50% thermal ellipsoids. 
 
The molecular packing involves an aurophilic interaction of 3.4586(2) Å between 
neighboring molecules related by the 21 operator parallel to the a axis, thus leading to a chain 
of molecules with Au-Au-Au angle 163.79(2)°. Otherwise the packing shows very few short 
contacts. 
 
IV.3.3.9. Synthesis of Bromo(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(QCD)-
1H-imidazolin-2(3H)-ylidene)gold(I) (66) 
The other enantiopure QCD-NHC-Au(I) complex 66 was synthesised in a similar 
manner starting from the corresponding 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-
(QCD)-imidazolium bromide (56). The isolated yield was slightly better (47%) than that 
forthe QCI analogue (41%). 
Results and discussion. NHC derivatives containing 1,2,4-oxadiazole motif 
104 
 
Scheme 71. Synthesis of bromo(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(QCD)-1H-imidazolin-2(3H)-
ylidene)gold(I) (66): i. KOtBu, [Au(DMS)Cl], THF, r.t. 
 
Peculiar NMR spectroscopic aspects of the new gold complex involve also the 
disappearance of the C2 proton belonging to the imidazolium salt 56 (10.96 ppm) in the 
1H 
NMR spectrum and a strong shift of the N-C-N resonance (from 137.6 to 181.9 ppm) in the 
13C NMR spectrum. The EI-mass spectrometry and elemental analyses further validate the 
proposed molecular structure. 
 
IV.3.3.10. Synthesis of Dichloro{1,1′-[5-(phenyl)-3-(tert-butyl)-1,2,4-oxadiazole]-3,3′-
methylene-diimidazolin-2,2′-diylidene}digold(I) (67). 
Following the silver transmetallation route, starting from 1,1′-[4-(3-tert-butyl-1,2,4-
oxadiazol-5-yl)phenyl]-3,3′-methylene diimidazolium bis(bromide) (57) it was possible to 
isolate compound 67, albeit in low yield (35%).  
Scheme 72. Synthesis of dichloro{1,1′-[5-(phenyl)-3-(tert-butyl)-1,2,4-oxadiazole]-3,3′-methylene-diimidazolin-
2,2′-diylidene}digold(I) (67): i. KOtBu, [Au(DMS)Cl], THF, r.t. 
 
The generation of the Bis-Au(I) carbene complex was established by IR, NMR, HR-
ESI and elemental analyses. The disappearance of the carbenic acidic protons at 10.56 ppm in 
the 1H NMR spectra and appearance of the NCN-Au signal at 171.9 ppm in the 13C NMR 
spectrum indicate the formation of a coordinative bond between the dicarbene and the gold 
atoms. The structure is also confirmed also by HR-ESI and elemental analyses. 
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IV.3.4. NMR features of the Au(I)-NHC-compounds 
The formation of the gold(I) complexes is proven beyond any doubt by NMR 
spectroscopy. The disappearance of the N-CH-N resonance in the 1H NMR along with the 
shifting in the up-fielded area (170.3-181.9 ppm) of the resonance for the carbene carbon 
atoms are strong hints that the imidazolium salts were deprotonated and the C-Au bond was 
established. These values are in the range of reported values for Au(I)-NHC complexes 
bearing a C-Au-X (X = halide) fragment. 
 
Table 5. Notable features in the 1H NMR and 13C NMR spectra of the imidazolium salts and the corresponding 
NHC-Au(I) complexes. 
NHC-Au(I) 
complex 
δC [ppm] 
(NHC-Au) a) 
Imidazolium 
salt 
Solvent 
δH [ppm] 
(NHC*HX) 
δC [ppm] 
(NHC*HX) 
ΔδC 
58 170.9 48 DMSO-d6 10.76 b)  
59 171.3 49 DMSO-d6 9.98 137.4 33.9 
60 173.7 50 DMSO-d6 10.41 137.8 35.9 
61 172.7 51 DMSO-d6 10.88 137.6 35.1 
62 170.6 52 DMSO-d6 10.49 147.2 23.4 
63 173.7 53 DMSO-d6 10.09 138.4 35.3 
64 171.0 54 CDCl3 11.09 137.8 33.2 
65 181.8 55 MeOH-d4 9.26 139.3 42.5 
66 181.9 56 CDCl3 10.96 136.6 45.3 
67 171.9 57 DMSO-d6 10.56 b)  
a) 13C NMR spectra were recorded using CDCl3 as solvent. b) The insufficient solubility prevented the collection 
of a meaningful 13C NMR data. 
 
IV.3.5. FT-IR of the NHC-compounds 
Haque et al.[312] employed FT-IR to determine the transformation of imidazolium salts to the 
corresponding Ag(I) derivatives. Therefore, I also recorded the FT-IR spectrum of my 
compounds 48 to 67. In general, it can be concluded that the FT-IR spectra of all pairs of 
imidazolium salt and corresponding Au(I) or Ag(I) complex look very similar. This is 
reasonable since there are only minor differences in the functional groups which can be 
characterized by IR spectroscopy. However, a notable feature in the IR spectra of the 
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imidazolium salts 49 to 57 is a strong and sharp stretch in the region of 1/λ = 1547-1555 cm-1. 
Only for compound 48 this stretch is shifted to 1/λ = 1524cm-1. Once the metal bond is 
formed this intense vibration significantly diminishes, whereas the other vibrations remain 
nearly uneffected. We therefore propose that this stretch may be attributed to the -HC=N- 
functionality. 
 
IV.3.6. In vitro anti-tumor activity of 1,2,4-oxadiazole-containing NHC-
Au(I) complexes towards human tumor cell lines 
The in vitro anti-tumor activity of the compounds 58-67 was assessed in a panel of 12 
human tumor cell lines using a monolayer cell survival and proliferation assay. As shown in 
Figure 89, excellent potency with mean IC50 values <0.1 µM was detected for 6 compounds, 
namely 61 (mean IC50 = 0.012 µM), 63 (0.019 µM), 64 (0.020 µM), 65 (0.049 µM), 60 
(0.053 µM) and 66 (0.058 µM). In addition, good potency was detected for 62 (mean 
IC50 = 0.208 µM) and at a lower level for 58 (IC50 in the range from 1 to 10 µM). 
 
Figure 89. In vitro anti-tumor activity of compounds 58-67 in a panel of 12 human tumor cell lines (mean IC50 
values). 
 
As shown in Figure 90 (IC50 heatmap presentation), the six most active compounds 
exhibit a selective activity profile across the 12 cell lines tested, with the cell lines GXF 251 
(gastric cancer), LXFA 629 (lung cancer), MAXF 401 (mammary cancer), 22RV1 (prostate 
cancer and UXF 1138 (cancer of the uteri body) showing above-average sensitivity, while 
OVXF 899 (ovarian cancer) and RXF 486 (renal cancer) appeared to be resistant. With 
respect to compound 61, strong selective activity was evident by individual IC50 values from 
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0.003 µM (MAXF 401) to 0.871 µM (RXF 486), corresponding to a 290-fold difference 
between the most sensitive and most resistant cell line. Importantly, the activity profiles of 
these six compounds were quite similar to each other, indicating a similar mode of action.  
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Figure 90. Heatmap presentation of individual IC50 values for compounds 58-67 in a panel of 12 human tumor 
cell lines. 
 
Figure 91 exemplarily shows the IC50 mean graph presentation for the two most active 
compounds 61 and 63 and also emphasizes the similar activity pattern. Good tumor selectivity 
was further indicated for 62, while all other compounds showed a lower level of selectivity or 
was not active at all. 
               
Figure 91. IC50 mean graph presentation for compounds 61 and 63. 
 
Comparing the in vitro activity of the compounds with established platinum 
compounds approved for cancer therapy revealed a markedly higher potency (Figure 92). Five 
platinum compounds of the first and second generation exhibited geometric mean IC50 values 
across the 12 cell line panel in the range from 0.96 µM (Satraplatin) to 11.68 µM 
(Carboplatin). In particular 61, 63, 64, 65, 60, 66 and 62 were clearly more potent than the 
approved reference platinum compounds. Further investigation on the mode of action and in 
vivo efficacy studies are warranted for these highly attractive anticancer compounds. 
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Figure 92. Heatmap presentation of individual IC50 values for approved platinum compounds in a panel of 12 
human tumor cell lines (historical data of Oncotest). 
 
IV.4. Synthesis and structural characterization of silver(I)-NHC complexes 
with 1,2,4-oxadiazole substituents 
IV.4.1. General Aspects 
In the last decade a large number of NHC imidazolium salts and their corresponding 
silver(I) complexes have been investigated as potential candidates against tumor growth. 
Thinking in this direction, in order to develop new bioactive silver(I)-NHC complexes, it was 
necessary to prepare a large number of functionalized and non-functionalized imidazole-based 
NHCs which could be tested for antitumor activity. 
 
Figure 93. Synthesis of the first Ag(I)-NHC complex. 
 
Arduengo et al. reported the first synthetic route of an Ag(I)-NHC complex (Fig. 
93).[352] The method used involved the generation of the free carbene after deprotonation of 
the imidazolium salt in the presence of a base. Nevertheless this method is limited by the 
difficulties that can occur in the process of generating and handling the free carbenes. It is 
well known that free carbenes are sensitive against air, humidity and high temperatures.[249,353] 
For this reason the most common method used now-days in the synthesis of Ag(I)-NHC 
complexes is the in situ deprotonation of imidazolium salts precursors with basic silver agents 
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(Ag2O, Ag2(OAc), Ag2CO3).
[248,354,355] From all this methods, the most accessible way to 
generate the Ag(I) complexes involves the use of Ag2O.
[356-358] This reaction can be 
performed at room temperature using a large number of solvents, including water.[359-361] 
Silver(I) NHC complexes can be used as carbene transfer reagents because of their labile 
silver-carbene bond. Lin et al.employed this method for the first time in the synthesis of 
palladium and gold complexes[348,354] and many transitional metal complexes were generated 
using this method thereafter. The application of silver complexes as antitumorals was not 
intensively explored until recent time. A series of silver carboxylates and phosphine 
derivatives have been shown to possess in vitro activity against several tumor cell lines.[362] 
Some Ag(I)-NHC complexes have been described as possible antitumor agents against 
ovarian and breast cancer cell lines,[363] other saturated and unsaturated NHC-Ag(I) chloride 
derivatives showed better cytotoxicity than the marketed cisplatin against several tumor cell 
lines.[361] Another good example in this sense are the Ag(I)-NHC acetate complexes which 
have been reported recently to exhibit antitumor activity against one of the kidney cancer cell 
line.[364] 
 
Figure 94. Examples of Ag(I)-NHC complexes with cytotoxic activity. 
 
This reported results represent a good motivation ground for the development of novel 
synthetic Ag(I)-NHC chemistry as antitumoral drugs. 
 
IV.4.2. Synthesis of 1,2,4-oxadiazole silver(I) NHC-complexes 
Taking into consideration earlier discussions regarding the antitumor activity of Ag(I)-
NHC complexes I built-up and investigated the antitumor activity of a small library of new 
compounds in which Ag(I)-NHC complexes contained the 1,2,4-oxadiazole motif. The bulky 
ligand confers higher stability to light and humidity (several days) to these molecules, making 
them possible candidates as antitumor agents. 
 
Results and discussion. NHC derivatives containing 1,2,4-oxadiazole motif 
110 
IV.4.2.1. Synthesis of neutral 1,2,4-oxadiazole silver(I) NHC-complexes 
The silver acetate complexes 68 and 69 belong to the Ag(I)-NHC complexes that were 
designed and investigated are. These two compounds were generated according to literature-
based procedure.[364] This class of silver complexes is considered to be more stable than the 
corresponding silver salts, especially in the in vivo conditions, where, the free silver ions can 
interact with other molecules and generate secondary complexes in the bloodstream. The 
synthetic route of the silver acetate complexes starting from the imidazolium salts 48 and 49 
is depicted in Scheme 73. 
 
Scheme 73. Synthesis of Ag(I)-NHC acetate complexes 68 and 69. 
 
The Ag(OAc) used in double molar excess, deprotonated in situ the imidazolium 
precursors and attacked in the same time the free carbene developed. The two new silver 
acetate complexes were isolated in good yields, characterized and tested for in vitro antitumor 
activity. The only noteworthy feature in their 1H NMR spectrum is the disappearance of the 
imidazolium proton signals from 10.7 and 9.9 ppm respectively. The 13C NMR spectrum 
shows the formation of new Ag-C bond at 179.04 ppm and 179.8 ppm, respectively, and the 
comittant disappearance of the resonance around 137 ppm. 
Apart from compounds 68 and 69 it was planned to produce other neutral Ag(I)-NHC 
complexes bearing more sophisticated substituents (Figure 95) starting from their 
corresponding imidazolium salts. 
 
Figure 95. Other targeted Ag(I)-NHC acetate complexes. 
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Unfortunately these four complexes could not be isolated in pure form regardless of 
the amount of AgOAc added, the reaction time or temperature. Under all conditions 
investigated the conversion was never complete reaching a maximum of 50% based on the 
integrations in the 1H NMR spectrum. Moreover, even if the new complexes were formed, 
they appeared to be unstable and I could not isolate a pure sample for characterization and 
biological testing. After many struggles and attempts this synthetic target was no longer 
pursued, but the idea to generate Ag(I)-NHC complexes with these four ligand incorporated 
was still in my mind. 
 
IV.4.2.2. Synthesis of cationic 1,2,4-oxadiazole silver(I) NHC-complexes 
Inspired by the reported work of Siciliano et al.,[365] the strategy was to build-up novel 
Ag(I)-NHC complexes having the imidazole ring which carries a 1,2,4-oxadiazole motif in 4-
position and benzyl, 2-pyridine, anthracene and carbohydrate substituents in 5-position 
(Figure 96). 
 
Figure 96. Target cationic Ag(I)-NHC complexes. 
 
These complexes were synthesized by reacting the analogous imidazolium nitrate salts 
with Ag2O. As shown in Scheme 74 the anion exchange from the imidazolium bromide or 
chloride salts was performed by treatment with an equivalent amount of AgNO3 in dry DCM. 
The imidazolium nitrate salts were isolated and immediately reacted with two molar 
equivalents of Ag2O in order to afford the target silver complexes 70-73 in moderate yields 
(47-67%). 
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Scheme 74. Synthesis of Ag(I)-NHC nitrate complexes. 
 
The generation of the new Ag(I)-NHC complexes 70-73 was confirmed by the 
disappearance of the acidic proton signals of the imidazolium salts (at 10.88, 10.41, 10.49  
and 11.09 ppm, respectively). Upon complexation with silver ions, the 13C NMR resonances 
of the carbene C-atom is detected in the range of 178.43-180.58 ppm (178.43, 179.03, 180.58, 
179.01, ppm). Furthermore, positive-ion mode ESI mass spectra of these complexes are 
dominated by [M+ - NO3] fragment peaks arising from the loss of the NO3 anion. 
The Ag(I) intermediate complexes generated during the salt metathesis reaction (74-
77) were also characterized and tested for their antitumor activity. The synthetic route is 
presented in schemes 75 and 76. 
 
Scheme 75. Synthesis of complex Ag(I)-transmetallation intermediates 74 and 76. 
 
For the synthesis of Ag(I)-NHC complexes 74 and 75 the basic silver precursors 
(silver oxide) was used to deprotonate the imidazolium salts in situ. Reaction of 1,3-bis(4-(3-
tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-imidazolium chloride (48) and 1-(4-(3-tert-butyl-
1,2,4-oxadiazol-5-yl)phenyl)-3-methyl-imidazolium iodide (49) with an stoichiometric 
amount of silver oxide in CH3CN at 60°C, produced the corresponding Ag(I)-NHC 
complexes 74 and 75, respectively. The expected signals were observed in the 1H and 13C 
NMR spectra. The MS-ESI spectra show the cationic fragment peaks [M+ - AgCl2 respective 
M+ - AgI2]. In order to confer a better solubility to the Ag(I)-NHC complexes, the negative 
counterions [AgCl2]
- and [AgI2]
- were exchanged by the [PF6]
- anion. Compounds 76 and 77 
were also tested for their antitumor activity. 
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Scheme 76. Synthesis of complex Ag(I)-transmetallation intermediates 75 and 77. 
 
IV.4.3. In vitro anti-tumor activity of silver(I)-NHC complexes with 1,2,4-
oxadiazole substituents towards human tumor cell lines. 
Compounds 68-77 were tested in vitro for anti-tumor activity in a panel of 11 human 
tumor cell lines by using a monolayer cell survival and proliferation assay. As shown in 
Figure 97, very good potency with mean IC50 values <0.3 µM was detected for 2 compounds, 
namely 73 (mean IC50 = 0.19 µM and 70 (0.22 µM). Additionally, good activity was detected 
also for 71 (mean IC50 = 0.53 µM) and at a lower level for 72 (mean IC50 = 1.8 µM). 
Moreover, compound 75 presented moderate activity with a mean IC50 value of 17.18 µM 
and, at a lower level, anticancer activity was found for 74, 76, 77, 68 and 69 with mean IC50 
values in the range from 31.21 µM to 58.5 µM. 
 
Figure 97. In vitro anti-tumor activity of compounds 68-77 in a panel of 12 human tumor cell lines (mean IC50 
values). 
 
As illustrated in the IC50 heatmap presentation (Figure 98), the two most active 
compounds reveal a selective activity profile across the 12 cell lines tested, with the cell lines 
UXF 1138 (cancer of the uteri body), LXFA 629 (lung cancer), MAXF 401 (mammary 
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cancer) and MEXF 462(melanoma) presenting above-average sensitivity. In the same time, 
the resistant cell lines are OVXF 899 (ovarian cancer) and RXF 486 (renal cancer). 
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Figure 98. Heatmap presentation of individual IC50 values for compounds 68-77 in a panel of 11 human tumor 
cell lines. 
 
From the transmetallation intermediates, compound 75, displayed individual IC50 
values in the range from 9.73 µM (GXF 251) to 32.66 µM (LXFA 629), but showed no 
pronounced selectivity for any of the tested cell lines. The other compounds showed moderate 
selectivity towards MAXF 401 (breast cancer).  
For comparison five platinum compounds of the first and second generation were 
tested and they exhibited geometric mean IC50 values across the 12 cell line panel in the range 
from 0.96 µM (Satraplatin) to 11.68 µM (Carboplatin).  
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Figure 99. Heatmap presentation of individual IC50 values for approved Platinum compounds. 
 
Specifically 73, 70, and 71 were undoubtedly more potent than the platinum reference 
compounds. Complex 72 proved to be the less active from the series, but still with a potency 
similar to the platinum derivatives Tetraplatin (IC50 = 1.49 µM) and Oxaliplatin 
(IC50 = 2.08 µM). The other compounds 68-77 are outside the activity range of the platinum 
drugs. 
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IV.5. Synthesis and structural characterization of gold(I) bis-NHC 
complexes 
IV.5.1. General Aspects 
Baker and co-workers were one of the first research groups that presented the 
synthesis and biological evaluation of linear, two-coordinate homoleptic cationic Au(I)-NHC 
complexes as mitochondrial antitumor agents. In order to improve the lipophilicity of the 
compounds, they inserted several alkyl substituents on the imidazolium ring, maintaining the 
main core of the complex unchanged.[366] 
 
Figure 100. Cationic NHC-Au(I) complexes reported by Baker et al.. 
 
Having as main target selective apoptosis in tumor cell lines, Weaver et al. develop 
besides the neutral gold(I) NHC complexes, a series of cationic gold(I) NHC complexes.[90] 
Although these complexes proved to be more active than the corresponding neutral 
derivatives, no selectivity was observed. 
 
Figure 101. Cationic NHC-Au(I) complexes reported by Weaver et al.. 
 
Comparable cationic NHC-Au(I)-complexes having 1,3-benzimidazol-2-ylidene core 
were evaluated as thioredoxin reductase (TrxR) inhibitors as well as for their 
antimitochondrial properties by Rubbiani et al..[91] The positive charged complexes showed 
remarkable antiproliferative effects against MCF-7 (human breast adenocarcinoma), HT-29 
(colon adenocarcinoma) and HEK-293 cells (human embryonic kidney), with IC50 values in 
the micromolar and submicromolar area. 
 
Figure 102. Cationic NHC-Au(I) complexes reported by Rubbiani et al.. 
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Gust et al. also prepared NHC-Au(I)-complexes in analogy to his neutral compounds.[94] 
 
Figure 103. Cationic NHC-Au(I) complexes reported by Gust et al.. 
 
He compared the growth inhibitory activity of the bis-NHC cationic complexes with the 
activity of the neutral NHC gold complexes and observed a boost of the activity in the case of 
breast and colon cancer cell line. A more exotic example is the caffeine related NHC gold(I) 
charged complexes developed by Casini et al..[367] These complexes were investigated in vitro 
against human lung cancer and human ovarian cancer cell lines. All compounds showed 
relative moderate activities. 
 
Figure 104. Cationic NHC-Au(I) complexes reported by Casini et al.. 
 
IV.5.2. Synthesis and structural characterization 
A series of five novel 1,2,4-oxadiazole related gold(I) bis-NHC complexes with 
various ligands were designed, isolated, characterized and tested for anti-tumor activity. The 
molecular structures of the new synthesized compounds are showed in Fig. 
105.
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Figure 105. Synthesized gold(I) bis-NHC complexes (78 - 82). 
 
IV.5.2.1. Synthesis starting from the imidazolium salts 
The gold(I) bis-NHC complexes 78 and 79 were prepared directly from the 
correspondent imidazolium salts 48 respectively 49 as shown in Scheme 77. The first trying 
for building-up these two complexes involved a two-step reaction. First one can generate the 
Ag(I)-NHC cationic complex (74 and 75) and then replace the silver atom with gold. The 
reaction worked but the isolated yield was less than 15%. In order to produce a better yield 
other bases, solvents and reaction conditions were screened. The best isolated yields for these 
two complexes were obtained when K2CO3 was used for the deprotonation in acetone at 
reflux (56% respectively 43%). 
Scheme 77. Synthetic route for gold(I) bis-NHC complexes 78 and 79. Reagents and conditions: i. K2CO3, 
AuCl(SMe2), acetone, 60 °C, 24 h. 
 
The two complexes were isolated and purified by flash column chromatography and 
characterized by IR, 1H NMR, 13C NMR spectroscopy and HR-ESI spectrometry. The acidic 
proton signals in the 1H NMR spectrum disappears and a strong shift of NCN-Au resonance in 
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the 13C NMR was observed for both compounds (184.3 and 182.8 ppm). The high resolution 
electrospray ionization mass analyses sustained the NMR interpretation. The cationic core of 
the two complexes showed the entire isotopic pattern. 
 
IV.5.2.2. Synthesis of gold(I) bis-NHC complexes starting from the Ag(I)-NHC 
analogues 
Other gold(I) bis-NHC complexes of 1,2,4-oxadiazole-2-ylidene class (80, 81 and 82) 
with diverse bioactive ligands (9-methyl-antracene, 2,3,4,5-tetra-O-acetyl-D-glucopyranosyl 
and benzyl) were also designed, structurally characterized and biologically investigated for 
antitumor activity. 
 
Scheme 78. Synthetic route for gold(I) bis-NHC nitrate complexes 80 - 82. Reagents and conditions: i. 
AuCl(SMe2), DCM, rt, 12 h. 
 
The synthesis of these complexes was accomplished using the transmetallation route 
via their silver(I) bis-NHC analogues 71, 72 and73. The Ag(I)-NHC derivatives were reacted 
with AuCl(SMe2) in an 1:1 ratio in dry DCM in the absence of light. However, any attempt to 
obtain gold(I) bis-NHC complexes of 1,2,4-oxadiazole-2-ylidene complex with 2-pyridine 
ligand starting from the silver complex 70 failed.  
 
Scheme 79. Unsuccessful transmetallation reaction. 
 
The reaction was repeated several times with small modifications in the synthetic 
protocol (lower temperatures, shorter reaction time), but in all cases an unidentified pink solid 
formed. 
The new gold(I) complexes with the [NO3]
- counterion 80-82 were purified by flash 
column chromatography and characterized by IR, 1H NMR, 13C NMR spectroscopy and HR-
ESI spectrometry. The carbene carbon resonances were found at 183.84, 180.87 and 182.39 
ppm, respectively, similar to the resonances of their silver analogs, 180.59, 179.01 and 179.03 
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ppm, respectively. The high resolution ESI mass spectrometry confirmed beyond any doubt 
the proposed molecular composition. 
 
IV.5.3. In vitro anti-tumor activity towards human tumor cell lines. 
The in vitro anti-tumor activity of the compounds 78-82 was assessed in a panel of 11 
human tumor cell lines by using a monolayer cell survival and proliferation assay. In Figure 
106 shows the mean IC50 values of the tested compounds. The carbohydrate containing 
complex 81, with a mean IC50 = 0.8 µM is the most potent candidate from this series. Good 
potency was also registered for 82 and 78 with a mean IC50 of 1.41, respectively 1.87 µM. the 
other two complexes showed week anti-proliferation properties. 
 
Figure 106. In vitro anti-tumor activity of compounds 78-82 in a panel of 11 human tumor cell lines (mean IC50 
values). 
 
Figure 107 shows the individual IC50 values as a heatmap presentation. The most 
effective compounds, 81, 82 and 78, displayed individual IC50 values in the range from 
0.12 µM (GFX 251) to 35.51 µM (OVXF 899). The three complexes were selective for GXF 
251, MAXF 401 and PXF 1752. The other two tested compounds 79 and 80, showed no 
pronounced selectivity for any of the cell lines investigated. 
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Figure 107. Heatmap presentation of individual IC50 values for compounds 78-82 in a panel of 11 human tumor 
cell lines. 
 
IV.6. Synthesis and structural characterization of Rhodium(I) NHC 
complexes 
IV.6.1. General Aspects  
Apart from the well-known gold and silver, other metals like ruthenium[368,369] or 
rhodium[370,371] have also been employed as bioactive cores of NHC complexes.[85,372] 
NHC complexes with rhodium and ruthenium were one of the first compounds 
described as antibacterial agents against Enterococcus faecalis, P. aeruginosa, E. coli and S. 
aureus. In this area of medicinal chemistry Cetinkaya et al. investigated a large library of 
rhodium and ruthenium NHC derivatives (Figure 108).[370] 
 
Figure 108. Examples of bioactive rhodium(I)-NHC derivatives. 
 
The best results, very active and selective in the inhibition of Gram-positive bacteria 
strains, were registered by the complexes in which R1 and R2 are methyl and ethyl groups, 
respectively. The ruthenium analogues proved to be less active as antibacterial agents. Aside 
from antibacterial activity, rhodium complexes have been widely studied as potential 
anticancer agents, especially the ones which contain Rh(III) coordinated to various ligands 
(polypyridyls or cyclopentadienyls).[80,92,95,373-378] The Rh(I) derivatives are not very often 
mentioned in biological research studies for their antitumor activity[93,94,371,379,380]. One of the 
few examples is the work of McAlpine et al.,[371] who reported Rh(I)-NHC derivatives that 
can modify the cell migration, DNA replication and DNA condensation. 
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Figure 109. Examples of rhodium complexes with antitumor activity. 
 
The fact that Rh(I) is isoelectronic with Pt(II) and that Rh(I) complexes displays a 
square-planar geometry similar to already marketed cisplatin derivatives, makes the Rh(I) a 
good metal center for possible antitumor activity. Additionally, the new Rh(I) derivatives 
possess the NHC core bearing 1,2,4-oxadiazole moiety and the COD ligand coordinating to 
the Rh(I) center. These moieties possess physico-chemical properties that could influence the 
biological activity of the target molecules. 
 
IV.6.2. Synthesis and structural characterization of Rh(I)-NHC complexes 
The most common synthetic route to generate Rh(I)-NHC complexes consist in the 
deprotonation of the imidazolium salt precursor. This can be achieved easily by using a strong 
base[381] or a basic ligand.[238] The employment of the free carbene is somehow limited by the 
dry, air-free conditions in which the reaction must be performed. At the same time the 
functionalities attached to the ligand are playing an important role. The path chosen involved 
two steps as shown in Scheme 80.  
 
Scheme 80. Synthetic route for Rh(I)-NHC complexes bearing 1,2,4-oxadiazol moiety. 
 
The rhodium-NHC complexes, Chloro(η4-1,5-cyclooctadiene)-(1,3-bis(4-(3-tert-butyl-1,2,4-
oxadiazol-5-yl)phenyl)-1H-imidazol-2(3H) ylidene)-rhodium(I) (83) and Chloro(η4-1,5-
cyclooctadiene)-(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-methyl-1H-imidazol-
2(3H)-ylidene)rhodium(I) (84), were prepared in moderate yields (59% and 44% respectively) 
using the transmetallation path. The [RhCl(COD)]2 was treated with the corresponding 
silver(I)-carbene complexes according to already established procedures.[248,382-386] In the first 
step it was generated Ag(I)-NHC complexes as intermediates. This was prepared in situ 
starting from the 1,2,4-oxadiazole-containing imidazolium salts (48-49) and silver oxide in 
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DCM at room temperature. The clear solution of Ag(I)-NHC complexes in DCM was slowly 
added (or added dropwise) into a solution of [RhCl(COD)]2 in DCM to afford the desired 
metal complex after purification using column chromatography. The isolated complexes are 
air and moisture stable. 
 
Figure 110. ORTEP representation of Chloro(η4-1,5-cyclooctadiene)-(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-
yl)phenyl)-3-methyl-1H-imidazol-2(3H)-ylidene)rhodium(I) (84) with thermal ellipsoids drawn at the 50% 
probability level. Hydrogen and disordered atoms were omitted for clarity. Selected bond lengths (Å) and angles 
(°):Rh-C(17) 2.021(2), Rh-Cl 2.3860(5), Rh-C(21) 2.1941(19), Rh-C(22) 2.2284(18), Rh-C(25) 2.113(2), Rh-
C(26) 2.1230(18), C(17)-Rh-Cl 88.58(5), N(3)-C(17)-N(1) 104.39(17), C(17)-N(3)-C(20) 123.90(17), C(17)-
N(1)-C(14)-C(15) -35.2(3). 
 
The two Rh(I) complexes 83 and 84 were characterized as monomeric species by IR, 
1H NMR, 13C NMR spectroscopy, mass spectrometry and elemental analyses. For 83 the 1H 
NMR spectra, aside from the COD specific signals, shows two multiplets corresponding for 
the eight aromatic protons at 8.60 and 8.36 ppm, one singlet at 7.44 ppm for the two protons 
of the imidazole ring and one singlet for the two t-butyl groups at 1.45 ppm. The 1H NMR 
spectra of complex 84 revealed the four aromatic protons as multiplets at 8.40 and 8.33 ppm, 
two doublets at 7.22 and 7.04 ppm for the imidazole ring protons with the JHH = 1.9 Hz, one 
singlet at 4.24 ppm for the methyl protons and nine protons at 1.46 ppm for t-butyl. The 13C 
NMR doublets for the carbenic carbons appear at δ = 185.9 (JRhC = 52.4 Hz) for 83 and 
184.35 (JRhC = 51.29 Hz) for 84. The positive ion MS-ESI analysis for complexes 84 showed 
as major peak the m/z [M-Cl]+ (493.1) fragment along with m/z [M + H]+ (528.1). The m/z EI 
analysis for 83 shows the molecular peak M+ (714.2) along with fragments resulted from the 
loose of Cl and COD moieties. Crystals suitable for X-ray crystallographic analysis were 
obtained by slow evaporation of a concentrated solution of 84 in DCM and thereby prove the 
structure of the complex. 
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As depicted in Figure 110 the central rhodium atom is coordinated by the 1,3-
cyclooctadiene unit, the chlorine atom and the corresponding carbene ligand in a typical 
square planar coordination. The bond length of Rh-Ccarbene, Rh-Cl, Rh-CCOD and Ccarbene-N are 
in the range observed for other Rh(I)COD-NHC complexes. 
 
IV.7. Synthesis and structural characterization 1,2,4-oxadiazole bridged 
bis-NHC complexes 
IV.7.1. Synthesis of Ag(I) bis-NHC complex (85) 
The original poiect-plan involved the synthesis of some binuclear gold 1,2,4-oxadiazol 
derivatives[387,388] and test their antitumor activity. In an attempt to generate the binuclear gold 
cationic complex 67, we first attempted to synthesize the binuclear silver cationic complex 85 
by the same method but using acetonitrile as reaction solvent.[388] The silver complex was 
obtained and characterized, but all attempts to isolate the gold derivative were unsuccessful. 
 
Scheme 81. Synthesis of binuclear Ag(I) 1,2,4-oxadiazole; i. Ag2O, [Au(DMS)Cl], DCM, rt. 
 
X-ray crystallographic analysis of derivative 85 confirms the presence of a dinuclear, 
dicationic complex with two dicarbene ligands, each of which bridges both silver atoms. (Fig. 
111). Similar dimeric structures have been observed for silver complexes of chelating CNC 
pincer[389,390] and C2N2 cyclophane bis(NHC) ligands.
[391] The Ag-C bond lengths (Ag1-C1 
2.071(5), Ag1-C3 2.090(5), Ag2-C2 2.087(5), Ag2-C4 2.085(5) Å) and near-linear C-Ag-C 
angles (169.85(17), 167.28(16)°) of 85 lie within the normal ranges for published silver NHC 
complexes. 
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Figure 111. Structure of the dicationic silver complex 85. Atoms are drawn as 30% thermal ellipsoids. Hydrogen 
atoms are omitted for clarity. Only one position of the disordered group (to the right of N4 in the lower ligand) is 
shown. 
 
An important characteristic of 85 is the short AgAg contact of 3.1642(4) Å. Such contacts 
shorter than twice the van der Waals radius (3.40 Å) are considered diagnostic for 
“argentophilic” interactions,[392] but these are not as common as their AuAu counterparts. 
 
IV.7.2. Synthesis of Au(I) bis-NHC complexes (86 and 87) 
In order to produce the compound 86, it was necessary to heat the imidazolium salt in 
DMF at high temperature in the presence of NaOAc as base. The yield after purification was 
moderate (40%). In order to increase the solubility of the di gold complex in organic solvents, 
it was necessary to change the counterion from [Br]- to [PF6]
-. 
 
Scheme 82. Synthesis of binuclear Au(I) 1,2,4-oxadiazole; i. NaOAc, [Au(DMS)Cl], DMF, 100°C; iii. NH4PF6, 
H2O, rt. 
 
The structures of the new binuclear gold compounds were confirmed by IR, NMR 
spectroscopy and hight resolution MS-ESI. Evenmore the elemental analyses were in 
accordance with the calculated ones. 
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IV.7.3. Synthesis of Rh bis-NHC complex (88) 
The {1,1′-[5-(phenyl)-3-(tert-butyl)-1,2,4-oxadiazole]-3,3′-methylene-diimidazolin-
2,2′-diylidene}Rh(η2:η2-COD)[BF4] (88) was prepared in accordance with literature.[433] 
Starting from 1,1′-[5-(phenyl)-3-(tert butyl)-1,2,4-oxadiazole]-3,3′-methylenediimidazolium 
bis(bromide) (57), it was possible to produce the bis-NHC-Ag(I) intermediate in a short time 
by adding a slight excess of Ag2O in DCM at room temperature. The brown solid thus 
obtained after filtration through Celite and removal of the solvent was used further as carbine 
transfer reagent without any further purification. In a second step the silver derivative was 
treated with AgBF4 in acetonitrile at reflux. Precipitation from DCM upon addition of ethanol 
afforded the biscarbene complex 88 as pure compound (Scheme 83). 
 
Scheme 83. Synthetic route for {1,1′-[5-(phenyl)-3-(tert-butyl)-1,2,4-oxadiazole]-3,3′-methylene-diimidazolin-
2,2′-diylidene}Rh(η2:η2-COD)[BF4]. 
 
The Rh(I)-bridged biscarbene 88 indicates the 1H NMR spectroscopy the expected 
signals for COD moiety along with two multiplets corresponding for the eight aromatic 
protons at 8.40 and 7.95 ppm, two doublets at 7.89 and 7.29 ppm related to the four protons of 
the imidazole rings with the JHH = 1.98 Hz, and one singlet for the two t-butyl groups at 1.49 
ppm. The two hydrogen atoms of the CH2 linker are geometrically inequivalent, giving in the 
1H NMR spectrum two separate doublets (JHH = 12.9 Hz). The 
13C NMR doublet for the 
carbenic carbons appear at δ = 179.5 (JRhC = 53 Hz). The positive ion MS (HR-ESI) analysis 
for complex 88 illustrate as main signal the m/z [M2+ (M-2xBF4
-)] (759.2642) and the m/z 
[M2+-COD] (651.1701) as a fragment. 
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IV.7.4. Synthesis of Ru bis-NHC complex (89) 
The {1,1′-[5-(phenyl)-3-(tert-butyl)-1,2,4-oxadiazole]-3,3′-methylene-diimidazolin-2,2′-
diylidene}RuCl(η6-p-cymene)[PF6] (89) was synthesized using a modified published 
protocol.[393] Reaction of the imidazolium salt precursor 1,1′-[5-(phenyl)-3-(tert butyl)-1,2,4-
oxadiazole]-3,3′-methylenediimidazolium bis(bromide) with [(η6-p-cymene)RuCl2]2 resulted 
in the expected bis-carbene complex in low yield (23%). The reaction mixture was treated 
with NH4PF6 in order to obtain the final cationic complex as [PF6]
- salt (Scheme 84). 
 
Scheme 84. Synthetic route for {1,1′-[5-(phenyl)-3-(tert-butyl)-1,2,4-oxadiazole]-3,3′-methylene-diimidazolin-
2,2′-diylidene}RhCl(η6-p-cymene)[PF6] (89). 
 
The complex was characterized by IR, NMR spectroscopy and mass spectrometry. The 
two imidazole rings are equivalent according to 1H NMR spectrum, confirming the 2-fold 
symmetry of the chelatíng ligand. The two hydrogen atoms of the methylene bridge are also 
inequivalent like in the case of the bis-carbene Rh(I) complex 89. The two hydrogen atoms 
shows two separate doublets with JHH = 13.1 Hz. The carbene carbon atom was found in the 
13C NMR spectra in the usual high frequency area (δ = 176.53 ppm). Positive ion MS (HR-
ESI) analyses of the isolated Ru(I) derivative showed a peak at m/z [M+] (819.2479). 
 
IV.7.5. Synthesis of Pd bis-NHC complex (90) 
The optimal reaction conditions for the synthesis and isolation of palladium bis-
carbene complex 90 is pictured in Scheme 85. 
 
Scheme 85. Synthetic aproach for compound 90. 
 
Initial atempts to generate complex 90 using published procedures,[394,395] where the 
reaction was performed in THF or DMSO, were unsatisfactory. Due to the low yield (lower 
than 15%) and the decomposition of the compounds involved in the reaction, the solvent and 
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the temperature of the reaction were changed. In order to isolate complex 92 in pure form and 
good yield (67%), it was nesessary to use acetonitril as solvent at 60°C for a period of 12 
hours. 
The palladium complex was fully characterized. The 1H NMR resonances are broader 
than those in the corresponding Rh or Ru biscarbene derivatives. The main difference appears 
at 8.95 ppm, where the protons from the two imidazole rings are more crowded giving a 
multiplet. Also the 6.55 ppm signal attributed to the two hydrogen atoms in the methylene 
bridge is broad and two expected doublets are not sharp like in the other cases. The 13C NMR 
spectrum reveals the Pd-C signal at a normal frequency of δ = 178.03 ppm. Positive ion MS 
(HR-ESI) analyses of 90 showed two main isotopic peaks due to the presence of bromine at 
m/z [M+ - HBr] (732.1633 and 733.9644) attributed to the loose of one HBr molecule. 
Crystals suitable for X-ray crystallographic analysis were obtained by slow evaporation of 
acetonitrile from a concentrated warm solution. 
 
Figure 112. ORTEP representation of 1,1′-[5-(phenyl)-3-(tert-butyl)-1,2,4-oxadiazole]-3,3′-
methylenediimidazolium palladium(II) dibromide (90) with thermal ellipsoids drawn at the 50% probability 
level. Hydrogen and disordered atoms were omitted for clarity. Selected bond lengths (Å) and angles (°):Pd-C(1) 
1.9918(19), Pd-C(2) 1.9952(19), Pd-Br(1) 2.4814(2), Pd-Br(2) 2.4763(3), C(1)-Pd-C(2) 84.57(8), C(1)-Pd-Br(1) 
92.70(5), C(2)-Pd-Br(1) 174.11(5), C(1)-N(2)-C(5) 122.41(16), N(2)-C(5)-N(3) 108.62(15), Br(1)-Pd-Br(2) 
90.238(8). 
 
The crystal structure determination of complex 90 shows that the molecule is 
monomeric with the dicarbene 1,2,4-oxadiazole ligand, which is chelating to the palladium(II) 
center in a cis fashion. The centered six-membered ring, C3N2Pd, has adopted a boat 
conformation. The bromine atoms are occupying the two remaining coordination sites of the 
distorted square planar coordinated palladium center. 
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IV.7.6. Synthesis of Nickel(II) bis-NHC complex (91) 
The synthesis of 1,1′-[5-(phenyl)-3-(tert-butyl)-1,2,4-oxadiazole]-3,3′-methylenediimi-
dazolium nickel(II) bis(hexafluorophosphate) (91) was performed by using the 
transmetallation route from the corresponding bis-silver carbene derivative in two reaction 
steps. 
From the best of my knowledge this kind of tetra-carbenic structure is not present in 
the literature until this moment. Similar structures have been observed for nickel complexes 
of picolyl-functionalized carbene[396] and cyclophane-based nickel carbene[397] (Figure 113). 
 
Figure 113. Examples of nickel(II) chelating complexes with N-heterocyclic carbenes. 
 
As shown in Scheme 86, the first reaction step is the deprotonation of the 1,1′-[5-
(phenyl)-3-(tert butyl)-1,2,4-oxadiazole]-3,3′-methylenediimidazolium bis(bromide) (57) by 
reaction with Ag2O. In this stage is generated the Ag(I) bis-carbene complex (85), which can 
be isolated or used in situ after a short filtration through Celite. The second step requires the 
addition of Ni(PPh3)2Cl2 in order to produce the desired nickel 1,2,4-oxadiazole complex.  
 
Scheme 86. Preparation of nickel(II) tetra-carbene complex 91. 
 
Unfortunately no complete conversion was achieved even after several days of stirring 
or reflux. The clean product could not be isolated for accurate analyses (NMR and elemental 
analyses). We measured positive ion ESI-MS analysis for complexes 6 and it was observed 
signals belonging to the cationic complex m/z (M+, 1154.44), m/z (M2++Ni, 606.33) and the 
m/z (M2+, 548.20) as a fragments. 
X-ray crystallographic analysis of nickel complex 91 confirms the presence of a 
mononuclear, dicationic complex with two dicarbene ligands, each of which bridges the 
nickel atom. (Figure 114). The molecular structure reveals a square planar geometry at the 
nickel atom. The tetra-carbenic complex has relatively longer Ni-C bonds (1.899(3), 1.901(3), 
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1.914(3), 1.909(3)), in comparison with other similar (pyridine chelating) compounds.[396,397] 
The two six-membered rings formed slightly distorts coordination geometry of the nickel, 
with C1-Ni-C2 bite angle reduced to 86.22(14)° and C3-Ni-C4 to 86.87(14)°. 
 
Figure 114. ORTEP representation of 1′-[5-(phenyl)-3-(tert-butyl)-1,2,4-oxadiazole]-3,3′-
methylenediimidazolium nickel(II) bis(hexafluorophosphate) 91 with thermal ellipsoids drawn at the 50% 
probability level. Hydrogen, PF6 and disordered atoms were omitted for clarity. Selected bond lengths (Å) and 
angles (°):Ni-C(1) 1.899(3), Ni-C(2) 1.901(3), Ni-C(3) 1.914(3), Ni-C(4) 1.909(3), C(1)-Ni-C(2) 86.22(14), 
C(4)-Ni-C(3) 86.87(14), C(1)-Ni-C(4) 179.67(18), C(2)-Ni-C(3) 179.60(18), C(1)-Ni-C(3) 93.41(14), C(2)-Ni-
C(4) 93.50(14), C(1)-Ni-C(2)-N(3) -44.3(2), C(3)-Ni-C(1)-N(1) 40.8(3). 
 
IV.7.7. In vitro anti-tumor activity of bridged bis-NHC complexes towards 
human tumor cell lines. 
Complexes 83-86, 88 and 90 were tested for their potential to produce a cytotoxic effect in a 
panel of 11 human tumor cell lines by using a monolayer cell survival and proliferation assay. 
In Figure 115 is presented the graphic mean IC50 values for the tested compounds. With a 
mean IC50 values of 5.35 µM, 5.5,44 µM and 5.99 µM, the bis-Ag(I)-NHC complex 85, bis-
Au(I)-NHC complex 86 and Rh(I)-NHC complex 84 were the most active compounds against 
the tested cell lines. Additionally, for 88 and 83 the anticancer activity was detected at a lower 
level with mean IC50 values of 43.43 µM to 47.2 µM. Compound 90 displayed just marginal 
activity. 
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Figure 115. In vitro anti-tumor activity of compounds 83-86, 88 and 90 in a panel of 11 human tumor cell lines 
(mean IC50 values). 
 
Figure 116 shows the individual IC50 values for 83-86, 88 and 90 as a heatmap 
presentation. The most active compound 85, presented besides good activity also good 
selectivity against MAXF 401 (breast cancer). In the same time, the Au(I) derivative 86 was 
found to be selective against UXF 1138 (uterus cancer). The third most active compound, 89, 
displayed individual IC50 values in the range from 3.11 µM (PAXF 1657) to 13.35 µM 
(LXFA 629), no pronounced selectivity was observed for any of the tested cell lines. Slight 
selectivity against GXF 251 (gastric cancer) and MAXF 401 (breast cancer) was observed for 
88. Complex 83 has also selectivity against GXF 251 (gastric cancer) and PAXF 1657 
(pancreatic cancer). The palladium complex 90 showed little antitumor activity and no 
selectivity. 
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Figure 116. Heatmap presentation of individual IC50 values for compounds 83-86, 88 and 90 in a panel of 11 
human tumor cell lines. 
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IV.8. Synthesis of miscellaneous organometallic complexes containing 1,2,4-
oxadiazole unit 
IV.8.1. Synthesis of organometallic complexes containing 1,2,4-oxadiazole 
alkynyl unit 
IV.8.1.1. General aspects 
Platinum(II) complexes containing alkynyl ligands are often employed as precursors in 
the synthesis of mono- and polynuclear organometallic platinum(II) compounds[398-403] or for 
building up homo- and heteropolymetallic compounds of platinum(II).[404] Additionally, this 
type of complexes can be engaged as catalysts or can be used as luminescent materials.[405-409] 
From the bioactivity point of view, Cullinare et al. reported that organometallic platinum 
complexes are stronger anticancer agents than the corresponding non-organometallic 
derivatives when tested against cancer cell lines.[410] Klein et al. prepared a series of 
[(COD)Pt(alkynyl)2] and evaluate their cytotoxicity against HT-29 colon carcinoma and 
MCF-7 breast adenocarcinoma cell lines.[411] This type of platinum alkynyl COD complexes 
showed very promising activities. On the other hand, the fact that the alkynyl group is linear 
and that gold(I) has an good affinity for linear two coordination, makes the alkynyl gold(I) 
derivatives good candidates for the design of rigid-rod molecules[412] or metal-containing 
linear-chain polymers.[413-417] Using known and proven synthetic routes such as the ‘‘acac 
method’’[416] and depolymerization,[417-419] it was possible to build-up novel alkynyl gold(I) 
complexes derived from 3-(tert-butyl)-5-(4-ethynylphenyl)-1,2,4-oxadiazole. 
 
IV.8.1.2. Synthesis of {(COD)Pt[3-(tert-butyl)-5-(4-ethynylphenyl)-1,2,4-oxadiazole]2} 
(92) 
The 1,2,4-oxadiazole Pt(II) complex was generated using 3-(tert-butyl)-5-(4-
ethynylphenyl)-1,2,4-oxadiazole and [(COD)PtCl2] as starting precursors. The reaction was 
performed in absolute ethanol in the presence of t-BuOK as base.  
 
Scheme 87. COD platinum(II) complex of 3-(tert-butyl)-5-(4-ethynylphenyl)-1,2,4-oxadiazole. 
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The new complex was characterized by IR, UV/Vis, NMR spectroscopy and mass 
spectrometry (HR-ESI). Specific COD resonances are visible in the 1H NMR spectra as broad 
signals. The coupling constant 2JPtH(=CH, COD) = 43 Hz suggests that the bond between Pt 
and the 1,2,4-oxadiazole-alkynyl ligand is rather strong. The HR-ESI measurement clearly 
proves the existence of the Pt(II)-complex with all isotopic signals corresponding to the mass 
of M + H+ and M + K+, respectively. 
 
IV.8.1.3. Synthesis of ((4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)ethynyl)gold polimer 
(93) 
The reaction between alkynyl-1,2,4-oxadiazole and [AuCl(SMe2)] in the presence of 
trimethylamine as base, afforded the neutral oligomers as yellow solids in very good yields 
(Scheme 88). Because such complexes in pure state tend to explode, no further purification 
was performed. Also due to their insolubility in most of organic solvents, they could not be 
characterized by NMR techniques. The elemental analysis agrees with the calculated formula. 
Also in the IR spectrum is present a band at approximatively 1985 cm-1 corresponding to 
ν(C≡C) stretching mode. 
 
Scheme 88. Synthetic route for the synthesis of 3-(tert-butyl)-5-(4-ethynylphenyl)-1,2,4-oxadiazole gold(I) 
derivatives. 
 
IV.8.1.4. Synthesis of ((4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)ethynyl)gold(I)-PPh3 
(94) and ((4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)ethynyl)gold(I)-dimethylamino-
pyridine (95) complexes 
After the generation of the neutral homoleptic 1,2,4-oxadiazole-gold(I) polymer (93), 
by a depolymerization reaction using a good σ-donor ligand (phosphines, isocyanides or 
halides), novel new (alkynyl)gold(I) compounds were prepared. The solvent of choice for this 
type reactions is dichloromethane, in which the 1,2,4-oxadiazole-gold(I) polymer is insoluble 
and the new formed gold(I) alkynyl complexes are perfectly soluble. The phosphine complex 
94 shows a singlet resonance at 42 ppm in the 31P NMR spectrum, being in agreement with 
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other alkynyl(phosphine)gold(I) complexes.[420,421] The 1H NMR spectra shows the 
resonances expected for the 1,2,4-oxadizole moiety as well as the auxiliary phosphine and 
dimethylaminopyridine ligands (94 and 95). The number of protons and relative intensities are 
in agreement with the proposed structures. In the 13C NMR spectra the signals attributed to 
the Au-C appear at103 ppm for 94 and 107 ppm for 95. 
 
IV.8.2. Synthesis of organometallic complexes containing 1,2,4-oxadiazole 
thioamide unit 
IV.8.2.1 General Aspects 
The role of Zinc in the living processes of organisms is known to be very important 
especially in the catalytic and regulatory systems.[422] The synthesis of complexes from the 
thioamide ligands is not a very popular topic in organometallic chemistry. One inspirational 
example which I used is the work of Isaia et al.[423] in which they prepareda series of Zn 
complexes of Methimazole, a thioamide derivative used as antithyroid drug.[424] Of course Zn-
pyrithione, a good antibacterial agent, also known to be the active ingredient in most of the 
anti-dandruff shampoos, is another example of medicinal marketed complexes of this 
kind.[425] 
 
Figure 117. Examples of Zn-thione organometalic complexes. 
 
IV.8.2.2. Synthesis of {Zn[4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)benzothioamide)]2Cl2} (96) 
The Zn complex of 1,2,4-oxadiazole derivative was generated according to Scheme 89. The 
thioamide 18 was refluxed in ethanol in the presence of ZnCl2 for two days. Upon cooling the 
solution to room temperature, the new complex precipitated in 24% yield.  
 
Scheme 89. Synthesis of Zn-1,2,4-oxadiazole complex 96. 
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Due to the low solubility of the compound no NMR or MS spectra could be collected. 
After several attempts, crystals suitable for X-ray determination were obtained upon cooling 
from a hot ethanolic solution. 
 
Figure 118. ORTEP representation of Zn complex (96) with thermal ellipsoids drawn at the 50% probability 
level. Hydrogen and disordered atoms were omitted for clarity. Selected bond lengths (Å) and angles (°):Zn-
Cl(1) 2.2139(8), Zn-Cl(2) 2.2555(8), Zn-S 2.3702(6), Zn-S(i) 2.3702(6), Cl(1)-Zn-S 105.52(2), Cl(2)-Zn-S 
113.39(18), S-Zn-S(i) 102.78(5), Cl(1)-Zn-Cl(2) 115.09(3). 
 
The complex 96 crystallized in an orthorhombic crystal system with the space group 
Pnma. The asymmetric unit contains one molecule with a Zn2+ cation taking a tetrahedral 
geometry with two 1.2.4-oxadiazole ligands. The coordination is made via the sulfur atoms 
and by two Cl- anions. 
 
IV.8.3. In vitro anti-tumor activity of miscellaneous organometallic 
complexes containing 1,2,4-oxadiazole unit towards human tumor cell lines 
In vitro anti-tumor activity of two synthesized compounds towards a panel of 12 cell lines was 
assessed using a monolayer cell survival and proliferation assay. By exhibiting a mean IC50 
value of 9.3 µM 92 was the most potent compound. Compound 94 and 95 have moderate anti-
tumor activity towards the 12 cell lines tested. On the opposite pole 96 exhibit just marginal 
activity (Figure 119). 
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Figure 119. In vitro anti-tumor activity of compounds 92, 94-96 in a panel of 12 human tumor cell lines (mean 
IC50 values). 
 
Investigation of the activity of compounds in a cell line panel representing various 
tumour histo-types, as performed in this study, allows the analysis of potency and tumour 
selectivity and the identification of active compounds that qualify for further preclinical 
development. Tumour selectivity of the compounds is illustrated in Fig. 120, representing a 
heat-map presentation of the individual IC50 values. Overall, good antitumor potency 
combined with good selectivity was observed for compound 92. Although 94 and 95 have 
good values for their activity, just 94 shows weak selectivity against MAXF 401 (mammary) 
cell lines. 
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Figure 120. Heatmap presentation of individual IC50 values for compounds 93-96 in a panel of 12 human tumor 
cell lines. 
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V. Summary and Conclusion 
The starting objective of this thesis was the synthesis and antitumor evaluation of new 
1,2,4-oxadiazole derivatives. This goal turned in time to the synthesis of unambiguous 
libraries of silver(I), gold(I), ruthenium(II) N-heterocyclic carbene complexes containing 
1,2,4-oxadiazole substituents, as potential candidates for antitumor activity, which represented 
finally the main target of the research (Fig. 121). Compounds with various steric and 
electronic properties were designed, isolated and characterised by IR, 1H, 13C NMR, MS (HR-
ESI) and X-ray diffraction.  
Moreover, the biological activity of the 1,2,4-oxadiazole containing ligands and their 
coresponding NHC complexes was investigated. In vitro assessment of anti-tumor activity in 
a panel of 12 human tumor cell lines by a monolayer assay was evaluated. 
 
Figure 121. Representative N-heterocyclic carbene complexes containing 1,2,4-oxadiazole substituents. 
 
First, using a one-pot methodology, it was synthesized a library of ten 3-(tert-butyl)-
1,2,4-oxadiazoles starting from cheap and available p-substituted benzoic acids (I, F, OH, CN, 
NH2, NO2, aldehyde, ketone, ether, alkyne) (Fig. 122) in order to have in the 4-position of the 
phenyl ring a moiety that could be further modified (e.g. -NH2 moiety for building 
heterocycles, -I group for cross-coupling reactions).  
 
Figure 122. Representative N-heterocyclic carbene complexes containing 1,2,4-oxadiazole substituents. 
 
Although it appears like a straightforward synthetic protocol, some p-substituents on the 
benzoic acid gave undesired reactions (e.g. in the case of a vinyl group, Scheme 90) or did not 
work at all. 
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Scheme 90. Synthetic strategies for the generation of 11. 
 
In the next stage these units were converted in other, more interesting moieties (e.g. 
carboxylic acid, succinimide, maleimide, hydrazine, hydroxyl-amines) as showed in Scheme 
91. 
 
Scheme 91. Retrosynthetic paths for the synthesis of 20, 21, 29 and 32. 
 
The synthetic plan also included the implementation of further heterocycles in order to 
increase the biological activity. In this direction, a series of 1,2,4-oxadiazoles incorporating a 
thiazole, oxazole, imidazole, pyrazole and pyrazol-pyrimidine core were designed, 
synthesized and investigated for antitumor activity (Fig. 123). Furthermore the results of the 
antitumor activity screening process guided the design of the new 1,2,4-oxadiazole 
compounds. 
 
Figure 123. Heterocycles incorporated in 1,2,4-oxadiazoles compounds. 
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Most of the tested compounds exhibited only moderate or marginal activity against the 
tested cell lines and only in three cases good antitumor activity (the pyrazol-pyrimidine 47 
with mean IC50 = 5.66 µM, the maleimide 29 with mean IC50 = 9.39 µM and the oxazoline 35 
with mean IC50 = 17.39 µM) was found (Fig 124). 
 
Figure 124. Best antitumoral candidates from a number of 47 synthesised 1,2,4-oxadiazole derivatives. 
 
Based on these results we turned our focus to organometallic chemistry, more 
specifically to N-heterocyclic carbenes (NHC) chemistry. Starting from 1,2,4-oxadiazole 
derivatives substituted with imidazole or NH2 functionalities, it was possible to generate a 
library of ten new imidazolium salts that were used as precursors for NHC complexes 
(Scheme 92). 
 
Scheme 92. Synthetic route for the imidazolium salts 48-56. 
 
The 1,2,4-oxadiazole-derived imidazolium salts were designed mostly 
unsymmetrically in order to introduced a second substituent of choice. The majority of these 
substituents are biologically active organic moieties. Some of them are exotic (anthracene, 2-
pyridine, 2,3,4,5-tetra-O-acetyl-D-glucopyranose) and others are quite unique (indole, 
quincorine (QCI) and quincoridine (QCD)) since no other examples are reported in the 
literature (Figs. 125, 126). 
 
Figure 125. 1,2,4-Oxadiazole-derived imidazolium salts 51-53 having as second substituent pyridine, anthracene 
and indole moiety. 
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The inclusion of QCI, QCD and carbohydrate moieties in 1,2,4-oxadiazole based 
compounds conferred chiral properties and increased the selectivity of the biological activity. 
In addition, the attachment of glucopyranose moiety to the 1,2,4-oxadiazole conferred not 
only chirality, but also improved pharmacological properties (for instance better solubility in 
water). 
 
Figure 126. 1,2,4-Oxadiazole-derived imidazolium salts 54-56 having as second substituent glucopyranose, QCI 
and QCD. 
 
The N-heterocyclic carbenes (NHC) chemistry also included the synthesis of novel 
metal (Ag(I), Au(I) and Rh(I)) containing NHC complexes bearing 1,2,4-oxadiazole 
substituents (Fig.127). 
 
Figure 127. Examples of Ag(I), Au(I) and Rh(I)) containing NHC complexes bearing 1,2,4-oxadiazole 
substituents. 
 
In Figure 128 are depicted six of the novel gold(I) N-heterocyclic carbenes (NHC) 
linked to 1,2,4-oxadiazole derivatives compounds revealed impressive potency (mean 
IC50 < 0.1 µM) and tumor selectivity, with individual IC50 values in the low nanomolar range, 
namely 61 (mean IC50 = 0.012 µM), 63 (0.019 µM), 64 (0.020 µM), 65 (0.049 µM), 60 
(0.053 µM) and 66 (0.058 µM). 
 
Figure 128. Gold(I)-NHC linked to 1,2,4-oxadiazole derivatives with impressive potency. 
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In summary, the work presented in this PhD thesis dealt with the synthesis and 
antitumor evaluation of 1,2,4-oxadiazole ligands and their related NHC complexes. Majority 
of the prepared 1,2,4-oxadiazole derivatives were tested for their antitumor activity in a 
monolayer cell survival and proliferation assay using human tumor cell lines of different 
origin/histotype. A tipically synthesis of the bioactive compounds starting from the 
substituted benzoic acid precursor is presented in Scheme 93. 
 
Scheme 93. Stepwise synthesis of Au(I)-NHC derivative 61 starting from the benzoic acid precursor. 
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VI. Outlook  
The work presented in this PhD thesis gives important contribution to three traditional 
disciplines, namely organic synthesis, inorganic synthesis and medicinal chemistry. 
Combining the features of this complementary areas leads to overcome barriers and increase 
the liberty of designing de novo bioactive compounds. But at the end of the work still remain 
some opened challenges. 
The synthesis of platinum NHC complexes of 1,2,4-oxadiazole-2-ylidene class and their 
biological evaluation remains an open chapter. This type of complexes could not be generated 
(Fig 129). 
The synthesis of iridium NHC complexes containing 1,2,4-oxadiazole ligands also remained 
unconquered territory although several synthetic methods were employed (Fig 129). 
 
Figure 129. Unexplored Pt and Ir NHC complexes containing 1,2,4-oxadiazole ligands. 
 
Building-up “sweet carbenes” - NHC complexes substituted with carbohydrate moieties in 
both (1 and 3) positions of the imidazolium core remains a big challenge especially because 
nobody managed to obtain this kind of sugar carbenes. The small number of publications 
related to sugar-NHC complexes, present just NHC-sugar examples mono-substituted. 
Building-up “bitter carbenes” - NHC complexes substituted with quinuclidine moieties (QCI 
or QCD) in both positions of the imidazolium core represent even a bigger challenge. 
Although the sensitivity of these special moieties will make the synthesis ambitious, the final 
compounds could lead to new strong biologically active drugs (Fig 130). 
 
Figure 130. New challenging compounds. 
 
Finally, the tendency to make laboratory innovations better and integrate them into real-live 
applications, represent the power-source of chemical advance. In the same time, the curiosity-
driven research and serendipity will continue to be a powerful weapon in the fight between 
chemical boundaries and mysteries of nature. 
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VII. Experimental section 
General Procedures. All reagents were purchased from commercial sources (Sigma-Aldrich 
or Acros) and used without further purification. Solvents were of analytical grade. 1H and 13C 
NMR spectra were recorded at room temperature on a Bruker Avance 300 operating at 300 
MHz for 1H and 75 MHz for 13C. Chemical shifts (δ) are reported relative to the 
tetramethylsilane peak (δ = 0.00 ppm). IR spectra were recorded with a Bruker Vertex 70 
ATR. Mass spectra were recorded on a Finnigan MAT 8400-MSS and Finnigan MAT 4515. 
High resolution mass spectra were recorded on a Finnigan MAT 95 XP. For elemental C, H, 
N analyses VarioMICRO V3.1.1. were used. All complexes reported in the manuscript 13-24 
have a purity of >95%. The purity of compounds 2-12 was ascertained to be >95% by HPLC 
on Shimadzu CBM-10A instrument with a Pinnacle DB C18 (5µm, 250 x 4.6 mm) column 
using (NEt3H)H2PO4 buffer (0.08M in H2O) / 95% MeCN with (NEt3H)H2PO4 buffer (0.08M 
in H2O) gradients as the eluents. Reactions were monitored by TLC, performed on silica gel 
plates 40 x 80 mm Polygram Sil G\UV254 (Macherey-Nagel). Visualization on TLC was 
achieved by UV light. Column chromatography was performed with Merck silica gel 60 (70–
200 mesh). 
 
In vitro antitumor activity towards human tumor cell lines 
Antitumor activity of these compounds was tested in a monolayer cell survival and 
proliferation assay using human tumor cell lines. Studies using panels of human tumor cell 
lines of different origin/histotype allow for analysis of potency and tumor selectivity of test 
compounds. 
Ten out of the twelve cell lines as tested were established at Oncotest from patient-
derived human tumor xenografts passaged subcutaneously in nude mice. The origin of the 
donor xenografts has been described. The cell line 22RV1 was supplied by ATCC 
((Rockville, MD), HT-29 was kindly provided by the National Cancer Institute (Bethesda, 
MA, USA). Cells were cultured in RPMI 1640 medium, supplemented with 10% fetal calf 
serum and 0.1 mg/mL gentamicin under standard conditions (37 °C, 5% CO2). Authenticity of 
all cell lines was proven by STR analysis at the DSMZ (Braunschweig, Germany). 
A modified propidium iodide assay was used to assess activity of the compounds 
toward human tumor cell lines. Briefly, cells were harvested from exponential phase cultures 
by trypsinization, counted and plated in 96-well flat-bottom microtiter plates at a cell density 
dependent on the cell line (4.000–20.000 cells/well). After a 24 h recovery period to allow the 
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cells to adhere and resume exponential growth, compounds were added at 10 concentrations 
in half-log increments and left for a further 4 d. The inhibition of proliferation was determined 
by measuring the DNA content using an aqueous propidium iodide solution (7 μg/mL). 
Fluorescence was measured using the Enspire Multimode-Plate Reader (excitation λ = 530 
nm, emission λ = 620 nm), providing a direct relationship to the total viable cell number. In 
each experiment, all data points were determined in duplicates. Anti-tumor activity was 
reported as the absolute IC50 value, which reflects the concentration of the test compound that 
achieves test/control values of 50%. Calculation was performed using a four-parameter non-
linear curve fit (Oncotest Data Warehouse Software). The overall potency of a compound was 
determined by the geometric mean IC50 values of all individual IC50 values. In the heatmap 
representation of IC50 values, the distribution of the IC50 values obtained for a test compound 
in the individual tumor models is given in relation to the geometric mean IC50 value, obtained 
over all cell lines tested. 
The individual IC values were highlighted in colors ranging from dark green (1/32-
fold geometric mean IC50, corresponds to very potent compound activity or high tumor 
sensitivity) to dark red (32-fold geometric mean IC50, corresponds to lack of compound 
activity or tumor resistance). The heatmap presentation, therefore, represents an anti-
proliferative “fingerprint” profile of a test compound. 
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Abbreviations                                                        Abbreviations in NMR-Spectroscopy 
THF tetrahydrofuran δ chemical shift 
DCM dichloromethane ppm parts per million 
DMF dimethylformamide s singulet 
CDI carboxyldiimidazol d doublet 
NHC N-heterocyclic carbene t triplet 
IC50 half maximal inhibitory 
concentration 
q quartet 
DMS dimethyl sulfide m multiplet 
THT tetrahydrothiophene br broad 
Me methyl o ortho 
t-Bu tert-butyl m meta 
Ph phenyl p para 
min minute   
h hour   
eq. equivalent   
r.t. room temperature   
calc. calculated   
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Synthesis of 3-tert-butyl-5-(4-iodophenyl)-1,2,4-oxadiazole (1) 
A solution of 4-iodobenzoic acid (15.0 g, 0.06 mol) in DMF (200 mL) was 
treated with a solution of CDI (10.78 g, 0.066 mol) in DMF (150 mL). After 
30 minutes of stirring at room temperature, a solution of tert-butylamidoxime (7.66 g, 0.066 
mol) in DMF (60 mL) was added and the reaction mixture was stirred for one hour at room 
temperature. A second portion of CDI (10.78 g, 0.066 mol.) solved in DMF (150 mL) was 
added and the mixture was heated to reflux for 3 hours. The mixture was cooled to room 
temperature and poured into a water-ice mixture. The solid thus formed was filtered off, 
washed with water, dried and flash chromatographed with ethyl acetate/hexane. Yield: 85% 
(16.73 g, 0.051 mol). 
1H NMR (200 MHz, CDCl3): δ = 7.96 – 7.79 (m, 4H, Ar-H), 1.42 (s, 9H, t-Bu) ppm. 13C 
NMR (50 MHz, CDCl3): δ = 178.19 (Cq, NCO), 175.25 (Cq, NCN), 138.31 (CH), 129.39 
(CH), 124.06 (Cq), 99.62 (Cq), 32.53 (Cq, C(CH3)3), 28.48((CH3)3C) ppm. MS: m/z = 328.0 
(M+, 70), 313.0 (20), 230.0 (100). 
 
Synthesis of 3-tert-butyl-5-(4-fluorophenyl)-1,2,4-oxadiazole (2) 
A solution of 4-fluorobenzoic acid (15.0 g, 0.107 mol) in DMF (200 mL) was 
treated with a solution of CDI (19.09 g, 0.117 mol) in DMF (150 mL). After 
30 minutes of stirring at room temperature, a solution of tert-butylamidoxime (13.59 g, 0.117 
mol) in DMF (60 mL) was added and the reaction mixture was stirred for one hour at room 
temperature. A second portion of CDI (19.09 g, 0.117 mol) solved in DMF (150 mL) was 
added and the mixture was heated to reflux for 3 hours. The mixture was cooled to room 
temperature and poured into a water-ice mixture. The solid thus formed was filtered off, 
washed with water, dried and flash chromatographed with ethyl acetate/hexane. Yield: 45% 
(10.61 g, 0.048 mol). 
1H NMR (200 MHz, CDCl3): δ = 8.22 – 8.08 (m, 2H, Ar-H), 7.28 – 7.13 (m, 2H, Ar-H), 1.43 
(s, 9H, t-Bu) ppm. 13C NMR (50 MHz, CDCl3): δ = 178.37 (Cq, NCO), 174.19 (Cq, NCN), 
167.77 (Cq, CF), 130.35 (CH), 121.04 (Cq), 116.47 (CH), 32.48 (Cq, C(CH3)3), 28.43 
((CH3)3C) ppm. MS: m/z = 220.1 (M
+, 30), 205.1 (24), 123.1 (100). 
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Synthesis of 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)aniline (3) 
A solution of 4-aminobenzoic acid (1.0 g, 7.29 mmol) in DMF (20 mL) was 
treated with a solution of CDI (1.28 g, 7.91 mmol) in DMF (30 mL). After 
30 minutes of stirring at room temperature, a solution of tert-
butylamidoxime (0.91 g, 7.91 mmol) in DMF (20 mL) was added, and the reaction mixture 
was stirred for one hour at room temperature. A second portion of CDI (1.28 g, 7.91 mmol.) 
solved in DMF (30 mL) was added and the mixture was heated to reflux for 3.5 hours. The 
mixture was cooled to room temperature and poured into a water-ice mixture. The solid thus 
formed was filtered off, washed with water, dried and flash chromatographed with ethyl 
acetate/hexane. Yield: 59% (0.92 g, 4.2 mmol). 
IR (ATR): 1/λ 3437 (w), 3326 (w), 3218 (w), 2966 (w), 2360 (w), 2162 (w), 1699 (w), 1652 
(w), 1603 (s), 1581 (m), 1522 (w), 1510 (m), 1491 (m), 1463 (m), 1442 (m), 1415 (w) 1394 
(w), 1351 (s), 1329 (w), 1291 (w), 1197 (m), 1186 (s), 1172 (s), 1096 (w), 1028 (w), 962 (w), 
845 (m), 835 (m), 777 (s), 700 (w), 645 (s) cm-1. 1H NMR (200 MHz, CDCl3): δ = 7.87 – 7.78 
(m, 2H, Ar-H), 6.68 – 6.56 (m, 2H, Ar-H), 4.08 (bs, 2H, NH2), 1.32 (s, 9H, t-Bu) ppm. 13C 
NMR (50 MHz, CDCl3): δ = 177.34 (Cq, NCO), 174.76 (Cq, NCN), 149.76 (Cq, CNH2), 
129.18 (CH), 113.76 (CH), 113.55 (Cq), 31.72 (Cq, C(CH3)3), 27.86 ((CH3)3C) ppm. MS: m/z 
= 217 (M+, 60), 202 (5), 120 (100); HRMS calcd. for C12H15N3O
+: 217.12096; found 
217.12159. M.p. 120-122°C. 
 
Synthesis of 3-tert-butyl-5-(4-nitrophenyl)-1,2,4-oxadiazole (4) 
To a mixture of 0.116 g (1 mmol) of tert-butylamidoxime in acetonitrile (5 
mL) was added 0.150 g (1 mmol) of 4-nitrobenzonitrile. To this reaction 
mixture was added 0.07 g (0.3 mmol) of 2-mesitylenesulfonic acid and 
0.067 g (0.3 mmol) of ZnBr2 and the mixture was heated to 80ºC for 2 hours. After the 
reaction was finished, the mixture was cooled to room temperature. The solvent was removed 
and ethyl acetate (20 mL) was added. The mixture was washed with sodium hydrogen 
carbonate solution, water and brine. The organic phase was dried over anhydrous sodium 
sulfate, filtered and the solvent was removed. The resulting residue was dried in vacuum and 
flash chromatographed (silica, ethyl acetate/hexane 2:1). Yield: 94% (0.232 g, 0.94 mmol). 
1H NMR (200 MHz, CDCl3): δ = 8.43 – 8.28 (m, 4H, Ar-H), 1.45 (s, 9H, t-Bu) ppm. 13C 
NMR (50 MHz, CDCl3): δ = 178.44 (Cq, NCO), 174.26 (Cq, NCN), 148.96 (Cq, CNO2), 
Experimental section 
147 
144.68 (CH), 129.86 (CH), 124.25 (Cq), 32.62 (Cq, C(CH3)3), 28.46 ((CH3)3C-) ppm. MS: 
m/z = 247 (M+, 25), 232 (45), 150 (100). 
 
Synthesis of 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)benzonitrile (5) 
A solution of 4-cyanobenzoic acid (50.0 g, 0.340 mol) in DMF (500 mL) 
was treated with a solution of CDI (1,1'-carbonyldiimidazole) (60.55 g, 
0.374 mol) in DMF (400 mL). After 30 min stirring at room temperature, a solution of tert-
butylamidoxime (43.38 g, 0.374 mol) in DMF (200 mL) was added and the reaction mixture 
was stirred for 1 h at room temperature. A second portion of CDI (60.55 g, 0.374 mol) 
dissolved in DMF (400 mL) was added and the mixture was heated to reflux for 5 h. The 
mixture was cooled to room temperature and poured into a water-ice mixture. The solid thus 
formed was filtered off, washed with water, dried and flash chromatographed with ethyl 
acetate/hexane. Yield: 76% (58.65 g, 0.258 mol). Crystals suitable for X-ray diffraction 
analysis were formed by slow evaporation of a chloroform solution at room temperature. 
1H NMR (200 MHz, CDCl3): δ = 8.32 – 8.19 (m, 2H, Ar-H), 7.97 – 7.78 (m, 2H, Ar-H), 1.43 
(s, 9H, t-Bu). 13C NMR (50 MHz, CDCl3): δ = 178.48 (Cq, NCO), 174.96 (Cq, NCN), 132.76 
(CH), 128.58(CH), 127.89 (Cq), 119.89 (Cq, CN), 111.82 (Cq, CCN) 32.62 (Cq, C(CH3)3), 
28.43 ((CH3)3C). MS: m/z = 227.1 (M
+, 65), 212.1 (40), 130.1 (100). 
 
Synthesis of 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenol (6) 
A solution of 4-hydroxybenzoic acid (5.0 g, 0.036 mol) in DMF (50 mL) 
was treated with a solution of CDI (6.45 g, 0.040 mol) in DMF (40 mL). 
After 30 minutes of stirring at room temperature, a solution of tert-
butylamidoxime (4.64 g, 0.040 mol) in DMF (20 mL) was added and the reaction mixture was 
stirred for one hour at room temperature. A second portion of CDI (6.45 g, 0.040 mol.) solved 
in DMF (40 mL) was added and the mixture was heated to reflux for 6 hours. The mixture 
was cooled to room temperature and poured into a water-ice mixture. The solid thus formed 
was filtered off, washed with water, dried and flash chromatographed with ethyl 
acetate/hexane. Yield: 64% (5.02 g, 0.023 mol). 
1H NMR (200 MHz, DMSO-d6): δ = 10.45 (broad signal, -OH), 7.98 – 7.86 (m, 2H, Ar-H), 
7.01 – 6.88 (m, 2H, Ar-H), 1.33 (s, 9H, t-Bu) ppm. 13C NMR (50 MHz, DMSO-d6): δ = 
177.42 (Cq, NCO), 174.73 (Cq, NCN), 161.64 (Cq, COH), 129.78 (CH), 116.14 (CH), 114.39 
(Cq), 31.94 (Cq, C(CH3)3), 28.10 ((CH3)3C) ppm. MS: m/z = 218.2 (M
+, 60), 203.2 (20), 
121.1 (100). 
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Synthesis of 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)benzaldehyde (7) 
A solution of 4-formylbenzoic acid (15.0 g, 0.1 mol) in DMF (150 mL) was 
treated with a solution of CDI (17.8 g, 0.11 mol) in DMF (100 mL). After 30 
minutes of stirring at room temperature, a solution of tert-butylamidoxime (12.66 g, 0.11 mol) 
in DMF (60 mL) was added and the reaction mixture was stirred for one hour at room 
temperature. A second portion of CDI (17.8 g, 0.11 mol.) solved in DMF (100 mL) was added 
and the mixture was heated to reflux for 4 hours. The mixture was cooled to room temperature 
and poured into a water-ice mixture. The solid thus formed was filtered off, washed with 
water, dried and flash chromatographed with ethyl acetate/hexane. Yield: 72% (16.57 g, 0.072 
mol). 
1H NMR (200 MHz, CDCl3): δ = 10.11 (s, 1H, COH), 8.38 – 8.26 (m, 2H, Ar-H), 8.09 – 7.98 
(m, 2H, Ar-H), 1.44 (s, 9H, t-Bu) ppm. 13C NMR (50 MHz, CDCl3): δ = 191.28 (CH, COH), 
165.68 (Cq, NCO), 156.55 (Cq, NCN), 138.70 (Cq), 130.08(CH), 129.13 (Cq), 128.70 (CH), 
32.61 (Cq, C(CH3)3), 28.46((CH3)3C) ppm. MS: m/z = 230.1 (M
+, 38), 215.1 (30), 133.1 
(100). 
 
Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)ethanone (8) 
A solution of 4-acetylbenzoic acid (10.0 g, 0.061 mol) in DMF (150 mL) 
was treated with a solution of CDI (10.86 g, 0.067 mol) in DMF (100 mL). 
After 30 minutes of stirring at room temperature, a solution of tert-
butylamidoxime (7.78 g, 0.067 mol) in DMF (60 mL) was added and the reaction mixture was 
stirred for one hour at room temperature. A second portion of CDI (10.86 g, 0.067 mol.) 
solved in DMF (100 mL) was added and the mixture was heated to reflux for 2 hours. The 
mixture was cooled to room temperature and poured into a water-ice mixture. The solid thus 
formed was filtered off, washed with water, dried and flash chromatographed with ethyl 
acetate/hexane. Yield: 96% (14.28 g, 0.058 mol). 
1H NMR (200 MHz, CDCl3): δ = 8.28 – 8.19 (m, 2H, Ar-H), 8.16 – 8.05 (m, 2H, Ar-H), 2.67 
(s, 3H, CH3), 1.35 (s, 9H, t-Bu) ppm. 
13C NMR (50 MHz, CDCl3): δ = 197.87 (Cq, CO), 
174.66 (Cq, NCO), 158.75 (Cq, NCN), 141.26 (Cq), 129.45 (CH), 129.03 (Cq), 128.96 (CH), 
31.65 (Cq, C(CH3)3), 29.12 ((CH3)3C), 27.89 (-CH3) ppm. MS: m/z = 244.1 (M
+, 38), 229.1 
(100), 147.1 (40). 
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Synthesis of 3-tert-butyl-5-(4-(1-methoxyethyl)phenyl)-1,2,4-oxadiazole (9) 
A solution of 4-(1-methoxyethyl)benzoic acid (10.0 g, 0.055 mol) in DMF 
(150 mL) was treated with a solution of CDI (9.9 g, 0.061 mol) in DMF 
(100 mL). After 30 minutes of stirring at room temperature, a solution of tert-butylamidoxime 
(7.02 g, 0.061 mol) in DMF (60 mL) was added and the reaction mixture was stirred for one 
hour at room temperature. A second portion of CDI (9.9 g, 0.061 mol.) solved in DMF (100 
mL) was added and the mixture was heated to reflux for 4 hours. The mixture was cooled to 
room temperature and poured into a water-ice mixture. The solid thus formed was filtered off, 
washed with water, dried and flash chromatographed with ethyl acetate/hexane. Yield: 92% 
(13.16 g, 0.05 mol). 
1H NMR (200 MHz, CDCl3): δ = 8.95 – 7.98 (m, 2H, Ar-H), 7.44 – 7.32 (m, 2H, Ar-H), 4.29 
(m, 1H, CH), 3.17 (s, 3H, CH3), 1.38 (m, 3H, CH3), 1.35 (s, 9H, t-Bu) ppm. 
13C NMR (50 
MHz, CDCl3): δ = 177.69 (Cq, NCO), 174.35 (Cq, NCN), 147.86 (Cq), 127.66 (CH), 126.04 
(CH), 123.13 (Cq), 78.58 (Cq), 55.99 (OCH3), 31.85 (Cq, C(CH3)3), 27.87((CH3)3C) ppm. 
MS: m/z = 260.2 (M+, 10), 245.2 (100), 189.2 (42). 
 
Synthesis of 3-tert-butyl-5-(4-ethynylphenyl)-1,2,4-oxadiazole (10) 
A solution of p-ethynylbenzoic acid (1.5 g, 10.273 mmol) in DMF (10 mL) 
was treated with a solution of CDI (1.83 g, 11.301 mmol) in DMF (10 mL). 
After 30 minutes of stirring at room temperature, a solution of t-butylamidoxime (1.3 g, 
11.301 mmol) in DMF (5 mL) was added and the reaction mixture was stirred for one hour at 
room temperature. A second portion of CDI (1.83 g, 11.301 mmol.) solved in DMF (10 mL) 
was added and the mixture was heated to reflux for 3.5 hours. The mixture was cooled to 
room temperature and poured into a water-ice mixture. The solid thus formed was filtered off, 
washed with water, dried and flash chromatographed with ethyl acetate/hexane. Yield: 86% 
(2.0 g, 8.834 mmol). 
1H NMR (200 MHz, CDCl3): δ = 8.13 – 8.05 (m, 2H, Ar-H), 7.66 – 7.58 (m, 2H, Ar-H), 3.26 
(s, 1H, CHAlkin), 1.43 (s, 9H, t-Bu) ppm. 
13C NMR (50 MHz, CDCl3): δ = 178.50 (Cq, NCO), 
174.41 (Cq, NCN), 132.64 (CH), 127.94 (CH), 126.28 (Cq), 124.59 (Cq), 82.69 (Cq), 80.25 
(CH), 32.54 (Cq, C(CH3)3), 28.48 ((CH3)3C) ppm. MS: m/z = 226.1 (M
+, 50), 221.1 (20), 
129.1 (100). 
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Synthesis of of 3-tert-butyl-5-(4-vinylphenyl)-1,2,4-oxadiazole (11) 
Method 1: 5 g of 3-tert-butyl-5-(4-ethynylphenyl)-1,2,4-oxadiazole (22.10 
mmol) was dissolved in 150 mL of THF and cooled to -10ºC. To this 
solution 0.5 g of Lindlar catalyst was added and hydrogen was bubbled 
through the mixture for 30 minutes. The progress of the reaction was monitored by 1H NMR. 
The mixture was filtered over silica gel, the silica gel was washed with diethyl ether and the 
organic phases were evaporated yielding 4.8 g (21.43 mmol, 97%) of a mixture 3-tert-butyl-5-
(4-ethynylphenyl)-1,2,4-oxadiazole 90% and 3-tert-butyl-5-(4-ethylphenyl)-1,2,4- oxadiazole 
(7%) as a colorless solid. Method 2: 5 g of  4-(3-tert-butyl-1,2,4- oxadiazol-5-yl)-
benzaldehyde (21.74 mmol), 3.3 g of 1,8-Diazabicyclo[5.4.0]undec-7-ene (21.74 mmol) and 
7.76 g of methyltriphenylphosphine bromide (21.74 mmol) were dissolved in 200 mL of THF 
and heated to 50ºC for 3 hours. The reaction mixture was filtered over silica gel, the silica gel 
was washed with diethyl ether and the organic phases were evaporated. The product was flash 
chromatographed with ethyl acetate/hexane yielding 3.87 g (16.95 mmol, 78%) 
1H NMR (200 MHz, CDCl3): δ = 8.13 – 8.02 (m, 2H, Ar-H), 7.57 – 7.46 (m, 2H, Ar-H), 6.75 
(dd, J = 17.6, 10.9 Hz, 1H, CH=CH2), 5.87 (dd, J = 17.5, 0.6 Hz, 1H, CH=CH2), 5.44 – 5.33 
(m, 1H, CH=CH2), 1.43 (s, 9H, t-Bu) ppm. 
13C NMR (50 MHz, CDCl3): δ = 178.31 (Cq, 
NCO), 174.85 (Cq, NCN), 141.41 (Cq), 135.85 (CH, CH=CH2), 128.28 (CH), 126.64 (CH), 
123.69 (Cq), 116.46 (CH2, CH=CH2), 30.28 (Cq, C(CH3)3), 28.47 ((CH3)3C) ppm. MS: m/z = 
228.1 (M+, 50), 213.1 (20), 131.1 (100). 
 
Synthesis of 3-tert-butyl-5-(4-ethylphenyl)-1,2,4- oxadiazole (12) 
5 g of 3-tert-butyl-5-(4-ethynylphenyl)-1,2,4-oxadiazole (22.10 mmol) was 
dissolved in 150 mL of THF. To this solution 0.5 g of Lindlar catalyst was 
added and hydrogen was bubbled through the solution for 1 hour. The reaction progress was 
monitored by 1H-NMR. The mixture was filtered over silica gel, the silica gel was washed 
with diethyl ether and the organic phases were evaporated yielding 4.98 g (21.66 mmol, 98%) 
1H NMR (200 MHz, CDCl3): δ = 7.91 – 7.83 (m, 2H, Ar-H), 7.20 – 7.09 (m, 2H, Ar-H), 2.55 
(q, J = 7.6 Hz, 2H, CH2), 1.31 (s, 9H, t-Bu), 1.18 – 1.03 (m, 3H, CH3) ppm. 13C NMR (50 
MHz, CDCl3): δ = 177.60 (Cq, NCO), 174.59 (Cq, NCN), 148.54 (Cq), 127.79 (CH), 127.48 
(CH), 121.48 (Cq), 31.81 (Cq, C(CH3)3), 28.31 (CH2CH3), 27.84 ((CH3)3C); 14.51 (CH2CH3) 
ppm. MS: m/z = 230.2 (M+, 40), 215.2 (M+, 20), 133.2 (M+, 100). 
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Synthesis of 5-(4-(bromoethynyl)phenyl)-3-tert-butyl-1,2,4-oxadiazole (13) 
A solution of 200 mg of 3-tert-butyl-5-(4-ethynylphenyl)-1,2,4-
oxadiazole (0.885 mmol) in acetone (10 mL) was treated with 60 mg of 
AgNO3 (0.353 mmol). The mixture was cooled to 0ºC and 157 mg of 
NBS (0.885 mmol) solved in acetone (10 mL) was dropped slowly. The reaction mixture was 
stirred for 24 hours at room temperature. The solvent was evaporated and the residue was 
flash chromatographed with ethyl acetate/hexane. Yield: 63% (170 mg, 0.557 mmol). 
1H NMR (200 MHz, CDCl3): δ = 8.16 – 8.03 (m, 2H, Ar-H), 7.68 – 7.51 (m, 2H, Ar-H), 1.43 
(s, 9H, t-Bu). 13C NMR (50 MHz, CDCl3): δ = 179.12 (Cq, NCO), 176.14 (Cq, NCN), 133.15 
(CH), 128.59 (CH), 127.47 (Cq), 125.03 (Cq), 80.59 (Cq, C CBr), 54.31 (Cq, C CBr), 
33.16 (Cq, C(CH3)3), 29.10 ((CH3)3C). MS: m/z = 304.0 (M
+, 50), 305.0 (M+, 15), 306.0 (M+, 
55), 307.0 (M+, 10), 289.0 (15), 290.0 (5), 291.0 (15), 292.0 (5), 209 (80), 207.0 (100). 
 
Synthesis of (E)-3-tert-butyl-5-(4-(1,2-dibromovinyl)phenyl)-1,2,4-oxadiazole (14) 
A solution of 200 mg of 3-tert-butyl-5-(4-ethynylphenyl)-1,2,4-oxadiazole 
(0.885 mmol) in acetone (10 mL) was treated with 60 mg of AgNO3 
(0.353 mmol). The mixture was cooled to 0ºC and 393.82 mg of NBS 
(2.21 mmol) solved in acetone (10 mL) was dropped slowly. The reaction mixture was stirred 
for 24 hours at room temperature. The solvent was evaporated and the residue was flash 
chromatographed with ethyl acetate/hexane. Yield: 43% (147 mg, 0.380 mmol). 
1H NMR (200 MHz, CDCl3): δ = 8.18 – 8.07 (m, 2H, Ar-H), 7.72 – 7.62 (m, 2H, Ar-H), 7.23 
(s, H, CHBr), 1.44 (s, 9H, t-Bu). 13C NMR (50 MHz, CDCl3): δ = 178.72 (Cq, NCO), 176.34 
(Cq, NCN), 140.47 (Cq), 128.30 (CH), 128.29 (CH), 125.31 (Cq, CBr), 123.13 (Cq), 111.06 
(CHBr), 33.26 (Cq, C(CH3)3), 28.48 ((CH3)3C). MS: m/z = 384.0 (M
+, 45), 385.0 (M+, 80), 
388.0 (M+, 45), 369.0 (15), 371.0 (25), 373.0 (15), 286.9 (65), 288.9 (100), 290.9 (55). 
 
Synthesis of 3-tert-butyl-5-(4-(1,2,2-tribromovinyl)phenyl)-1,2,4-oxadiazole (15) 
A solution of 200 mg of 3-tert-butyl-5-(4-ethynylphenyl)-1,2,4-oxadiazole 
(0.885 mmol) in acetone (10 mL) was treated with 60 mg of AgNO3 
(0.353 mmol). The mixture was cooled to 0ºC and 393.82 mg of NBS 
(2.21 mmol) solved in acetone (10 mL) was dropped slowly. The reaction mixture was stirred 
for 24 hours at room temperature. The solvent was evaporated and the residue was flash 
chromatographed with ethyl acetate/hexane. Yield: 26% (107 mg, 0.230 mmol). 
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1H NMR (200 MHz, CDCl3): δ = 8.14 – 8.04 (m, 2H, Ar-H), 7.53 – 7.42 (m, 2H, Ar-H), 1.36 
(s, 9H, t-Bu). 13C NMR (50 MHz, CDCl3): δ = 178.93 (Cq, NCO), 176.14 (Cq, NCN), 143.47 
(Cq), 129.46 (CH), 128.26 (CH), 125.61 (Cq, CBr), 122.73 (Cq), 93.36 (Cq, CBr2), 33.56 
(Cq, C(CH3)3), 28.46 ((CH3)3C). MS: m/z = 461.9-467.9 (M
+, 80), 364.8-370.8 (100). 
 
Synthesis of (Z)-4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)-N'-hydroxybenzimidamide (16) 
15.28 g of hydroxylamine hydrochloride (220 mmol) and 30.4 g of 
anhydrous potassium carbonate (220 mmol) were dissolved in 200 mL of 
dry isopropanol and stirred for 0.5 h at room temperature. The 4-(3-tert-butyl-1,2,4-oxadiazol-
5-yl)benzonitrile (10 g, 44 mmol) was added, and the reaction mixture was heated to reflux 12 
h. After filtration of inorganic salts, the solvent was evaporated under reduced pressure. The 
product was purified by column chromatography (petroleum ether/acetone, 2:1, v/v). Yield: 
64% (7.33 g, 28 mmol). 
1H NMR (200 MHz, CDCl3): δ = 8.23 – 8.12 (m, 2H, Ar-H), 7.86 – 7.75 (m, 2H, Ar-H), 5.04 
– 4.78 (bs, 2H, NH2), 1.71 – 1.53 (bs, OH), 1.44 (s, 9H, t-Bu) ppm. 13C NMR (50 MHz, 
CDCl3): δ = 178.68 (Cq, NCO), 170.67 (Cq, NCN), 152.57 (Cq, NCN), 136.11 (Cq), 128.38 
(CH), 126.29 (CH), 125.45 (Cq), 32.56 (Cq, C(CH3)3), 28.50 ((CH3)3C) ppm. MS: m/z = 
260.1 (M+, 100), 243.1 (50), 130.1 (80). 
 
Synthesis of 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)benzimidamide (17) 
To 3g of (Z)-4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)-N'-hydroxy-
benzimidamide (11.52 mmol) dissolved in glacial HOAc (50 mL) was 
added slowly 3.63 g of ammonium formate (57.62 mmol) and 1.5 g Pd/C (10%) and the 
mixture was heated at reflux until consumption of the starting material. The mixture was 
cooled and filtered through Celite. The filtrate was evaporated, and the residue was basified 
with aq NaOH (1 M) and extracted with EtOAc (3×250 mL). The combined organic layers 
were washed with H2O (5×200 mL), brine and dried over Na2SO4. Yield: 69% (1.93 g, 7.94 
mmol). 
1H NMR (200 MHz, CDCl3): δ = 8.23 – 8.11 (m, 2H, Ar-H), 7.83 – 7.71 (m, 2H, Ar-H), 4.95 
– 5.45 (bs, 3H, NH, NH2), 1.44 (s, 9H, t-Bu) ppm. 13C NMR (50 MHz, CDCl3): δ = 178.46 
(Cq, NCO), 174.66 (Cq, NH2CNH), 164.63 (Cq, NCN), 140.02 (Cq), 128.36 (CH), 126.71 
(CH), 126.17 (Cq), 32.47 (Cq, C(CH3)3), 28.40 ((CH3)3C) ppm. MS (ESI): 245.13 [100, 
M+H+], 246.13 [18]. 
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Synthesis of 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)benzothioamide (18) 
To a solution of 4.48 g of NaSH (80 mmol, 68 % in H2O) and 8.13 g of 
MgCl2.6H2O (40 mmol) in DMF (90 mL) was added 9 g of 4-(3-tert-
butyl-1,2,4-oxadiazol-5-yl)benzonitrile (40 mmol). The reaction was stirred at room 
temperature for 4 hours. Water (300 mL) was added and the precipitate thus formed was 
filtrated and washed with 500 mL 1N HCl, H2O and then was dried in vacuum to afford 9.6 g 
of yellow powder. Yield: 92% (9.6 g, 36.8 mmol). 
1H NMR (200 MHz, CDCl3): δ = 8.24 – 8.13 (m, 2H, Ar-H), 8.06 – 7.95 (m, 2H, Ar-H), 7.82 
– 7.67 (bs, SH), 7.33 – 7.18 (bs, NH), 1.44 (s, 9H, t-Bu) ppm. 13C NMR (50 MHz, CDCl3): δ 
= 187.63 (Cq, SCNH2), 176.56 (Cq, NCO), 164.66 (Cq, NCN), 141.22 (Cq), 128.81 (CH), 
128.08 (CH), 126.47 (Cq), 31.27 (Cq, C(CH3)3), 29.12 ((CH3)3C) ppm. MS: m/z = 261.1 (M
+, 
40), 227.1 (20), 164.1 (40), 130.1 (20). 
 
Synthesis of (E)-ethyl N-4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenoxyacetimidate (19) 
To a solution of 5.12 g of (Z)-ethyl N-hydroxyacetimidate (49.6 mmol) 
in DMF (40 mL) was added at 0ºC 6.12 g of t-BuOK (54.6 mmol). 
After stirring the reaction mixture for 60 min at room temperature, 12.0 
g of 3-tert-butyl-5-(4-fluorophenyl)-1,2,4-oxadiazole (54.6 mmol) was added and the reaction 
mixture was heated at 80ºC for 2.5 h. The reaction was cooled to 0ºC and H20 (250 mL) was 
added. The aqueous layer was extracted with ethyl acetate (300 mL) and the combined 
organic layer was washed with brine (150 mL), dried over N2SO4, and concentrated. The 
residue was chromatographed on a column of silica gel with ethyl acetate-hexane. Yield: 68% 
(11.26 g, 37.12 mmol). 
1H NMR (200 MHz, CDCl3): δ = 8.12 – 8.01 (m, 2H, Ar-H), 7.32 – 7.20 (m, 2H, Ar-H), 4.28 
– 4.15 (q, 2H, CH2), 2.14 (s, 3H, CH3), 1.42 (s, 9H, t-Bu), 1.37 (t, 3H, CH3) ppm. 13C NMR 
(50 MHz, CDCl3): δ = 178.19 (Cq, NCO), 175.09 (Cq, NC(CH3)O), 166.45 (Cq, NCN), 
162.92 (Cq, CNO), 129.71 (CH), 117.59 (Cq), 114.15 (CH), 63.18 (CH2, OCH2CH3), 32.45 
(Cq, C(CH3)3), 28.52 ((CH3)3C), 14.41 (CCH3), 14.32 (CH3, O-CH2-CH3) ppm. MS: m/z = 
303.1 (M+, 90), 215.1 (50), 121.1 (100). 
 
Synthesis of O-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)hydroxylamine (20) 
To a solution of 9.09 g of (E)-ethyl N-4-(3-tert-butyl-1,2,4-oxadiazol-5-
Experimental section 
154 
yl)phenoxyacetimidate (30.0 mmol) in dioxane (7.5 mL) cooled at 0ºC was added dropwise 
70% HClO4, (22.17 mL). After stirring the reaction mixture for 3 h at room temperature, the 
mixture was poured into ice-water (750 mL). The aqueous layer was made basic by addition 
of NaOH and it was extracted with ethyl acetate (250 mL x 3). The combined organic layer 
was washed with brine, dried over Na2SO4, and concentrated. The residue was 
chromatographed on a column of silica gel with ethyl acetate-hexane (2: 1). Yield: 51% (3.56 
g, 15.3 mmol). 
1H NMR (200 MHz, CDCl3): δ = 8.11 – 7.97 (m, 2H, Ar-H), 7.33 – 7.19 (m, 2H, Ar-H), 6.11 
– 5.82 (bs, NH2), 1.42 (s, 9H, t-Bu) ppm. 13C NMR (50 MHz, CDCl3): δ = 178.18 (Cq, NCO), 
175.02 (Cq, NCN), 164.61 (Cq, CNO), 129.71 (CH), 117.57 (Cq), 113.54 (CH), 32.43 (Cq, 
C(CH3)3), 28.49 ((CH3)3C) ppm. MS: m/z = 233.1 (M
+, 30), 218.1 (40), 121.1 (100). 
 
Synthesis of N-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)hydroxylamine (21) 
To a solution of 6.18 g of 3-tert-butyl-5-(4-nitrophenyl)-1,2,4-oxadiazole 
(25.0 mmol) in ethanol (75 mL) and water (40 mL) was added 1.57 g of 
BiCl3 (10.0 mmol). To this mixture, 5.39 g of KBH4 (100.0 mmol) was 
added gradually with stirring under an atmosphere of nitrogen. After the addition, the mixture 
was stirred at room temperature for 15 minutes. Then, under bubbling of nitrogen, the mixture 
was acidified to pH 7 with 1N HCl and immediately extracted with Et2O. The extract was 
washed with brine and dried over anhydrous Na2S04. After removing the solvent under 
reduced pressure the residue was chromatographed on a column of silica gel with ethyl 
acetate-hexane.Yield: 76% (4.43 g, 19.0 mmol). 
1H NMR (200 MHz, CDCl3): δ = 8.09 – 7.94 (m, 2H, Ar-H), 7.14 – 6.96 (m, 3H, Ar-H, OH), 
6.49 (bs, NH), 1.43 (s, 9H, t-Bu) ppm. 13C NMR (50 MHz, CDCl3): δ = 177.46 (Cq, NCO), 
174.62 (Cq, NCN), 153.10 (Cq, CNHOH), 128.72 (CH), 116.77 (Cq), 112.95 (CH), 31.81 
(Cq, C(CH3)3), 27.82 ((CH3)3C) ppm. MS: m/z = 233.1 (M
+, 25), 218.1 (50), 136.1 (20), 120.1 
(100). 
 
Synthesis of tert-butyl 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)benzyl(methyl)carbamate (22) 
A solution of 5 g of 4-((methyl(pivaloyloxy)amino)methyl)benzoic acid 
(18.84 mmol) in DMF (28 mL) was treated with a solution of CDI (3.36 
g, 20.77 mmol) in DMF (22.2 mL). After 30 minutes of stirring at room temperature, a 
solution of tert-butylamidoxime (2.41 g, 20.77 mmol) in DMF (10 mL) was added and the 
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reaction mixture was stirred for one hour at room temperature. A second portion of CDI (3.36 
g, 20.77 mmol.) solved in DMF (22.2 mL) was added and the mixture was heated to reflux for 
2 hours. The mixture was cooled to room temperature and poured into a water-ice mixture. 
The solid thus formed was filtered off, washed with water, dried and flash chromatographed 
with ethyl acetate/hexane. Yield: 86% (5.59 g, 16.2 mmol). 
1H NMR (200 MHz, CDCl3): δ = 8.18 – 8.04 (m, 2H, Ar-H), 7.44 – 7.28 (m, 2H, Ar-H), 4.49 
(s, 2H, CH2), 2.87 (s, 3H, CH3), 1.47 (s, 9H, t-Bu), 1.43 (s, 9H, t-Bu) ppm. 
13C NMR (50 
MHz, CDCl3): δ = 178.31 (Cq, NCO), 174.89 (Cq, NCN), 143.03 (Cq, NCOO), 128.31 (CH), 
127.72 (Cq), 123.54 (Cq), 79.96 (Cq, OC(CH3)3), 53.93 (PhCH2N), 34.22 (Cq, C(CH3)3), 
32.46 (NCH3), 28.45 ((CH3)3C), 28.37 ((CH3)3C) ppm. MS: EI m/z = 345.2 (M
+, 10), 330.2 
(20), 289.2 (70), 244.2 (100), 203.2 (90). 
 
Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-N-methylmethanamine (23) 
A solution of 5 g of tert-butyl 4-(3-tert-butyl-1,2,4-oxadiazol-5-
yl)benzyl(methyl)carbamate (14.47 mmol) in Et2O (250 mL) was cooled to 
0ºC and 22 mL of a 2N solution of HCl (43.4 mmol) in Et2O was added dropwise. The solid 
thus formed was filtered off, washed with Et2O, dried and dissolved in H2O. The pH was 
adjusted to basic value and the solution was extracted with ethyl acetate. After the separation 
of the two phases the organic one was dried over Na2SO4 and the solvent was removed under 
reduced pressure. Yield: 96% (3.4 g, 13.89 mmol). 
1H NMR (200 MHz, CDCl3): δ = 8.14 – 8.05 (m, 2H, Ar-H), 7.53 – 7.42 (m, 2H, Ar-H), 3.84 
(s, 2H, CH2), 2.47 (s, 3H, CH3), 1.43 (s, 9H, t-Bu) ppm. 
13C NMR (50 MHz, CDCl3): δ = 
178.33 (Cq, NCO), 175.07 (Cq, NCN), 145.54 (Cq), 128.61 (CH), 128.18 (CH), 123.35 (Cq), 
55.61 (PhCH2N), 35.96 (Cq, C(CH3)3), 32.49 (HNCH3), 28.49 ((CH3)3C) ppm. MS: EI m/z = 
245.2 (M+, 40), 230.2 (10), 203.2 (100). 
 
Synthesis of tert-butyl 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenylcarbamate (24) 
To a solution of 1.5 g of 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)aniline (6.9 
mmol) in THF (50 mL) was added 276.17 g of NaOH (7.0 mmol) 
dissolved in 20 mL of water. The mixture was cooled at 0°C when 1.5 g of Boc2O (6.9 mmol) 
was added. The reaction mixture was warmed to room temperature and was stirred for 24h. 
Afterwards the THF was removed under reduced pressure. The aqueous residue was extracted 
two times with Et2O. After the separation of the two phases the organic one was dried over 
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Na2SO4 and the solvent was removed under reduced pressure. The residue was loaded on a 
silica column. (Et2O:Hexane // 2:1). Yield: 88% (1.92 g, 6.07 mmol). 
1H NMR (200 MHz, CDCl3): δ = 8.03 – 7.89 (m, 2H, Ar-H), 7.49 – 7.38 (m, 3H, Ar-H), 6.88 
(bs, NH), 1.43 (s, 9H, t-Bu), 1.43 (s, 9H, t-Bu) ppm. 13C NMR (50 MHz, CDCl3): δ = 177.56 
(Cq, NCO), 174.16 (Cq, NCN), 151.58 (Cq, NHCOO), 141.72 (Cq), 128.54 (CH), 118.20 
(Cq), 117.36 (CH), 80.58 (Cq, OC(CH3)3), 31.79 (Cq, C(CH3)3), 27.84 ((CH3)3C), 27.59 
((CH3)3C-) ppm. MS (ESI): 318.2 (25, M + H
+), 340.2 (100, M + Na+), 657.4 (75, 2 x M + 
Na+). 
 
Synthesis of 4-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenylamino)-4-oxobutanoic acid (25) 
0.3 g (1.38 mmol) of 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)aniline was 
mixed under inert conditions with 0.138 g (1.38 mmol) of succinic 
anhydride in 20 mL of DCM. This mixture was vigorously stirred at 
room temperature for 5 hours. The remaining residue was freed from solvent, suspended in 50 
mL of water and the pH value adjusted to 2-3 with a 1 N solution of HCl. The resulting 
suspension was filtered and the product was dried in vacuum. The residue was purified by 
flash chromatography. Yield: 91% (0.398 g, 1.25 mmol). 
IR (ATR): 1/λ 3385 (w), 2964 (w), 1696 (s), 1608 (m), 1594 (w), 1506 (s) 1492 (m), 1464 
(w), 1410 (m)1394 (w), 1351 (m), 1337 (m), 1313 (m), 1281 (w), 1249 (w), 1200 (m), 1177 
(m), 1159 (s), 994 (w), 859 (m), 830 (w), 802 (w), 773 (m), 681 (m), 612 (m) cm-1. 1H NMR 
(200 MHz, DMSO-d6): δ = 12.24 (bs, 1H, -COOH), 10.42 (s, 1H, -NH), 8.07 – 8.02 (m, 2H, 
Ar-H), 7.92-7.96 (m, 2H, Ar-H), 2.67-2.59 (m, 4H, 2 x CH2), 1.38 (s, 9H, t-Bu) ppm. 
13C 
NMR (50 MHz, DMSO-d6): δ = 177.51 (Cq, NHCO), 174.35 (Cq, NCO), 173.63 (Cq, 
COOH), 170.75 (Cq, NCN), 143.31 (Cq), 128.70 (CH), 118.89 (CH), 117.61 (Cq), 31.96 (Cq, 
C(CH3)3), 31.12 (CH2), 28.53 (CH2), 28.46 ((CH3)3C) ppm. MS: m/z = 317 (M
+, 15), 299 
(55), 217 (50), 202 (100), 120 (55). HR-MS calcd. for C16H19N3O4
+: 317.13701; found 
317.13717. M.p. 201-203°C. 
 
Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)pyrrolidine-2,5-dione (26) 
0.3 g (0.94 mmol) of 4-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenylamino)-
4-oxobutanoic acid was mixed with 0.077 g of sodium acetate (0.94 mmol) 
in 15 mL of acetic anhydride, and the mixture was then heated for 4 h at 80-
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85ºC. After cooling, the product was washed with 100 mL of H2O at pH ≈ 2-3. The solid was 
dried in vacuum and flash chromatographed. Yield: 87% (0.244 g, 0.81 mmol,). 
IR (ATR): 1/λ 2970 (w), 2875 (w), 1776 (w), 1709 (s), 1613 (w), 1520 (w), 1500 (w), 1465 
(w), 1419 (w), 1382 (m), 1351 (w), 1275 (w), 1197 (m), 1171 (s), 923 (w), 904 (w), 841 (m), 
810 (w), 771 (w), 737 (w), 697 (m), 659 (w) cm-1. 1H NMR (200 MHz, CDCl3): δ = (200 
MHz, CDCl3): 8.18 – 8.09 (m, 2H, Ar-H), 7.48-7.39 (m, 2H, Ar-H), 2.80 (s, 4H, 2 x CH2), 
1.34 (s, 9H, t-Bu) ppm. 13C NMR (50 MHz, CDCl3): δ = 178.34 (Cq, NCO), 175.53 (Cq, 
C=O), 174.04 (Cq, NCN), 135.35 (Cq), 128.65 (CH), 126.63 (CH), 124.20 (Cq), 32.39 (Cq, 
C(CH3)3), 29.51(CH2), 28.31 ((CH3)3C) ppm. MS: m/z = 299 (M
+, 55), 284 (15), 202 (100). 
HR-MS calcd. for C16H17N3O3
+: 299.12644; found 299.12695. M.p. 136-138°C. 
 
Synthesis of methyl 4-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenylamino)-4-oxobutanoate 
(27) 
A suspension of 0.3 g (0.94 mmol) of 4-(4-(3-tert-butyl-1,2,4-
oxadiazol-5-yl)phenylamino)-4-oxobutanoic acid in 10 mL of diethyl 
ether was cooled in an ice bath and an solution of diazomethane in 
diethyl ether 2.5 N was added dropwise until the colorless solid 
disappeared and the gas evolution stopped. The solvent was removed under high vacuum. No 
further purification was necessary. Yield: 96% (0.298 g, 0.9 mmol). 
IR (ATR): 1/λ 3391 (w), 2966 (w), 1738 (m), 1702 (m), 1607 (m), 1595 (w), 1507 (s), 1492 
(m), 1524 (w), 1392 (w), 1351 (m), 1327 (s), 1274 (w), 1251 (w), 1197 (m), 1172 (s), 1156 
(s), 1097 (w), 991 (w), 988 (w), 863 (m), 836 (w), 797 (w), 773 (m), 699 (w), 690 (w), 617 (s) 
cm-1. 1H NMR (200 MHz, CDCl3): δ = 8.34 (s, 1H, -NH), 8.11 – 8.02 (m, 2H, Ar-H), 7.70-
7.66 (m, 2H, Ar-H), 3.72 (s, 3H, CH3), 2.82-2.67 (m, 4H, 2 x CH2) 1.42 (s, 9H, t-Bu) ppm. 
13C NMR (50 MHz, CDCl3): δ = 177.62 (Cq, NHCO), 173.97 (Cq, NCO), 173.05 (Cq, 
COOMe), 169.52 (Cq, NCN), 141.06 (Cq), 128.43 (CH), 119.31 (Cq), 118.77 (CH), 51.43 
(CH3, OCH3 ), 31.79 (CH2), 28.38 (CH2), 28.34 (Cq, C(CH3)3), 27.80 ((CH3)3C) ppm. MS: 
m/z = 331 (M+, 10), 299 (50), 284 (15), 202 (100). HR-MS calcd. for C17H21N3O4
+: 
331.15266; found 331.15275. 
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Synthesis of (Z)-4-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenylamino)-4-oxobut-2-enoic 
acid (28) 
0.3 g (1.38 mmol) of 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)aniline was 
mixed under inert conditions with 0.135 g (1.38 mmol) of maleic 
anhydride in 20 mL of DCM. This mixture was vigorously stirred at 
room temperature for 3 hours. The remaining residue was freed from 
solvent and suspended in 50 mL of water, and the pH value was adjusted to 2-3 using a 1 N 
solution of HCl. The resulting suspension was filtered and the solid obtained was dried in 
vacuum and flash chromatographed. Yield: 84% (0.365 g, 1.15 mmol). 
IR (ATR): 1/λ 3288 (w), 3104 (w), 2974 (w), 1707 (m), 1633 (w), 1616 (w), 1586 (m), 1566 
(w), 1532 (s), 1520 (s), 1496 (s), 1467 (m), 1409 (w), 1396 (w), 1348 (w), 1325 (m), 1281 
(w), 1267 (w), 1188 (m), 1101 (w), 976 (m), 899 (w), 849 (s), 776 (m), 737 (w), 738 (w), 632 
(w), 615 (m) cm-1. 1H NMR (200 MHz, DMSO-d6): δ = 12.94 (bs, 1H, -COOH), 10.73 (s, 1H, 
-NH), 8.14 – 8.03 (m, 2H, Ar-H), 7.96-7.85 (m, 2H, Ar-H), 6.61-6.32 (m, 2H, 2 x CH), 1.38 
(s, 9H, t-Bu) ppm. 13C NMR (50 MHz, DMSO-d6): δ = 177.56 (Cq, NHCO), 174.28 (Cq, 
NCO), 166.80 (Cq, COOH), 163.67 (Cq, NCN), 142.77 (Cq), 131.50 (CH=CH), 130.19 
(CH=CH), 128.73 (CH), 119.44 (CH), 118.30 (Cq), 31.98 (Cq, C(CH3)3), 28.07 ((CH3)3C) 
ppm. MS: m/z = 315 (M+, 15), 297 (50), 217 (55), 200 (100), 120 (75). HR-MS calcd. for 
C16H17N3O4
+: 315.12136; found 315.12144. M.p. 214-216°C. 
 
Synthesis of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-1H-pyrrole-2,5-dione (29) 
0.25 g (0.79 mmol) of (Z)-4-(4-(3-tert-butyl-1,2,4-oxadiazol-5-
yl)phenylamino)-4-oxobut-2-enoic acid was mixed with 0.065 g of sodium 
acetate (0.79 mmol) in 15 mL of acetic anhydride, and the mixture was then 
heated for 4 h at 80-85ºC. After cooling, the product was washed with 100 mL of water at pH 
≈ 2-3. The solid was dried in vacuum and flash chromatographed. Yield: 75% (0.176 g, 0.59 
mmol). 
IR (ATR): 1/λ 3474 (w), 3096 (w), 2975 (w), 2927 (w), 1713 (s), 1614 8w), 1567 (w), 1521 
(m), 1502 (m), 1466 (w), 1395 (m), 1385 (m), 1351 (w), 1306 (w), 1238 (w), 1195 (m), 1149 
(s), 1064 (w), 1022 (w), 988 (w), 949 (w), 905 (w), 842 (m), 827 (s), 771 (m), 737 (w), 700 
(s), 686 (m), 652 (w), 624 (w) cm-1. 1H NMR (200 MHz, CDCl3): δ = 8.26 – 8.14 (m, 2H, Ar-
H), 7.62-7.54 (m, 2H, Ar-H), 6.88 (s, 2H, 2 x CH), 1.44 (s, 9H, t-Bu) ppm. 13C NMR (50 
MHz, CDCl3): δ = 178.21 (Cq, NCO), 174.03 (Cq, NCN), 168.66 (Cq, CO), 134.87 (Cq), 
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134.21 (Cq), 128.58 (CH), 125.54 (CH), 123.24 (Cq), 32.31 (Cq, C(CH3)3), 28.27 ((CH3)3C) 
ppm. MS: m/z = 297 (M+, 60), 282 (15), 200 (100). HR-MS calcd. for C16H15N3O3
+: 
297.11079; found 297.11127. M.p. 123-125°C. 
 
Synthesis of 5-(4-(1H-imidazol-1-yl)phenyl)-3-tert-butyl-1,2,4-oxadiazole (30) 
4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)aniline (10.0 g, 0.046 mol) in MeOH 
(20 mL) was treated with 40% aqueous glyoxal (5.25 mL, 0.046 mol) at 
room temperature for 10 min to form a yellow mixture. NH4Cl (4.92 g, 0.092 mol) was added 
followed by 37% aqueous formaldehyde (7.37 mL, 0.092 mol). The mixture was diluted with 
MeOH (100 mL) and heated to reflux for 1 h before H3PO4 (6.45 mL, 85%) was slowly 
added. The resulting mixture was then stirred at reflux for another 12 h. After removal of the 
solvent, the dark residue was poured onto ice (300 g) and stirred at room temperature for 1 
hour. The suspension was filtered and the filtrate was made basic to pH 12 with NaOH 
solution. The colorless solid thus formed was filtered, washed with plenty of water and dried. 
Yield: 48% (5.9 g, 0.022 mmol). 
1H NMR (200 MHz, CDCl3): δ = 8.33 – 8.21 (m, 2H, Ar-H), 7.97 (s, 1H, CHIm), 7.62 – 7.53 
(m, 2H, Ar-H), 7.42 -7.36 (m, 1H, CHIm), 7.28 -7.25 (m, 1H, CHIm), 1.45 (s, 9H, t-Bu). 
13C 
NMR (50 MHz, CDCl3): δ = 179.13 (Cq, NCO), 174.54 (Cq, NCN), 140.85 (Cq), 135.96 
(CH, NCHN), 131.81 (CH, NCHCH), 130.51 (CH), 124.10 (Cq), 121.82 (CH), 118.29 (CH, 
CHCHN), 33.14 (Cq, C(CH3)3), 29.06 ((CH3)3C). MS: m/z = 268.1 (M
+, 90), 253.1 (20), 171 
(100). 
 
Synthesis of 5-(4-((1H-imidazol-1-yl)methyl)phenyl)-3-tert-butyl-1,2,4-oxadiazole (31) 
(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)methanamine (1.07 g, 0.0046 
mol) in MeOH (2 mL) was treated with 40% aqueous glyoxal (0.525 mL, 
0.0046 mol) at room temperature for 10 min to form a yellow mixture. 
NH4Cl (0.492 g, 0.0092 mol) was added followed by 37% aqueous formaldehyde (0.737 mL, 
0.0092 mol). The mixture was diluted with MeOH (10 mL) and heated to reflux for 1 h before 
H3PO4 (0.645 mL, 85%) was slowly added. The resulting mixture was then stirred at reflux 
for another 8 h. After removal of the solvent, the dark residue was poured onto ice (10 g) and 
neutralized with 40% aqueous KOH solution until the solution was at pH = 9. The resulting 
mixture was extracted with dichloromethane (3x10 mL). The organic phases were combined 
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and dried (MgSO4). The product was flash chromatographed with ethyl acetate/hexane. Yield: 
30% (0.3895 g, 0.0013 mmol). 
1H NMR (200 MHz, CDCl3): δ = 8.17 – 8.08 (m, 2H, Ar-H), 7.58 (s, 1H, CHIm), 7.32 – 7.23 
(m, 2H, Ar-H), 7.16 -7.12 (m, 1H, CHIm), 6.94 -6.89 (m, 1H, CHIm), 5.21 (s, 2H, CH2), 1.43 
(s, 9H, t-Bu). 13C NMR (50 MHz, CDCl3): δ = 177.67 (Cq, NCO), 173.51 (Cq, NCN), 140.02 
(Cq), 136.89 (CH, NCHN), 129.62 (CH, NCHCH), 128.09 (CH), 126.99 (CH), 123.78 (Cq), 
118.60 (CH, CHCHN), 49.74 (CH2), 31.88 (Cq, -C(CH3)3), 27.82 ((CH3)3C-). MS: m/z = 
282.2 (M+, 60), 267.1 (5), 215.2 (100). 
 
Synthesis of 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)benzoic acid (32) 
A suspension of 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)benzonitrile (10 g, 
44.00 mmol) and 8.8 g of NaOH (220.00 mmol) in H2O (150 mL) was 
heated to reflux for 3 h. The mixture was cooled to room temperature and the pH was adjusted 
2 using 2 N HCl. The solid thus formed was filtered off, washed with plenty of water (100 
mL) and dried. Yield: 56% (5.59 g, 24.64 mmol). 
1H NMR (200 MHz, CDCl3): δ = 8.26 (s, 4H, Ar-H), 1.45 (s, 9H, t-Bu). 13C NMR (50 MHz, 
CDCl3): δ = 179.13 (Cq, NCO), 165.67 (Cq, COOH), 158.45 (Cq, NCN), 131.41 (Cq, 
CCOOH), 129.25 (Cq), 128.82 (CH), 34.76 (Cq, C(CH3)3), 28.12 ((CH3)3C). MS: EI m/z = 
246.1 (M+, 30), 231.1 (35), 149.1 (100). 
 
Synthesis of methyl 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)benzoate (33) 
A suspension of 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)benzoic acid (1.0 g, 
4.06 mmol) in 50 mL of diethyl ether was cooled in an ice bath and a 2.5 N 
solution of diazomethane in diethyl ether was added dropwise until the colorless solid 
disappeared and the gas evolution stopped. The solvent was removed under high vacuum to 
afford a colorless solid. No further purification was necessary. Yield: 1.02 g (39.43 mmol, 
97%). Crystals suitable for X-ray diffraction analysis were formed by slow evaporation of a 
dichloromethane solution at room temperature. 
1H NMR (200 MHz, CDCl3): δ = 8.27 -8.13 (m, 4H, Ar-H), 3.96 (s, 3H, CH3), 1.44 (s, 9H, t-
Bu). 13C NMR (50 MHz, CDCl3): δ = 178.61 (Cq, NCO), 174.23 (Cq, COOMe), 166.09 (Cq, 
NCN), 133.45 (Cq, CCOOMe), 130.14 (CH), 128.30 (Cq), 128.05 (CH), 52.47 (Cq, CH3), 
32.57 (Cq, C(CH3)3), 28.47 ((CH3)3C). MS: EI m/z = 260.1 (M
+, 30), 245.1 (30), 163.1 (100). 
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Synthesis of 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)-N-(1-hydroxy-2-methylpropan-2-
yl)benzamide (34) 
A mixture of 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)benzoic acid (5 g, 
20.3 mmol) and 4.42 mL of SOCl2 (7.24 g, 60.91 mmol) was stirred at 
ambient temperature under an argon atmosphere for 3 h. The excess SOCl2 was removed by 
distillation and the residue, 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)benzoyl chloride, was 
dissolved in DCM (25 mL) and added dropwise to a solution containing 3.61 g of 2-amino-2-
methyl-1-propanol (40.6 mmol) in DCM (25 mL) at 0 ºC. After the addition was complete, 
the reaction was stirred for 12 h. The precipitate was removed by filtration. The filtrate was 
evaporated and the resulting residue was crystallized from Et2O. Yield: 76% (4.89 g, 15.42 
mmol). 
1H NMR (300 MHz, CDCl3): δ = 8.13 – 8.07 (m, 2H, Ar-H), 7.82 – 7.77 (m, 2H, Ar-H), 6.37 
(bs, 1H, NH), 4.33 (bs, 1H, OH), 3.66 (s, 2H, CH2), 1.38 (s, 6H, 2 x CH3), 1.36 (s, 9H, t-Bu). 
13C NMR (100 MHz, CDCl3): δ = 178.57 (Cq, NCO), 174.09 (Cq, NHCO), 167.09 (Cq, 
NCN), 138.26 (Cq, CCONH), 128.25 (CH), 127.56 (CH), 127.13 (Cq, CCONH), 70.38 (Cq), 
70.38 (Cq), 56.66 (CH2OH), 32.54 (Cq, C(CH3)3), 28.45 ((CH3)3C), 24.49 ((CH3)2C). MS 
(ESI): 318.13 (100, M + H+), 340.0 (60, M + Na+), 656.8 (55, 2 x M + Na+). 
 
Synthesis of 3-tert-butyl-5-(4-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)phenyl)-1,2,4-
oxadiazole (35) 
15 mL of SOCl2 was added dropwise to 4 g of the amide (12.6 mmol) 
under argon atmosphere. After the solution was stirred for 2 h, 15 mL of 
methanol was added to destroy the excess of SOCl2. The reaction 
mixture was then poured into 100 mL of KOH (4 N) solution and twice extracted with Et2O (2 
× 100 mL). The ethereal layer was separated, dried over Na2SO4 and evaporated. Yield: 86% 
(3.24 g, 10.8 mmol). Single crystals suitable for X-ray diffraction analysis were generated by 
slow diffusion of hexane into a concentrated DCM solution. 
1H NMR (300 MHz, CDCl3): δ = 8.11 – 8.06 (m, 2H, Ar-H), 8.02 – 7.97 (m, 2H, Ar-H), 4.06 
(s, 2H, CH2), 1.35 (s, 9H, t-Bu), 1.32 (s, 6H, 2 x CH3). 
13C NMR (100 MHz, CDCl3): δ = 
178.43 (Cq, NCO), 174.41 (Cq, NCO), 161.07 (Cq, NCN), 131.64 (Cq, CCON), 128.73 (CH), 
127.88 (CH), 126.64 (Cq), 79.27 (OCH2C), 67.88 (Cq), 32.48 (Cq, C(CH3)3), 28.46 
((CH3)3C), 28.34((CH3)2C). MS (ESI): 300.17 (100, M + H
+), 301.17 (20, M + H+). 
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Synthesis of 2-[4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl]acetonitrile (36) 
A solution of 4-(cyanomethyl)benzoic acid (27.3 g, 0.17 mol) in DMF (250 
mL) was treated with a solution of CDI (30.2 g, 0.187 mol) in DMF (200 
mL). After 30 min stirring at room temperature, a solution of tert-butylamidoxime (21.7 g, 
0.187 mol) in DMF (100 mL) was added, and the reaction mixture was stirred for 1 h at room 
temperature. A second portion of CDI (27.3 g, 0.17 mol) dissolved in DMF (200 mL) was 
added and the mixture was heated to reflux for 6 h. The mixture was cooled to room 
temperature and poured into a water-ice mixture. The solid thus formed was filtered off, 
washed with water and dried. Yield raw: 70% (17.13 g, 0.12 mol). The substance is 
approximatively 60% pure according to the spectroscopical data. 
1H NMR (200 MHz, CDCl3): δ = 8.12 – 8.03 (m, 2H, Ar-H), 7.78 – 7.62 (m, 2H, Ar-H), 3.65 
(s, 2H, CH2) 1.44 (s, 9H, t-Bu). 
13C NMR (50 MHz, CDCl3): δ = 179.18 (Cq, NCO), 171.46 
(Cq, NCN), 132.56 (CH), 128.38 (CH), 127.69 (Cq), 126.89 (Cq), 110.62 (Cq, CN), 40.12 
(CH2), 32.22 (Cq, C(CH3)3), 28.23 ((CH3)3C). 
 
Synthesis of 2-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)acetic acid (37) 
A suspension of 15 g 2-(4-(3-tert-butyl-1,2,4-oxadiazol-5-
yl)phenyl)acetonitrile (62.24 mmol) and 12.44 g of NaOH (311.20 mmol) 
in H2O (200 mL) was heated to reflux for 5 h. The mixture was cooled to 
room temperature and the pH was adjusted to 2 using 2 N HCl. The solid thus formed was 
filtered off, washed with plenty (150 mL) of water and dried. Yield: 66% (10.68 g, 41.08 
mmol). Single crystals were grown by slow evaporation of a concentrated solution in 
MeOH/DCM. 
1H NMR (200 MHz, CDCl3): δ = 8.06 – 7.96 (m, 2H, Ar-H), 7.41 – 7.29 (m, 2H, Ar-H), 3.65 
(s, 2H, CH2), 1.35 (s, 9H, t-Bu). 
13C NMR (50 MHz, CDCl3): δ = 179.97 (Cq, COOH), 179.11 
(Cq, NCO), 158.65 (Cq, NCN), 137.37 (Cq), 129.43 (CH), 127.73 (CH), 123.05 (Cq), 40.32 
(CH2), 31.87 (Cq, C(CH3)3), 27.83 ((CH3)3C). MS: EI m/z = 260.1 (M
+, 30), 245.1 (35), 163.1 
(100). 
 
Synthesis of 3-tert-butyl-5-(4-hydrazinylphenyl)-1,2,4-oxadiazole (38) 
To a solution of 5.0 g 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)aniline (23.02 
mmol) in propionic acid (30 mL) cooled at 0ºC was added dropwise to a 
solution of 1.75 g of NaNO2 (25.32 mmol) in H2SO4 (14.7 mL). After stirring the reaction 
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mixture for 1 h at 0ºC the cooling was removed and the mixture was stirred 1h at room 
temperature. The reaction was cooled again to 0ºC and a solution of 13.9 g of SnCl2 (73.6) in 
37% HCl (12.5 mL) was added dropwise. The cooling was removed and the mixture was 
stirred 1h at room temperature. Afterwards the reaction was diluted with a solution of NaOH 
(50%) until pH-14, and the mixture was extracted with Et2O (3x100 mL). The combined 
organic layer was washed with brine, dried over Na2SO4, and concentrated. The residue was 
chromatographed on a column of silica gel with ethyl acetate-hexane (1: 1). Yield: 80% (4.3 
g, 18.5 mmol). 
1H NMR (200 MHz, CDCl3): δ = 7.94 – 7.84 (m, 2H, Ar-H), 6.85 – 6.73 (m, 2H, Ar-H), 5.72 
– 5.44 (bs, NH), 3.71 – 3.48 (bs, NH2), 1.34 (s, 9H, t-Bu) ppm. 13C NMR (50 MHz, CDCl3): δ 
= 178.05 (Cq, NCO), 175.34 (Cq, NCN), 154.16 (Cq, CNHNH2), 129.67 (CH), 114.78 (Cq), 
111.32 (CH), 32.38 (Cq, C(CH3)3), 28.52 ((CH3)3C) ppm. MS: m/z = 232.2 (M
+, 55), 217.2 
(15), 145.1 (100). 
 
Synthesis of 5-amino-1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(methylthio)-1H-
pyrazole-4-carbonitrile (39) 
A mixture of 3 g 3-tert-butyl-5-(4-hydrazinylphenyl)-1,2,4-oxadiazole 
(12.93 mmol) and 2.20 g (12.93 mmol) of 
(bis(methylthio)methylene)malononitrile in methanol (50 mL) was refluxed for 6 h. After 
cooling, the resulting precipitate was collected and crystallized from methanol to afford 
colorless solid. Yield: 76% (3.48 g, 9.8 mmol). 
1H NMR (300.1 MHz, DMSO-d6): δ = 8.24 – 8.19 (m, 2H, Ar-H), 7.82 – 7.76 (m, 2H, Ar-H), 
7.19 – 7.06 (bs, NH2), 2.80 (s, 3H, -CH3), 1.40 (s, 9H, t-Bu) ppm. 13C NMR (75.47 MHz, 
DMSO-d6): δ = 177.86 (Cq, NCO), 173.95 (Cq, NCN), 152.68 (Cq, CNH2), 152.68 (Cq, 
CSCH3), 150.11 (Cq), 140.85 (Cq), 129.05 (CH), 124.04 (CH), 124.04 (Cq, CN), 73.94 (Cq, 
CCN), 32.12 (Cq, C(CH3)3), 28.12 ((CH3)3C), 13.16 (SCH3) ppm. MS (HR-ESI): calcd. For 
C17H19N6OS + H: 355, 1341; found: 355,1362 (100). 
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Synthesis of N-(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-4-cyano-3-(methylthio)-
1H-pyrazol-5-yl)acetamide (40) 
A solution of 2 g 5-amino-1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-
yl)phenyl)-3-(methylthio)-1H-pyrazole-4-carbonitrile (5.64 mmol) in 
glacial acetic acid (15 mL) and acetic anhydride (20 mL) was heated to 
reflux for 12 h. The solvent was removed under reduced pressure to give a solid, which was 
crystallized from methanol to afford colorless crystals. Yield: 57% (1.27 g, 3.21 mmol). 
1H NMR (300.1 MHz, DMSO-d6): δ = 10.98 – 10.72 (bs, NH), 8.29 – 8.22 (m, 2H, Ar-H), 
7.84 – 7.72 (m, 2H, Ar-H), 2.63 (s, 3H, CH3), 2.08 (s, 3H, CH3), 1.40 (s, 9H, t-Bu) ppm. 13C 
NMR (75.47 MHz, DMSO-d6): δ = 177.90 (Cq, NCO), 173.78 (Cq, C=O), 168.90 (Cq, NCN), 
150.87 (Cq, CNH), 142.42 (Cq, CS), 140.56 (Cq), 129.11 (CH), 124.19 (CH), 123.20 (Cq), 
111.75 (Cq, CN), 89.23 (Cq, CCN), 32.13 (Cq, C(CH3)3), 28.11 ((CH3)3C), 22.61 (COCH3), 
13.51 (SCH3) ppm. MS (HR-ESI): calcd. For C19H20N6O2S + Na: 419,1266; found: 419,1254 
(100); (2 X C19H20N6O2S) + Na: 815,2634; found: 815,2617 (35). 
 
Synthesis of 3-tert-butyl-5-(4-isothiocyanatophenyl)-1,2,4-oxadiazole (41) 
To a solution of 6.1 g Na2CO3 (57.52 mmol) in 30 mL of water (cooled at 
0-5ºC) a solution of 7.51 g of triphosgene (25.31 mmol) in DCM (30 mL) 
was added. The mixture was stirred vigorously for 5 minutes at 0-5ºC. Then 5 g of 4-(3-tert-
butyl-1,2,4-oxadiazol-5-yl)aniline (23.01 mmol) dissolved in 10 mL of DCM was added 
slowly and the cooling was removed. The resulting mixture was stirred for 4 hours at room 
temperature. When the reaction was finished, the two phases were separated. The aqueous 
phase was washed 2 times with dichloromethane and then all DCM phases were combined 
and washed with water, dried on Na2SO4 and evaporated. Yield: 96% (5.73 g, 22.09 mmol). 
1H NMR (200 MHz, CDCl3): δ = 8.12 – 7.97 (m, 2H, Ar-H), 7.33 – 7.24 (m, 2H, Ar-H), 1.36 
(s, 9H, t-Bu) ppm. 13C NMR (50 MHz, CDCl3): δ = 178.53 (Cq, NCO), 173.93 (Cq, NCN), 
135.24 (Cq, NCS), 129.45 (CH), 129.36 (Cq), 126.29 (CH), 123.15 (Cq), 32.55 (Cq, 
C(CH3)3), 28.46 ((CH3)3C) ppm. MS: EI m/z = 259.1 (M
+, 60), 244.1 (15), 162.1 (100). 
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Synthesis of 2-(((4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)amino)(methylthio)-
methylene)malononitrile (42) 
To an ice cooled solution of 1.32 g malononitrile (20mmol), 5.18 g of 3-
tert-butyl-5-(4-isothiocyanatophenyl)-1,2,4-oxadiazole (20 mmol) and 
2.84 g of iodomethane (20 mmol) in anhydrous DMF (25 mL), was 
added in a single portion 0.88 g of 60% sodium hydride dispersion in mineral oil (0.88 g, 20 
mmol). The resulting mixture was stirred at room temperature for 2 h, then at 50–55 ºC for 30 
min. The solid formed after adding water (150 mL) was filtered, dissolved in dichloromethane 
and dried. Evaporating the solvent in vacuum gave a residue that was crystallized from 
methanol dichloromethane 4:1 to give a colorless solid. Yield: 90% (6.11 g, 18 mmol). 
1H NMR (200 MHz, DMSO-d6): δ = 11.01 – 10.73 (bs, NH), 8.22 – 8.09 (m, 2H, Ar-H), 7.63 
– 7.47 (m, 2H, Ar-H), 2.59 (s, 3H, -CH3), 1.39 (s, 9H, t-Bu) ppm. 13C NMR (50 MHz, 
DMSO-d6): δ = 177.66 (Cq, NHCS), 173.95 (Cq, NCO), 171.79 (Cq, NCN), 142.61 (Cq), 
128.69 (CH), 123.26 (CH), 121.21 (Cq, CN), 120.39 (Cq), 55.65 (Cq, C(CN)2), 31.98 (Cq, 
C(CH3)3), 28.02 ((CH3)3C), 15.87 (SCH3) ppm. MS: EI m/z = 339.1 (M
+, 60), 291.1 (50), 
194.0 (100). 
 
Synthesis of 5-amino-3-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenylamino)-1H-pyrazole-
4-carbonitrile (43) 
A mixture of 5 g 2-((4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenylamino)-
(methylthio)methylene)malononitrile (14.75 mmol) and 0.866 mL of 
hydrazine monohydrate (0.894, 17.85 mmol) in methanol  (20 mL) was 
stirred for 1 h at 65 °C. After cooling at room temperature, the mixture was diluted with water 
(50 ml) and stirred for 1 h. The resulting precipitate was collected by filtration and washed 
with water (50 ml) to give a colorless solid. Yield: 93% (4.43 g, 13.71 mmol). 
1H NMR (200 MHz, DMSO-d6): δ = 11.46 – 11.32 (bs, NH), 9.18 – 9.02 (bs, NH), 7.96 – 
7.85 (m, 2H, Ar-H), 7.67 – 7.56 (m, 2H, Ar-H), 6.48 – 6.28 (bs, NH2), 1.35 (s, 9H, t-Bu) ppm. 
13C NMR (50 MHz, DMSO-d6): δ = 177.32 (Cq, NCO), 174.75 (Cq, NCN), 152.89 (Cq, 
NHC), 149.59 (Cq, CNH2), 146.85 (Cq), 128.68 (CH), 115.75 (CH), 114.74 (Cq), 113.86 (Cq, 
CN), 31.90 (Cq, C(CH3)3), 28.11 ((CH3)3C) ppm. MS (HR-ESI): calcd. for C16H17N7O + H: 
324,1572; found: 324,1568 (15); C16H17N7O + Na: 346,1392; found: 346,1388 (100). 
 
Experimental section 
166 
Synthesis of 3-((4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)amino)-1,5-dihydro-4H-
pyrazolo[3,4-d]pyrimidin-4-one (44) 
A mixture of 1.0 g 5-amino-3-(4-(3-tert-butyl-1,2,4-oxadiazol-5-
yl)phenylamino)-1H-pyrazole-4-carbonitrile (3.09 mmol) and formic 
acid (35 mL) was refluxed for 2 h. The reaction mixture was cooled to 
room temperature, and then added slowly to ice water. The solid thus formed was collected by 
filtration, washed with water and dried. The solid was chromatographed on a column of silica 
gel with ethyl acetate-hexane (1: 2). Yield: 63% (0.685 g, 1.95 mmol). 
1H NMR (400 MHz, DMSO-d6): δ = 13.27 – 12.92 (bs, NH), 12.24 – 11.96 (bs, NH), 8.74 – 
8.65 (bs, NH), 8.02 (s, 1H, -CHPyrimidine), 7.98 – 7.94 (m, 2H, Ar-H), 7.87 – 7.81 (m, 2H, Ar-
H), 1.36 (s, 9H, t-Bu) ppm. 13C NMR (100 MHz, DMSO-d6): δ = (DMSO-d6, 100 MHz): 
177.45 (Cq, NCO), 174.80 (Cq, C=O), 157.75 (Cq, NCN), 152.80 (Cq, NHCN), 148,67 (Cq, 
NHCN), 146,16 (NHCHN), 146,05 (Cq), 128.79 (CH), 116.37 (CH), 114.24 (Cq), 113.03 
(Cq), 32.01 (Cq, C(CH3)3), 28.19 ((CH3)3C) ppm. MS (ESI): 352.15 (20, M + H
+), 374.13 
(100, M + Na+). 
 
Synthesis of 3-((4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)amino)-1,7-dihydro-4H-
pyrazolo[3,4-d]pyrimidine-4,6(5H)-dithione (45) 
A mixture of 1.0 g 5-amino-3-(4-(3-tert-butyl-1,2,4-oxadiazol-5-
yl)phenylamino)-1H-pyrazole-4-carbonitrile (3.09 mmol) and CS2 (5 
mL) in pyridine (25 mL) was refluxed for 24 h. The reaction mixture 
was cooled to room temperature and the solid thus formed was collected by filtration and 
recrystallized from DMF. Yield: 16% (0.197 g, 0.494 mmol). 
1H NMR (400 MHz, DMSO-d6): δ = 13.35 – 12.70 (bs, NH), 9.64 – 9.53 (bs, 2H, 2 x NH), 
8.07 – 7.99 (m, 2H, Ar-H), 7.80 – 7.69 (m, 2H, Ar-H), 3.69 – 3.09 (-bs, NH), 1.35 (s, 9H, t-
Bu) ppm. 13C NMR (100 MHz, DMSO-d6): δ = 179.71 (Cq, C=S), 177.54 (Cq, NCO), 174.56 
(Cq, C=S), 172.34 (Cq, NCN), 157,58 (Cq, NHCN), 147,37 (Cq, NHCN), 143,92 (Cq), 
129.21 (CH), 116.97 (CH), 115.59 (Cq), 101.23 (Cq), 32.05 (Cq, C(CH3)3), 28.20 ((CH3)3C) 
ppm. MS (ESI): 400.10 (100, M + H+). 
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Synthesis of N3-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-1H-pyrazolo[3,4-
d]pyrimidine-3,4-diamine (46) 
A mixture of 1.0 g 5-amino-3-(4-(3-tert-butyl-1,2,4-oxadiazol-5-
yl)phenylamino)-1H-pyrazole-4-carbonitrile (3.09 mmol) and 
formamide (35 mL) was refluxed for 5 h. The reaction mixture was 
cooled to room temperature, and then slowly added into ice water. The solid thus formed was 
collected by filtration, washed with water and cold ethanol and dried. The solid was 
chromatographed on a column of silica gel with ethyl acetate-hexane (1: 1). Yield: 51% 
(0.552 g, 1.57 mmol). 
1H NMR (400 MHz, DMSO-d6): δ = 12.83 – 12.74 (bs, NH), 9.02 – 8.98 (bs, NH), 8.12 (s, 
1H, -CHPyrimidine), 8.03 – 7.97 (m, 2H, Ar-H), 7.83 – 7.77 (m, 2H, Ar-H), 7.56 – 7.48 (bs, 2H, 
NH2), 1.33 (s, 9H, t-Bu) ppm. 
13C NMR (100 MHz, DMSO-d6): δ = 177.46 (Cq, NCO), 
170.28 (Cq, NCN), 157.35 (Cq, CNH2), 156,28 (Cq, NHCN), 154,88 (CH, NHCHN), 146,87 
(Cq, NHCN), 142,18 (Cq), 128.90 (CH), 116.26 (CH), 114.16 (Cq), 90.88 (Cq), 32.01 (Cq, 
C(CH3)3), 28.18 ((CH3)3C) ppm. MS (HR-ESI): calcd. for C17H18N8O+ H: 351,1681; found: 
351,1676 (100). 
 
Synthesis of N3-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)-6-phenyl-1H-pyrazolo[3,4-
d]pyrimidine-3,4-diamine (47) 
A mixture of 1.0 g 5-amino-3-(4-(3-tert-butyl-1,2,4-oxadiazol-5-
yl)phenylamino)-1H-pyrazole-4-carbonitrile (3.09 mmol), 0.726 g 
benzamidine hydrochloride hydrate (4.63 mmol) and 0.507 g of 
sodium acetate (6.18 mmol) was heated for 30 minutes at 220ºC in naphthalene (20 g). The 
reaction mixture was cooled to room temperature, and then slowly added into ice water. The 
solid thus formed was collected by filtration, washed with water and cold ethanol and dried. 
The solid was chromatographed on a column of silica gel with chloroform-methanol (10: 1). 
Yield: 23% (0.303 g, 0.710 mmol). 
1H NMR (400 MHz, DMSO-d6): δ = 12.91 – 12.82 (bs, NH), 9.07 – 8.98 (bs, NH), 8.43 – 
8.34 (m, 2H, Ar-H), 8.05 – 7.98 (m, 2H, Ar-H), 7.87 – 7.82 (m, 2H, Ar-H), 7.69 – 7.56 (bs, 
2H, NH2), 7.53 – 7.44 (m, 3H, Ar-H), 1.36 (s, 9H, t-Bu) ppm. 13C NMR (100 MHz, DMSO-
d6): δ = 177.51 (Cq, NCO), 174.85 (Cq, BzCN2), 161.37 (Cq, NCN), 157.35 (Cq, NCNH2), 
156.29 (Cq, NHCN), 146.90 (Cq, NHCN), 142,36 (Cq), 138.15 (Cq), 130.10 (Cq), 128.96 
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(CH), 128.21 (CH), 127.89 (CH), 116.34 (CH), 114.19 (Cq), 89.78 (Cq), 32.05 (Cq, 
C(CH3)3), 28.23 ((CH3)3C) ppm. MS (HR-ESI): calcd. for C23H22N8O+ H: 427,1994; found: 
427,1987 (100); C23H22N8O+ Na: 449,1814; found: 449,1805 (30). 
 
1,3-bis(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-imidazolium chloride (48) 
To a solution of paraformaldehyde (0.98 g, 33 
mmol) in toluene (40 mL) was added 4-(3-tert-
butyl-1,2,4-oxadiazol-5-yl)aniline (14.16 g, 65.2 
mmol) and 40% (v/v) aqueous glyoxal (4.74 g, 
32.6 mmol) followed by the dropwise addition of 37% (v/v) HCl (3.72 mL, 32.6 mmol). The 
mixture was heated to reflux and the water was removed using a Dean-Stark apparatus. The 
solvent was removed under reduced pressure, and the resulting residue was triturated with 
acetone, leaving a pale-brown solid. Yield: 55% (10.5 g, 20.7 mmol). 
IR (ATR): 1/λ = 3415, 3360, 3063, 2970, 2931, 2908, 2872, 1610, 1584, 1553, 1524, 1510, 
1495, 1467, 1435, 1399, 1353, 1340, 1303, 1270, 1219, 1194, 1106, 1083, 1023, 1006, 987, 
952, 909, 854, 840, 773, 735, 696 cm-1. 1H NMR (300.1 MHz, DMSO-d6): δ = 10.76 (s, 1 H, 
NCHN), 8.78 (br s, 2 H, NCHCHN), 8.49-8.41 (m, 4 H, Ar-H), 8.31-8.22 (m, 4 H, Ar-H), 
1.42 (s, 18 H, t-Bu) ppm. MS (HR-ESI): calcd. for C27H29N6O2
+: 469.2352; found: 469.2357 
(100). 
 
1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-methyl-imidazolium iodide (49) 
A solution of 5-(4-(1H-imidazol-1-yl)phenyl)-3-(tert-butyl)-1,2,4-
oxadiazole (2.5 g, 9.31 mmol) and CH3I (1.45 g, 0.639 mL, 10.24 
mmol) in dry THF (20 mL) was placed under an argon atmosphere 
and stirred at room temperature for 24 h. The precipitate was 
collected by filtration, washed with diethyl ether and dried in vacuo, giving a colorless solid. 
Yield: 98% (3.6 g, 9.12 mmol). 
IR (ATR): 1/λ = 3152, 3106, 3077, 3053, 3024, 2972, 2929, 2869, 1926, 1700, 1675, 1616, 
1594, 1582, 1547, 1522, 1507, 1470, 1441, 1414, 1392, 1356, 1319, 1291, 1241, 1200, 1139, 
1099, 1066, 1029, 991, 972, 954, 898, 847, 772, 733, 692, 679, 632, 620 cm-1. 1H NMR 
(300.1 MHz, DMSO-d6): δ = 9.98 (s, 1 H, NCHN), 8.45 (br s, 1 H, NCHCHN), 8.41-8.33 (m, 
2 H, Ar-H), 8.13-8.01 (m, 3 H, Ar-H, NCHCHN), 3.99 (s, 3 H, CH3), 1.39 (s, 9 H, t-Bu) ppm. 
13C NMR (75.47 MHz, DMSO-d6): δ = 177.9 (NCO), 173.5 (NCNox), 137.3 (NCHNIm), 136.4 
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(NCAr), 129.7 (CHAr), 124.7 (CAr), 124.3 (CHNCH3Im), 122.5 (CHAr), 120.6 (CHNArIm), 36.3 
(CH3), 32.1 (CCH3), 28.0 (CCH3) ppm. MS (HR-ESI): calcd. for C16H19N4O
+: 283.1559; 
found: 283.1554 (100). 
 
1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(benzyl)-imidazolium bromide (50) 
A solution of 5-(4-(1H-imidazol-1-yl)phenyl)-3-(tert-butyl)-
1,2,4-oxadiazole (0.5 g, 1.86 mmol) and 0.22 mL of benzyl 
bromide (0.318 g, 1.86 mmol) in dry Toluene (10 mL) was 
placed under an inert atmosphere and stirred for 48 h. After 
cooling, the imidazolium salt was precipitated by adding Et2O (50 mL). After filtration and 
drying under vacuum, a colorless solid was obtained. Yield: 84% (0.685 g, 1.56 mmol).  
IR (ATR): 1/λ = 3357, 3153, 3114, 3030, 2973, 2930, 2904, 2870, 1614, 1566, 1545, 1521, 
1507, 1497, 1468, 1452, 1434, 1419, 1396, 1371, 1352, 1287, 1236, 1224, 1194, 1100, 1066, 
1028, 954, 858, 846, 827, 813, 772, 759, 735, 716, 691, 691, 626 cm-1. 1H NMR (300.1 MHz, 
DMSO-d6): δ = 10.41 (s, 1 H, NCHN), 8.53 (s, 1 H, CHIm), 8.42-8.33 (m, 2 H, Ar-H), 8.22-
8.15 (m, 2 H, Ar-H), 8.12 ( s, 1 H, CHIm), 7.67-7.58 (m, 2 H, Ar-HBn), 7.52-7.38 (m, 3 H, Ar-
HBn), 5.61 (s, 2 H, CH2), 1.39 (s, 9 H, t-Bu) ppm. 
13C NMR (75.47 MHz, DMSO-d6): δ = 
177.9 (NCO), 173.5 (NCNox), 137.8 (NCHNIm), 136.0, 134.3 (NCAr), 129.6, 128.9, 128.8, 
128.6, 124.3, 123.4 (CHIm), 122.7, 121.3 (CHIm), 52.4 (CH2-Bn), 32.1 (CCH3), 28.1 (CCH3) 
ppm. MS (HR-ESI): calculated for C22H23ON4
+: 359.1866 (100), 360.1900 (25), 361.1932 (5); 
found: 359.1856 (100), 360.1885 (25), 361.1919 (5). 
 
1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(2-pyridine)-imidazolium bromide (51) 
A solution of 5-(4-(1H-imidazol-1-yl)phenyl)-3-(tert-butyl)-
1,2,4-oxadiazole (0.3 g, 1.12 mmol) and 2-bromopyridine 
(3.314 g, 2 mL, 20.97 mmol) was placed under an argon 
atmosphere and stirred at 160 °C for 48 h. The reaction was 
cooled to room temperature and Et2O was added. The precipitate thus formed was collected 
by filtration, washed with diethyl ether and dried in vacuum. It remained a light grey solid. 
Yield: 93% (0.36 g, 1.04 mmol). 
IR (ATR): 1/λ = 3538, 3176, 3097, 3060, 3042, 2974, 2931, 2903, 2869, 2819, 2359, 2339, 
1805, 1727, 1646, 1617, 1598, 1573, 1548, 1523, 1509, 1476, 1443, 1445, 1395, 1351, 1322, 
1290, 1271, 1198, 1148, 1102, 1064, 1017, 992, 971, 950, 882, 850, 830, 785, 772, 735, 711, 
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694, 639, 617 cm-1. 1H NMR (300.1 MHz, DMSO-d6): δ = 10.88 (s, 1 H, NCHN), 8.83 (m, 1 
H, CHPy), 8.77 (m, 1 H, CHPy), 8.73 (d, 1 H, CHPy), 8.43-8.38 (m, 2 H, Ar-H), 8.36-8.27 (m, 4 
H, CHIm, Ar-H), 7.77-7,69 (m, 1 H, CHPy), 1.41 (s, 9 H, t-Bu) ppm. 
13C NMR (75.47 MHz, 
DMSO-d6): δ = 177.9 (NCO), 173.5 (NCNox), 149.2 (CPy), 146.1 (CHPy), 140.6 (CHPy), 137.6 
(NCHNIm), 134.8 (NCAr), 129.5 (CHAr), 125.6 (CAr), 124.7 (CHPy), 123.1 (CHAr), 121.9 
(CHIm), 120.1 (CHIm), 114.9 (CHPy), 32.2 (CCH3), 28.1 (CCH3) ppm. MS (HR-ESI): calcd. 
for C20H20AuN5O
+: 346.1668 (100), 347.1701 (20), 348.1735 (3); found: 346.1663 (100), 
347.1704 (20), 348.1731 (3). 
 
1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(9-methyl-anthracene)-imidazolium 
chloride (52) 
A solution of 5-(4-(1H-imidazol-1-yl)phenyl)-3-(tert-
butyl)-1,2,4-oxadiazole (1 g, 3.72 mmol) and 9-
(chloromethyl)anthracene (0.85 g, 3.72 mmol) in dry 
toluene (50 mL) was placed under an inert atmosphere 
and stirred under reflux for 48 h. The precipitate was 
collected by filtration, washed with diethyl ether and dried in vacuum, giving a gray solid. 
Yield: 24% (0.45 g, 0.9 mmol).  
IR (ATR): 1/λ = 3167, 3051, 3024, 2974, 2958, 2933, 2905, 2846, 2822, 1949, 1928, 1617, 
1596, 1552, 1523, 1508, 1476, 1465, 1451, 1439, 1424, 1395, 1373, 1356, 1314, 1291, 1235, 
1198, 1159, 1144, 1112, 1102, 1071, 1055, 1018, 993, 953, 886, 868, 854, 844, 827, 796, 774, 
736, 721, 697, 624 cm-1. 1H NMR (300.1 MHz, DMSO-d6): δ = 10.49 (s, 1 H, NCHN), 8.86 
(s, 1 H, CHAn), 8.62-8.52 (m, 2 H, Ar-H), 8.44 ( s, 1 H, NCHCHN), 8.36-8.15 (m, 4 H, CHAn), 
8.12-7.98 (m, 2 H, Ar-H), 7.93-7.44 (m, 5 H, CHAn, NCHCHN), 6.67 (s, 2 H, CH2), 1.38 (s, 9 
H, t-Bu) ppm. 13C NMR (75.47 MHz, DMSO-d6): δ = 177.9 (NCO), 173.4 (NCNox), 147.2 
(NCHNIm), 135.8 (NCAr), 131.0, 130.8, 130.3, 129.5, 129.3, 127.8, 125.5, 124.3 (CHIm), 
123.6, 123.1, 122.7, 121.2 (CHIm), 45.5 (CH2-An), 32.1 (CCH3), 28.1 (CCH3) ppm. MS (HR-
ESI): calcd. for C30H27N4O
+: 459.2185; found: 459.2185 (100). 
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1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-((2-ethyl)indole)-imidazolium bromide 
(53) 
A solution of 5-(4-(1H-imidazol-1-yl)phenyl)-3-(tert-
butyl)-1,2,4-oxadiazole (0.5 g, 1.86 mmol) and 3-(2-
bromoethyl)indole (0.418 g, 1.86 mmol) in dry toluene 
(30 mL) was placed under an inert atmosphere and stirred 
under reflux for 48 h. The precipitate was collected by 
filtration, washed with diethyl ether, dried and flash chromatographed with DCM/MeOH. 
Yield: 20% (0.180 g, 0.365 mmol).  
IR (ATR): 1/λ = 3357, 3129, 3063, 2974, 2972, 2869, 1616, 1542, 1475, 1429, 1403, 1355, 
1281, 1228, 1196, 1097, 1011, 963, 854, 783, 743, 699, 685, 643, 608, 591, 558. 1H NMR 
(300.1 MHz, DMSO-d6): δ = 11.04 (s, 1 H, NH), 10.09 (s, 1 H, NCHN), 8.47 (s, 1 H, CHIn), 
8.42-8.31 (m, 2 H, Ar-H), 8.14 ( s, 1 H, CHIm), 8.08-7.97 (m, 2 H, Ar-H), 7.66-7.58 (m, 1 H, 
CHIn), 7.44-7.35 (m, 1 H, CHIn), 7.26 ( s, 1 H, CHIm), 7.14-7.06 (m, 1 H, CHIn), 7.05-6.94 (m, 
1 H, CHIn), 4.68-4.53 (m, 2 H, CH2), 3.47-3.38 (m, 2 H, CH2), 1.41 (s, 9 H, t-Bu) ppm. 
13C 
NMR (75.47 MHz, DMSO-d6): δ = 177.9 (NCO), 173.5 (NCNox), 138.4 (NCHNIm), 137.7, 
136.1, 135.8, 135.3, 129.6, 129.5, 126.8, 124.3, 123.8, 123.5, 123.2, 122.5, 122.3, 121.2, 
120.6, 119.96, 118.5, 117.9, 111.5 (Ar-CHIn), 109.1 (CH2-CIn), 50.2 (CH2), 32.2 (CCH3), 28.1 
(CCH3), 25.6 (CH2) ppm. MS (HR-ESI): calculated for C25H26N5O
+: 412.2137; found: 
412.2135. 
 
1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(2,3,4,5-tetra-O-acetyl-D-glucopyra-
nosyl)-imidazolium nitrate (54) 
To a solution of 2,3,4,5-tetra-O-acetyl-D-
glucopyranosylbromide (1.68 g, 4.09 mmol) in 
acetonitrile (20 ml) were added silver nitrate (0.7 g, 
4.09 mmol) and 5-(4-(1H-imidazol-1-yl)phenyl)-3-
(tert-butyl)-1,2,4-oxadiazole (1 g, 3.72 mmol). The 
reaction mixture was stirred at 50° C for 24 h. All insoluble materials were removed by 
filtration through Celite, and the solution was concentrated under reduced pressure. The 
resulting solid was dissolved in DCM and stirred over Na2CO3 for 30 min. After filtration the 
product was recrystallized several times from DCM / Methyl-tert-butylether to give a 
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colorless solid. Only the β isomer was observed in NMR spectra. Yield: 18% (0.45 g, 0.68 
mmol).  
IR (ATR): 1/λ = 3098, 2972, 2933, 2360, 2340, 1754, 1747, 1618, 1552, 1510, 1432, 1396, 
1368, 1350, 1331, 1314, 1244, 1219, 1195, 1162, 1122, 1090, 1068, 1052, 1017, 954, 943, 
919, 896, 852, 828, 775, 737, 696, 652, 625 cm-1. 1H NMR (300.1 MHz, CDCl3): δ = 11.09 (s, 
1 H, NCHN), 8.39-8.31 (m, 2 H, Ar-H), 8.12 (s, 1 H, CHIm), 8.02-7.94 (m, 2 H, Ar-H), 7.91 
(s, 1 H, CHIm), 6.46 (d, JHH = 8.6 Hz, 1 H, N-CH-O), 5.58 (d, JHH = 2.5 Hz, 1 H, CH2), 5.51-
5.34 (m, 2 H, 2xCHcarbohydrate), 4.49 (t, JHH = 12.6 Hz, 1 H, CHcarbohydrate), 4.29-4.15 (m, 1 H, 
CHcarbohydrate), 4.21 (d, JHH = 2.3 Hz, 1 H, CH2), 2.23 (s, 3 H, CH3), 2.06 (s, 3 H, CH3), 2.05 (s, 
3 H, CH3), 1.99 (s, 3 H, CH3), 1.43 (s, 9 H, t-Bu) ppm. 
13C NMR (75.47 MHz, CDCl3): δ = 
178.6 (NCO), 173.1 (NCNox), 137.8 (NCHNIm), 170.4 (CH3-C=O), 169.8 (CH3-C=O), 169.3 
(CH3-C=O), 137.3 (N-CH-N), 136.8 (CAr), 130.3 (CHAr), 126.6 (CHIm), 122.4 (CHAr), 121.5 
(CAr), 120.9 (CHIm), 85.2 (N-CHcarbohydrate-O), 74.3 (O-CHcarbohydrate-CH2), 70.3 (CHcarbohydrate), 
68.2 (CHcarbohydrate), 66.8 (CHcarbohydrate), 61.1 (CH-CH2carbohydrate-OAc), 32.5 (C-CH3), 28.4 
(C-CH3), 20.6 (COO-CH3), 20.5 (COO-CH3), 20.3 (COO-CH3) ppm. MS (HR-ESI): 
calculated for C29H35O10N4
+: 599.2347 (100), 600.2378 (30), 601.2404 (10); found: 599.2348 
(100), 600.2375 (30), 601.2400 (10). 
 
1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(QCI)-imidazolium bromide (55) 
A solution of 5-(4-(1H-imidazol-1-yl)phenyl)-3-(tert-
butyl)-1,2,4-oxadiazole (0.3 g, 1.11 mmol) and 0.22 mL of 
QCI-C9-Br (0.257 g, 1.11 mmol) in dry toluene (10 mL) 
was placed under an inert atmosphere and refluxed for 12 
h. After cooling, the imidazolium salt was precipitated by 
adding Et2O (50 mL). After filtration and drying under 
vacuum, a colorless solid was obtained. Yield: 58% (0.32 g, 0.643 mmol).  
IR (ATR): 1/λ = 3162, 3121, 3083, 2957, 2945, 2875, 2865, 1963, 1932, 1829, 1734, 1689, 
1666, 1639, 1622, 1597, 1589, 1571, 1543, 1514, 1499, 1465, 1456, 1425, 1407, 1395, 1369, 
1349, 1328, 1290, 1275, 1260, 1245, 1198, 1175, 1139, 1124, 1112, 1061, 1053, 1037, 989, 
958, 941, 912, 893, 876, 853, 832, 795, 778, 747, 726, 712, 678, 668, 639, 619 cm-1. 1H NMR 
(300.1 MHz, CD3OD): δ = 9.26 (bs, 1 H, NCHN), 8.42-8.38 (m, 2 H, Ar-H), 8.28 (d, JHH = 
2.1 Hz, 1 H, CHIm), 8.17 (d, JHH = 2.1 Hz, 1 H, CHIm), 8.12-8.09 (m, 2 H, Ar-H), 6.06 (ddd, 
JHH = 17.49, JHH = 10.01, JHH = 7.50, 1 H, H-10), 5.28-5.13 (m, 2 H, H-11, H-11), 4.17 (dd, J 
= 15.34, J = 5.82, 1 H, H-9), 3.67 (dd, J = 15.4, J = 6.12, 1 H, H-9), 3.53-3.44 (m, 1 H; H-2), 
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3.19-3.07 (m, 2 H; H-6, H-7), 2.79-2.71 (m, 1 H, H-6), 2.38-2.39 (m, 1 H, H-7), 2.09-1.91 
(m,3 H, H-5, H-3, H-4), 1.45 (s, 9 H, t-Bu), 1.41-1.38 (m, 2 H, H-8, H-8), 0.93-0.74 (m, 1 H, 
H-3) ppm. 13C NMR (75.47 MHz, CD3OD): δ = 179.8 (NCO), 175.1 (NCNox), 140.3 (CH, C-
10), 139.3 (NCHNIm), 130.9 (NCAr), 126.9, 125.0 (CHIm), 124.5, 123.0 (CHIm), 116.8 (CH2, 
C-11), 56.8 (CH2, C-9), 55.3 (CH, C-2), 51.4 (CH2, C-7), 42.2 (CH2, C-6), 39.1 (CH, C-4), 
33.5 (CCH3), 28.8 (CCH3), 28.2 (CH2, C-8), 26.0 (CH, C-5), 25.5 (CH2, C-3) ppm. MS (HR-
ESI): calculated for C25H32N5O
+: 418.2607 (100), 419.2640 (35); found: 418.2588 (100), 
419.2583 (35). 
 
1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(QCD)-imidazolium bromide (56) 
A solution of 5-(4-(1H-imidazol-1-yl)phenyl)-3-(tert-
butyl)-1,2,4-oxadiazole (0.3 g, 1.11 mmol) and 0.22 mL 
of QCD-C9-Br (0.257 g, 1.11 mmol) in dry toluene (10 
mL) was placed under an inert atmosphere and refluxed 
for 12 h. After cooling, the imidazolium salt was 
precipitated by adding Et2O (50 mL). After filtration and drying under vacuum, a colorless 
solid was obtained. Yield: 63% (0.348 g, 0.699 mmol).  
IR (ATR): 1/λ = 3125, 3099, 2979, 2949, 2907, 2875, 2859, 1957, 1912, 1731, 1699, 1639, 
1619, 1599, 1578, 1551, 1518, 1499, 1468, 1459, 1431, 1396, 1349, 1325, 1311, 1247, 1234, 
1199, 1129, 1093, 1063, 1032, 988, 959, 917, 897, 849, 799, 782, 759, 739, 729, 699, 677, 
643, 625 cm-1. 1H NMR (300.1 MHz, CDCl3): δ = 10.96 (s, 1 H, NCHN), 8.68 (s, 1 H, CHIm), 
8.27-8.18 (m, 3 H, Ar-H, CHIm), 8.11-8.02 (m, 2 H, Ar-H), 6.02-5.91 (m, 1 H, H-10), 5.62-
5.45 (m, 1 H, H-9), 5.39-5.11 (m, 2 H, H-11, H-11), 4.92-4.73 (m, 1 H, H-9), 3.88-3.71 (m, 1 
H; H-2), 3.62-3.36 (m, 2 H; H-6, H-6), 3.31-3.01 (m, 1 H, H-7), 2.76-2.63 (m, 1 H, H-7), 
2.31-1.68 (m, 5 H, H-5, H-3, H-4, H-8, H-8), 1.41 (s, 9 H, t-Bu), 0.95-0.81 (m, 1 H, H-3) 
ppm. 13C NMR (75.47 MHz, CDCl3): δ = 178.3 (NCO), 173.1 (NCNox), 137.2 (CH, C-10), 
136.6 (NCHNIm), 136.1 (NCAr), 129.7, 125.5, 124.3 (CHIm), 122.7, 121.4 (CHIm), 117.6 (CH2, 
C-11), 57.2 (CH, C-2), 48.4 (CH2, C-9), 46.1 (CH2, C-7), 37.2 (CH2, C-6), 40.1 (CH, C-4), 
32.3 (CCH3), 28.2 (CCH3), 27.0 (CH, C-5), 24.2 (CH2, C-8), 23.3 (CH2, C-3) ppm. MS (HR-
ESI): calculated for C25H32N5O
+: 418.2607 (100), 419.2640 (35); found: 418.2584 (100), 
419.2593 (35). 
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1,1′-[4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl]-3,3′-methylenediimidazolium bis-
(bromide) (57) 
A mixture of 5-(4-(1H-imidazol-1-
yl)phenyl)-3-(tert-butyl)-1,2,4-oxadiazole (3 
g, 11.13 mmol) and CH2Br2 (7.9 mL) was 
placed under an argon atmosphere and 
stirred at room temperature for 24 h. The precipitate thus formed was collected by filtration, 
washed with THF and dried in vacuo, giving a colorless solid. Yield: 78% (3.08 g, 8.68 
mmol). 
IR (ATR): 1/λ = 3121, 3048, 2969, 2957, 2929, 2902, 2870, 2360, 2340, 1767, 1618, 1555, 
1520, 1506, 1493, 1469, 1462, 1441, 1395, 1351, 1328, 1286, 1223, 1196, 1099, 1073, 1024, 
990, 957, 891, 837, 789, 773, 761, 745, 733, 719, 690, 624 cm-1. 1H NMR (200.1 MHz, 
DMSO-d6): δ = 10.56 (s, 2 H, NCHN), 8.62 (s, 2 H, NCHCHN), 8.51 (NCHCHN), 8.47-8.36 
(m, 4 H, Ar-H), 8.19-8.06 (m, 4 H, Ar-H), 7.02 (s, 2 H, CH2), 1.41 (s, 18 H, t-Bu) ppm. MS 
(HR-ESI): calculated for C31H34N8O2
2+: 549.2716 (100), 550.2776 (35), 551.2735 (10); 
found: 549.2623 (100), 550.2756 (35), 551.2795 (10). 
 
Chloro(1,3-bis(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-1H-imidazolin-2(3H)-ylidene) 
gold(I) (58) 
A mixture of 1,3-bis(4-(3-tert-butyl-1,2,4-
oxadiazol-5-yl)phenyl)imidazolium chloride 
(100 mg, 0.198 mmol) and silver(I) oxide 
(27.5 mg, 0.118 mmol) in dry 
dichloromethane (15 mL) was stirred for 24 h at room temperature in the dark. The mixture 
was filtered over Celite, and (dimethyl sulfide)chlorogold(I) (58.32 mg, 0.198 mmol) was 
added. The resulting mixture was stirred for 12 h and filtered over Celite. The solvent was 
removed in vacuo, and dichloromethane (2 mL) was added. The product was precipitated as a 
colorless solid upon addition of pentane and purified by column chromatography (DCM/Ethyl 
Acetate, 3:1). Yield: 59% (83 mg, 0.118 mmol). Single crystals suitable for X-ray diffraction 
were obtained by slow diffusion of hexane into a concentrated solution of 58 in 
dichloromethane. 
IR (ATR): 1/λ = 3103, 3047, 2967, 2963, 2925, 2852, 2360, 2340, 1733, 1719, 1614, 1593, 
1565, 1523, 1511, 1495, 1463, 1436, 1426, 1393, 1351, 1316, 1287, 1260, 1222, 1198, 1096, 
1073, 1032, 1017, 992, 972, 943, 884, 849, 803, 775, 745, 737, 697, 679, 629 cm-1. 1H NMR 
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(300.1 MHz, CDCl3): δ = 8.38-8.29 (m, 4 H, Ar-H), 7.99-7.91 (m, 4 H, Ar-H), 7.52 (s, 2 H, 
CH), 1.45 (s, 18 H, t-Bu) ppm. 13C NMR (75.47 MHz, CDCl3): δ = 178.7 (NCO), 173.6 
(NCNox), 170.9 (AuCN) 141.7 (NCAr), 129.7, 125.8 (CHIm), 125.4, 122.3 (CHIm), 32.6 
(CCH3), 28.4 (CCH3) ppm. MS (EI): 700.1 (100, M
+), 665.2 (80), 609.1 (70), 540.1 (35) MS 
(HR-ESI): calcd. for C27H28AuClN6O2Na
+ (M + Na+) 723.1525; found 723.1523. Anal. Calcd 
for C27H28AuClN6O2.H2O: C, 45.10; H, 4.21; N, 11.69. Found: C, 44.50; H, 3.57; N, 12.27. 
 
Chloro(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-methyl-1H-imidazolin-2(3H)-
ylidene) gold(I) (59) 
A mixture of 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-
methyl-imidazolium iodide (100 mg, 0.24 mmol) and silver(I) 
oxide (35 mg, 0.15 mmol) in dry dichloromethane (15 mL) was 
stirred for 24 h at room temperature in the dark. The mixture was 
filtered over Celite, and (dimethyl sulfide)chlorogold(I) (71 mg, 0.24 mmol) was added. The 
resulting mixture was stirred for 12 h and filtered over Celite. The solvent was removed in 
vacuo, and dichloromethane (2 mL) was added. The product was precipitated as a colorless 
solid upon addition of pentane and purified by column chromatography (DCM/ethyl acetate, 
3:1). Yield: 52% (64 mg, 0.124 mmol). Single crystals suitable for X-ray diffraction were 
obtained by slow evaporation of a concentrated solution of 59 in dichloromethane. 
IR (ATR): 1/λ = 3116, 3097, 3067, 2965, 2927, 2871, 1616, 1593, 1519, 1463, 1424, 1410, 
1391, 1347, 1319, 1282, 1244, 1193, 1138, 1091, 1032, 986, 970, 956, 890, 854, 775, 743, 
696, 673, 632, 602, 551 cm-1. UV/Vis (DCM): λmax. (lg ε) = 223 (1.134), 253 (1.745) nm. 1H 
NMR (300.1 MHz, CDCl3): δ = 8.34-8.24 (m, 2 H, Ar-H), 7.89-7.81 (m, 2 H, Ar-H), 7.31 (d, 
J = 1.9, 1 H, CH), 7.19 (d, J = 1.9, 1H, CH), 3.96 (s, 3 H, CH3), 1.45 (s, 9 H, t-Bu) ppm. 
13C 
NMR (75.47 MHz, CDCl3): δ = 178.6 (NCO), 173.7 (NCNox), 171.3 (AuCN), 141.8 (NCAr), 
129.5, 125.2, 125.2 (CHIm), 122.8, 121.3 (CHIm), 38.9 (CH3), 32.5 (CCH3), 28.4 (CCH3) ppm. 
MS (EI): C16H18AuClN4O 514.1 (100, M
+), 479.1 (60), 423.1 (75), 380.1 (35), 282.1. Anal. 
Calcd for C16H18AuClN4O: C, 37.33; H, 3.52; N, 10.88. Found: C, 37.52; H, 3.65; N, 10.67. 
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Bromo(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(benzyl)-1H-imidazolin-2(3H) 
ylidene) gold(I) (60) 
Dry THF (5 mL) was added to a mixture of 1-(4-(3-tert-
butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(benzyl)-imidazolium 
bromide (88 mg, 0.2 mmol), potassium tert-butoxide (22.6 
mg, 0.2 mmol) and (dimethyl sulfide)gold(I)chloride (59.5 
mg, 0.2 mmol) under an inert atmosphere and the suspension was stirred for 24 h at room 
temperature in the dark. The resulting mixture was filtered over Celite. The solvent was 
removed in vacuo, and dichloromethane (2 mL) was added. The product was precipitated as a 
colorless solid upon addition of hexane and purified by column chromatography (DCM/ethyl 
acetate, 3:1). Yield: 78% (99 mg, 0.156 mmol). Single crystals suitable for X-ray diffraction 
were obtained by slow diffusion of pentane into a solution of 60 in dichloromethane. 
IR (ATR): 1/λ = 3101, 2969, 2927, 2869, 1617, 1576, 1512, 1495, 1449, 1421, 1398, 1347, 
1327, 1284, 1249, 1191, 1088, 1023, 989, 958, 900, 848, 775, 728, 695, 676, 633, 604, 581, 
550 cm-1. 1H NMR (300.1 MHz, CDCl3): δ = 8.27-8.22 (m, 2 H, Ar-H), 7.92-7.86 (m, 2 H, 
Ar-H), 7.44-7.34 (m, 5 H, Ar-HBn), 7.29 (d, JHH = 2.0 Hz, 1 H, CHIm), 7.10 (d, JHH = 2.0 Hz, 1 
H, CHIm), 5.46 (s, 2 H, CH2), 1.44 (s, 9 H, t-Bu) ppm. 
13C NMR (75.47 MHz, CDCl3): δ = 
179.5 (NCO), 174.1 (NCNox), 173.7 (AuCN), 141.8 (NCAr), 134.3, 129.4, 129.1, 128.9, 128.3, 
125.2, 125.1 (CHIm), 121.7, 121.4 (CHIm), 55.6 (CH2-Bn), 32.5 (CCH3), 28.4 (CCH3) 
ppm.MS (EI): calcd. for C22H22AuBrN4O: 634.0 / 636.0; found: M
+ 634.0 / 636.0; fragments: 
555.0 (M-Br, 15), 357.1 (M-Br-Au, 100), 268.1 (MIm, 35). MS (HR-ESI): calcd. for 
C22H22AuBrN4ONa: 657.0534 (100), 658.0532 (20), 659.0516 (100), 660.0545 (20); found: 
657.0523 (100), 658.0531 (20), 659.0502 (100), 660.0534 (20). Anal. Calcd for 
C22H22AuBrN4O: C, 41.59; H, 3.49; N, 8.82. Found: C, 41.60; H, 3.59; N, 9.22. 
 
Bromo(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(2-pyridine)-1H-imidazolin-
2(3H)-ylidene)gold(I) (61) 
Dry THF (5 mL) was added to a mixture of 1-(4-(3-tert-butyl-
1,2,4-oxadiazol-5-yl)phenyl)-3-(2-pyridine)-imidazolium 
bromide (86 mg, 0.2 mmol), potassium tert-butoxide (22.6 
mg, 0.2 mmol) and (dimethyl sulfide)chlorogold(I) (59.5 mg, 
0.2 mmol) under an inert atmosphere and the suspension was stirred for 24 h at room 
temperature in the dark. The resulting mixture was filtered over Celite. The solvent was 
removed in vacuo and dichloromethane (2 mL) was added. The product was precipitated as a 
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colorless solid upon addition of hexane and purified by column chromatography (DCM/ethyl 
acetate, 3:1). Yield: 85% (105.8 mg, 0.17 mmol). Single crystals suitable for X-ray diffraction 
were obtained by slow evaporation of a concentrated solution of 61 in dichloromethane. 
IR (ATR): 1/λ = 3172, 3130, 3105, 2962, 2930, 2869, 1612, 1590, 1512, 1469, 1440, 1421, 
1390, 1349, 1316, 1280, 1196, 1177, 1091, 1046, 994, 949, 888, 852, 777, 740, 716, 698, 681, 
646, 609, 580, 538 cm-1. 1H NMR (300.1 MHz, CDCl3): δ = 8.83 (m, 1 H, CHPy), 8.57 (m, 1 
H, CHPy), 8.33-8.28 (m, 2 H, Ar-H), 8.03 (d, JHH = 2.0 Hz, 1 H, CHIm), 7.99-7.92 (m, 3 H, 
CHPy, Ar-H), 7.48 (d, JHH = 2.0 Hz, 1 H, CHIm), 7.47-7,44 (m, 1 H, CHPy), 1.44 (s, 9 H, t-Bu) 
ppm. 13C NMR (75.47 MHz, CDCl3): δ = 178.5 (NCO), 173.6 (NCNox), 172.7 (AuCN), 150.1 
(CPy), 148.9 (CHPy), 141.9 (CHPy), 139.1 (NCAr), 129.5 (CHAr), 125.5 (CAr), 125.5 (CHPy), 
124.4 (CHAr), 121.7 (CHIm), 121.4 (CHIm), 117.3 (CHPy), 32.5 (CCH3), 28.4 (CCH3) ppm. MS 
(HR-EI): calcd. for C20H19AuBrN5O: 621.0438; found: M
+ 621.0433; fragments: 542.0 (M-
Br, 35), 345.1 (M-Br-Au, 100), 288.1 (60). Anal. Calcd for C20H19AuBrN5O: C, 38.60; H, 
3.08; N, 11.25. Found: C, 38.65; H, 3.23; N, 11.31. 
 
Chloro(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(9-methyl-anthracene)-1H-
imidazolin -2(3H) -ylidene)gold(I) (62)  
Dry THF (5 mL) was added to a mixture of 1-(4-(3-
tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(9-methyl-
anthracene)-imidazolium chloride (100 mg, 0.2 
mmol), potassium tert-butoxide (22.6 mg, 0.2 mmol) 
and (dimethyl sulfide)chlorogold(I) (59.5 mg, 0.2 
mmol) under an inert atmosphere and the suspension was stirred for 24 h at room temperature 
in the dark. The resulting mixture was filtered over Celite. The solvent was removed in vacuo, 
and dichloromethane (2 mL) was added. The product was precipitated as a colorless solid 
upon addition of hexane and purified by column chromatography (DCM/ethyl acetate, 3:1). 
Yield: 63% (87 mg, 0.126 mmol). Single crystals suitable for X-ray diffraction were obtained 
by slow evaporation of a concentrated solution of 62 in dichloromethane. 
IR (ATR): 1/λ = 3130, 3053, 2968, 2928, 2870, 1616, 1594, 1572, 1511, 1495, 1464, 1425, 
1396, 1348, 1324, 1283, 1229, 1196, 1117, 1089, 1019, 957, 902, 850, 798, 775, 727, 700, 
678, 649, 630, 601, 574, 553. 1H NMR (300.1 MHz, CDCl3): δ = 8.58 (s, 1 H, CHAn), 8.33-
8.27 (m, 2 H, CHAn), 8.22-8.17 (m, 2 H, Ar-H), 8.12-8.06 (m, 2 H, CHAn), 7.94-7.86 (m, 2 H, 
Ar-H), 7.67-7.51 (m, 4 H, CHAn), 7.01 (d, JHH = 2 Hz, 1 H, CHIm), 6.49 (d, JHH = 2 Hz, 1 H, 
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CHIm), 6.32 (s, 2 H, CH2), 1.43 (s, 9 H, t-Bu).
13C NMR (75.47 MHz, CDCl3): δ = 178.4 
(NCO), 173.6 (NCNox), 170.6 (AuCN), 142.1 (NCAr), 131.3, 130.9, 130.2, 129.5, 129.4, 
127.9, 125.5, 125.3, 125.1 (CHIm), 123.2, 123.0, 121.1, 120.8 (CHIm), 47.6 (CH2-An), 32.5 
(CCH3), 28.4 (CCH3). MS (HR-EI): calcd. for C30H26AuClN4O: 690.1461; found: 690.1455. 
Anal. Calcd for C30H26AuClN4O: C, 52.15; H, 3.79; N, 8.11. Found: C, 51.94; H, 3.83; N, 
8.14. 
 
Bromo(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-((2-ethyl)indole)-1H-imidazolin-
2(3H)-ylidene)gold(I) (63) 
Dry THF (5 mL) was added to a mixture of 1-(4-(3-tert-
butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-((2-ethyl)indole)-
imidazolium bromide (98.5 mg, 0.2 mmol), potassium 
tert-butoxide (22.6 mg, 0.2 mmol) and (dimethyl sulfide)chlorogold(I) (59.5 mg, 0.2 mmol) 
under an inert atmosphere and the suspension was stirred for 24 h at room temperature in the 
dark. The resulting mixture was filtered over Celite. The solvent was removed in vacuo, and 
dichloromethane (2 mL) was added. The product was precipitated as a colorless solid upon 
addition of hexane and purified by column chromatography (DCM/ethyl acetate, 3:1). Yield: 
46% (64 mg, 0.092 mmol). 
IR (ATR): 1/λ = 3350, 3127, 3058, 2969, 2927, 2868, 1616, 1512, 1457, 1422, 1399, 1350, 
1279, 1227, 1195, 1093, 1013, 959, 849, 775, 739, 699, 678, 636, 602, 585, 555. 1H NMR 
(300.1 MHz, CDCl3): δ = 8.31 (s, 1 H, NH), 8.21-8.14 (m, 2 H, Ar-H), 7.67-7.61 (m, 2 H, Ar-
H), 7.47-7.35 (m, 2 H, CHIn), 7.22 (m, 1 H, CHIn), 7.09-7.01 (m, 3 H, CHIm, CHIn, CHIn), 6.84 
(d, J = 2.0, 1H, CHIm), 4.50 (t, 2 H, CH2), 3.34 (t, 2 H, CH2), 1.44 (s, 9 H, t-Bu). 
13C NMR 
(75.47 MHz, CDCl3): δ = 178.5 (NCO), 173.8 (NCNox), 173.7 (AuCN), 141.9 (NCAr), 136.1, 
129.3, 127.2, 125.2, 125.1, 124.9, 122.9, 122.2, 122.0, 120.6, 119.6, 117.9, 111.5 (Ar-CHIn), 
110.8 (CH2-CIn), 52.9 (CH2), 32.5 (CCH3), 28.4 (CCH3), 27.2 (CH2). MS (EI): calcd. for 
C25H25AuBrN5O 687.0 / 689.0; found: M
+ 687.0 / 689.0 ;fragments: 608.1 (M-Br, 10), 411.1 
(M-Br-Au, 15), 268.1 (MIm, 55). Anal. Calcd for C25H25AuBrN5O.C5H12: C, 47.38; H, 4.90; 
N, 9.21. Found: C, 47.06; H, 4.47; N, 9.84. 
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Chloro(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(2,3,4,5-tetra-O-acetyl-D-
glucopyranosyl)-1H-imidazolin-2(3H)-ylidene)gold(I) (64) 
Dry THF (5 mL) was added to a mixture of 1-(4-(3-tert-
butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(2,3,4,5-tetra-O-
acetyl-D-glu-copyranosyl)-imidazolium nitrate (132 mg, 
0.2 mmol), potassium tert-butoxide (22.6 mg, 0.2 
mmol) and (dimethyl sulfide)gold(I)chloride (59.5 mg, 0.2 mmol) under an inert atmosphere 
and the suspension was stirred for 24 h at room temperature in the dark. The resulting mixture 
was filtered over Celite. The solvent was removed in vacuo, and dichloromethane (2 mL) was 
added. The product was precipitated as a colorless solid upon addition of hexane and purified 
by column chromatography (DCM/ethyl acetate, 3:1). Yield: 52% (85 mg, 0.104 mmol). 
IR (ATR): 1/λ = 3095, 2963, 2928, 2354, 2332, 1748, 1745, 1615, 1513, 1424, 1391, 1362, 
1342, 1328, 1311, 1239, 1212, 1187, 1154, 1110, 1081, 1065, 1048, 1011, 952, 935, 911, 885, 
842, 822, 767, 733, 691, 651, 615 cm-1. 1H NMR (300.1 MHz, CDCl3): δ = 8.36-8.28 (m, 2 H, 
Ar-H), 7.86-7.79 (m, 2 H, Ar-H), 7.50 (d, JHH = 2.1 Hz, 1 H, CHIm), 7.36 (d, JHH = 2.1 Hz, 1 
H, CHIm), 6.17 (d, JHH = 8.5 Hz, 1 H, N-CH-O), 5.58 (d, JHH = 3.1 Hz, 1 H, CH2), 5.45-5.31 
(m, 2 H, 2 x Hcarbohydrate), 4.39-4.28 (m, 1 H, CHcarbohydrate), 4.27-4.15 (m, 2 H, CHcarbohydrate, 
CH2), 2.23 (s, 3 H, CH3), 2.09 (s, 3 H, CH3), 2.07 (s, 3 H, CH3), 2.03 (s, 3 H, CH3), 1.45 (s, 9 
H, t-Bu) ppm. 13C NMR (75.47 MHz, CDCl3): δ = 178.6 (NCO), 173.5 (NCNox), 170.9 
(AuCN), 170.3 (CH3-C=O), 169.8 (CH3-C=O), 169.7 (CH3-C=O), 169.4 (CH3-C=O), 141.5 
(CAr), 129.6 (CHAr), 125,7 (CHIm), 125.2 (CHAr), 122.4 (CAr), 118.9 (CHIm), 87.4 (N-
CHcarbohydrate-O), 74.0 (O-CHcarbohydrate-CH2), 70.2 (CHcarbohydrate), 68.6 (CHcarbohydrate), 66.8 
(CHcarbohydrate), 61.3 (CH-CH2carbohydrate-OAc), 32.5 (C-CH3), 28.4 (C-CH3), 20.8 (COO-CH3), 
20.6 (COO-CH3), 20.4 (COO-CH3) ppm. MS (HR-ESI): calcd. for C29H34AuClN4O10Na: 
853.1521 (100), 854.1552 (30), 855.1508 (30), 856.1531 (10); found: 853.1530 (100), 
854.1558 (30), 855.1510 (40), 856.1530 (10). MS (EI): calcd. for C29H34AuClN4O10 830.2 
/832.2; found: M+ 830.2 / 832.2; fragments: 795.2 (M-Cl, 70), 595.1 (45), 553.1 (100), 493.1 
(80). Anal. Calcd for C29H34AuClN4O10: C, 41.91; H, 4.12; N, 6.74. Found: C, 42.19; H, 4.22; 
N, 6.86. 
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Bromo(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(QCI)-1H-imidazolin-2(3H)-
ylidene)gold(I) (65) 
Dry THF (5 mL) was added to a mixture of 1-(4-(3-
tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(QCI)-
imidazolium bromide (100 mg, 0.2 mmol), potassium 
tert-butoxide (22.6 mg, 0.2 mmol) and (dimethyl 
sulfide)gold(I)chloride (59.5 mg, 0.2 mmol) under an 
inert atmosphere and the suspension was stirred for 24 h at room temperature in the dark. The 
resulting mixture was filtered over Celite. The solvent was removed in vacuo and 
dichloromethane (2 mL) was added. The product was precipitated as a colorless solid upon 
addition of hexane and purified by column chromatography (DCM/MeOH, 15:1). Yield: 41% 
(57 mg, 0.082 mmol). Single crystals suitable for X-ray diffraction were obtained by slow 
diffusion of pentane into a solution of 65 in dichloromethane. 
IR (ATR): 1/λ = 3171, 3123, 3095, 2966, 2920, 2867, 2851, 1958, 1929, 1825, 1730, 1688, 
1665, 1635, 1614, 1591, 1574, 1560, 1524, 1512, 1496, 1464, 1450, 1424, 1407, 1392, 1367, 
1349, 1327, 1290, 1272, 1259, 1244, 1195, 1177, 1137, 1124, 1100, 1065, 1051, 1037, 989, 
956, 941, 909, 892, 871, 853, 821, 793, 776, 745., 726., 699, 676., 663, 636, 618 cm-1. 1H 
NMR (300.1 MHz, CDCl3): δ = 8.29-8.23 (m, 2 H, Ar-H), 7.91-7.86 (m, 2 H, Ar-H), 7.51 (d, 
JHH = 1.98 Hz, 1 H, CHIm), 7.28 (d, JHH = 1.98 Hz, 1 H, CHIm), 5.82 (ddd, JHH = 17.40, JHH = 
10.32, JHH = 7.4, 1 H, H-10), 5.06-4.99 (m, 2 H, H-11, H-11), 4.17 (d, J = 7.05 Hz, 2 H, H-9), 
3.53-3.36 (m, 2 H; H-2, H-6), 3.31-3.16 (m, 1 H; H-7), 2.89-2.81 (m, 1 H, H-6), 2.72-2.59 (m, 
1 H, H-7), 2.49-1.35 (m, 1 H, H-5), 2.18-2.03 (m, 1 H, H-3), 1.92-1.85 (m, 1 H, H-4), 1.77-
1.68 (m, 2 H, H-8, H-8), 1.44 (s, 9 H, t-Bu), 0.90-0.83 (m, 1 H, H-3) ppm. 13C NMR (75.47 
MHz, CDCl3): δ = 181.8 (AuCN), 178.5 (NCO), 173.7 (NCNox), 141.9 (CH, C-10), 140.1 
(NCAr), 129.4 (CHAr), 125.3, 125.1 (CHIm), 122.2, 121.5 (CHIm), 115.6 (CH2, C-11), 57.94 
(CH2, C-9), 56.9 (CH, C-2), 52.9 (CH2, C-7), 42.2 (CH2, C-6), 38.7 (CH, C-4), 32.5 (CCH3), 
28.4 (CCH3), 27.0 (CH2, C-8), 26.9 (CH, C-5), 25.8 (CH2, C-3) ppm. MS (HR-ESI): 
calculated for C25H31AuN5O + H
+: 694.1450 (100), 695.1484 (30), 696.1430 (100), 697.1463 
(30), 698.1496 (5); found: 694.1439 (100), 695.1470 (30), 696.1419 (100), 697.1446 (30), 
698.1479 (5). MS (EI): 693.1 / 695.1 (M+, 100), 614.2 (M+ - Br), 560.1 (M+- Br - tBu), 417.2 
(M+ - AuBr). Anal. Calcd for C25H25AuBrN5O.CH2Cl2: C, 40.07; H, 4.27; N, 8.99. Found: C, 
39.73; H, 4.43; N, 8.66. 
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Bromo(1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(QCD)-1H-imidazolin-2(3H)-
ylidene)gold(I) (66) 
Dry THF (5 mL) was added to a mixture of 1-(4-(3-tert-
butyl-1,2,4-oxadiazol-5-yl)phenyl)-3-(QCD)-imidazolium 
bromide (100 mg, 0.2 mmol), potassium tert-butoxide 
(22.6 mg, 0.2 mmol) and (dimethyl sulfide)gold(I)chloride 
(59.5 mg, 0.2 mmol) under an inert atmosphere and the suspension was stirred for 24 h at 
room temperature in the dark. The resulting mixture was filtered over Celite. The solvent was 
removed in vacuo and dichloromethane (2 mL) was added. The product was precipitated as a 
colorless solid upon addition of hexane and purified by column chromatography 
(DCM/MeOH, 15:1). Yield: 47% (65 mg, 0.093 mmol). 
IR (ATR): 1/λ = 3116, 3095, 2972, 2942, 2903, 2870, 2857, 1953, 1906, 1725, 1694, 1637, 
1614, 1591, 1572, 1560, 1512, 1496, 1465, 1452, 1424, 1394, 1348, 1324, 1308, 1242, 1229, 
1195, 1124, 1088, 1059, 1029, 986, 958, 914, 891, 849, 798, 776, 754, 734, 722, 698, 678, 
636, 621 cm-1. 1H NMR (300.1 MHz, CDCl3): δ = 8.29-8.24 (m, 2 H, Ar-H), 7.92-7.86 (m, 2 
H, Ar-H), 7.45 (d, JHH = 1.8 Hz, 1 H, CHIm), 7.26 (d, JHH = 1.9 Hz, 1 H, CHIm), 5.98-5.84 
(ddd, JHH = 16.8 Hz, JHH = 11.05 Hz, JHH = 9.15 Hz, 1 H, H-10), 5.19-5.11 (m, 2 H, H-11, H-
11), 4.45 (dd, JHH = 14.1 Hz, JHH = 4.7 Hz, 1 H, H-9), 4.37-4.21 (m, 1 H, H-9), 3.49-3.33 (m, 
1 H; H-2), 3.19-2.78 (m, 4 H; H-6, H-6, H-7, H-7), 2.48-2.33 (m, 1 H; H-5), 1.89-1.83 (m, 1 
H; H-4), 1.79-1.62 (m, 3 H, H-3, H-8, H-8), 1.44 (s, 9 H, t-Bu), 1.27-1.23 (m, 1 H, H-3) ppm. 
13C NMR (75.47 MHz, CDCl3): δ = 181.9 (AuCN), 178.5 (NCO), 173.7 (NCNox), 141.9 (CH, 
C-10), 139.0 (NCAr), 129.4 (CHAr), 125.2, 125.1 (CHIm), 122.6, 121.1 (CHIm), 115.5 (CH2, C-
11), 57.7 (CH2, C-9), 56.6 (CH, C-2), 52.4 (CH2, C-7), 49.1 (CH2, C-6), 39.1 (CH, C-4), 32.5 
(CCH3), 28.4 (CCH3), 27.1 (CH2, C-8), 25.9 (CH, C-5), 25.2 (CH2, C-3) ppm. MS (HR-ESI): 
calculated for C25H31AuN5O + H
+: 694.1450 (100), 695.1484 (30), 696.1430 (100), 697.1463 
(30), 698.1496 (5); found: 694.1429 (100), 695.1459 (30), 696.1409 (100), 697.1436 (30), 
698.1467 (5). MS (EI): 693.1 / 695.1 (M+, 100), 614.2 (M+ - Br), 560.1 (M+- Br - tBu), 417.2 
(M+ - AuBr). Anal. Calcd for C25H25AuBrN5O.CHCl3: C, 38.37; H, 3.96; N, 8.61. Found: C, 
38.90; H, 4.29; N, 8.29. 
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Dichloro{1,1′-[5-(phenyl)-3-(tert-butyl)-1,2,4-oxadiazole]-3,3′-methylene-diimidazolin-
2,2′-diylidene}digold(I) (67) 
A mixture of 1,1′-[4-(3-tert-butyl-1,2,4-
oxadiazol-5-yl)phenyl]-3,3′-methylene di-
imidazolium bis(bromide) (100 mg, 0.140 
mmol) and silver(I) oxide (39.16 mg, 0.169 
mmol) in dry dichloromethane (20 mL) was stirred for 36 h at room temperature in the dark. 
The mixture was filtered over Celite, and AuCl(THT) (41.23 mg, 0.140 mmol) was added. 
The resulting mixture was stirred for 12 h and filtered over Celite. The solvent was removed 
in vacuo, and dichloromethane (2 mL) was added. The product was precipitated as a colorless 
solid upon addition of pentane and purified by column chromatography (DCM/ethyl acetate, 
3:1). Yield: 35% (49.5 mg, 0.049 mmol). 
IR (ATR): 1/λ = 3496, 3305, 3102, 2967, 2926, 2869, 1691, 1614, 1512, 1462, 1427, 1396, 
1349, 1279, 1252, 1232, 1194, 1093, 1063, 1020, 991, 958, 892, 850, 775, 723, 698, 677, 634, 
603, 557 cm-1. 1H NMR (300.1 MHz, CDCl3): δ = 8.34-8.27 (m, 4 H, Ar-H), 8.15 (d, J = 1.95, 
2 H, CH), 7.91-7.83 (m, 4 H, Ar-H), 7.35 (d, J = 1.95, 2 H, CH), 6.62 (s, 2 H, CH2), 1.44 (s, 
18 H, t-Bu) ppm. 13C NMR (75.47 MHz, CDCl3): δ = 178.0 (NCO), 173.1 (NCNox), 171.9 
(AuCNIm), 141.1 (NCAr), 129.8 (CHAr), 128.2 (CAr), 125.7 (CHCHNIm), 124.9 (CHAr), 121.9 
(CHCHNIm), 63.2 (NCH2N), 32.2 (CCH3), 28.1 (CCH3) ppm. MS (ESI): C31H32Au2Cl2N8O2 + 
Na+ 1035.13 (100), 1037.00 (70), 977.33 (M-Cl, 60); (HR-ESI): calcd. for C31H32Au2ClN8O2 
(M-Cl) 977.1668 (100), 978.1701, (35), 979.1638, (30), 980.1672 (10); found 977.1667 (100), 
978.1700, (35), 979.1639, (30), 980.1672 (10). Anal. Calcd for C31H32Au2Cl2N8O2.0.5 
AuCl(THT): C 33.77; H, 3.09; N, 9.55. Found: C, 33.72; H, 3.14; N, 9.94. 
 
Synthesis of (1-(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)-3-methyl-1,3-dihydro-2H-
imidazol-2-ylidene)argentio acetate (68) 
1-(3-tert-butyl-5-phenyl-1,2,4-oxadiazole)-3-methyl-imidazolium 
iodide (0.198 mmol, 81.23 mg) and silver(I) acetate (0.495 mmol, 
82.67 mg) were mixed in a round-bottomed flask containing 3 Å 
molecular sieves and dry CH2Cl2 (20 mL). The reaction mixture 
was stirred at ambient temperature for 48 h in the absence of light. The suspension was then 
filtered through Celite, and the solvent was removed under reduced pressure to afford the 
desired product as a yellow-grey solid. Yield: 94% (83.6 mg, 0.186 mmol). 
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IR (ATR): 1/λ = 3370, 3164, 3080, 2970, 2873, 1613, 1568, 1511, 1466, 1421, 1395, 1349, 
1269, 1243, 1196, 1105, 1092, 1012, 955, 922, 889, 849, 775, 743, 697, 668, 616, 603, 548 
cm-1. UV/Vis (DCM): λmax. (lg ε) = 193 (0.802), 196 (0.700), 266 (0.500), 358 (0.011) nm. 
1H NMR (300.1 MHz, CDCl3): 8.22-8.14 (m, 2 H, Ar-H), 7.72-7.65 (m, 2 H, Ar-H), 7.29 (d, J 
= 1.8, 1H, CHimidazol), 7.13 (d, J = 1.8, 1H, CHimidazol), 3.89 (s, 3H, CH3), 1.96 (s, 3H, COCH3), 
1.35 (s, 9 H, t-Bu) ppm. 13C NMR (75.47 MHz, CDCl3): δ = 179.85 (AgCN), 178.52 
(CH3COO), 178.12 (NCO), 173.71 (NCN), 142.61 (NCN), 129.71 (CHAr), 125.01 (CAr), 
124.25 (CHAr), 123.27 (CAr), 121.45 (CHim), 39.39 (C(CH3)3), 32.53 (NCH3), 28.41 
(C(CH3)3), 22.81 (COOCH3) ppm. MS (ESI): 283.2 (M-AgCOOCH3 + H
+, 100). 
C18H21AgN4O3 (448.07): calcd. C 48.12, H 4.71, N 12.47; found C 47.25, H 4.84, N 11.60. 
 
Synthesis of 1-((1,3-bis(4-(3-(tert-butyl)-1,2,4-oxadiazol-5-yl)phenyl)-1H-imidazol-2(3H)-
ylidene)argentio acetate (69)  
1,3-Bis(3-tert-butyl-5-phenyl-1,2,4-oxadiazole) 
imidazolium chloride (0.198 mmol, 100 mg) and 
silver(I) acetate (0.495 mmol, 82.67 mg) were mixed 
in a round-bottomed flask containing 3 Å molecular 
sieves and dry CH2Cl2 (20 mL). The reaction mixture was stirred at ambient temperature for 
48 h in the absence of light. The suspension was then filtered through Celite, and the solvent 
was removed under reduced pressure to afford the desired product as a yellow-grey solid. 
Yield: 87% (109.4 mg, 0.172 mmol). 
IR (ATR): 1/λ = 3361, 3121, 2968, 2929, 2871, 1613, 1568, 1511, 1465, 1415, 1395, 1350, 
1280, 1260, 1195, 1083, 1016, 944, 891, 849, 800, 774, 736, 698, 671, 609, 572 cm-1. 1H-
NMR (300.1 MHz, CDCl3): 8.39-8.31 (m, 4 H, Ar-H), 7.94-7.85 (m, 4 H, Ar-H), 7.60 (s, 2 H, 
CHimidazol), 2.01 (s, 3 H, CH3), 1.45 (s, 18 H, t-Bu) ppm. 
13C-NMR (75.47 MHz, CDCl3): δ = 
179.04 (AgCN), 178.60 (CH3COO, NCO), 173.63 (NCN), 142.39 (CAr), 129.94 (CHAr), 
125.60 (CHAr), 124.46 (CAr), 122.53 (CHimidazol), 32.57 (C-(CH3)3), 28.43 (C(CH3)3), 22.60 
(COOCH3) ppm. MS (ESI): 469.2 (M-AgCOOCH3 + H
+, 100), 413.2 (M-AgCOOCH3 - t-Bu 
+ H+, 60), 357.2 [M-AgCOOCH3 – 2 x t-Bu +H+, 55]. 
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Synthesis of bis(1-(3-tert-butyl-5-phenyl-1,2,4-oxadiazole)-3-(2-pyridine)-imidazolium-2-
ylidene) silver (I) nitrate (70) 
A mixture of 1-(3-tert-butyl-5-phenyl-1,2,4-
oxadiazole)-3-(2-pyridine)-imidazolium bromide 
(100 mg, 0.23 mmol) and AgNO3 (0.040 g, 0.23 
mmol) were stirred in CH2Cl2 (10 mL) for 30 
minutes at room temperature. The mixture was filtered and the volatile components were 
removed under vacuum. The resulting solid was washed with Et2O. The Et2O was decanted 
and the product was dried under vacuum. Yield: 87% (81.6 mg, 0.2 mmol). Ag2O (46 mg, 0.2 
mmol) was added to a solution of 1-(3-tert-butyl-5-phenyl-1,2,4-oxadiazole)-3-(2-pyridine)-
imidazolium Nitrate (0.80 g, 0.2 mmol) in DCM (30 mL) and the mixture was stirred at room 
temperature for 24 h. After filtration through Celite a clear solution was obtained. The volatile 
components were removed under vacuum and the resulting solid was washed with OEt2 and 
dried to yield a white-grey solid. Yield: 47% (41 mg, 0.047 mmol). 
1H NMR (300.1 MHz, DMSO-d6): δ = 8.48 (m, 2H, CHPy), 8.29 (m, 2H, CHPy), 8.21 (m, 2H, 
CHPy), 8.15-7.95 (m, 12H, Ar-H, CHIm), 7.51-7,44 (m, 2H, CHPy), 1.42 (s, 18H, t-Bu) ppm. 
13C NMR (75.47 MHz, CDCl3): δ = 178.43 (AgCN), 173.46 (NCNox), 172.81 (NCO), 155.26 
(CPy), 148.58 (CHPy), 143.39 (CHPy), 141.09 (NCAr), 128.45 (CHAr), 124.50 (CAr), 124.25 
(CHPy), 123.41 (CHAr), 121.64 (CHIm), 121.16 (CHIm), 115.75 (CHPy), 32.14 (CCH3), 28.10 
(CCH3) ppm. MS (HR-ESI): calcd. for C40H38AgN10O2
+: 797.2224 (100), 798.2253 (45), 
799.2227 (95), 800.2252 (45), 801.2279 (10); found: 797.2231 (100), 798.2268 (45), 
799.2226 (95), 800.2262 (45), 801.2304 (10). 
 
Synthesis of bis(1-(3-tert-butyl-5-phenyl-1,2,4-oxadiazole)-3-(benzyl)-imidazolium -2-
ylidene) silver (I) nitrate (71) 
A mixture of 1-(3-tert-butyl-5-phenyl-1,2,4-
oxadiazole)-3-(benzyl)-imidazolium bromide (176 
mg, 0.4 mmol) and AgNO3 (0.078 g, 0.4 mmol) 
were stirred in CH2Cl2 (10 mL) for 30 minutes at 
room temperature. The mixture was filtered and 
the volatile components were removed under vacuum. The resulting solid was washed with 
OEt2. The OEt2 was decanted and the product was dried under vacuum. Yield: 93% (157 mg, 
0.372 mmol). Ag2O (85 mg, 0.36 mmol) was added to a solution of 1-(3-tert-butyl-5-phenyl-
1,2,4-oxadiazole)-3-(benzyl)-imidazolium Nitrate (0.15 g, 0.36 mmol) in CH3CN (30 mL) and 
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the mixture was stirred at room temperature for 24 h. After filtration through Celite a clear 
solution was obtained. The volatile components were removed under vacuum and the 
resulting solid was washed with OEt2 and dried to yield a light-yellow solid. Yield: 58% (96 
mg, 0.108 mmol). 
IR (ATR): 1/λ = 3469, 3126, 3095, 2969, 2929, 2871, 1615, 1512, 1496, 1454, 1417, 1394, 
1349, 1320, 1283, 1246, 1195, 1103, 1085, 1029, 956, 893, 851, 775, 739, 713, 637, 603, 578, 
550 cm-1. 1H NMR (300.1 MHz, CDCl3): δ = 8.19-8.13 (m, 4H, Ar-H), 7.77-7.71 (m, 4H, Ar-
H), 7.43 (d, JHH = 1.9 Hz, 2H, CHIm), 7.34-7.26 (m, 12H, 7.30 d, JHH = 1.9 Hz CHIm, Ar-HBn), 
5.36 (s, 4H, CH2), 1.44 (s, 18H, t-Bu) ppm. 
13C NMR (75.47 MHz, CDCl3): δ = 179.03 
(AgCN), 178.43 (NCO), 173.55 (NCNOx), 142.63 (NCAr), 135.04, 129.58, 129.14, 128.76, 
127.89, 124.95 (CHIm), 124.32, 122.94, 121.99 (CHIm), 56.16 (CH2-Bn), 32.48 (CCH3), 28.38 
(CCH3) ppm. MS (HR-ESI): calcd. for C44H44AgN8O2
+: 823.2632 (100), 824.2672 (50), 
825.2637 (95), 826.2662 (50), 827.2690 (10); found: 823.2613 (100), 824.2663 (50), 
825.2608 (95), 826.2629 (50), 827.2658 (10). 
 
Synthesis of bis(1-(3-tert-butyl-5-phenyl-1,2,4-oxadiazole)-3-(9-methyl-antracene)-
imidazolium -2-ylidene) silver (I) nitrate (72) 
A mixture of 1-(3-tert-butyl-5-phenyl-1,2,4-
oxadiazole)-3-(9-methyl-antracene)-imidazolium 
chloride (200 mg, 0.4 mmol) and AgNO3 (0.078 
g, 0.4 mmol) were stirred in CH2Cl2 (10 mL) for 
30 minutes at room temperature. The mixture was 
filtered and the volatile components were 
removed under vacuum. The resulting solid was 
washed with Et2O. The Et2O was decanted and the product was dried under vacuum. Yield: 
96% (200 mg, 0.384 mmol). Ag2O (88 mg, 0.38 mmol) was added to a solution of 1-(3-tert-
butyl-5-phenyl-1,2,4-oxadiazole)-3-(9-methyl-antracene)-imidazolium Nitrate (0.2 g, 0.38 
mmol) in CH3CN (30 mL) and the mixture was stirred at room temperature for 24 h. After 
filtration through Celite a clear solution was obtained. The volatile components were removed 
under vacuum and the resulting solid was washed with Et2O and dried to yield a light-yellow 
solid. Yield: 56% (116 mg, 0.106 mmol). 
IR (ATR): 1/λ = 3461, 3057, 2969, 2928, 2870, 1615, 1512, 1418, 1392, 1349, 1281, 1232, 
1195, 1105, 1027, 954, 892, 848, 796, 775, 727, 700, 628, 601, 551 cm-1. 1H NMR (300.1 
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MHz, CD3CN): δ = 8.42 (s, 2H, CHAn), 8.22-8.15 (m, 4H, CHAn), 7.96-7.85 (m, 8H, CHAn, Ar-
H), 7.54-7.32 (m, 16H, Ar-H, CHAn, CHIm), 6.05 (s, 4H, CH2), 1.41 (s, 18H, t-Bu) ppm. 
13C 
NMR (75.47 MHz, CD3CN): δ = 180.59 (AgCN), 179.31 (NCO), 174.82 (NCNox), 143.89 
(NCAr), 132.18, 131.58, 130.69, 130.35, 129.88, 128.43, 126.19, 126.05, 125.23, 125.18, 
124.32, 124.24 (CHIm), 122.16 (CHIm), 48.39 (CH2-An), 33.21 (CCH3), 28.71 (CCH3) ppm. 
MS (HR-ESI): calcd. for C60H52AgN8O: 1023.3264 (98), 1024.3298 (60), 1025.3261 (100), 
1026.3289 (60), 1027.3320 (20), 1028.3351 (10); found: 1023.3272 (90), 1024.3293 (60), 
1025.3275 (100), 1026.3295 (60), 1027.3324 (20), 1028.3354 (10). 
 
Synthesis of bis(1-(3-tert-butyl-5-phenyl-1,2,4-oxadiazole)-3-(2,3,4,5-tetra-O-acetyl-D-
glucopyranosyl)-imidazolium-2-ylidene) silver (I) nitrate (73) 
A mixture of 1-(3-tert-butyl-5-phenyl-1,2,4-
oxadiazole)-3-(2,3,4,5-tetra-O-acetyl-D-gluco-
pyranosyl)-imidazolium nitrate (265 mg, 0.4 
mmol) and Ag2O (89 mg, 0.4 mmol) in CH3CN 
(30 mL) was stirred at room temperature for 48 h. 
After filtration through Celite a clear solution was obtained. The volatile components were 
removed under vacuum and the resulting solid was washed with OEt2 and dried to yield a 
white-yellow solid. Yield: 67% (366 mg, 0.268 mmol). 
IR (ATR): 1/λ = 3134, 2972, 1747, 1616, 1513, 1420, 1367, 1210, 1087, 1056, 953, 919, 852, 
776, 739, 700, 652, 597, 554, 534 cm-1. 1H NMR (300.1 MHz, CDCl3): δ = 8.31-8.24 (m, 4H, 
Ar-H), 7.82-7.75 (m, 4H, Ar-H), 7.59 (d, JHH = 1.9 Hz, 2H, CHIm), 7.51 (d, JHH = 1.9 Hz, 2H, 
CHIm), 6.12 (d, JHH = 8.1 Hz, 2H, NCHO), 5.60 (d, JHH = 2.0 Hz, 2H, CH2), 5.52-5.41 (m, 4H, 
4 x CHcarbohidrate), 4.57-4.47 (m, 2H, CHcarbohidrate), 4.32-4.16 (m, 4H, CHcarbohydrate, CH2), 2.23 
(s, 6H, CH3), 2.05 (s, 6H, CH3), 2.01 (s, 6H, CH3), 1.98 (s, 6H, CH3), 1.44 (s, 18H, t-Bu) 
ppm. 13C NMR (75.47 MHz, CDCl3): δ = 179.01 (AgCN),178.33 (NCO), 173.42 (NCNox), 
170.25 (CH3CO), 169.78 (CH3CO), 169.38 (CH3CO), 169.34 (CH3CO), 142.28 (CAr), 129.62 
(CHAr), 125,16 (CHIm), 124.27 (CHAr), 122.21 (CAr), 120.13 (CHIm), 87.72 (NCHcarbohidrateO), 
73.57 (OCHcarbohidrateCH2), 70.27 (CHcarbohidrate), 68.87 (CHcarbohidrate), 67.03 (CHcarbohidrate), 
61.12 (CHCH2carbohidrateOAc), 32.36 (CCH3), 28.23 (CCH3), 20.49 (COOCH3), 20.41 
(COOCH3), 20.33 (COOCH3), 20.29 (COOCH3) ppm. MS (ESI): calcd. for C58H68AgN8O20: 
1303.3575 (90), 1304.3607 (60), 1305.3583 (100), 1306.3605 (60), 1307.3630 (20); found: 
1303.3595 (90), 1304.3626 (60), 1305.3605 (100), 1306.3629 (60), 1307.3655 (20). 
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Synthesis of bis[1,3-di(4-(3-(tert-butyl)-1,2,4-oxadiazol)imidazolin-2-yliden]silver(I) 
dichloroargenate (74) 
A solution of 1,3-bis(3-tert-butyl-5-phenyl-
1,2,4-oxadiazole) imidazolium chloride (100 mg, 
0.198 mmol) and Ag2O (31.68 g, 0.138 mmol) in 
CH3CN (4 mL) was stirred at 60°C for 24 h with 
exclusion of light. The suspension was filtered 
through Celite, and the solvent was concentrated under reduced pressure to ca. 0.5 mL and 
ethanol (2 ml) was added to give white-grey solid of bis[1,3-di(4-(3-(tert-butyl)-1,2,4-
oxadiazol)imidazolin-2-yliden]silver(I) dichloroargenate. Yield: 93% (121.3 mg, 0.184 
mmol). 
IR (ATR): 1/λ = 3304, 3098, 2970, 2930, 2871, 1691, 1610, 1511, 1465, 1414, 1394, 1350, 
1317, 1279, 1194, 1094, 1026, 991, 972, 944, 891, 844, 774, 735, 698, 606 cm-1. 1H NMR 
(300.1 MHz, DMSO-d6): 8.51-8.37 (m, 8H, Ar-H), 8.34-8.07 (m, 12H, Ar-H, CHIm), 1.42 (s, 
36H, t-Bu) ppm. 13C NMR (75.47 MHz, DMSO-d6): δ = 179.01 (AgCN), 178.02 (NCO), 
173.54 (NCN), 137.65 (NCN), 135.53 (CAr), 129.75 (CHAr), 124.77 (CAr), 124.46 (CHAr), 
122.89 (CHIm), 32.20 (C(CH3)3), 28.14 (C(CH3)3) ppm. MS (ESI): 1043.48 (M
 +-AgCl2, 75), 
1044.48 (M +-AgCl2, 45), 1045.37 (M
 +-AgCl2, 100), 1046.32 (M
 +-AgCl2, 45), 1047.30 (M
 +-
AgCl2, 10), 469.2 (M
 +, NHC). 
 
Synthesis of bis[1-((4-(3-(tert-butyl)-1,2,4-oxadiazol)-3-methyl)imidazolin-2-yliden]-Ag(I) 
diiodoargenate (75) 
A solution of 1-(3-tert-butyl-5-phenyl-1,2,4-
oxadiazole)-3-methyl-imidazolium iodide (81.23 
mg, 0.198 mmol) and Ag2O (31.68 g, 0.138 mmol) 
in CH3CN (4 mL) was stirred at 60°C for 24 h with 
exclusion of light. The suspension was filtered through Celite, and the solvent was 
concentrated under reduced pressure to ca. 0.5 mL. Diethyl-ether (2 ml) was added in order to 
give pale-grey solid of bis[1-((4-(3-(tert-butyl)-1,2,4-oxadiazol)-3-methyl)imidazolin-2-
yliden]silver(I) diiodoargenate. Yield: 73% (149.5 mg, 0.14 mmol). 
IR (ATR): 1/λ = 3441, 3098, 2969, 3930, 2871, 1614, 1512, 1465, 1424, 1396, 1348, 1269, 
1238, 1195, 1094, 1017, 991, 956, 892, 850, 774, 735, 695, 603, 547 cm-1. UV/Vis (DCM): 
λmax. (lg ε) = 193 (1.084), 196 (1.078), 265 (0.678), 425 (0.021) nm. 1H NMR (300.1 MHz, 
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DMSO-d6): 8.08-8.03 (m, 4H, Ar-H), 7.99-7.93 (m, 6H, Ar-H, CHIm), 7.76 (d, J = 1.8, 2H, 
CHIm), 3.36 (s, 6H, CH3), 1.39 (s, 18H, t-Bu) ppm. 
13C NMR (75.47 MHz, DMSO-d6): δ = 
180.38 (CAg), 177.69 (NCO), 173.51 (NCN), 142.70 (CAr), 128.93 (CHAr), 124.56 (CAr), 
124.36 (CHAr), 123.19 (CHIm), 121.91 (CHIm), 38.66 (C(CH3)3), 32.10 (NCH3), 28.09 
(C(CH3)3) ppm. MS (ESI): 671.24 (M
+ - AgI2, 100), 672.26 (M
+ - AgI2, 30), 673.20 (M
+ - 
AgCl2, 95), 674.18 (M
+ - AgCl2, 20), 283.13 (M
+, NHC). C32H36Ag2I2N8O2 (1031.91): calcd. 
C 37.16, H 3.51, N 10.83; found C 37.04, H 3.68, N 11.71. 
 
Synthesis of bis[1,3-di(4-(3-(tert-butyl)-1,2,4-oxadiazol)imidazolin-2-yliden]silver(I) 
hexafluorophosphate (76) 
To a solution of bis[1,3-di(4-(3-(tert-butyl)-
1,2,4-oxadiazol)imidazolin-2-yliden]-silver(I) 
dichloroargenate (74) (0.1 g, 0.08 mmol) in hot 
water (50 mL) was added a saturated aqueous 
solution of NH4PF6 (15 mL). The colorless 
precipitate which formed immediately was collected by filtration and washed with water. 
Yield: 95% (92 mg, 0.077 mmol). 
IR (ATR): 1/λ = 3152, 2970, 2931, 2872, 1616, 1546, 1510, 1465, 1428, 1396, 1349, 1256, 
1195, 1104, 1065, 1021, 992, 974, 951, 830, 774, 736, 696, 647, 607, 556 cm-1. 1H NMR 
(300.1 MHz, DMSO-d6): 8.38-8.27 (m, 8H, Ar-H), 8.18-8.88 (m, 12H, Ar-H, CHim), 1.43 (s, 
36H, t-Bu) ppm. 13C NMR (75.47 MHz, DMSO-d6): δ = 178.91 (AgCN), 177.65 (NCO), 
173.28 (NCN), 142.52 (NCN), 129.77 (CAr), 128.83 (CHAr), 124.54 (CHAr), 123.63 (CAr), 
122.89 (CHIm), 32.12 (C(CH3)3), 28.09 (C(CH3)3) ppm. MS (ESI): 1043.45 (M
+ - PF6, 70), 
1044.45 (M+ - PF6, 50), 1045.35 (M
+ - PF6, 100), 1046.32 (M
+ - PF6, 55), 1047.32 (M
+ - PF6, 
13), 469.2 (M+, NHC). 
 
Synthesis of Bis[1-((4-(3-(tert-butyl)-1,2,4-oxadiazol)-3-methyl)imidazolin-2-yliden]Ag(I) 
hexafluorophosphate (77) 
To a solution of bis[1-((4-(3-(tert-butyl)-1,2,4-
oxadiazol)-3-methyl)imidazolin-2-yliden]silver(I) 
diiodoargenate (75) (0.1 g, 0.096 mmol) in hot water 
(50 mL) was added a saturated aqueous solution of 
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NH4PF6 (15 mL). The colorless precipitate which formed immediately was collected by 
filtration and washed with water. Yield: 90% (71 mg, 0.086 mmol) 
IR (ATR): 1/λ = 3441, 3098, 2969, 3930, 2871, 1614, 1512, 1465, 1424, 1396, 1348, 1269, 
1238, 1195, 1094, 1017, 991, 956, 892, 850, 774, 735, 695, 603, 547 cm-1. UV/Vis (DCM): 
λmax. (lg ε) = 193 (1.084), 196 (1.078), 265 (0.678), 425 (0.021) nm. 1H NMR (300.1 MHz, 
DMSO-d6): 8.08-8.03 (m, 4H, Ar-H), 7.99-7.93 (m, 6H, Ar-H, CHim), 7.76 (d, J = 1.8, 2H, 
CHIm), 3.36 (s, 6H, CH3), 1.39 (s, 18H, t-Bu) ppm. 
13C NMR (75.47 MHz, DMSO-d6): δ = 
180.38 (CAg), 177.69 (NCO), 173.51 (NCN), 142.70 (CAr), 128.93 (CHAr), 124.56 (CAr), 
124.36 (CHAr), 123.19 (CHIm), 121.91 (CHIm), 38.66 (C(CH3)3), 32.10 (NCH3), 28.09 
(C(CH3)3) ppm. MS (ESI): 671.24 (M
+ - AgI2, 100), 672.26 [M
+ - AgI2, 30), 673.20 (M
+ - 
AgCl2, 95), 674.18 (M
+ - AgCl2, 20), 283.13 (M
+, NHC]. C32H36Ag2I2N8O2 (1031.91): calcd. 
C 37.16, H 3.51, N 10.83; found C 37.04, H 3.68, N 11.71. 
 
Synthesis of bis[1,3-di(4-(3-(tert-butyl)-1,2,4-oxadiazol)imidazolin-2-yliden]gold(I) 
chloride (78) 
To a mixture of 74 (101 mg, 0.2 mmol) in 
acetone (5 mL), were added Me2SAuCl 
(58.9 mg, 0.2 mmol) and K2CO3 (83 mg, 
0.6 mmol). The resulting mixture was 
stirred for 24 h at 60 ºC in the absence of 
light. The solvent was removed in vacuum 
and the residue was flashed-chromatographed (DCM/Ethyl Acetate, 3:1). Yield: 56% (65 mg, 
0.11 mmol). 
IR (ATR): 1/λ = 3508, 3376, 3166, 2971, 2931, 1614, 1572, 1511, 1466, 1327, 1396, 1348, 
1287, 1195, 1093, 1018, 991, 974, 944, 892, 850, 773, 751, 697, 611, 575, 544 cm-1. 1H NMR 
(300.1 MHz, CDCl3): 8.09-8.01 (m, 8H, Ar-H), 7.94-7.82 (m, 8H, Ar-H), 7.73 (s, 4H, CHIm), 
1.46 (s, 36H, t-Bu) ppm. 13C NMR (75.47 MHz, CDCl3): δ = 184.3 (AuCN), 178.45 (NCO), 
173.29 (NCNox), 141.36 (NCAr), 129.27 (CHAr), 125.44 (CHIm), 32.58 (C(CH3)3), 28.43 
(C(CH3)3) ppm. MS (HR-ESI): calcd. for C54H56AuN12O4
+: 1133.4207 (100), 1134.4239 (60), 
1135.4269 (20), 1136.4300 (5); found: 1133.4216 (100), 1134.4237 (60), 1135.4262 (20), 
1136.4295 (5). 
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Synthesis of bis[1-((4-(3-(tert-butyl)-1,2,4-oxadiazol)-3-methyl)imidazolin-2-yliden]-
gold(I) iodide (79) 
To a mixture of 75 (82 mg, 0.2 mmol) in 
acetone (5 mL), were added Me2SAuCl (58.9 
mg, 0.2 mmol) and K2CO3 (83 mg, 0.6 mmol). 
The resulting mixture was stirred for 24 h at 
60ºC in the absence of light. The solvent was removed in vacuo and the residue was flashed-
chromatographed (DCM/Ethyl Acetate, 3:1). Yield: 43% (38.3 mg, 0.04 mmol). 
IR (ATR): 1/λ = 3428, 3070, 2969, 2928, 2871, 1615, 1562, 1512, 1460, 1425, 1395, 1350, 
1322, 1281, 1242, 1195, 1093, 1018, 991, 959, 891, 849, 774, 745, 698, 634, 603, 550 cm-1. 
1H NMR (300.1 MHz, CDCl3): 8.15-8.08 (m, 4H, Ar-H), 7.85-7.78 (m, 4H, Ar-H), 7.54 (d, 
JHH = 1.9 Hz, 2H, CHIm), 7.43 (d, JHH = 1.9 Hz, 2H, CHIm), 4.05 (s, 6 H, CH3), 1.44 (s, 18H, t-
Bu) ppm. 13C NMR (75.47 MHz, CDCl3): δ = 182.78 (AuCN), 178.43 (NCO), 173.43 
(NCNox), 141.80 (NCAr), 129.10 (CHAr), 125.27 (CHAr), 125.01 (CHIm), 124.38 (CAr), 121.87 
(CHIm), 39.19 (CH3), 32.50 (C(CH3)3), 28.37 (C(CH3)3) ppm. MS (HR-ESI): calcd. for 
C32H36AuN8O2
+: 761.2627 (100), 762.2625 (40), 763.2678 (10); found: 761.2624 (100), 
762.2648 (40), 763.2676 (10). 
 
Synthesis of bis(1-(3-tert-butyl-5-phenyl-1,2,4-oxadiazole)-3-(9-methyl-antracene)-
imidazolium-2-ylidene) gold (I) nitrate (80) 
To a solution of bis(1-(3-tert-butyl-5-phenyl-1,2,4-
oxadiazole)-3-(9-methyl-antracene)-imidazolium-2-
ylidene) silver(I) nitrate (0.1 g, 0.09 mmol) in dry 
CH2Cl2 (20 mL), AuCl(SMe2) (27 mg, 0.09 mmol) 
was added and the mixture was stirred at room 
temperature for 12 h. A clear solution was obtained 
after filtration. The volatile components were removed under vacuum. The crude product was 
flash-chromatographed using DCM as eluent (r.f = 0.3). Yield: 73% (77 mg, 0.066 mmol). 
IR (ATR): 1/λ = 3136, 3055, 2967, 2927, 2869, 1616, 1560, 1512, 1430, 1394, 1350, 1326, 
1280, 1233, 1197, 1091, 1022, 958, 886, 847, 799, 774, 727, 706, 561, 630, 600, 577, 551 cm-
1. 1H NMR (300.1 MHz, CDCl3): δ = 8.60 (s, 2H, CHAn), 8.31-8.25 (m, 4H, CHAn), 8.09-8.03 
(m, 4H, CHAn), 8.01-7.92 (m, 4H, Ar-H), 7.83-7.76 (m, 4H, Ar-H), 7.58-7.45 (m, 8H, CHAn), 
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7.41 (d, JHH = 2 Hz, 2H, CHIm), 6.94 (d, JHH = 2 Hz, 2H, CHIm), 6.32 (s, 4H, CH2), 1.36 (s, 
18H, t-Bu) ppm. 13C NMR (75.47 MHz, CDCl3): δ = 183.84 (AuCN), 179.13 (NCO), 174.53 
(NCNox), 143.21 (NCAr), 132.34, 131.93, 130.04, 130.41, 129.91, 128.57, 126.70, 126.35, 
125.79, 125.26, 124.27, 123.40 (CHIm), 123.05 (CHIm), 48.47 (CH2-An), 33.13 (CCH3), 28.69 
(CCH3) ppm. MS (HR-ESI): calcd. for C60H52AuN8O
+: 1113.3879 (100), 1114.3904 (70), 
1115.3935 (25), 1116.3965 (10); found: 1113.3879 (100), 1114.3901 (70), 1115.3927 (25), 
1116.3957 (10). 
 
Synthesis of bis(1-(3-tert-butyl-5-phenyl-1,2,4-oxadiazole)-3-(2,3,4,5-tetra-O-acetyl-D-
glucopyranosyl)-imidazolium-2-ylidene) gold (I) nitrate (81) 
To a solution of bis(1-(3-tert-butyl-5-phenyl-1,2,4-
oxadiazole)-3-(2,3,4,5-tetra-O-acetyl-D-glucopyrano-
syl)-imidazolium-2-ylidene) silver(I) nitrate (0.123 g, 
0.09 mmol) in dry CH2Cl2 (20 mL), AuCl(SMe2) (27 
mg, 0.09 mmol) was added and the mixture was 
stirred at room temperature for 12 h. A clear solution was obtained after filtration. The 
volatile components were removed under vacuum. The crude product was flash-
chromatographed using DCM:MeOH 10:1 as eluent (r.f = 0.4). Yield: 34% (44.5 mg, 0.03 
mmol). 
1H NMR (300.1 MHz, CDCl3): δ = 8.12-8.06 (m, 4H, Ar-H), 7.76-7.68 (m, 6H, Ar-H, CHIm), 
7.59 (d, JHH = 1.9 Hz, 2H, CHim), 7.51 (d, JHH = 1.9 Hz, 2H, CHim), 6.63 (d, JHH = 8.9 Hz, 2H, 
NCHO), 5.77-5.71 (m, 2H, 2 x CHcarbohidrate), 5.60 (d, JHH = 2.9 Hz, 2H, CH2), 5.52-5.41 (m, 
2H, 2 x CHcarbohidrate), 4.59-4.48 (m, 2H, CHcarbohidrate), 4.28-4.16 (m, 4H, CHcarbohydrate, CH2), 
2.17 (s, 6H, CH3), 2.05 (s, 6H, CH3), 2.01 (s, 6H, CH3), 1.81 (s, 6H, CH3), 1.45 (s, 18H, t-Bu) 
ppm. 13C NMR (75.47 MHz, CDCl3): δ = 180.87 (AuCN),178.46 (NCO), 173.06 (NCNox), 
170.41 (CH3CO), 169.72 (CH3CO), 169.47 (CH3CO), 169.39 (CH3CO), 141.44 (CAr), 129.25 
(CHAr), 125.62 (CHIm), 125.50 (CHAr), 123.41 (CAr), 120.23 (CHIm), 86.60 (NCHcarbohidrateO), 
73.53 (OCHcarbohidrateCH2), 70.26 (CHcarbohidrate), 69.87 (CHcarbohidrate), 67.40 (CHcarbohidrate), 
60.87 (CHCH2carbohidrateOAc), 32.54 (CCH3), 28.37 (CCH3), 20.66 (COOCH3), 20.56 
(COOCH3), 20.44 (COOCH3), 20.41 (COOCH3) ppm. MS (ESI): calcd. for C58H68AuN8O20
+: 
1393.4187 (100), 1394.4207 (70), 1395.4230 (30), 1396.4255 (10); found: 1393.4209 (100), 
1394.4241 (70), 1395.4269 (30), 1396.4296 (10). 
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Synthesis of bis(1-(3-tert-butyl-5-phenyl-1,2,4-oxadiazole)-3-(benzyl)-imidazolium-2-
ylidene) gold (I) nitrate (82) 
To a solution of bis(1-(3-tert-butyl-5-phenyl-1,2,4-
oxadiazole)-3-(benzyl)-imidazolium-2-ylidene) silver 
(I) nitrate (0.08 g, 0.09 mmol) in dry CH2Cl2 (20 mL), 
AuCl(SMe2) (27 mg, 0.09 mmol) was added and the 
mixture was stirred at room temperature for 12 h. A 
clear solution was obtained after filtration. The volatile components were removed under 
vacuum. The crude product was flash-chromatographed using DCM : Methanol as eluent (r.f 
= 0.5). Yield: 43% (38 mg, 0.039 mmol). 
1H NMR (300.1 MHz, CDCl3): δ = 8.29-8.23 (m, 4H, Ar-H), 7.93-7.87 (m, 4H, Ar-H), 7.48-
7.32 (m, 14H, CHIm, Ar-HBn), 5.49 (s, 4H, CH2), 1.44 (s, 18H, t-Bu) ppm. 
13C NMR (75.47 
MHz, CDCl3): δ = 182.39 (AuCN), 178.49 (NCO), 173.65 (NCNox), 141.85 (NCAr), 134.51, 
129.42, 129.22, 129.12, 129.05, 128.86, 128.24, 127.36 (CHIm), 125.28, 121.92 (CHIm), 55.63 
(CH2-Bn), 32.48 (CCH3), 28.36 (CCH3). MS (HR-ESI): calcd. for C44H44AuN8O2
+: 913.3247 
(100), 914.3277 (50), 915.3307 (15); found: 913.3237 (100), 914.3260 (50), 915.3288 (15). 
 
Synthesis of Chloro(η4-1,5-cyclooctadiene) (1,3-bis(4-(3-tert-butyl-1,2,4-oxadiazol-5-
yl)phenyl)-1H-imidazol-2(3H)-ylidene)rhodium(I) (83) 
A mixture of 1,3-bis(3-tert-butyl-5-phenyl-1,2,4-
oxadiazole)imidazolium chloride (50.5 mg, 0.1 mmol) 
and silver(I) oxide (14 mg, 0.06 mmol) in dry 
dichloromethane (10 mL) was stirred for 24 h at room 
temperature in the absence of light. The mixture was filtered over Celite and [Rh(COD)Cl]2 
(25 mg, 0.05 mmol) was added. The resulting mixture was stirred for 12 h and filtered over 
Celite. The solvent was removed in vacuum and dichloromethane (2 mL) was added. The 
product was precipitated as a colorless solid upon addition of pentane and purified by column 
chromatography (DCM/Ethyl Acetate, 3:1). Yield: 59% (51 mg, 118 mmol). 
IR (ATR): 1/λ = 3128, 2965, 2924, 2871, 2826, 1720, 1612, 1565, 1510, 1464, 1423, 1399, 
1350, 1275, 1195, 1100, 1076, 1028, 992, 970, 935, 892, 845, 775, 724, 698, 636, 610, 575, 
544 cm-1. 1H NMR (300.1 MHz, CDCl3): δ = 8.63-8.57 (m, 4H, Ar-H), 8.39-8.34 (m, 4H, Ar-
H), 7.44 (s, 2H, CH), 5.13 (bs, 2H, CODvinyl), 2.78 (bs, 2H, CODvinyl), 2.01 (m, 4H, CODallyl), 
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1.71 (m, 4H, CODallyl), 1.45 (s, 18H, t-Bu) ppm. 
13C NMR (75.47 MHz, CDCl3): δ = 185.9 (d, 
JRhC = 52.4 Hz, RhC), 178.5, 173.73, 143.66, 128.74, 125.62, 125.42, 122.43, 96.4 (d, 
CODvinyl), 96.4 (d, CODvinyl), 68.9 (d, CODvinyl), 33.0 (CODallyl), 32.61, 29.8 (CODallyl), 28.9 
(CODallyl), 28.45 ppm. MS (EI): 714.2 (25, M
+), 715.2 (15, M+), 717.2 (5, M+), 678.2 (30), 
570.1 (20), 469.2 (100). 
 
Synthesis of Chloro(η4-1,5-cyclooctadiene) (1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-
yl)phenyl)-3-methyl-1H-imidazol-2(3H)-ylidene)rhodium(I) (84) 
A mixture of 1-bis(3-tert-butyl-5-phenyl-1,2,4-oxadiazole)-3-
methyl-imidazolium iodide (100 mg, 0.24 mmol) and silver(I) 
oxide (35 mg, 0.15 mmol) in dry dichloromethane (15 mL) was 
stirred for 24 h at room temperature in the absence of light. The 
mixture was filtered over Celite and [Rh(COD)Cl]2 (59 mg, 0.12 mmol) was added. The 
resulting mixture was stirred for 12 h and filtered over Celite. The solvent was removed in 
vacuum and dichloromethane (2 mL) was added. The product was precipitated as a colorless 
solid upon addition of pentane and purified by column chromatography (DCM/Ethyl Acetate, 
3:1). Yield: 44% (57 mg, 107 mmol). 
IR (ATR): 1/λ = 3163, 3098, 2967, 2913, 2871, 2829, 1700, 1612, 1593, 1512, 1466, 1448, 
1425, 1397, 1350, 1320, 1268, 1242, 1193, 1132, 1095, 1076, 991, 957, 887, 864, 846, 817, 
775, 749, 697, 634, 603, 544 cm-1. UV/Vis (DCM): λmax. (lg ε) = 227 (1.102), 264 (1.291), 
395 (0.114) nm. 1H NMR (300.1 MHz, CDCl3): δ = 8.48-8.43 (m, 2H, Ar-H), 8.36-8.28 (m, 
2H, Ar-H), 7.22 (d, J = 1.9, 1H, CH), 7.04 (d, J = 1.9, 1H, CH), 5.19-4.98 (m, 2H, CODvinyl), 
4.24 (s, 3H, CH3), 3.29-3.23 (m, 1H, CODvinyl), 2.58-2.51 (m, 1H, CODvinyl), 2.41-2.32 (m, 
2H, CH2), 2.22-2.13 (m, 1H, CH2), 1.91-1.73 (m, 4H, CH2), 1.76-1.72 (m, 1H, CH2), 1.46 (s, 
9H, t-Bu) ppm. 13C NMR (75.47 MHz, CDCl3): δ = 184.35 (d, JRhC = 51.29 Hz, RhC), 
178.50, 174.20, 143.19, 128.63, 124.78, 123.83, 123.20, 120.75, 98.20 (d, JRhC = 7.08 Hz, 
RhC), 78.70, 78.51, 68.25 (d, JRhC = 14.53 Hz, RhC), 60.31, 38.54, 33.15, 32.51, 31.88, 
30.79, 28.88, 28.48, 28.45 ppm. MS (ESI): 528.1 (M+H+), 493.1 (M-Cl); MS (EI): 528.1 (30, 
M+), 530.1 (15, M+), 531.1 (5, M+), 492.1 (25), 384.1 (25), 283.1 (100). Anal. Calcd for 
C24H30ClN4ORh: C, 54.5; H, 5.72; N, 10.59. Found: C, 53.95; H, 5.69; N, 10.25. 
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Bis {1,1′-[5-(phenyl)-3-(tert-butyl)-1,2,4-oxadiazole]-3,3′-methylene-diimidazolin-2,2′-
diylidene}disilver(I) bis(hexafluorophosphate) (85) 
A mixture of 1,1′-[5-(phenyl)-3-(tert-
butyl)-1,2,4-oxadiazole]-3,3′-methylene-
diimidazo-lium bis(hexafluorophosphate) 
(200 mg, 0.238 mmol) and Ag2O (56 mg, 
0.238 mmol) in CH3CN (10 mL) was 
stirred for 48 h at 25°C under an inert 
atmosphere in the dark. The mixture was 
filtered over Celite and the solvent was 
removed in vacuum to yield a yellowish-white solid. The solid was dissolved in CH2Cl2, 
filtered, and concentrated to 1 mL under reduced pressure. Addition of Et2O afforded a 
colorless solid which was filtered off and washed with ethyl acetate. Yield: 16% (90 mg, 
0.068 mmol). Single crystals suitable for X-ray diffraction were obtained by slow evaporation 
of a concentrated solution of 85 in MeOH/DCM. 
IR (ATR): 1/λ = 3144, 2971, 2931, 2873, 1616, 1512, 1463, 1425, 1395, 1351, 1249, 1196, 
1104, 958, 827, 775, 735, 699, 603, 554 cm-1. 1H NMR (300.1 MHz, CD3CN): 7.89 (d, JHH = 
1.9 Hz, 4H, NCHCHN), 7.76-7.67 (m, 12H, Ar-H, NCHCHN), 7.65-7.58 (m, 8H, Ar-H), 7.06 
(bs, 2H, CH2), 6.56 (bs, 2H, CH2), 1.43 (s, 36H, t-Bu) ppm. 
13C NMR (75.47 MHz, CD3CN): 
δ = 188.1 (AgCN), 179.2 (NCO), 174.4 (NCNox), 143.2 (NCAr), 129.9 (CHAr), 125.5 (CAr), 
125.1 (CHAr), 124.3 (CHIm), 123.7 (CHIm), 66.2 (NCH2N), 33.2 (CCH3), 28.8 (CCH3) ppm. 
MS (HR-ESI): calcd. for C31H32AgN8O2 (M
2+/2): 655.1693 (60), 655.6708 (40), 656.1695 
(100), 656.6707 (70), 657.1698 (60), 657.6709 (40), 658.1721 (10); found: 655.1701 (60), 
655.6716 (40), 656.1701 (100), 656.6709 (70), 657.1698 (70), 657.6707 (40), 658.1717 (10). 
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Bis{1,1′-[5-(phenyl)-3-(tert-butyl)-1,2,4-oxadiazole]-3,3′-methylene-diimidazolin-2,2′-
diylidene}digold(I) bis(bromide) (86) 
A suspension of 1,1′-[5-(phenyl)-3-(tert 
butyl)-1,2,4-oxadiazole]-3,3′-methylene-
diimidazolium bis(bromide) (323.27 mg, 
0.45 mmol) and (Me2S)AuCl (134 mg, 
0.48 mmol) in DMF (20 mL) was heated to 
100 °C under an inert atmosphere. Sodium 
acetate (150 mg, 1.8 mmol) was added and 
the mixture was stirred at 100°C for 5 h, 
then cooled to room temperature and filtered. To the clear filtrate ether was added, yielding a 
colorless precipitate which was collected, washed with ether and dried. Yield: 40% (300 mg, 
0.18 mmol). 
IR (ATR): 1/λ = 3400, 3064, 2969, 2930, 2871, 1615, 1564, 1512, 1462, 1426, 1394, 1349, 
1325, 1282, 1254, 1195, 1091, 1062, 1019, 991, 958, 892, 848, 774, 758, 736, 722, 698, 603, 
551 cm-1. 1H NMR (300.1 MHz, DMSO-d6): 8.59 (s, 4H, NCHCHN), 8.19 (s, 4H, 
NCHCHN), 7.99-7.51 (m, 16H, Ar-H), 6.92-6.68 (bs, 4H, CH2), 1.41 (s, 36H, t-Bu) ppm. 13C 
NMR (75.47 MHz, DMSO-d6): δ = 181.6 (AuCNIm), 177.5 (NCO), 173.1 (NCNox), 141.2 
(NCAr), 128.4 (CHAr), 125.1 (CHAr), 124.1 (CAr), 123.5 (CHCHNIm), 123.2 (CHCHNIm), 63.1 
(NCH2N), 32.1 (CCH3), 28.1 (CCH3) ppm. MS (HR-ESI): calcd. for C31H32AuN8O2 (M
2+/2) 
745.2308 (100), 745.7322 (80), 746.2336 (30), 746.7350 (10); found 745.2315 (100), 
745.7322 (80), 746.2332 (30), 746.7346 (10). Anal. Calcd for C62H64Au2Br2N16O4.NH4Br: C, 
42.58; H, 3.92; N, 13.61. Found: C, 42.25; H, 3.96; N, 13.88. 
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Bis{1,1′-[5-(phenyl)-3-(tert-butyl)-1,2,4-oxadiazole]-3,3′-methylene-diimidazolin-2,2′-
diylidene}digold(I) bis(hexafluorophosphate) (87) 
To a solution of 86 (0.1 g, 0.06 mmol) in 
hot water (50 mL) was added a saturated 
aqueous solution of NH4PF6 (15 mL). 
The colorless precipitate which formed 
immediately was collected by filtration 
and washed with water. Yield: 80% (86 
mg, 0.048 mmol). 
IR (ATR): 1/λ = 3187, 3158, 2970, 2930, 2872, 1616, 1512, 1463, 1427, 1396, 1375, 1349, 
1326, 1260, 1193, 1093, 1022, 960, 833, 774, 731, 699, 603, 556 cm-1. 1H NMR (300.1 MHz, 
CDCl3): 7.97 (s, 4H, NCHCHN), 7.88-7.76 (m, 8H, Ar-H), 7.62-49 (m, 8H, Ar-H), 7.45 (s, 
4H, NCHCHN), 6.56-6.41 (bs,  H, CH2), 1.41 (s, 36H, t-Bu). 
13C NMR (75.47 MHz, CDCl3): 
δ = 182.3 (AuCNIm), 178.4 (NCO), 173.4 (NCNox), 141.2 (NCAr), 129.1 (CHAr), 125.3 (CHAr), 
124.9 (CAr), 123.4 (CHCHNIm), 123.2 (CHCHNIm), 63.2 (NCH2N), 32.5 (CCH3), 28.4 
(CCH3). MS (HR-ESI): calcd. for C31H32AuN8O2 (M
2+/2) 745.2308 (100), 745.7322 (80), 
746.2336 (30), 746.7350 (10); found 745.2316 (100), 745.7323 (80), 746.2333 (30), 746.7347 
(10). Anal. Calcd for C62H64Au2F12N16O4P2.C4H10O: C, 42.73; H, 4.02; N, 12.08. Found: C, 
42.92; H, 3.97; N, 12.48. 
 
Synthesis of {1,1′-[5-(phenyl)-3-(tert-butyl)-1,2,4-oxadiazole]-3,3′-methylene-
diimidazolin-2,2′-diylidene}Rh(η2:η2-COD)[BF4] (88) 
A suspension of 85(BF4 salt) (120 mg, 
0.086 mmol) and [Rh(COD)Cl]2 (43 mg, 
0.086 mmol) was stirred in CH2Cl2 (15 
mL) at 60°C for 5 h in the absence of light. 
The cooled reaction mixture was filtered, 
the solution was concentrated in vacuum to 1 mL and hexane was added to afford an orange 
solid. Yield: 81% (118 mg, 0.138 mmol). 
IR (ATR): 1/λ = 3480, 3149, 2970, 2930, 2874, 2832, 1615, 1512, 1465, 1423, 1401, 1351, 
1314, 1267, 1238, 1195, 1056, 851, 805, 774, 730, 697, 634, 604, 550 cm-1. 1H NMR (300.1 
MHz, CDCl3): 8.44-8.36 (m, 4H, Ar-H), 7.98-7.91 (m, 4H, Ar-H), 7.89 (d, J = 1.98 Hz, 2H, 
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NCHCHN), 7.29 (d, J = 1.98 Hz, 2H, NCHCHN), 6.73 (d, J = 12.9 Hz, 1H, CH2), 6.52 (d, J = 
12.9 Hz, 1H, CH2), 4.59 (s, 2H, COD, CH), 3.59 (m, 2H, COD, CH), 2.14 (m, 2H, COD 
CH2), 1.93 (m, 4H, COD, CH2), 1.49 (s, 18H, t-Bu), 1.42 (m, 2H, COD, CH2) ppm. 
13C NMR 
(75.47 MHz, CDCl3): δ = 179.50 (d, JRhC = 53 Hz, RhC), 178.68 (NCO), 173.71 (NCNox), 
142.05 (NCAr), 129.20 (CHAr), 125.13 (CHAr), 125.11 (CAr), 123.59 (CHCHNIm), 121.36 
(CHCHNIm), 93.58 (d, JRhC = 8.0 Hz, COD, CH), 89.08 (d, JRhC = 7.1 Hz, COD, CH), 63.76 
(NCH2N), 32.61 (CCH3), 30.12 (COD, CH2), 30.01 (COD, CH2), 28.48 (CCH3) ppm. MS 
(HR-ESI): Calcd. for C39H44N8O2Rh (M
+): 759.2642 (100), 760.2676 (50), 761.2709 (15), 
761.2709 (10). Found 759.2642 (100), 760.2666 (50), 761.2694 (10). Calcd. for 
C31H32N8O2Rh (M
+-COD): 651.1703 (100), 652.1737 (30), 653.1770 (5). Found: 651.1701 
(30), 652.1728 (10), 653.1767 (5). 
 
Synthesis of RuCl(1,1′-[5-(phenyl)-3-(tert-butyl)-1,2,4-oxadiazole]-3,3′-methylenedi-
imidazol) (η6-p-cymene)]PF6 (89) 
To a solution of 1,1′-[5-(phenyl)-3-(tert-butyl)-
1,2,4-oxadiazole]-3,3′-methylene di-
imidazolium bis(bromide) (177.5 mg, 0.25 
mmol) in H2O (15 mL) was added Ag2O (145 
mg, 0.625 mmol). After stirring at room 
temperature in the absence of light for 60 min, the mixture was filtered over Celite. The clear 
filtrate was treated with NH4PF6 (325 mg, 2.0 mmol) and the colorless precipitate thus formed 
was collected and subsequently washed with H2O and with Et2O. The dry residue was 
dissolved in CH2Cl2 (10 mL) and [(η6-p-cymene)-RuCl2]2 (75 mg, 125 mmol) was added. The 
reaction mixture was stirred for 24 hours at room temperature. Upon addition of Et2O a 
precipitate as a brown solid was formed. The product was collected by filtration and dried 
under vacuum. Yield: 23% (56 mg, 0.057 mmol). 
IR (ATR): 1/λ = 3494, 3439, 3098, 2973, 2933, 2873, 1615, 1574, 1512, 1465, 1425, 1398, 
1348, 1272, 1242, 1196, 1106, 1090, 1016, 992, 956, 888, 849, 773, 695, 603, 551 cm-1. 1H 
NMR (300.1 MHz, DMSO-d6): 8.33-8.24 (m, 4H, Ar-H), 8.14-8.05 (m, 4H, Ar-H), 7.89-7.81 
(m, 4H, CHIm), 6.63 (d, JHH = 13.1 Hz, 1 H, NCH2), 5.65 (d, JHH = 13.1 Hz, 1H, NCH2), 5.31-
5.19 (m, 2H, (CH3)2CH-C6H4-(CH3)-p), 4.89-4.78 (m, 2H, (CH3)2CH-C6H4-(CH3)-p), 2.72 
(m, 1H, (CH3)2CHC6H4(CH3)-p), 2.09 (s, 3H, (CH3)2CHC6H4-(CH3)-p), 1.41 (s, 18H, t-Bu), 
0.76 (d, JHH = 6.9 Hz, 6H, (CH3)2CHC6H4(CH3)-p) ppm. 
13C NMR (75.47 MHz, DMSO-d6): 
δ = 179.23 (NCO), 176.53 (RuC), 174.34 (NCNox), 143.65 (NCAr), 129.71 (CHAr), 128.47 
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(CAr), 125.76 (CHCHNIm), 124.44 (CHAr), 122.63 (CHCHNIm), 110.89 (CHCym), 106.45 
(CHCym), 91.93 (CCym), 86.72 (CCym), 66.16 (NCH2N), 33.27 (CCH3), 31.34 (CH3Cym), 28.48 
(CCH3), 22.7 (CHiPr), 18.7 (CH3iPr) ppm. MS (HR-ESI): calculated for C41H46ClN8O2Ru
+: 
819.2476; found: 819.2479. 
 
Synthesis of 1,1′-[5-(phenyl)-3-(tert-butyl)-1,2,4-oxadiazole]-3,3′-methylenedi-
imidazolium palladium(II) dibromide (90) 
A suspension of 1,1′-[5-(phenyl)-3-(tert-butyl)-
1,2,4-oxadiazole]-3,3′-methylenediimidazo-lium 
bis-bromide (100 mg, 0.140 mmol) and Pd(OAc)2 
(16 mg, 0.071 mmol) was stirred in CH3CN (25 
mL) at 60°C for 12 hours. The reaction mixture 
was cooled to room temperature and the colorless precipitate thus formed was filtered and 
dried. Yield: 67% (77 mg, 0.094 mmol). 
IR (ATR): 1/λ = 3491, 3086, 2968, 2928, 2871, 1616, 1571, 1512, 1466, 1429, 1412, 1395, 
1352, 1316, 1279, 1239, 1194, 1129, 1094, 1023, 993, 959, 896, 846, 802, 775, 730, 698, 683, 
672, 634, 603, 542 cm-1. 1H-NMR (300.1 MHz, DMSO-d6): 8.48-8.36 (m, 4H, Ar-H), 8.17-
8.06 (m, 4H, Ar-H), 8.03-7.89 (m, 4H, CHim), 6.68-6.49 (m, 2H, CH2), 1.44 (s, 18H, t-Bu) 
ppm. 13C NMR (75.47 MHz, DMSO-d6): δ = 178.03 (PdCN), 177.94 (NCO), 174.88 
(NCNox), 143.49 (NCAr), 129.92 (CHAr), 128.17 (CAr), 124.91 (CHIm), 122.94 (CHAr), 121.56 
(CHIm), 65.42 (NCH2N), 32.19 (CCH3), 28.14 (CCH3) ppm. MS (HR-ESI): calcd. for 
C31H31BrN8O2Pd (M-HBr): 732.0788 (100), 733.9542 (100); found: 732.1633 (100), 
733.9644 (100). 
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Synthesis of 1,1′-[5-(phenyl)-3-(tert-butyl)-1,2,4-oxadiazole]-3,3′-
methylenediimidazolium nickel(II) bis(hexafluorophosphate) (91) 
A suspension of 1,1′-[5-(phenyl)-3-(tert 
butyl)-1,2,4-oxadiazole]-3,3′-
methylenediimi-dazolium di-silver(I) 
bis(hexafluorophospha-te) (100 mg, 0.062 
mmol) and Ni(PPh3)2Cl2 (89 mg, 0.125 
mmol) was stirred in DCM (25 mL) at room temperature for 12 hours. The precipitate thus 
formed was filtered and the solvent was removed. The product was recrystallized from 
MeOH/ether. 
MS-ESI: calcd. for C62H64N16O4Ni (M
+): 1154.46; found: 1154.44. MS-ESI: calcd. for 
C31H32N8O2Ni (M
2++Ni): 606.20; found: 606.33. MS-ESI: calcd. for C31H32N8O2Ni (M
2+): 
548.26; found: 548.20.3. 
 
Synthesis of {(COD)Pt[3-(tert-butyl)-5-(4-ethynylphenyl)-1,2,4-oxadiazole]2} (92) 
A suspension of 100 mg (0.267 mmol) [(COD)PtCl2] in 
10 mL of ethanol was cooled at -5°C. A freshly prepared 
mixture of 132.82 mg of 3-(tert-butyl)-5-(4-
ethynylphenyl)-1,2,4-oxadiazole (0.587 mmol, 2.2 eq.) 
and 66 mg (0.587 mmol, 2.2 eq.) of potassium tert-
butoxide in 5 mL of ethanol were added dropwise with 
constant stirring. The solution changed color (became 
darker), and after 1 h the solid thus formed was filtered 
off. Recrystallization from CH2Cl2/hexane gave the pure 
product as microcrystalline material. Yield: 54% (108.7 
mg, 0.144 mmol). 
IR (ATR): 1/λ = 3049, 2968, 2928, 2904, 2872, 2124, 1606, 1580, 1547, 1509, 1464, 1411, 
1395, 1350, 1313, 1270, 1195, 1178, 1093, 995, 970, 886, 848, 775, 739, 699, 653, 591 cm-1. 
UV/Vis (DCM): λmax. (lg ε) = 221 (0.555), 229 (0.811), 303 (1.799), 480 (0.040) nm. 1H 
NMR (300.1 MHz, CDCl3): 8.04-7.97 (m, 4H, Ar-H), 7.55-7.48 (m, 4H, Ar-H), 5.91-5.62 (m, 
4H, COD, CH, JPtH = 43 Hz), 2.71-2.53 (m, 8H, COD, CH2), 1.42 (s, 18H, t-Bu) ppm. 
13C 
NMR (75.47 MHz, CDCl3): δ = 178.34, 175.2, 132.23, 131.02, 127.61, 122.4, 108.23, 105.05, 
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99.12, 32.45, 30.41, 28.48 ppm. MS (HR-ESI): calcd. for C36H38N4O2PtH
+ (M + H+) 
754.2721, found 754.2719; C36H38N4O2PtK
+ (M + K+) 792.2280 found 792.2279. 
 
Synthesis of ((4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)ethynyl)gold polimer (93) 
To a solution of 398.3 mg of 3-tert-butyl-5-(4-ethynylphenyl)-
1,2,4-oxadiazole (1.76 mmol) in CH2Cl2 (20 mL) were 
successively added NEt3 (1 mL) and 519 mg [AuCl(SMe2)], 
(1.76 mmol). The reaction mixture was stirred for 1 h. The resulting solution was 
concentrated under reduced pressure to ca. 10 mL and MeOH (10 mL) was added to 
precipitate a yellow-green powder which was filtered, washed with Et2O (2 x 5 mL) and 
dried. Yield 71% (530 mg, 1.25 mmol). 
IR (ATR): 1/λ = 2968, 2929, 2870, 1985, 1609, 1581, 1549, 1505, 1463, 1407, 1394, 1347, 
1270, 1194, 1092, 1016, 989, 971, 896, 841, 772, 735, 695, 650, 589 cm-1. Anal. Calc. for 
C14H13AuN2O: C 39.82; H 3.10; N 6.63. Found: C, 39.59; H 3.09; N, 6.61%. 
 
Synthesis of ((4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)ethynyl)gold(I)-PPh3 (94) 
To a suspension of 223.6 mg ((4-(3-tert-butyl-1,2,4-
oxadiazol-5-yl)phenyl)ethynyl)gold polymer (0.53 
mmol) in CH2Cl2 (25 mL) was added 209 mg of PPh3 
(0.8 mmol). The reaction mixture was stirred for 1h and 
filtered through anhydrous MgSO4. The solution was concentrated under vacuum to 1 mL and 
hexane (10 mL) was added. After stirring for 15 hours, the suspension was filtered and the 
solid was air dried to give a colorless solid. Yield 66% (240 mg, 0.35mmol). 
1H NMR (300.1 MHz, CDCl3): 8.06-7.99 (m, 2H, Ar-H), 7.65-7.41 (m, 17H, Ar-H, PPh3), 
1.43 (s, 9H, t-Bu) ppm. 13C NMR (75.47 MHz, CDCl3): δ = 178.26, 174.92, 134.35, 134.16, 
132.73, 131.61, 131.58, 129.96, 129.32, 129.24, 129.09, 127.70, 122.39, 103.35, 32.44, 28.45 
ppm. 31P NMR (121 MHz, CDCl3): δ = 42.13 (s, PPh3) ppm. MS (ESI): 721.18 (M + K+, 
100), 722.14 (M + K+, 40), 723.11 (M + K+, 8). 
 
Synthesis of ((4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)ethynyl)gold(I)-
dimethylaminopyridine complex (95) 
To a suspension of 100 mg ((4-(3-tert-butyl-1,2,4-
oxadiazol-5-yl)phenyl)ethynyl)-gold(I) polymer (0.183 
mmol) in CH2Cl2 (5 mL) was added 22.44 mg of 
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DMAP (0.183 mmol). The reaction mixture was stirred for 2h and filtered through anhydrous 
Celite. The solution was concentrated under vacuum to 1 mL and Et2O (10 mL) was added. 
After stirring for 15 hours, the suspension was filtered and the solid was air dried to give a 
colorless solid. Yield 53% (52.7 mg, 0.096mmol). 
1H NMR (300.1 MHz, CDCl3): 8.07-7.95 (m, 4H, Py-H, Ar-H), 7.62-7.53 (m, 2H, Ar-H), 
6.62-6.51 (m, 2H, Py-H), 3.07 (s, 6H, CH3), 1.42 (s, 9H, t-Bu). 
13C NMR (75.47 MHz, 
CDCl3): δ = 178.24, 174.97, 154.76, 150.12, 132.77, 127.60, 107.42, 39.33, 32.43, 28.46. MS 
(HR-ESI): calcd. for C36H38N4O2PtH
+ (M + H+) 754.2721, found 754.2719; C21H23AuN4Na
+ 
(M + Na+) 567.1429 (100), 568.1459 (20), 569.1488 (5); found 567.1430 (100), 568.1462 
(20), 569.1495 (5). 
 
Synthesis of {Zn[4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)benzothioamide)]2Cl2} (96) 
A solution of 300 mg of 4-(3-tert-butyl-1,2,4-oxadiazol-
5-yl)benzothioamide (1.14 mmol) and 82 mg of ZnCl2 
(0.6 mmol) in absolut ethanol (10 mL ) was refluxed for 
48 hours under inert atmosphere. After cooling, the precipitate thus formed was filtrated and 
washed with 5 mL ethanol and then was dried in vacuum to afford 96 mg of powdery 
colorless solid. Yield: 24% (96 mg, 0.145 mmol). 
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VIII. Crystallographic data 
Compound 1 3 4 
Identification code cmx6 cmx7 cmx12 
Empirical formula C12H13IN2O C12H15N3O C12H13N3O3 
Formula weight 328.14 217.27 247.25 
Crystal system Monoclinic Monoclinic Orthorhombic 
Space group P21/c P21/c Pbca 
Crystal size [mm] 0.17 x 0.17 x 0.06 0.15 x 0.15 x 0.1  0.24 x 0.12 x 0.07 
   a (Å) 14.2079(4) 15.6514(10) 6.7175(4) 
   b (Å) 6.6247(2) 9.0961(6) 13.8116(6) 
   c (Å) 14.2917(4) 18.4999(12) 26.1018(9) 
Volume (Å3) 1257.67(6) 2399.1(3) 2421.7(2) 
   α (°) 90 90 90 
   β (°) 110.781(2) 114.371(8) 90 
   δ (°) 90 90 90 
Z 4 8 8 
Density (calc.) [g/cm-3] 1.733 1.203 1.356 
µ [mm-1] 2.528 0.08 0.10 
Temperature [K] 100(2) 100(2) 100(2) 
Wavelength [Å] 0.71073 0.71073 0.71073 
Theta range [°] 2.89 to 26.37 2.24 to 26.37 2.95 to 27.48 
Reflections collected 38888 41755 55696 
Independent reflections 2574 4908 2483 
R1 with I0>2σ(I0) 0.0154 0.035 0.031 
wR2 0.0388 0.057 0.061 
G0F 1.057 0.73 0.81 
Largest diff. peak and hole [e/Å3] 0.473 and -0.237 0.165 and -0.187 0.195 and -0.159 
Structure solved by Daniliuc Constantin Daniliuc Constantin Daniliuc Constantin 
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Compound 5 7 8 
Identification code cmx1 cmx5 cmx3 
Empirical formula C13H13N3O C13H14N2O2 C14H16N2O2 
Formula weight 227.26 230.26 244.29 
Crystal system Monoclinic Monoclinic Triclinic 
Space group P21/m P21/m P-1 
Crystal size [mm] 0.31 x 0.25 x 0.17 0.25 x 0.22 x 0.13 0.10 x 0.04 x 0.04 
   a (Å) 9.1200(4) 9.2714(2) 7.0155(6) 
   b (Å) 6.7180(4) 6.7055(2) 12.9272(10) 
   c (Å) 9.4957(4) 9.6182(2) 15.9808(12) 
Volume (Å3) 575.75(5) 592.58(3) 1293.93(18) 
   α (°) 90 90 113.416(8) 
   β (°) 98.259(4) 97.689(2) 101.242(6) 
   δ (°) 90 90 92.092(6) 
Z 2 2 4 
Density (calc.) [g/cm-3] 1.311 1.290 1.254 
µ [mm-1] 0.086 0.089 0.687 
Temperature [K] 100(2) 100(2) 100(2) 
Wavelength [Å] 0.71073 0.71073 1.54184 
Theta range [°] 2.17 to 29.13 2.87 to 30.49 3.75 to 75.99 
Reflections collected 15358 29178 21903 
Independent reflections 1842 1949 5348 
R1 with I0>2σ(I0) 0.0365 0.0363 0.0374 
wR2 0.1068 0.1103 0.1018 
G0F 1.07 1.089 1.035 
Largest diff. peak and hole [e/Å3] 0.349 and -0.263 0.456 and -0.234 0.172 and -0.244 
Structure solved by Daniliuc Constantin Daniliuc Constantin Daniliuc Constantin 
 
 
 
Crystallographic data 
204 
Compound 13 18 19 
Identification code cmx47 cmx99 cmx16 
Empirical formula C14H13BrN2O C13H15N3OS C16H21N3O3 
Formula weight 305.17 261.34 303.36 
Crystal system Orthorhombic Triclinic Triclinic 
Space group P n a 21 P-1 P-1 
Crystal size [mm] 0.34 x 0.29 x 0.14 0.11 x 0.07 x 0.06 0.27 x 0.18 x 0.13 
   a (Å) 22.5232(4) 5.5204(4) 8.2544(4) 
   b (Å) 8.4735(2) 10.3978(8) 10.0923(4) 
   c (Å) 7.0442(2) 11.3847(8) 10.6207(6) 
Volume (Å3) 1344.39(6) 643.80(8) 807.27(7) 
   α (°) 90 93.567(6) 105.700(4) 
   β (°) 90 93.498(6) 93.484(4) 
   δ (°) 90 98.277(6) 106.559(4) 
Z 4 2 2 
Density (calc.) [g/cm-3] 1.508 1.348 1.248 
µ [mm-1] 3.047 0.243 0.088 
Temperature [K] 100(2) 100(2) 100(2) 
Wavelength [Å] 0.71073 0.71073 0.71073 
Theta range [°] 2.57 to 29.13 2.58 to 27.10 2.21 to 27.87 
Reflections collected 57174 24223 27623 
Independent reflections 3627 2824 3856 
R1 with I0>2σ(I0) 0.0188 0.0347 0.0339 
wR2 0.0489 0.0798 0.0969 
G0F 1.011 1.059 1.063 
Largest diff. peak and hole [e/Å3] 0.298 and -0.653 0.359 and -0.237 0.288 and -0.304 
Structure solved by Daniliuc Constantin Daniliuc Constantin Daniliuc Constantin 
 
 
 
Crystallographic data 
205 
Compound 20 24 26 
Identification code cmx17 cmx31 cmx55 
Empirical formula C12H15N3O2 C17H23N3O3 C16H17N3O3 
Formula weight 233.27 317.38 299.33 
Crystal system Orthorhombic Monoclinic Monoclinic 
Space group P212121 P21/c P21/c 
Crystal size [mm] 0.19 x 0.19 x 0.16 0.19 x 0.04 x 0.04 0.11 x 0.05 x 0.02 
   a (Å) 10.3093(2) 9.8062(2) 13.8569(4) 
   b (Å) 10.4887(2) 17.6339(4) 15.3562(4) 
   c (Å) 11.3309(4) 10.0402(2) 6.8926(2) 
Volume (Å3) 1225.22(5) 1735.09(6) 1461.27(7) 
   α (°) 90 90 90 
   β (°) 90 92.022(2) 94.918(2) 
   δ (°) 90 90 90 
Z 4 4 4 
Density (calc.) [g/cm-3] 1.265 1.215 1.361 
µ [mm-1] 0.089 0.686 0.789 
Temperature [K] 100(2) 100(2) 100(2) 
Wavelength [Å] 0.71073 1.54184 1.54184 
Theta range [°] 2.65 to 29.12 4.51 to 76.13 3.20 to 75.96 
Reflections collected 53131 26793 16680 
Independent reflections 1888 3591 3034 
R1 with I0>2σ(I0) 0.0289 0.0356 0.0323 
wR2 0.0772 0.0943 0.086 
G0F 1.062 1.055 1.06 
Largest diff. peak and hole [e/Å3] 0.261 and -0.160 0.193 and -0.226 0.210 and -0.190 
Structure solved by Daniliuc Constantin Daniliuc Constantin Daniliuc Constantin 
 
 
 
Crystallographic data 
206 
Compound 27 28 31 
Identification code cmx53_twin5 cmx52 cmx10 
Empirical formula C17H21N3O4 C16H17N3O4 C16H20N4O2 
Formula weight 331.37 315.33 300.36 
Crystal system Monoclinic Trigonal Triclinic 
Space group P(-1) R(-3) P-1 
Crystal size [mm] 0.18 x 0.09 x 0.02 0.07 x 0.05 x 0.03 0.18 x 0.09 x 0.04 
   a (Å) 5.4494(5) 28.0192(16) 7.1791(6) 
   b (Å) 6.1403(6) 28.0192(16) 9.5004(8) 
   c (Å) 25.283(2) 10.0740(8) 23.8791(9) 
Volume (Å3) 805.57(13) 6849.3(8) 1617.7(2) 
   α (°) 86.906(8) 90 95.138(6) 
   β (°) 85.277(8) 90 94.122(6) 
   δ (°) 72.926(8) 120 90.648(6) 
Z 2 18 4 
Density (calc.) [g/cm-3] 1.366 1.376 1.233 
µ [mm-1] 0.814 0.837 0.084 
Temperature [K] 100(2) 100(2) 100(2) 
Wavelength [Å] 1.54184 1.54184 0.71073 
Theta range [°] 3.51 to 76.03 3.15 to 75.91 2.15 to 26.37 
Reflections collected 3747 28530 44110 
Independent reflections 3747 3156 6586 
R1 with I0>2σ(I0) 0.039 0.0385 0.0488 
wR2 0.098 0.0923 0.1012 
G0F 1.04 1.039 0.721 
Largest diff. peak and hole [e/Å3] 0.377 and -0.339 0.174 and -0.219 0.507 and -0.248 
Structure solved by Daniliuc Constantin Daniliuc Constantin Daniliuc Constantin 
 
 
 
Crystallographic data 
207 
Compound 33 35 37 
Identification code cmx9a cmx89 cmx24 
Empirical formula C14H16N2O3 C17H21N3O2 C14H16N2O3 
Formula weight 260.29 299.37 260.29 
Crystal system Monoclinic Monoclinic Orthorhombic 
Space group P21/m P21/c Pbcn 
Crystal size [mm] 0.11 x 0.09 x 0.06 0.14 x 0.12 x 0.04 0.24 x 0.16 x 0.03 
   a (Å) 7.6876(6) 5.4582(4) 24.459(5) 
   b (Å) 6.5688(6) 11.0023(6) 12.310(3) 
   c (Å) 13.3016(10) 26.3293(16) 8.9524(18) 
Volume (Å3) 666.89(9) 1571.93(17) 2695.4(9) 
   α (°) 90 90 90 
   β (°) 96.867(8) 96.191(6) 90 
   δ (°) 90 90 90 
Z 2 4 8 
Density (calc.) [g/cm-3] 1.296 1.265 1.283 
µ [mm-1] 0.092 0.679 0.091 
Temperature [K] 100(2) 100(2) 100(2) 
Wavelength [Å] 0.71073 1.54184 0.71073 
Theta range [°] 2.67 to 27.48 3.38 to 74.47 2.93 to 27.88 
Reflections collected 24572 20138 76664 
Independent reflections 1493 3266 3204 
R1 with I0>2σ(I0) 0.033 0.034 0.032 
wR2 0.068 0.092 0.0565 
G0F 0.82 1.05 0.802 
Largest diff. peak and hole [e/Å3] 0.196 and -0.236 0.221 and -0.185 0.165 and -0.205 
Structure solved by Daniliuc Constantin Daniliuc Constantin Daniliuc Constantin 
 
 
 
Crystallographic data 
208 
Compound 39 40 41 
Identification code cmx87 cmx87a cmx43 
Empirical formula C17H18N6OS C19H20N6O2S C13H13N3OS 
Formula weight 354.43 396.47 259.32 
Crystal system Monoclinic Monoclinic Monoclinic 
Space group C2/c P21/n P21/n 
Crystal size [mm] 0.05 x 0.03 x 0.03 0.14 x 0.08 x 0.06 0.05 x 0.05 x 0.03 
   a (Å) 16.1767(4) 5.1644(4) 14.9371(4) 
   b (Å) 14.8235(4) 12.2462(8) 6.4523(2) 
   c (Å) 14.6649(4) 30.864(2) 15.5069(4) 
Volume (Å3) 3429.24(16) 1947.6(2) 1317.51(6) 
   α (°) 90 90 90 
   β (°) 102.796(2) 93.867(6) 118.170(4) 
   δ (°) 90 90 90 
Z 8 4 4 
Density (calc.) [g/cm-3] 1.373 1.352 1.307 
µ [mm-1] 1.832 1.712 2.116 
Temperature [K] 100(2) 100(2) 100(2) 
Wavelength [Å] 1.54184 1.54184 1.54184 
Theta range [°] 4.09 to 76.10 3.88 to 74.48 3.39 to 76.01 
Reflections collected 26821 16881 17130 
Independent reflections 3571 4039 2710 
R1 with I0>2σ(I0) 0.0478 0.038 0.033 
wR2 0.1313 0.096 0.096 
G0F 1.05 1.02 1.09 
Largest diff. peak and hole [e/Å3] 0.600 and -0.752 0.268 and -0.327 0.408 and -0.407 
Structure solved by Daniliuc Constantin Daniliuc Constantin Daniliuc Constantin 
 
 
 
Crystallographic data 
209 
Compound 42 43 . CH3OH 47 . 5/3DMSO 
Identification code cmx73 cmx76 cmx78 
Empirical formula C17H17N5OS C17H21N7O2 C26.33 H32 N8 O2.67 S1.67 
Formula weight 339.42 355.41 556.70 
Crystal system Triclinic Monoclinic Triclinic 
Space group P-1 P21/n P-1 
Crystal size [mm] 0.28 x 0.20 x 0.03 0.26 x 0.20 x 0.14 0.17 x 0.10 x 0.02 
   a (Å) 8.8850(4) 7.5681(2) 10.5098(6) 
   b (Å) 14.5822(8) 15.8937(4) 17.6996(14) 
   c (Å) 14.6106(10) 16.0537(4) 23.2169(16) 
Volume (Å3) 1754.05(17) 1915.66(8) 4145.7(5) 
   α (°) 111.830(6) 90 75.968(6) 
   β (°) 92.985(4) 97.231(2) 82.825(6) 
   δ (°) 90.506(4) 90 84.179(6) 
Z 4 4 6 
Density (calc.) [g/cm-3] 1.285 1.232 1.338 
µ [mm-1] 0.198 0.086 1.862 
Temperature [K] 100(2) 100(2) 100(2) 
Wavelength [Å] 0.71073 0.71073 1.54184 
Theta range [°] 2.30 to 27.48 2.56 to 26.37 3.60 to 75.95 
Reflections collected 59195 54249 48006 
Independent reflections 7162 3906 17122 
R1 with I0>2σ(I0) 0.039 0.049 0.0556 
wR2 0.072 0.09 0.147 
G0F 0.76 0.94 0.923 
Largest diff. peak and hole [e/Å3] 0.35 and -0.25 0.191 and -0.184 0.735 and -0.732 
Structure solved by Daniliuc Constantin Daniliuc Constantin Daniliuc Constantin 
 
 
 
Crystallographic data 
210 
Compound 58 . 2CHCl3 59 60 
Identification code ict03 ict05 ict21 
Empirical formula C29H30AuCl7N6O2 C16H18AuClN4O C22H22AuBrN4O 
Formula weight 939.71 514.76 635.31 
Crystal system Triclinic Monoclinic Monoclinic 
Space group P-1 P21/c  P21/c  
Crystal size [mm] 0.24 x 0.06 x 0.02 0.20 x 0.08 x 0.04 0.18 x 0.18 x 0.10 
   a (Å) 9.4854(3) 13.1177(5) 26.501(2) 
   b (Å) 13.2761(5) 7.5040(3) 13.3853(10) 
   c (Å) 15.1158(6) 17.5691(8) 12.3462(11) 
Volume (Å3) 1772.41(11) 1701.72(12) 4379.5(6) 
   α (°) 110.499(3) 90 90 
   β (°) 93.416(3) 100.270(4) 90.277(8) 
   δ (°) 93.686(3) 90 90 
Z 2 4 8 
Density (calc.) [g/cm-3] 1.761 2.009 1.927 
µ [mm-1] 4.715 8.811 8.6 
Temperature [K] 293(2) 100(2) 100(2) 
Wavelength [Å] 0.71073 0.71073 0.71073 
Theta range [°] 2.16 to 27.88 2.36 to 30.87 2.16 to 28.28 
Reflections collected 76226 83443 81844 
Independent reflections 8426 5200 10871 
R1 with I0>2σ(I0) 0.0314 0.0289 0.0382 
wR2 0.0655 0.0415 0.0811 
G0F 1.034 1.069 1.03 
Largest diff. peak and hole [e/Å3] 2.213 and -1.626 2.901 and -0.804 1.89 and -1.94 
Structure solved by Freitag Mathias Freitag Mathias Freitag Mathias 
 
 
 
Crystallographic data 
211 
Compound 61 . CH2Cl2 62 65 
Identification code Ict22 Ict20 Ict24 
Empirical formula C21H21AuBrCl2N5O C30H26AuClN4O C25H31AuBrN5O 
Formula weight 707.20 690.96 694.42 
Crystal system Triclinic Monoclinic Orthorhombic 
Space group P(-1) C2/c P212121 
Crystal size [mm] 0.20 x 0.10 x 0.09 0.20 x 0.12 x 0.08  0.20 x 0.11 x 0.04 
   a (Å) 9.7277(5) 20.6859(3) 6.84802(15) 
   b (Å) 9.9275(5) 15.29914(12) 9.5220(2) 
   c (Å) 13.7791(8) 18.8633(2) 39.9463(8) 
Volume (Å3) 1203.06(11) 5246.80(10) 2604.76(9) 
   α (°) 70.949(5) 90 90 
   β (°) 83.029(4) 118.4908(17) 90 
   δ (°) 73.116(4) 90 90 
Z 2 8 4 
Density (calc.) [g/cm-3] 1.952 1.749 1.771 
µ [mm-1] 8.0 5.741 7.21 
Temperature [K] 100(2) 100(2) 100(2) 
Wavelength [Å] 0.71073 0.71073 0.71073 
Theta range [°] 2.19 to 30.88 2.24 to 30.94 2.20 to 30.17 
Reflections collected 40101 136619 109977 
Independent reflections 7005 8056 7499 
R1 with I0>2σ(I0) 0.0240 0.0207 0.0235 
wR2 0.0495 0.0415 0.0478 
G0F 1.047 1.06 1.07 
Largest diff. peak and hole [e/Å3] 0.750 and -1.509 0.72 and -0.509 1.384 and -1.764 
Structure solved by Freitag Mathias Freitag Mathias Freitag Mathias 
 
 
 
Crystallographic data 
212 
Compound 84 85 90 
Identification code ict04 cmx110 cmx111 
Empirical formula C24H30ClN4ORh C62H64Ag2F12N16O4P2 C34H44Br2N8O5Pd 
Formula weight 528.88 1602.97 910.99 
Crystal system Orthorhombic Monoclinic Triclinic 
Space group P212121 P21/c P-1 
Crystal size [mm] 0.40 x 0.04 x 0.02 0.07 x 0.05 x 0.02 0.20 x 0.10 x 0.03 
   a (Å) 7.1389(2) 21.5675(8) 9.6255(4) 
   b (Å) 13.2415(3) 22.9596(10) 16.5083(8) 
   c (Å) 25.0382(6) 14.4042(6) 23.9408(10) 
Volume (Å3) 2366.84(10) 6729.2(5) 3736.0(3) 
   α (°) 90 90 91.567(4) 
   β (°) 90 109.365(4) 95.478(4) 
   δ (°) 90 90 99.067(4) 
Z 4 4 4 
Density (calc.) [g/cm-3] 1.484 1.582 1.620 
µ [mm-1] 7.050 5.929 6.937 
Temperature [K] 100(2) 100(2) 100(2) 
Wavelength [Å] 1.54184 1.54184 1.54184 
Theta range [°] 3.53 to 76.07 3.78 to 70.07 3.22 to 74.50 
Reflections collected 55717 82550 49515 
Independent reflections 4914 13960 15253 
R1 with I0>2σ(I0) 0.0191 0.0516 0.0260 
wR2 0.0487 0.1172 0.0679 
G0F 1.033 1.01 1.040 
Largest diff. peak and hole [e/Å3] 0.401 and -0.553 0.80 and -0.73 0.819 and -0.808 
Structure solved by Freitag Mathias Daniliuc Constantin Daniliuc Constantin 
 
 
 
Crystallographic data 
213 
Compound 91 96  
Identification code cmx116 cmx113a  
Empirical formula C68H78F12N18NiO6P2 C26H30Cl2N6O2S2Zn  
Formula weight 1592.13 658.95  
Crystal system Monoclinic Orthorhombic  
Space group P 21 Pnma  
Crystal size [mm] 0.26 x 0.26 x 0.19 0.18 x 0.14 x 0.03  
   a (Å) 18.4043(8) 10.983(2)  
   b (Å) 11.6515(4) 23.896(5)  
   c (Å) 19.0696(8) 11.349(2)  
Volume (Å3) 3817.0(3) 2978.4(10)  
   α (°) 90 90  
   β (°) 111.023(6) 90  
   δ (°) 90 90  
Z 2 4  
Density (calc.) [g/cm-3] 1.385 1.470  
µ [mm-1] 0.387 1.179  
Temperature [K] 100(2) 100(2)  
Wavelength [Å] 0.71073 0.71073  
Theta range [°] 2.19 to 27.10 2.58 to 27.88  
Reflections collected 131574 98658  
Independent reflections 16815 3641  
R1 with I0>2σ(I0) 0.0493 0.0349  
wR2 0.1256 0.0682  
G0F 1.075 1.042  
Largest diff. peak and hole [e/Å3] 1.170 and -0.511 0.449 and -0.333  
Structure solved by Daniliuc Constantin Daniliuc Constantin  
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[404] Dıéz, A.; García, A.; Lalinde, E.; Martıń , A.; Moreno, M. T. Eur. J. Inorg. Chem. 
2009, 3060-3066. 
[405] Berenguer, J. R.; Lalinde, E.; Torroba, J. Inorg. Chem. 2007, 46, 9919-9930. 
[406] Kui, S. C. F.; Hung, F.-F.; Lai, S.-L.; Yuen, M.-Y.; Kwok, C.-C.; Low, K.-H.; Chui, S. 
S.-Y.; Che, C.-M. Chem. Eur. J. 2012, 18, 96-109. 
[407] Du, P.; Eisenberg, R. Chem. Sci. 2010, 1, 502-506. 
[408] Adams, C. J.; Fey, N.; Harrison, Z. A.; Sazanovich, I. V.; Towrie, M.; Weinstein, J. A. 
Inorg. Chem. 2008, 47, 8242-8257. 
[409] Saha, R.; Qaium, Md. A.; Debnath, D.; Younus, M.; Chawdhury, N.; Sultana, N.; 
Kociok-Ko ̈hn, G.; Ooi, L.-L.; Raithby, P. R.; Kijima, M. Dalton Trans. 2005, 2760-
2765. 
[410] Cullinane, C.; Deacon, G. B.; Drago, P. R.; Hambley, T. W.; Nelson, K. T.; Webster, 
L. K. J. Inorg. Biochem. 2002, 89, 293-301. 
[411] Klein, A.; Schurr, T.; Scherer, H.; Sen Gupta, N. Organometallics 2007, 26, 230-233. 
[412] Vicente, J.; Chicote, M. T.; Alvarez-Falcon, M. M.; Fox, M. A.; Bautista, D.; 
Organometallics 2003, 22, 4792-4797. 
[413] Wong, W.-Y.; Choi, K.-H.; Lu, G.-L.; Shi, J.-X.; Lai, P.-Y.; Chan, S.-M.; Lin, Z. 
Organometallics 2001, 20, 5446-5454. 
[414] Irwin, M. J.; Vittal, J. J.; Puddephatt, R. J. Organometallics 1997, 16, 3541-3547. 
[415] Jia, G. C.; Payne, N. C.; Vittal, J. J.; Puddephatt, R. J. Organometallics 1993, 12, 
4771-4778. 
[416] Vicente, J.; Chicote, M. T. Coord. Chem. Rev. 1999, 195, 1143-1161. 
[417] Mingos, D. M. P.; Vilar, R.; Rais, D. J. Organomet. Chem. 2002, 641, 126-133. 
[418] Vicente, J.; Chicote, M. T.; Alvarez-Falcon, M. M.; Abrisqueta, M. D.; Hernandez, F. 
J.; Jones, P. G. Inorg. Chim. Acta 2003, 347, 67-74. 
 235 
[419] McArdle, C. P.; Vittal, J. J.; Puddephatt, R. J. Angew. Chem., Int. Ed. 2000, 39, 3819-
3822. 
[420] Mohr, F.; Jennings, M. C.; Puddephatt, R. J.; Eur. J. Inorg. Chem. 2003, 217-223. 
[421] Wong, W.-Y.; Ho, K.-Y.; Choi, K.-H.J. Organomet. Chem. 2003, 670, 17-26. 
[422] Auld, D. S. BioMetals 2001, 14, 271-273. 
[423] Isaia, F.; Aragoni, M. C.; Arca, M.; Caltagirone, C.; Garau, A.; Jones, P. G.; Lippolis, 
V.; Montis R. CrystEngComm, 2014, 16, 3613-3623. 
[424] Laurence, C.; El Ghomari, M. J.; Le Questel, J.-Y.; Mokhlisse, R. J. Chem. Soc., 
Perkin Trans. 2 1998, 1545-1551. 
[425] Faergemann, J. American Journal of Clinical Dermatology 2000, 1, 75-80. 
 
